{"doi":"10.3310\/hta13470","coreId":"177121","oai":"oai:aura.abdn.ac.uk:2164\/291","identifiers":["oai:aura.abdn.ac.uk:2164\/291","10.3310\/hta13470"],"title":"A randomised controlled trial of the use of aciclovir and\/or prednisolone for the early treatment of Bell\u2019s palsy: the BELLS study","authors":["Sullivan, F.M.","Swan, I.R.C","Donnan, P.T.","Morrison, J.M.","Smith, Blair Hamilton","McKinstry, B","Davenport, R.J.","Vale, Luke David","Clarkson, J.E.","Hern\u00e1ndez, Rodolfo Andr\u00e9s","Stewart, K","Hammersley, V","Hayavi, S","McAteer, Anne","Gray, Denise Ann","Daley, F"],"enrichments":{"references":[{"id":6607,"title":"acute.and.transient.facial.paralysis..Ann Otol Rhinol Laryngol.1995;104:574\u201381.","authors":[],"date":null,"doi":null,"raw":"acute.and.transient.facial.paralysis..Ann Otol Rhinol Laryngol.1995;104:574\u201381. 3.. Morgan.M,.Moffat.M,.Ritchie.L,.Collacott.I,.Brown. T..Is.Bell\u2019s.palsy.a.reactivation.of.varicella.Zoster.","cites":null},{"id":6608,"title":"paralysis).(Cochrane.Review)..In:.The Cochrane Library,.Issue.2,.2002..Oxford:.Update.Software.","authors":[],"date":null,"doi":"10.1007\/bf03083401","raw":"paralysis).(Cochrane.Review)..In:.The Cochrane Library,.Issue.2,.2002..Oxford:.Update.Software. 8.. Sipe.J,.Dunn.L..Acyclovir.for.Bell\u2019s.palsy.(idiopathic.","cites":null},{"id":6609,"title":"AR,.Moher.M,.et al..Does.quality.of.reports.of. randomised.trials.affect.estimates.of.intervention.","authors":[],"date":null,"doi":"10.1016\/S0140-6736(98)01085-X","raw":null,"cites":null},{"id":6610,"title":"controlled.trial..Ann Otol Rhinol Laryngol.","authors":[],"date":"1996","doi":null,"raw":"controlled.trial..Ann Otol Rhinol Laryngol. 1996;105:371\u20138.","cites":null},{"id":6611,"title":"WC,.Grimshaw.J,.et al..The.Chronic.Pain.Grade.","authors":[],"date":null,"doi":"10.1016\/s0304-3959(97)03347-2","raw":"23.. Smith.BH,.Penny.KI,.Purves.AM,.Munro.C,.Smith. WC,.Grimshaw.J,.et al..The.Chronic.Pain.Grade. questionnaire:.acceptability.and.validity.in.postal. research..Pain.1997;71:141\u20137.","cites":null},{"id":6612,"title":"Information.and.Statistics.Division..ISD Scotland Guide: an","authors":[],"date":null,"doi":null,"raw":null,"cites":null},{"id":6613,"title":"Queen\u2019s Printer and Controller of HMSO. All rights reserved. 67 A.Trial.Steering.Committee.(TSC).should.be.set.up.with.the.following.terms.of.reference: Terms of reference 1..","authors":[],"date":"2009","doi":null,"raw":null,"cites":null},{"id":6614,"title":"Data Monitoring and Ethics Committee Professor.Marion.Campbell,.University.of. Aberdeen Dr.Carl.Counsell,.University.of.Aberdeen Mr.Rodney.Mountain,.University.of.Dundee Dr.Simon.Ogston.(Statistician),.University.of. Dundee DOI:","authors":[],"date":"2009","doi":null,"raw":null,"cites":null},{"id":6615,"title":"Queen\u2019s Printer and Controller of HMSO. All rights reserved. 77 Scottish.Bell\u2019s.Palsy.Study.The.\u2018BELLS\u2019.study HTA.02\/09\/04 The.application.to.HTA.was.naturally.preceded.by.","authors":[],"date":"2009","doi":null,"raw":null,"cites":null},{"id":6616,"title":"Local ethical approvals Our.applications.for.local.ethics.approvals.","authors":[],"date":null,"doi":null,"raw":"3.  Local ethical approvals Our.applications.for.local.ethics.approvals. commenced.on.18.December.2003.with.13. applications.despatched.to.regional.committees.. Later.it.emerged.that.some.Glasgow.hospitals.have. their.own.committees.and.Greater.Glasgow.has.its. own.Primary.Care.ethics.committee,.and.another. five.applications.were.despatched.up.to.March. 2004. Appendix 5 Timetable of approvals Copy of report to Chief Scientist OfficeAppendix 5 78 We.had.been.led.to.believe,.and.it.was.the. intention.of.the.new.MREC.structure,.that.the. process.of.local.approvals.for.a.multi-centre.trial. would.be.substantially.eased,.but.in.practice.this. was.not.the.case..The.new.procedures.would. only.come.into.place.in.May.2004,.and.the.study. team.found.themselves.caught.between.the.new. MREC.application.form.and.old.procedures.in.the. regions. For.instance,.one.ethics.committee.requested.their. own.version.of.the.previously.approved.Patient. Information.Sheet.for.the.study..In.practice.this.is. a.requirement.that.could.have.been.met.without. great.effort.(and.the.labour.of.its.construction. might.have.been.less.than.that.expended.during. a.discussion.of.the.principles.involved).but.the. formal.requirements.at.this.time.were.very.blurred. for.all.concerned.","cites":null},{"id":6617,"title":"Local R&D approvals","authors":[],"date":null,"doi":"10.3403\/00325172","raw":"4.  Local R&D approvals At.the.same.time.(18.December.2003).we.made. simultaneous.applications.to.19.primary.and.acute. care.R&D.departments,.with.another.three.up. to.March.2004..The.first.approval.came.through. before.the.new.year,.but.three.difficulties.became. apparent.in.February. First,.the.study.team.wish.to.reimburse.the.efforts. of.general.practitioners.in.referring.patients.into. the.study..Early.discussion.with.the.HTA.had. confirmed.the.principle,.but.HTA.insisted.that. the.funding.for.this.should.come.from.Support. for.Science..At.this.stage.neither.the.mechanisms. for.making.and.paying.claims,.nor.the.amount. to.be.reimbursed.had.been.agreed..It.became. apparent.that.not.all.R&D.departments.had. applied.for.Support.for.Science.and.therefore.not. all.had.funding.available.to.make.reimbursements,. which.had.been.agreed.at.\u00a351.per.referral..This. situation.is.now.resolved,.though.not.without.some. administrative.difficulties.and.some.feeling.on.both. sides.that.advantage.had.been.taken. Second,.in.order.to.smooth.the.process.of. claim,.it.was.required.to.identify.research-active. professionals.additional.to.the.team.of.nine. principal.investigators.and.17.local.principal. investigators,.and.two.additional.local.principal. investigators.were.added.to.the.list.of.team. members..Notwithstanding.the.professional. wisdom.and.experience.added.to.the.team.by.their. appointment,.this.is.essentially.a.device.invented. for.no.better.reason.than.to.allow.an.administrative. process.to.take.place.. Third,.as.a.consequence.of.the.requirement.for. uniformity.in.appearance.of.the.study.medications,. the.study.budget.has.been.used.for.the.purchase. of.all.treatments,.active.and.placebo..In.fact.the. study.is.funded.only.for.the.costs.of.placebo,. according.to.the.reasonable.principle.that.primary. care.organisations.should.bear.the.cost.of.active. treatment..These.costs.needed.to.be.recovered. from.the.primary.care.organisations.by.the.study,. but.only.through.an.administrative.mechanism.that. has.yet.to.be.invented.","cites":null},{"id":6618,"title":"Queen\u2019s Printer and Controller of HMSO. All rights reserved. 81 Appendix 6 How cruel to call it Bell\u2019s palsy by Graeme Garden On.December.1st.2002,.while.driving.south.along.the.M6,.I.discovered.that.I.couldn\u2019t.","authors":[],"date":"2009","doi":null,"raw":null,"cites":null},{"id":6619,"title":"Queen\u2019s Printer and Controller of HMSO. All rights reserved. 85 What is Bell\u2019s palsy and how is it treated?","authors":[],"date":"2009","doi":null,"raw":"GlasgowDOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 85 What is Bell\u2019s palsy and how is it treated? A.doctor.has.told.you.that.you.may.have.a.condition.known.as.Bell\u2019s.palsy..The.most.common.symptoms. are.weakness.or.paralysis.on.one.side.of.your.face,.with.others.that.may.include.dizziness,.difficulty.with. blinking,.problems.tasting.and.increased.sensitivity.to.sound..The.cause.of.Bell\u2019s.palsy.is.not.known,.but.it. may.be.due.to.local.swelling.or.a.viral.infection.of.the.facial.nerve.on.one.side.of.your.face..There.is.good. recovery.in.the.majority.of.cases..Unfortunately.there.is.no.medical.treatment.that.is.known.for.certain.to. improve.how.quickly.people.recover,.and.most.patients.with.Bell\u2019s.palsy.in.the.UK.are.currently.given.no. medication. It.has.been.suggested.that.some.medicines.might.improve.patients\u2019.recovery,.and.the.two.most.commonly. used.by.doctors.are.prednisolone.(a.steroid).and.aciclovir.(a.medicine.for.treating.viral.infections)..These. medicines.are.in.common.use.and.licensed.for.other.conditions,.but.not.for.use.in.treating.Bell\u2019s.palsy,. because.it.is.not.known.which,.if.either,.is.better.at.aiding.recovery,.or.if.giving.no.medication.at.all.is.just. as.good. The NHS has asked us to find out whether either of these medicines, separately or together, is most helpful in achieving a good recovery from Bell\u2019s palsy. To.do.this,.we.need.your.help..The.Scottish.Bell\u2019s.Palsy.Study.(\u2018BELLS\u2019).is.being.conducted.throughout. Scotland.and.has.been.approved.as.an.ethical.study.by.the.Scottish.Multicentre.Research.Ethics. Committee.and.by.all.the.regional.Research.Ethics.Committees. We.would.like.to.invite.you.to.join.the.Study..Please.take.time.to.read.the.following.information.carefully. and.discuss.it.with.others.if.you.wish..Ask.if.there.is.anything.that.is.not.clear,.or.if.you.would.like.more. information. \u2022. The.purpose.of.the.study.is.to.try.to.find.out.which.of.two.treatments,.a.steroid.(prednisolone).and.an. antiviral.medicine.(aciclovir),.or.neither,.or.both,.is.most.effective.in.achieving.a.good.recovery.from. Bell\u2019s.palsy. \u2022. You.have.been.invited.to.join.the.study.because.you.have.recently.been.diagnosed.with.Bell\u2019s.palsy.. It.is.fairly.common.(about.1.person.in.60.during.their.lifetime).and.there.will.be.up.to.500.fellow. sufferers.included.in.the.study. \u2022. It.is.up.to.you.to.decide.whether.to.join..If.you.decide.not.to.(or.if.after.joining.the.study.you.change. your.mind).your.decision.will.not.affect.your.future.care..You.don\u2019t.have.to.say.why,.and.the.doctor.will. just.treat.you.as.they.normally.would.if.the.study.was.not.taking.place. What will happen if I decide I am interested in taking part in the study? If.you.decide.you.do.want.to.take.part.in.the.study.(and.if.you.are.suitable:.not.everybody.will.be).then.this. is.what.will.happen.to.you. \u2022. You.will.be.given.two.bottles.of.tablets.by.a.doctor.to.take.away.with.you,.providing.a.10-day.course.of. treatment,.starting.immediately..One.bottle.will.contain.prednisolone.(the.steroid).or.a.\u2018placebo\u2019.(a. harmless.substance.that.looks.exactly.the.same.as.the.medicine,.but.has.no.effect)..The.second.bottle. will.contain.aciclovir.(the.medicine.for.treating.viral.infections).or.another.placebo. Appendix 8 Scottish Bell\u2019s Palsy Study: \u2018BELLS\u2019 Patient Information Sheet www.dundee.ac.uk\/bells\/Appendix 8 86 So.the.four.possible.combinations.of.tablets.are: Steroid.and. Antiviral Steroid.and. Placebo Placebo.and. Antiviral Placebo.and. Placebo There.is.an.equal.chance.that.you.will.be.given.any.of.these.combinations..Since.nobody.knows.which. of.these.possibilities.is.better.than.any.other,.you.are.not.advantaged.or.disadvantaged.by.the.choice.of. treatment.allocated.to.you. \u2022. The doctor has checked that there is no reason why you cannot take either of these medicines. The.choice.of.treatment.is.made.by.a.computer,.and.neither.you.nor.the.doctor.will.know.which.tablets. you.have.been.given..We.will.only.find.this.out.after.all.the.results.of.the.study.are.collected..If.for.medical. reasons.we.need.to.find.out.before.the.end.of.the.study.what.medication.you.are.taking,.we.can.do.this.. You.can.carry.on.your.life.completely.as.normal.during.the.treatment.and.thereafter..There.will.be.no. added.difficulty.or.complications.from.taking.part.in.the.study.other.than.remembering.to.take.your. medicine,.and.some.assessments.that.would.comprise.part.of.normal.care.anyway..You.can.continue.to.take. exercise,.drive,.and.eat.and.drink.as.you.normally.do. You.may.take.any.additional.medicines.you.may.require.such.as.pain.relief,.headache.remedies,. indigestion.pills.and.so.on:.however,.you.should.avoid.any.other.steroid.or.antiviral.preparations. How will recovery be measured? The.severity.of.your.condition,.and.how.fast.and.how.well.you.recover,.will.be.assessed.three.times:.once. as.soon.as.possible.during.the.10-day.treatment.period,.again.after.3.months,.and.finally.after.9.months.. A.researcher.will.visit.you.at.home.or.you.can.meet.them.at.your.GP\u2019s.surgery,.if.you.prefer..If.you.have.to. travel.from.home.for.the.assessments,.then.your.travelling.expenses.will.be.reimbursed. The.assessment.will.consist.of.questionnaires.to.record.your.symptoms,.and.a.series.of.photographs,. taken.to.provide.a.record.of.how.the.condition.has.affected.the.appearance.and.control.of.your.face..The. photographs.and.all.other.information.collected.that.is.personal.to.you.will.be.stored.securely.and.will. only.be.made.available.to.those.connected.with.the.study.in.an.official.capacity..If.at.any.time.you.decide. to.withdraw.from.the.study,.it.will.be.necessary.to.retain.your.data.for.safety.and.monitoring.purposes,. but.it.will.be.maintained.as.carefully.and.with.the.same.security.as.that.of.other.patients.who.complete.the. study..You.will.not.be.identified.in.any.report. When do I need to decide? \u2022. We.think.that.if.these.medicines.are.effective,.then.they.have.to.be.taken.early,.preferably.within.48. hours.of.you.first.noticing.your.condition.and.definitely.within.72.hours.","cites":null},{"id":6620,"title":"please let us know very soon if you are happy to join the study so that treatment can commence. Preferably, tell the doctor that gave you this information sheet now. Will there be side effects?","authors":[],"date":null,"doi":null,"raw":"\u2022. So, please let us know very soon if you are happy to join the study so that treatment can commence. Preferably, tell the doctor that gave you this information sheet now. Will there be side effects? Almost.all.medicines.lead.to.occasional.side.effects,.as.well.as.helping.the.condition.for.which.they.were. given..These.\u2018side.effects\u2019.are.usually.unwanted,.but.they.are.well-known. For.the.medicines.used.in.this.study.the.side.effects.may.include.sickness,.headache,.dizziness,.sleepiness. or.rash. So, what are we saying? We.cannot.guarantee.you.a.benefit.by.taking.part.in.the.study,.but.given.current.medical.knowledge,. you.are.not.being.disadvantaged.by.joining.the.study,.whichever.choice.of.treatment.is.allocated.to.you.. Other.people.in.the.future.will.be.helped.when.we.know.which.treatment.is.best..Thank.you.very.much.for. helping.us.to.learn.more.about.an.effective.and.appropriate.treatment.for.patients.with.Bell\u2019s.palsy. Finally\u2026 If.at.any.time.you.would.like.additional.advice.or.consultation.whilst.you.are.on.the.study,.then.this.can.be. obtained.from.<.contact name and details.>..The.results.of.this.study.will.be.published.in.medical.journals.. An.internal.report.will.be.written.on.completion.of.the.study.in.2006.and.will.be.distributed.to.all.taking.","cites":null},{"id":6621,"title":"Queen\u2019s Printer and Controller of HMSO. All rights reserved. 87 Appendix 9 Form A Appendix 9 88 Scottish Bell\u2019s Palsy Study \u2018BELLS\u2019 Patient case record form Form A v.8 dated 19th","authors":[],"date":"2009","doi":null,"raw":null,"cites":null},{"id":6622,"title":"Queen\u2019s Printer and Controller of HMSO. All rights reserved. 91 Appendix 10 Consent form Appendix 10 92 Scottish Bell\u2019s Palsy Study Consent Form v.6 dated 18th","authors":[],"date":"2009","doi":null,"raw":null,"cites":null},{"id":6623,"title":"Queen\u2019s Printer and Controller of HMSO. All rights reserved.","authors":[],"date":"2009","doi":null,"raw":"Littlejohns.P,.Ross.FM,.Axford.JS.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 133 Volume 4, 2000 No. 1 The.estimation.of.marginal.time. preference.in.a.UK-wide.sample. (TEMPUS).project. A.review.by.Cairns.JA,. van.der.Pol.MM. No. 2 Geriatric.rehabilitation.following. fractures.in.older.people:.a.systematic. review. By.Cameron.I,.Crotty.M,.Currie.C,. Finnegan.T,.Gillespie.L,.Gillespie.W,. et al. No. 3 Screening.for.sickle.cell.disease.and. thalassaemia:.a.systematic.review.with. supplementary.research. By.Davies.SC,.Cronin.E,.Gill.M,. Greengross.P,.Hickman.M,.Normand.C. No. 4 Community.provision.of.hearing.aids. and.related.audiology.services. A.review.by.Reeves.DJ,.Alborz.A,. Hickson.FS,.Bamford.JM. No. 5 False-negative.results.in.screening. programmes:.systematic.review.of. impact.and.implications. By.Petticrew.MP,.Sowden.AJ,. Lister-Sharp.D,.Wright.K. No. 6 Costs.and.benefits.of.community. postnatal.support.workers:.a. randomised.controlled.trial. By.Morrell.CJ,.Spiby.H,.Stewart.P,. Walters.S,.Morgan.A. No. 7 Implantable.contraceptives.(subdermal. implants.and.hormonally.impregnated. intrauterine.systems).versus.other. forms.of.reversible.contraceptives:.two. systematic.reviews.to.assess.relative. effectiveness,.acceptability,.tolerability. and.cost-effectiveness. By.French.RS,.Cowan.FM,. Mansour.DJA,.Morris.S,.Procter.T,. Hughes.D,.et al. No. 8 An.introduction.to.statistical.methods. for.health.technology.assessment. A.review.by.White.SJ,.Ashby.D,. Brown.PJ. No. 9 Disease-modifying.drugs.for.multiple. sclerosis:.a.rapid.and.systematic.review. By.Clegg.A,.Bryant.J,.Milne.R. No. 10 Publication.and.related.biases. A.review.by.Song.F,.Eastwood.AJ,. Gilbody.S,.Duley.L,.Sutton.AJ. No. 11 Cost.and.outcome.implications.of.the. organisation.of.vascular.services. By.Michaels.J,.Brazier.J,. Palfreyman.S,.Shackley.P,.Slack.R. No. 12 Monitoring.blood.glucose.control.in. diabetes.mellitus:.a.systematic.review. By.Coster.S,.Gulliford.MC,.Seed.PT,. Powrie.JK,.Swaminathan.R. No. 13 The.effectiveness.of.domiciliary. health.visiting:.a.systematic.review.of. international.studies.and.a.selective. review.of.the.British.literature. By.Elkan.R,.Kendrick.D,.Hewitt.M,. Robinson.JJA,.Tolley.K,.Blair.M,.et al. No. 14 The.determinants.of.screening.uptake. and.interventions.for.increasing. uptake:.a.systematic.review. By.Jepson.R,.Clegg.A,.Forbes.C,. Lewis.R,.Sowden.A,.Kleijnen.J. No. 15 The.effectiveness.and.cost-effectiveness. of.prophylactic.removal.of.wisdom. teeth. A.rapid.review.by.Song.F,.O\u2019Meara.S,. Wilson.P,.Golder.S,.Kleijnen.J. No. 16 Ultrasound.screening.in.pregnancy:. a.systematic.review.of.the.clinical. effectiveness,.cost-effectiveness.and. women\u2019s.views. By.Bricker.L,.Garcia.J,.Henderson.J,. Mugford.M,.Neilson.J,.Roberts.T,.et al. No. 17 A.rapid.and.systematic.review.of.the. effectiveness.and.cost-effectiveness.of. the.taxanes.used.in.the.treatment.of. advanced.breast.and.ovarian.cancer. By.Lister-Sharp.D,.McDonagh.MS,. Khan.KS,.Kleijnen.J. No. 18 Liquid-based.cytology.in.cervical. screening:.a.rapid.and.systematic. review. By.Payne.N,.Chilcott.J,.McGoogan.E. No. 19 Randomised.controlled.trial.of.nondirective.counselling,.cognitive\u2013 behaviour.therapy.and.usual.general. practitioner.care.in.the.management.of. depression.as.well.as.mixed.anxiety.and. depression.in.primary.care. By.King.M,.Sibbald.B,.Ward.E,. Bower.P,.Lloyd.M,.Gabbay.M,.et al. No. 20 Routine.referral.for.radiography.of. patients.presenting.with.low.back.pain:. is.patients\u2019.outcome.influenced.by.GPs\u2019. referral.for.plain.radiography? By.Kerry.S,.Hilton.S,.Patel.S,. Dundas.D,.Rink.E,.Lord.J. No. 21 Systematic.reviews.of.wound.care. management:.(3).antimicrobial.agents. for.chronic.wounds;.(4).diabetic.foot. ulceration. By.O\u2019Meara.S,.Cullum.N,.Majid.M,. Sheldon.T. No. 22 Using.routine.data.to.complement. and.enhance.the.results.of.randomised. controlled.trials. By.Lewsey.JD,.Leyland.AH,.Murray. GD,.Boddy.FA. No. 23 Coronary.artery.stents.in.the.treatment. of.ischaemic.heart.disease:.a.rapid.and. systematic.review. By.Meads.C,.Cummins.C,.Jolly.K,. Stevens.A,.Burls.A,.Hyde.C. No. 24 Outcome.measures.for.adult.critical. care:.a.systematic.review. By.Hayes.JA,.Black.NA,.Jenkinson.C,. Young.JD,.Rowan.KM,.Daly.K,.et al. No. 25 A.systematic.review.to.evaluate.the. effectiveness.of.interventions.to. promote.the.initiation.of.breastfeeding. By.Fairbank.L,.O\u2019Meara.S,. Renfrew.MJ,.Woolridge.M,.Sowden.AJ,. Lister-Sharp.D. No. 26 Implantable.cardioverter.defibrillators:. arrhythmias..A.rapid.and.systematic. review. By.Parkes.J,.Bryant.J,.Milne.R. No. 27 Treatments.for.fatigue.in.multiple. sclerosis:.a.rapid.and.systematic.review. By.Bra\u00f1as.P,.Jordan.R,.Fry-Smith.A,. Burls.A,.Hyde.C. No. 28 Early.asthma.prophylaxis,.natural. history,.skeletal.development.and. economy.(EASE):.a.pilot.randomised. controlled.trial. By.Baxter-Jones.ADG,.Helms.PJ,. Russell.G,.Grant.A,.Ross.S,.Cairns.JA,. et al. No. 29 Screening.for.hypercholesterolaemia. versus.case.finding.for.familial. hypercholesterolaemia:.a.systematic. review.and.cost-effectiveness.analysis. By.Marks.D,.Wonderling. D,.Thorogood.M,.Lambert.H,. Humphries.SE,.Neil.HAW. No. 30 A.rapid.and.systematic.review.of. the.clinical.effectiveness.and.costeffectiveness.of.glycoprotein.IIb\/IIIa. antagonists.in.the.medical.management. of.unstable.angina. By.McDonagh.MS,.Bachmann.LM,.","cites":null},{"id":6624,"title":"The number of the Randomisation Service is 1611 111111.. Before you begin you will need your npw*(p w+vmp( which is","authors":[],"date":null,"doi":null,"raw":null,"cites":null},{"id":6625,"title":"Queen\u2019s Printer and Controller of HMSO. All rights reserved. 97 Appendix 12 Recruiters\u2019 notes","authors":[],"date":"2009","doi":null,"raw":null,"cites":null},{"id":6627,"title":"After all visits send letters to GP and patient, keep copies despatch original completed questionnaires to TCGP, keep copies email photographs to TCGP DOI: 10.3310\/hta13470 Health Technology Assessment","authors":[],"date":"2009","doi":null,"raw":null,"cites":null},{"id":6629,"title":"d ur in g th e la st 2 4 ho ur s.","authors":[],"date":"2009","doi":null,"raw":null,"cites":null},{"id":6630,"title":"Queen\u2019s Printer and Controller of HMSO. All rights reserved. 125 For questions 1 to 33 use the scale","authors":[],"date":"2009","doi":null,"raw":"DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 125  For questions 1 to 33 use the scale 1  2  3  4  N\/A Almost never  Sometimes  Often  Almost always  Does not apply  1  I am self-concious of my \u2018feature\u2019  1  2  3  4  N\/A 2  I avoid children in the street   1  2  3  4  N\/A 3  I find it difficult to make friends  1  2  3  4  N\/A 4  I avoid undressing in front of my spouse \/ partner  1  2  3  4  N\/A 5  At present I try to avoid going to my school \/ college \/ work   1  2  3  4  N\/A 6  I avoid going to pubs \/ restaurants   1  2  3  4  N\/A 7  I avoid going to parties \/ discos   1  2  3  4  N\/A 8  I take a special interest in what other people\u2019s \u2018feature\u2019 looks like  1  2  3  4  N\/A 9  I avoid communal changing rooms   1  2  3  4  N\/A 10  I avoid having my photograph taken  1  2  3  4  N\/A 11  1 avoid getting my hair wet   1  2  3  4  N\/A 12  I have been hurt by other people saying things about my \u2018feature\u2019   1  2  3  4  N\/A 13  I avoid shopping in department stores   1  2  3  4  N\/A 14  I avoid going out of the house   1  2  3  4  N\/A 15  I raise the subject of my \u2018feature\u2019 in conversation before other people do  1  2  3  4  N\/A 16  I close into my shell   1  2  3  4  N\/A 17  My self-consciousness makes me  irritable at home   1  2  3  4  N\/A 18  Other people misjudge me because of my \u2018feature\u2019   1  2  3  4  N\/A 19  In the past I have tried to avoid going to school \/ college \/ work   1  2  3  4  N\/A 20  I feel an embarrassment to my friends   1  2  3  4  N\/A 21  I feel a freak   1  2  3  4  N\/A 22  I worry about my sanity   1  2  3  4  N\/A 23  My self-consciousness has an adverse effect on my sex life   1  2  3  4  N\/A 24  My self-consciousness has an adverse effect on my marriage   1  2  3  4  N\/A 25  My \u2018feature\u2019 causes me pain or discomfort   1  2  3  4  N\/A 26  My \u2018feature\u2019 physically limits my ability to do the things I want to do   1  2  3  4  N\/A 27  My \u2018feature\u2019 makes me feel unattractive   1  2  3  4  N\/A 28  My \u2018feature\u2019 makes me feel unlovable   1  2  3  4  N\/A 29  My \u2018feature\u2019 makes me feel isolated   1  2  3  4  N\/A 30  My \u2018feature\u2019 makes me feel embarrassed   1  2  3  4  N\/A 21  My \u2018feature\u2019 makes me feel inferior   1  2  3  4  N\/A 32  My \u2018feature\u2019 makes me feel rejected   1  2  3  4  N\/A 33  My \u2018feature\u2019 makes me feel useless   1  2  3  4  N\/A  Appendix 20 126 For questions 34 to 51 use the scale 1  2  3  4  5  N\/A Not at all distressed    Moderately distressed    Extremely distressed  Does not apply  HOW DISTRESSED DO YOU GET WHEN: 34  Other people stare at your \u2018feature\u2019  1  2  3  4  5  N\/A 35  Other people make remarks about your \u2018feature\u2019   1  2  3  4  5  N\/A 36  Other people ask about your \u2018feature\u2019   1  2  3  4  5  N\/A 37  You go to the beach   1  2  3  4  5  N\/A 38  Others see you in a particular view (eg. front, side)   1  2  3  4  5  N\/A 39  You go to your school \/ college \/ work   1  2  3  4  5  N\/A 40  You travel on public transport   1  2  3  4  5  N\/A 41  You see yourself in a mirror \/ window   1  2  3  4  5  N\/A 42  You meet strangers   1  2  3  4  5  N\/A  HOW DISTRESSED ARE YOU BY: 43  Being unable to wear your favourite clothes   1  2  3  4  5  N\/A 44  Being unable to change your hairstyle   1  2  3  4  5  N\/A 45  Not being able to go swimming   1  2  3  4  5  N\/A 46  Not being able to play games   1  2  3  4  5  N\/A 47  Not being able to go to social events   1  2  3  4  5  N\/A 48  Being unable to answer the front door at home   1  2  3  4  5  N\/A 49  Being unable to look at yourself in the mirror   1  2  3  4  5  N\/A 50  Being unable to go to pubs \/ restaurants   1  2  3  4  5  N\/A 51  Not being able to go out in windy weather   1  2  3  4  5  N\/A  For questions 52 to 59 use the scale 1  2  3  4  5 Not at all  Slightly  Moderately  Greatly  Extremely","cites":null},{"id":6631,"title":"This.patient.never.commenced.BELLS.medications Patient reference 2617009 Date.of.Consent.to.BELLS.study.","authors":[],"date":null,"doi":null,"raw":"Compliance. This.patient.never.commenced.BELLS.medications Patient reference 2617009 Date.of.Consent.to.BELLS.study. 17.12.2004. Site. Glasgow.Royal.Infirmary.","cites":null},{"id":6632,"title":"Assessment reports published to date 132","authors":[],"date":"1999","doi":null,"raw":"Buxton.MJ,.Jones.DR.Health Technology Assessment reports published to date 132 No. 15 Ethical.issues.in.the.design.and.conduct. of.randomised.controlled.trials. A.review.by.Edwards.SJL,.Lilford.RJ,. Braunholtz.DA,.Jackson.JC,.Hewison.J,. Thornton.J. No. 16 Qualitative.research.methods.in.health. technology.assessment:.a.review.of.the. literature. By.Murphy.E,.Dingwall.R,. Greatbatch.D,.Parker.S,.Watson.P. No. 17 The.costs.and.benefits.of.paramedic. skills.in.pre-hospital.trauma.care. By.Nicholl.J,.Hughes.S,.Dixon.S,. Turner.J,.Yates.D. No. 18 Systematic.review.of.endoscopic. ultrasound.in.gastro-oesophageal. cancer. By.Harris.KM,.Kelly.S,.Berry.E,. Hutton.J,.Roderick.P,.Cullingworth.J,. et al. No. 19 Systematic.reviews.of.trials.and.other. studies. By.Sutton.AJ,.Abrams.KR,.Jones.DR,. Sheldon.TA,.Song.F. No. 20 Primary.total.hip.replacement.surgery:. a.systematic.review.of.outcomes. and.modelling.of.cost-effectiveness. associated.with.different.prostheses. A.review.by.Fitzpatrick.R,.Shortall. E,.Sculpher.M,.Murray.D,.Morris.R,. Lodge.M,.et al. Volume 3, 1999 No. 1 Informed.decision.making:.an. annotated.bibliography.and.systematic. review. By.Bekker.H,.Thornton.JG,. Airey.CM,.Connelly.JB,.Hewison.J,. Robinson.MB,.et al. No. 2 Handling.uncertainty.when.performing. economic.evaluation.of.healthcare. interventions. A.review.by.Briggs.AH,.Gray.AM. No. 3 The.role.of.expectancies.in.the.placebo. effect.and.their.use.in.the.delivery.of. health.care:.a.systematic.review. By.Crow.R,.Gage.H,.Hampson.S,. Hart.J,.Kimber.A,.Thomas.H. No. 4 A.randomised.controlled.trial.of. different.approaches.to.universal. antenatal.HIV.testing:.uptake.and. acceptability..Annex:.Antenatal.HIV. testing.\u2013.assessment.of.a.routine. voluntary.approach. By.Simpson.WM,.Johnstone.FD,. Boyd.FM,.Goldberg.DJ,.Hart.GJ,. Gormley.SM,.et al. No. 5 Methods.for.evaluating.area-wide.and. organisation-based.interventions.in. health.and.health.care:.a.systematic. review. By.Ukoumunne.OC,.Gulliford.MC,. Chinn.S,.Sterne.JAC,.Burney.PGJ. No. 6 Assessing.the.costs.of.healthcare. technologies.in.clinical.trials. A.review.by.Johnston.K,.Buxton.MJ,. Jones.DR,.Fitzpatrick.R. No. 7 Cooperatives.and.their.primary.care. emergency.centres:.organisation.and. impact. By.Hallam.L,.Henthorne.K. No. 8 Screening.for.cystic.fibrosis. A.review.by.Murray.J,.Cuckle.H,. Taylor.G,.Littlewood.J,.Hewison.J. No. 9 A.review.of.the.use.of.health.status. measures.in.economic.evaluation. By.Brazier.J,.Deverill.M,.Green.C,. Harper.R,.Booth.A. No. 10 Methods.for.the.analysis.of.qualityof-life.and.survival.data.in.health. technology.assessment. A.review.by.Billingham.LJ,. Abrams.KR,.Jones.DR. No. 11 Antenatal.and.neonatal. haemoglobinopathy.screening.in.the. UK:.review.and.economic.analysis. By.Zeuner.D,.Ades.AE,.Karnon.J,. Brown.J,.Dezateux.C,.Anionwu.EN. No. 12 Assessing.the.quality.of.reports.of. randomised.trials:.implications.for.the. conduct.of.meta-analyses. A.review.by.Moher.D,.Cook.DJ,. Jadad.AR,.Tugwell.P,.Moher.M,. Jones.A,.et al. No. 13 \u2018Early.warning.systems\u2019.for.identifying. new.healthcare.technologies. By.Robert.G,.Stevens.A,.Gabbay.J. No. 14 A.systematic.review.of.the.role.of. human.papillomavirus.testing.within.a. cervical.screening.programme. By.Cuzick.J,.Sasieni.P,.Davies.P,. Adams.J,.Normand.C,.Frater.A,.et al. No. 15 Near.patient.testing.in.diabetes.clinics:. appraising.the.costs.and.outcomes. By.Grieve.R,.Beech.R,.Vincent.J, Mazurkiewicz.J. No. 16 Positron.emission.tomography:. establishing.priorities.for.health. technology.assessment. A.review.by.Robert.G,.Milne.R. No. 17 (Pt 1) The.debridement.of.chronic.wounds:.a. systematic.review. By.Bradley.M,.Cullum.N,.Sheldon.T. No. 17 (Pt 2) Systematic.reviews.of.wound.care. management:.(2).Dressings.and.topical. agents.used.in.the.healing.of.chronic. wounds. By.Bradley.M,.Cullum.N,.Nelson.EA,. Petticrew.M,.Sheldon.T,.Torgerson.D. No. 18 A.systematic.literature.review.of. spiral.and.electron.beam.computed. tomography:.with.particular.reference. to.clinical.applications.in.hepatic. lesions,.pulmonary.embolus.and. coronary.artery.disease. By.Berry.E,.Kelly.S,.Hutton.J,. Harris.KM,.Roderick.P,.Boyce.JC,.et al. No. 19 What.role.for.statins?.A.review.and. economic.model. By.Ebrahim.S,.Davey.Smith. G,.McCabe.C,.Payne.N,.Pickin.M,. Sheldon.TA,.et al. No. 20 Factors.that.limit.the.quality,.number. and.progress.of.randomised.controlled. trials. A.review.by.Prescott.RJ,.Counsell.CE,. Gillespie.WJ,.Grant.AM,.Russell.IT,. Kiauka.S,.et al. No. 21 Antimicrobial.prophylaxis.in.total.hip. replacement:.a.systematic.review. By.Glenny.AM,.Song.F. No. 22 Health.promoting.schools.and.health. promotion.in.schools:.two.systematic. reviews. By.Lister-Sharp.D,.Chapman.S,. Stewart-Brown.S,.Sowden.A. No. 23 Economic.evaluation.of.a.primary. care-based.education.programme.for. patients.with.osteoarthritis.of.the.knee. A.review.by.Lord.J,.Victor.C,.","cites":null},{"id":6635,"title":"Health Technology Assessment reports published to date 136","authors":[],"date":"2003","doi":null,"raw":null,"cites":null},{"id":6638,"title":"Health Technology Assessment reports published to date 142","authors":[],"date":"2006","doi":null,"raw":null,"cites":null},{"id":6640,"title":"Health Technology Assessment reports published to date 144","authors":[],"date":"2007","doi":null,"raw":null,"cites":null},{"id":6642,"title":"Assessment reports published to date 146","authors":[],"date":"2008","doi":null,"raw":null,"cites":null},{"id":6644,"title":"Health Technology Assessment reports published to date","authors":[],"date":"2009","doi":null,"raw":null,"cites":null},{"id":6645,"title":"Queen\u2019s Printer and Controller of HMSO. All rights reserved. 151 Health Technology Assessment programme","authors":[],"date":"2009","doi":null,"raw":"Dundar.Y.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 151 Health Technology Assessment programme Director, Professor Tom Walley, Director,.NIHR.HTA. programme,.Professor.of. Clinical.Pharmacology,. University.of.Liverpool Deputy Director, Professor Jon Nicholl, Director,.Medical.Care.Research. Unit,.University.of.Sheffield Prioritisation.Strategy.Group Members Chair, Professor Tom Walley, Director,.NIHR.HTA. programme,.Professor.of. Clinical.Pharmacology,. University.of.Liverpool Deputy Chair, Professor Jon Nicholl, Director,.Medical.Care.Research. Unit,.University.of.Sheffield Dr.Bob.Coates, Consultant.Advisor,.NETSCC,. HTA Dr.Andrew.Cook, Consultant.Advisor,.NETSCC,. HTA Dr.Peter.Davidson, Director.of.Science.Support,. NETSCC,.HTA Professor.Robin.E.Ferner,. Consultant.Physician.and. Director,.West.Midlands.Centre. for.Adverse.Drug.Reactions,. City.Hospital.NHS.Trust,. Birmingham Professor.Paul.Glasziou,. Professor.of.Evidence-Based. Medicine,.University.of.Oxford Dr.Nick.Hicks, Director.of.NHS.Support,. NETSCC,.HTA Dr.Edmund.Jessop, Medical.Adviser,.National. Specialist,.National. Commissioning.Group.(NCG),. Department.of.Health,.London Ms.Lynn.Kerridge, Chief.Executive.Officer,. NETSCC.and.NETSCC,.HTA Dr.Ruairidh.Milne, Director.of.Strategy.and. Development,.NETSCC Ms.Kay.Pattison, Section.Head,.NHS.R&D. Programme,.Department.of. Health Ms.Pamela.Young, Specialist.Programme.Manager,. NETSCC,.HTA HTA.Commissioning.Board Members Programme Director, Professor Tom Walley, Director,.NIHR.HTA. programme,.Professor.of. Clinical.Pharmacology,. University.of.Liverpool Chair, Professor Jon Nicholl, Director,.Medical.Care.Research. Unit,.University.of.Sheffield Deputy Chair, Dr Andrew Farmer, Senior.Lecturer.in.General. Practice,.Department.of. Primary.Health.Care,. University.of.Oxford Professor.Ann.Ashburn, Professor.of.Rehabilitation. and.Head.of.Research,. Southampton.General.Hospital Professor.Deborah.Ashby, Professor.of.Medical.Statistics,. Queen.Mary,.University.of. London Professor.John.Cairns, Professor.of.Health.Economics,. London.School.of.Hygiene.and. Tropical.Medicine Professor.Peter.Croft, Director.of.Primary.Care. Sciences.Research.Centre,.Keele. University Professor.Nicky.Cullum, Director.of.Centre.for.EvidenceBased.Nursing,.University.of. York Professor.Jenny.Donovan, Professor.of.Social.Medicine,. University.of.Bristol Professor.Steve.Halligan, Professor.of.Gastrointestinal. Radiology,.University.College. Hospital,.London Professor.Freddie.Hamdy, Professor.of.Urology, University.of.Sheffield Professor.Allan.House, Professor.of.Liaison.Psychiatry,. University.of.Leeds Dr.Martin.J.Landray, Reader.in.Epidemiology,. Honorary.Consultant.Physician,. Clinical.Trial.Service.Unit,. University.of.Oxford. Professor.Stuart.Logan, Director.of.Health.&.Social. Care.Research,.The.Peninsula. Medical.School,.Universities.of. Exeter.and.Plymouth Dr.Rafael.Perera, Lecturer.in.Medical.Statisitics,. Department.of.Primary.Health. Care,.Univeristy.of.Oxford Professor.Ian.Roberts,. Professor.of.Epidemiology.&. Public.Health,.London.School. of.Hygiene.and.Tropical. Medicine Professor.Mark.Sculpher, Professor.of.Health.Economics,. University.of.York Professor.Helen.Smith, Professor.of.Primary.Care,. University.of.Brighton Professor.Kate.Thomas, Professor.of.Complementary.&. Alternative.Medicine.Research,. University.of.Leeds Professor.David.John. Torgerson, Director.of.York.Trials.Unit,. University.of.York Professor.Hywel.Williams, Professor.of.DermatoEpidemiology,.University.of. Nottingham Observers Ms.Kay.Pattison, Section.Head,.NHS.R&D. Programme,.Department.of. Health Dr.Morven.Roberts, Clinical.Trials.Manager,. Medical.Research.CouncilHealth Technology Assessment programme 152 Current and past membership details of all HTA programme \u2018committees\u2019 are available from the HTA website (www.hta.ac.uk) Diagnostic.Technologies.&.Screening.Panel Members Chair, Professor Paul Glasziou, Professor.of.Evidence-Based. Medicine,.University.of.Oxford Deputy Chair, Dr David Elliman, Consultant.Paediatrician.and. Honorary.Senior.Lecturer,. Great.Ormond.Street.Hospital,. London Professor.Judith.E.Adams,. Consultant.Radiologist,. Manchester.Royal.Infirmary,. Central.Manchester.&. Manchester.Children\u2019s. University.Hospitals.NHS.Trust,. and.Professor.of.Diagnostic. Radiology,.Imaging.Science. and.Biomedical.Engineering,. Cancer.&.Imaging.Sciences,. University.of.Manchester Ms.Jane.Bates, Consultant.Ultrasound. Practitioner,.Ultrasound. Department,.Leeds.Teaching. Hospital.NHS.Trust Dr.Stephanie.Dancer, Consultant.Microbiologist,. Hairmyres.Hospital,.East. Kilbride Professor.Glyn.Elwyn, Primary.Medical.Care.Research. Group,.Swansea.Clinical.School,. University.of.Wales Dr.Ron.Gray, Consultant.Clinical. Epidemiologist,.Department. of.Public.Health,.University.of. Oxford Professor.Paul.D.Griffiths,. Professor.of.Radiology,. University.of.Sheffield Dr.Jennifer.J.Kurinczuk, Consultant.Clinical. Epidemiologist,.National. Perinatal.Epidemiology.Unit,. Oxford Dr.Susanne.M.Ludgate, Medical.Director,.Medicines.&. Healthcare.Products.Regulatory. Agency,.London Dr.Anne.Mackie, Director.of.Programmes,.UK. National.Screening.Committee Dr.Michael.Millar,. Consultant.Senior.Lecturer.in. Microbiology,.Barts.and.The. London.NHS.Trust,.Royal. London.Hospital Mr.Stephen.Pilling, Director,.Centre.for.Outcomes,. Research.&.Effectiveness,. Joint.Director,.National. Collaborating.Centre.for. Mental.Health,.University. College.London Mrs.Una.Rennard, Service.User.Representative Dr.Phil.Shackley, Senior.Lecturer.in.Health. Economics,.School.of. Population.and.Health. Sciences,.University.of. Newcastle.upon.Tyne Observers Dr.Tim.Elliott, Team.Leader,.Cancer. Screening,.Department.of. Health Dr.Catherine.Moody, Programme.Manager,. Neuroscience.and.Mental. Health.Board Dr.Ursula.Wells, Principal.Research.Officer,. Department.of.Health Dr.W.Stuart.A.Smellie, Consultant.in.Chemical. Pathology,.Bishop.Auckland. General.Hospital Dr.Nicholas.Summerton,. Consultant.Clinical.and.Public. Health.Advisor,.NICE Ms.Dawn.Talbot, Service.User.Representative Dr.Graham.Taylor, Scientific.Advisor,.Regional. DNA.Laboratory,.St.James\u2019s. University.Hospital,.Leeds Professor.Lindsay.Wilson. Turnbull, Scientific.Director.of.the. Centre.for.Magnetic.Resonance. Investigations.and.YCR. Professor.of.Radiology,.Hull. Royal.Infirmary Pharmaceuticals.Panel Members Chair, Professor Robin Ferner, Consultant.Physician.and. Director,.West.Midlands.Centre. for.Adverse.Drug.Reactions,. City.Hospital.NHS.Trust,. Birmingham Deputy Chair, Professor Imti Choonara, Professor.in.Child.Health,. University.of.Nottingham Mrs.Nicola.Carey, Senior.Research.Fellow,.. School.of.Health.and.Social. Care,.The.University.of. Reading Mr.John.Chapman, Service.User.Representative Dr.Peter.Elton, Director.of.Public.Health, Bury.Primary.Care.Trust Dr.Ben.Goldacre, Research.Fellow,.Division.of. Psychological.Medicine.and. Psychiatry,.King\u2019s.College. London Mrs.Barbara.Greggains, Service.User.Representative Dr.Bill.Gutteridge, Medical.Adviser,.London. Strategic.Health.Authority Dr.Dyfrig.Hughes, Reader.in.Pharmacoeconomics. and.Deputy.Director,.Centre. for.Economics.and.Policy.in. Health,.IMSCaR,.Bangor. University Professor.Jonathan.Ledermann, Professor.of.Medical.Oncology. and.Director.of.the.Cancer. Research.UK.and.University. College.London.Cancer.Trials. Centre Dr.Yoon.K.Loke, Senior.Lecturer.in.Clinical. Pharmacology,.University.of. East.Anglia Professor.Femi.Oyebode, Consultant.Psychiatrist. and.Head.of.Department,. University.of.Birmingham Dr.Andrew.Prentice, Senior.Lecturer.and.Consultant. Obstetrician.and.Gynaecologist,. The.Rosie.Hospital,.University. of.Cambridge Dr.Martin.Shelly, General.Practitioner,.Leeds,. and.Associate.Director,.NHS. Clinical.Governance.Support. Team,.Leicester Dr.Gillian.Shepherd, Director,.Health.and.Clinical. Excellence,.Merck.Serono.Ltd Mrs.Katrina.Simister, Assistant.Director.New. Medicines,.National.Prescribing. Centre,.Liverpool Mr.David.Symes, Service.User.Representative Dr.Lesley.Wise, Unit.Manager,. Pharmacoepidemiology. Research.Unit,.VRMM,. Medicines.&.Healthcare. Products.Regulatory.Agency Observers Ms.Kay.Pattison, Section.Head,.NHS.R&D. Programme,.Department.of. Health Mr.Simon.Reeve, Head.of.Clinical.and.CostEffectiveness,.Medicines,. Pharmacy.and.Industry.Group,. Department.of.Health Dr.Heike.Weber, Programme.Manager,. Medical.Research.Council Dr.Ursula.Wells, Principal.Research.Officer,.","cites":null},{"id":6013165,"title":"AR,.Moher.M,.et al..Does.quality.of.reports.of.","authors":[],"date":null,"doi":"10.1016\/s0140-6736(98)01085-x","raw":"13.. Moher.D,.Pham.B,.Jones.A,.Cook.DJ,.Jadad. AR,.Moher.M,.et al..Does.quality.of.reports.of. randomised.trials.affect.estimates.of.intervention.Appendix 1 66 efficacy.reported.in.meta-analyses?.Lancet. 1998;352:609\u201313. 14.. Adour.KK,.Ruboyianes.JM,.Von.Doeersten.PG,.Byl. FM,.Trent.CS,.Queensberry.CP,.et al..Bell\u2019s.palsy. treatment.with.acyclovir.and.prednisone.compared. with.prednisone.alone:.a.double-blind,.randomised,.","cites":null},{"id":6013173,"title":"Utilities.Index..Pharmacoeconomics 1995;7:490\u2013502. 25.. Information.and.Statistics.Division..ISD Scotland Guide: an","authors":[],"date":null,"doi":"10.2165\/00019053-199507060-00004","raw":"24.. Feeny.D,.Furlong.W,.Boyle.M,.Torrance.GW..Multiattribute.health.status.classification.systems..Health. Utilities.Index..Pharmacoeconomics 1995;7:490\u2013502. 25.. Information.and.Statistics.Division..ISD Scotland Guide: an A-Z of the work of the Information & Statistics Division..Edinburgh:.Information.&.Statistics.","cites":null},{"id":6013174,"title":"Queen\u2019s Printer and Controller of HMSO. All rights reserved. 67 A. Trial.Steering.Committee.(TSC).should.be.set. up.with.the.following.terms.of.reference: Terms of reference 1..","authors":[],"date":"2009","doi":null,"raw":"Division;.1996.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 67 A. Trial.Steering.Committee.(TSC).should.be.set. up.with.the.following.terms.of.reference: Terms of reference 1.. To.monitor.and.supervise.the.progress.of.the. trial.towards.its.interim.and.overall.objectives. 2.. To.review.at.regular.intervals.relevant. information.from.other.sources.(e.g..other. related.trials). 3.. To.consider.the.recommendations.of.the.Data. Monitoring.and.Ethics.Committee.(DMEC). 4.. To.advise.on.publicity.and.the.presentation.of. all.aspects.of.the.trial. Membership of TSC The.membership.should.be.limited.and.include. an.independent.Chairman.(not.involved.directly. with.the.trial.other.than.as.a.member.of.the. TSC),.two.or.more.other.independent.expert. members.and.the.Principal.Investigator..Where. possible.the.membership.should.include.a.lay\/ consumer.representative..The.trial.co-ordinator,. trial.statistician,.etc.,.should.attend.meetings.as. appropriate..Observers.from.the.Host.Institution. may.be.invited.to.all.meetings. Guidance notes Meetings Before.the.trial.starts,.the.PI.should.organise.a. meeting.of.the.TSC.to.finalise.the.protocol..The. TSC.should.then.meet.at.least.annually,.although. there.may.be.periods.when.more.frequent.meetings. are.necessary..Meetings.should.be.organised.by.the. PI..Papers.for.the.meeting.should.be.circulated.in. advance..An.accurate.minute.should.be.prepared. by.the.PI.and.agreed.by.all.the.members. Trial steering and management The.role.of.the.TSC.is.to.provide.overall. supervision.of.the.trial..In.particular,.the.TSC. should.concentrate.on.the.progress.of.the.trial,. adherence.to.the.protocol,.patient.safety.and. consideration.of.new.information..Day-to-day. management.of.the.trial.is.the.responsibility.of. the.PI..The.PI.may.wish.to.set.up.a.separate.Trial. Management.Group.to.assist.with.this.function. Good clinical practice The.TSC.should.endeavour.to.ensure.that.the.trial. is.conducted.at.all.times.to.the.standards.set.out. in.the.MRC.Guidelines.for.Good.Clinical.Practice. (GCP). Patient safety In.all.the.deliberations.of.the.TSC.the.rights,.safety. and.well-being.of.the.trial.participants.are.the.most. important.considerations..The.TSC.should.ensure. that.freely.given.informed.consent.is.obtained.from. each.trial.participant..The.TSC.should.advise.the. investigators.on.the.completeness.and.suitability.of. the.patient.information.provided. Progress of the trial It.is.the.role.of.the.TSC.to.monitor.the.progress. of.the.trial.and.to.maximise.the.chances.of. completing.the.trial.within.the.agreed.time.scale.. At.the.first.TSC.meeting,.targets.for.recruitment,. data.collection,.compliance,.etc.,.should.be.agreed. with.the.PI..Based.on.these.targets,.the.TSC.should. agree.a.set.of.data.that.should.be.presented.at.each. meeting.(see.template). The.PI.is.required.to.submit.an.annual.report. to.HTA..This.report.should.be.endorsed.by.the. TSC,.should.stand.alone,.and.contain.sufficient. information.to.enable.HTA.to.assess.the.progress. of.the.trial.without.the.need.to.refer.back.to.the. original.application..The.annual.report.should. inform.HTA.of.any.new.information.that.has.a. bearing.on.safety.or.ethical.acceptability.of.the. trial.or.any.significant.complaints.arising,.with.a. justification.of.the.decisions.taken. The.DMEC.should.be.asked.to.advise.the.TSC,. and.may.be.required.to.provide.information.on. the.availability.of.data.collected.to.date.(from.this. and.other.studies).and.advice.on.the.likelihood. that.continuation.of.the.trial.will.allow.detection. of.an.important.effect..This.should.be.done.using. methods.that.do.not.unblind.the.trial. Adherence to protocol The.full.protocol.should.be.presented.and.agreed. at.the.first.TSC.meeting..Any.subsequent.changes. to.the.protocol.must.be.approved.by.the.TSC,. LREC\/MREC.(and.by.HTA). Appendix 2 Trial Steering CommitteeAppendix 2 68 Data Monitoring and Ethics Committee At.its.first.meeting,.the.TSC.should.establish.a.Data. Monitoring.and.Ethics.Committee.(DMEC).that. meets.regularly.to.review.the.data.and.results.of. any.interim.analyses. Members.of.the.DMEC.should.be.independent.of. both.the.trial.and.TSC. Consideration of new information The.TSC.should.consider.new.information.relevant. to.the.trial.including.reports.from.the.DMEC..It. is.the.responsibility.of.the.PI,.the.Chairman.and. other.independent.members.to.bring.results.from. other.studies.that.may.have.a.direct.bearing.on. future.conduct.of.the.trial.to.the.attention.of.the. TSC. On.consideration.of.this.information.the.TSC. should.recommend.appropriate.action,.such. as.changes.to.the.protocol,.additional.patient. information,.or.stopping.the.trial..The.rights,. safety.and.well-being.of.the.trial.participants. should.be.the.most.important.consideration. It.is.the.responsibility.of.the.PI.to.notify.the. TSC,.DMEC.and.relevant.regulatory.authority.(if. applicable).immediately.of.any.unexpected.serious. adverse.events.occurring.during.the.course.of.the. trial. Template for Trial Steering Committee agendas and reports The.TSC.should.meet.at.least.once.a.year.and. compose.an.annual.report. The.table.below.outlines.the.information.that. should.be.provided.by.the.PI.at.each.meeting..This. template.should.be.used.as.a.basis.for.the.agenda. of.TSC.meetings.and.a.template.for.the.annual. report..These.headings.may.not.be.appropriate.at. every.stage.of.an.individual.trial,.or.for.all.trials.","cites":null},{"id":6013186,"title":"Queen\u2019s Printer and Controller of HMSO. All rights reserved. 87 Appendix 9 Form AAppendix 9 88 Scottish Bell\u2019s Palsy Study \u2018BELLS\u2019 Patient case record form Form A v.8 dated 19th","authors":[],"date":"2009","doi":null,"raw":"part.in.it..Individuals.will.not.be.identified.in.any.report.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 87 Appendix 9 Form AAppendix 9 88 Scottish Bell\u2019s Palsy Study \u2018BELLS\u2019  Patient case record form Form A v.8 dated 19th April 2004 Patient number (allocated by HSRU) 2 6 0 4  __  __  __   To be completed by the consultant\/ registrar\/ SHO on arrival of any patient presenting at the Acute Receiving Clinic with a possible Bell\u2019s Palsy. Section 1    This section is to be completed for all patients. Patient name title  forename  surname Address   postcode Telephone day  evening  mobile  Date of birth day \/ month \/ year  Sex m\/f Who sent the patient here? e.g. GP \/ A&E \/ NHS24 \/ dentist \/ patient\u2019s own decision \/ other Name (consultant\/registrar\/SHO) title  initial(s)  surname  In your opinion does this patient have Bell\u2019s palsy? yes  no  If your answer is NO, complete the next box, sign and date the form and STOP. File the form. Otherwise, leave the next box entirely BLANK and proceed directly to Section 2. Diagnosis Signature and date signature  date","cites":null},{"id":6013187,"title":"Patient number (allocated by","authors":[],"date":"2009","doi":"10.1787\/comms_outlook-2009-table5_10-en","raw":"Patient number (allocated by HSRU)  2 6 0 4  __  __  __ 1 or 2 or 3 or 4 Signature and date signature  date DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 91 Appendix 10 Consent formAppendix 10 92 Scottish Bell\u2019s Palsy Study  Consent Form  v.6 dated 18th November 2003   Scottish Bell\u2019s Palsy Study \u2018BELLS\u2019 Consent Form Initials I confirm that I have read and understand the BELLS Patient Information Sheet, and that I have had the opportunity to ask questions.   I understand that my participation is voluntary, and that I am free to withdraw from the study at any time, without giving any reason, and without my medical care or legal rights being affected.  I understand that sections of my medical notes may be looked at by responsible persons associated with the study, or by regulatory authorities where it is relevant to my taking part in the research. I give permission for these persons to have access to my records.  I understand that I may be approached for follow-up information, after my final assessment visit, by responsible persons associated with the study, and I give permission for such an approach to be made.  I agree to take part in the BELLS Study.    Name of patient (print)   Date  Signature Name of person taking consent (who should witness the patient\u2019s signature)","cites":null},{"id":6013188,"title":"advise the BELLS Coordinator IMMEDIATELY that a new patient has been recruited, and provide the patient\u2019s name, address and telephone number: f.daly@tcgp.dundee.ac.uk 01382 000000 (W) \/ 01738 000000 (H) \/ 0771 000 0000 (M) DOI:","authors":[],"date":"2009","doi":null,"raw":"(iii)  Please advise the BELLS Coordinator IMMEDIATELY that a new patient has been recruited, and provide the patient\u2019s name, address and telephone number: f.daly@tcgp.dundee.ac.uk 01382 000000 (W) \/ 01738 000000 (H) \/ 0771 000 0000 (M) DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 97 Appendix 12 Recruiters\u2019 notesAppendix 12 98 You.probably.already.know.that.your.hospital.is.one.of.17.sites.in.Scotland.that.is.contributing.to.a. NHS-funded.national.study,.aimed.at.establishing.once.and.for.all.the.effectiveness.or.otherwise.of. prednisolone\/aciclovir.separately.or.in.combination.as.treatments.for.Bell\u2019s.palsy. The.stationery.for.the.study \u2022. patient.information.sheet.(for.issue) \u2022. patient.case.record.form.(\u2018Form.A\u2019,.for.completion.and.filing) \u2022. consent.form.(for.signature.and.filing) is.already.provided.at.your.site,.as.are.the.medications,.labelled \u2022. Treatment.1.or.2.or.3.or.4 There.is.also.a \u2022. laminated.telephone.dialling.instruction.sheet explaining.the.procedures.for.registration.and.randomisation.to.treatment..If.a.patient.with.suspected. Bell\u2019s.palsy.presents.at.your.clinic.(usually.though.not.necessarily.as.a.referral.from.their.GP).then.please. explain.that.this.important.national.study.is.in.progress,.and \u2022. complete.Form.A.(confirmation.of.diagnosis,.inclusions\/exclusions) \u2022. if.patient.is.eligible.and.interested,.issue.Patient.Information.Sheet \u2022. if.appropriate,.get.signatures.on.Consent.Form then \u2022. complete.registration.and.randomisation.to.treatment by \u2022. dialling.HSRU.at.0800.000000.and.following.instructions Two things might go wrong: \u2022. If for some reason the allocated treatment pack is not available to you, please do not make a 2nd call to HSRU; simply allocate at random from the treatments available to you and note your decision on Form A.","cites":null},{"id":6013189,"title":"After all visits send letters to GP and patient, keep copies despatch original completed questionnaires to TCGP, keep copies email photographs to TCGP DOI:","authors":[],"date":"2009","doi":null,"raw":"After all visits  send letters to GP and patient, keep copies despatch original completed questionnaires to TCGP, keep copies email photographs to TCGP DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 109 Appendix 16 Form BAppendix 16 110 Scottish Bell\u2019s Palsy Study \u2018BELLS\u2019 Patient visit record Form B Patient number (allocated by HSRU) 2  6  __  __  __  __  __  To be completed by the researcher at the patient\u2019s first assessment visit title  used name  surname Name all forenames Personal details sex  date of birth marital status mother\u2019s maiden name Other details required for General Register Office for Scotland any previous surnames address     postcode Contact details previous address and postcode if present < 3 years     Telephone numbers  work  home  mobile  Email address Consent details date of consent  age at consent Details of onset date \/ time (approx)  symptoms GP\u2019s name and address      Treatment interval start date  end date Arrangements for 3-month visit date \/ time  place Researcher name  today\u2019s date DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 111 Mr.Iain.Swan,.Glasgow.Royal.Infirmary Dr.Richard.Davenport,.Western.General.Hospital,.Edinburgh Mr.Ken.Stewart,.St.John\u2019s.Hospital,.Livingston Appendix 17 House\u2013Brackmann AssessorsDOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 113 Appendix 18 Health Utilities Index Mark 3Appendix 18 114  Scottish Bell\u2019s Palsy Study  HEALTH  UTILITIES  INDEX:  Multi-Attribute Health Status Classification System Health Utilities Index Mark 3 (HUI3)     Patient name  Patient ID    _ _ _ _ _ _ _  Date  Assessment visit no.  Researcher   For the given attribute, circle the most appropriate level. Provide only one answer for each attribute  VISION  1  Able to see well enough to read ordinary newsprint and recognize a friend on the other side of the street, without glasses or contact lenses. 2  Able to see well enough to read ordinary newsprint and recognize a friend on the other side of the street, but with glasses. 3  Able to read ordinary newsprint with or without glasses but unable to recognize a friend on the other side of the street, even with glasses. 4  Able to recognize a friend on the other side of the street with or without glasses but unable to read ordinary newsprint, even with glasses. 5  Unable to read ordinary newsprint and unable to recognize a friend on the other side of the street, even with glasses. 6  Unable to see at all.","cites":null},{"id":6013190,"title":"Queen\u2019s Printer and Controller of HMSO. All rights reserved. 121 F o r Q u e s t i o n s 6 t o 1 2 c i r c l e o n e n u m b e r o n l y t h a t d e s c r i b e s h o w","authors":[],"date":"2009","doi":null,"raw":"DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 121    F o r  Q u e s t i o n s  6  t o  1 2  c i r c l e  o n e  n u m b e r  o n l y  t h a t  d e s c r i b e s  h o w  D U R I N G  T H E  L A S T  2 4  H O U R S  y o u r  p a i n  h a s  i n t e r f e r e d  w i t h  y o u r  l i f e  f r o m  0  ( D O E S  N O T  I N T E R F E R E )  t o  1 0  ( I N T E R F E R E S  C O M P L E T E L Y )   Q u e s t i o n  6     G e n e r a l  a c t i v i t y   0         1         2         3         4         5         6         7         8         9         1 0   Q u e s t i o n  7     M o o d   0         1         2         3         4         5         6         7         8         9         1 0   Q u e s t i o n  8     W a l k i n g  a b i l i t y   0         1         2         3         4         5         6         7         8         9         1 0   Q u e s t i o n  9     N o r m a l  w o r k  ( i n c l u d e s  b o t h  w o r k  o u t s i d e  t h e  h o m e  a n d  h o u s e w o r k )   0         1         2         3         4         5         6         7         8         9         1 0      R e m e m b e r ,  f o r  t h e s e  q u e s t i o n s  c i r c l e  o n e  n u m b e r  o n l y  t h a t  d e s c r i b e s  h o w  D U R I N G  T H E  L A S T  2 4  H O U R S  y o u r  p a i n  h a s  i n t e r f e r e d  w i t h  y o u r  l i f e  f r o m  0  ( D O E S  N O T  I N T E R F E R E )  t o  1 0  ( I N T E R F E R E S  C O M P L E T E L Y )   Q u e s t i o n  1 0     R e l a t i o n s  w i t h  o t h e r  p e o p l e   0         1         2         3         4         5         6         7         8         9         1 0   Q u e s t i o n  1 1     S l e e p   0         1         2         3         4         5         6         7         8         9         1 0   Q u e s t i o n  1 2     E n j o y m e n t  o f  l i f e   0         1         2         3         4         5         6         7         8         9         1 0      T h a n k  y o u  v e r y  m u c h  f o r  h e l p i n g  u s  b y  p r o v i d i n g  y o u r  a n s w e r s  t o  t h i s  q u e s t i o n n a i r e","cites":null},{"id":6013193,"title":"52 How confident do you feel?","authors":[],"date":"2009","doi":null,"raw":"IN GENERAL 52  How confident do you feel?   1  2  3  4  5 53  How irritable do you feel?   1  2  3  4  5 54  How secure do you feel?   1  2  3  4  5 55  How cheerful do you feel?   1  2  3  4  5 56  How normal do you feel?   1  2  3  4  5 57  How feminine \/ masculine do you feel?   1  2  3  4  5 58  How hurt do you feel?   1  2  3  4  5 59  How hostile do you feel?   1  2  3  4  5 DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 127 Appendix 21 Patient deaths on the BELLS study Patient reference 2613014 Date.of.Consent.to.BELLS.study. 27.03.2005. Site. Monklands.Hospital.Airdrie.","cites":null},{"id":6013201,"title":"Assessment reports published to date 134","authors":[],"date":"2001","doi":null,"raw":"Golder.S,.Kleijnen.J,.ter.Riet.G.Health Technology Assessment reports published to date 134 No. 31 A.randomised.controlled.trial. of.prehospital.intravenous.fluid. replacement.therapy.in.serious.trauma. By.Turner.J,.Nicholl.J,.Webber.L,. Cox.H,.Dixon.S,.Yates.D. No. 32 Intrathecal.pumps.for.giving.opioids.in. chronic.pain:.a.systematic.review. By.Williams.JE,.Louw.G,. Towlerton.G. No. 33 Combination.therapy.(interferon. alfa.and.ribavirin).in.the.treatment. of.chronic.hepatitis.C:.a.rapid.and. systematic.review. By.Shepherd.J,.Waugh.N,. Hewitson.P. No. 34 A.systematic.review.of.comparisons.of. effect.sizes.derived.from.randomised. and.non-randomised.studies. By.MacLehose.RR,.Reeves.BC,. Harvey.IM,.Sheldon.TA,.Russell.IT,. Black.AMS. No. 35 Intravascular.ultrasound-guided. interventions.in.coronary.artery. disease:.a.systematic.literature.review,. with.decision-analytic.modelling,.of. outcomes.and.cost-effectiveness. By.Berry.E,.Kelly.S,.Hutton.J,. Lindsay.HSJ,.Blaxill.JM,.Evans.JA,.et al. No. 36 A.randomised.controlled.trial.to. evaluate.the.effectiveness.and.costeffectiveness.of.counselling.patients. with.chronic.depression. By.Simpson.S,.Corney.R,. Fitzgerald.P,.Beecham.J. No. 37 Systematic.review.of.treatments.for. atopic.eczema. By.Hoare.C,.Li.Wan.Po.A,. Williams.H. No. 38 Bayesian.methods.in.health.technology. assessment:.a.review. By.Spiegelhalter.DJ,.Myles.JP,. Jones.DR,.Abrams.KR. No. 39 The.management.of.dyspepsia:.a. systematic.review. By.Delaney.B,.Moayyedi.P,.Deeks.J,. Innes.M,.Soo.S,.Barton.P,.et al. No. 40 A.systematic.review.of.treatments.for. severe.psoriasis. By.Griffiths.CEM,.Clark.CM,. Chalmers.RJG,.Li.Wan.Po.A,. Williams.HC. Volume 5, 2001 No. 1 Clinical.and.cost-effectiveness. of.donepezil,.rivastigmine.and. galantamine.for.Alzheimer\u2019s.disease:.a. rapid.and.systematic.review. By.Clegg.A,.Bryant.J,.Nicholson.T,. McIntyre.L,.De.Broe.S,.Gerard.K,.et al. No. 2 The.clinical.effectiveness.and.costeffectiveness.of.riluzole.for.motor. neurone.disease:.a.rapid.and.systematic. review. By.Stewart.A,.Sandercock.J,.Bryan.S,. Hyde.C,.Barton.PM,.Fry-Smith.A,.et al. No. 3 Equity.and.the.economic.evaluation.of. healthcare. By.Sassi.F,.Archard.L,.Le.Grand.J. No. 4 Quality-of-life.measures.in.chronic. diseases.of.childhood. By.Eiser.C,.Morse.R. No. 5 Eliciting.public.preferences.for. healthcare:.a.systematic.review.of techniques. By.Ryan.M,.Scott.DA,.Reeves.C,.Bate. A,.van.Teijlingen.ER,.Russell.EM,.et al. No. 6 General.health.status.measures.for. people.with.cognitive.impairment:. learning.disability.and.acquired.brain. injury. By.Riemsma.RP,.Forbes.CA,. Glanville.JM,.Eastwood.AJ,.Kleijnen.J. No. 7 An.assessment.of.screening.strategies. for.fragile.X.syndrome.in.the.UK. By.Pembrey.ME,.Barnicoat.AJ,. Carmichael.B,.Bobrow.M,.Turner.G. No. 8 Issues.in.methodological.research:. perspectives.from.researchers.and. commissioners. By.Lilford.RJ,.Richardson.A,.Stevens. A,.Fitzpatrick.R,.Edwards.S,.Rock.F,.et al. No. 9 Systematic.reviews.of.wound. care.management:.(5).beds;. (6).compression;.(7).laser.therapy,. therapeutic.ultrasound,.electrotherapy. and.electromagnetic.therapy. By.Cullum.N,.Nelson.EA,. Flemming.K,.Sheldon.T. No. 10 Effects.of.educational.and.psychosocial. interventions.for.adolescents.with. diabetes.mellitus:.a.systematic.review. By.Hampson.SE,.Skinner.TC,.Hart.J,. Storey.L,.Gage.H,.Foxcroft.D,.et al. No. 11 Effectiveness.of.autologous.chondrocyte. transplantation.for.hyaline.cartilage. defects.in.knees:.a.rapid.and.systematic. review. By.Jobanputra.P,.Parry.D,.Fry-Smith. A,.Burls.A. No. 12 Statistical.assessment.of.the.learning. curves.of.health.technologies. By.Ramsay.CR,.Grant.AM,.Wallace. SA,.Garthwaite.PH,.Monk.AF,.Russell.IT. No. 13 The.effectiveness.and.cost-effectiveness. of.temozolomide.for.the.treatment.of. recurrent.malignant.glioma:.a.rapid. and.systematic.review. By.Dinnes.J,.Cave.C,.Huang.S,. Major.K,.Milne.R. No. 14 A.rapid.and.systematic.review.of. the.clinical.effectiveness.and.costeffectiveness.of.debriding.agents.in. treating.surgical.wounds.healing.by. secondary.intention. By.Lewis.R,.Whiting.P,.ter.Riet.G,. O\u2019Meara.S,.Glanville.J. No. 15 Home.treatment.for.mental.health. problems:.a.systematic.review. By.Burns.T,.Knapp.M,.Catty.J,. Healey.A,.Henderson.J,.Watt.H,.et al. No. 16 How.to.develop.cost-conscious. guidelines. By.Eccles.M,.Mason.J. No. 17 The.role.of.specialist.nurses.in.multiple. sclerosis:.a.rapid.and.systematic.review. By.De.Broe.S,.Christopher.F,. Waugh.N. No. 18 A.rapid.and.systematic.review. of.the.clinical.effectiveness.and. cost-effectiveness.of.orlistat.in.the. management.of.obesity. By.O\u2019Meara.S,.Riemsma.R,. Shirran.L,.Mather.L,.ter.Riet.G. No. 19 The.clinical.effectiveness.and.costeffectiveness.of.pioglitazone.for. type.2.diabetes.mellitus:.a.rapid.and. systematic.review. By.Chilcott.J,.Wight.J,.Lloyd.Jones. M,.Tappenden.P. No. 20 Extended.scope.of.nursing.practice:. a.multicentre.randomised.controlled. trial.of.appropriately.trained.nurses. and.preregistration.house.officers.in. preoperative.assessment.in.elective. general.surgery. By.Kinley.H,.Czoski-Murray.C,.","cites":null},{"id":6013202,"title":"Reilly.C,.et al.DOI: 10.3310\/hta13470 Health Technology Assessment","authors":[],"date":"2009","doi":null,"raw":"George.S,.McCabe.C,.Primrose.J,. Reilly.C,.et al.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 135 No. 21 Systematic.reviews.of.the.effectiveness. of.day.care.for.people.with.severe. mental.disorders:.(1).Acute.day.hospital. versus.admission;.(2).Vocational. rehabilitation;.(3).Day.hospital.versus. outpatient.care. By.Marshall.M,.Crowther.R,. Almaraz-.Serrano.A,.Creed.F,.Sledge.W,. Kluiter.H,.et al. No. 22 The.measurement.and.monitoring.of. surgical.adverse.events. By.Bruce.J,.Russell.EM,.Mollison.J,. Krukowski.ZH. No. 23 Action.research:.a.systematic.review.and. guidance.for.assessment. By.Waterman.H,.Tillen.D,.Dickson.R,. de.Koning.K. No. 24 A.rapid.and.systematic.review.of. the.clinical.effectiveness.and.costeffectiveness.of.gemcitabine.for.the. treatment.of.pancreatic.cancer. By.Ward.S,.Morris.E,.Bansback.N,. Calvert.N,.Crellin.A,.Forman.D,.et al. No. 25 A.rapid.and.systematic.review.of.the. evidence.for.the.clinical.effectiveness. and.cost-effectiveness.of.irinotecan,. oxaliplatin.and.raltitrexed.for.the. treatment.of.advanced.colorectal. cancer. By.Lloyd.Jones.M,.Hummel.S,. Bansback.N,.Orr.B,.Seymour.M. No. 26 Comparison.of.the.effectiveness.of. inhaler.devices.in.asthma.and.chronic. obstructive.airways.disease:.a.systematic. review.of.the.literature. By.Brocklebank.D,.Ram.F,.Wright.J,. Barry.P,.Cates.C,.Davies.L,.et al. No. 27 The.cost-effectiveness.of.magnetic. resonance.imaging.for.investigation.of. the.knee.joint. By.Bryan.S,.Weatherburn.G,.Bungay. H,.Hatrick.C,.Salas.C,.Parry.D,.et al. No. 28 A.rapid.and.systematic.review.of. the.clinical.effectiveness.and.costeffectiveness.of.topotecan.for.ovarian. cancer. By.Forbes.C,.Shirran.L,.Bagnall.A-M,. Duffy.S,.ter.Riet.G. No. 29 Superseded.by.a.report.published.in.a. later.volume. No. 30 The.role.of.radiography.in.primary. care.patients.with.low.back.pain.of.at. least.6.weeks.duration:.a.randomised. (unblinded).controlled.trial. By.Kendrick.D,.Fielding.K,.Bentley. E,.Miller.P,.Kerslake.R,.Pringle.M. No. 31 Design.and.use.of.questionnaires:.a. review.of.best.practice.applicable.to. surveys.of.health.service.staff.and. patients. By.McColl.E,.Jacoby.A,.Thomas.L,. Soutter.J,.Bamford.C,.Steen.N,.et al. No. 32 A.rapid.and.systematic.review.of. the.clinical.effectiveness.and.costeffectiveness.of.paclitaxel,.docetaxel,. gemcitabine.and.vinorelbine.in.nonsmall-cell.lung.cancer. By.Clegg.A,.Scott.DA,.Sidhu.M,. Hewitson.P,.Waugh.N. No. 33 Subgroup.analyses.in.randomised. controlled.trials:.quantifying.the.risks. of.false-positives.and.false-negatives. By.Brookes.ST,.Whitley.E,.Peters.TJ,. Mulheran.PA,.Egger.M,.Davey.Smith.G. No. 34 Depot.antipsychotic.medication. in.the.treatment.of.patients.with. schizophrenia:.(1).Meta-review;.(2). Patient.and.nurse.attitudes. By.David.AS,.Adams.C. No. 35 A.systematic.review.of.controlled. trials.of.the.effectiveness.and.costeffectiveness.of.brief.psychological. treatments.for.depression. By.Churchill.R,.Hunot.V,.Corney.R,. Knapp.M,.McGuire.H,.Tylee.A,.et al. No. 36 Cost.analysis.of.child.health. surveillance. By.Sanderson.D,.Wright.D,.Acton.C,. Duree.D. Volume 6, 2002 No. 1 A.study.of.the.methods.used.to.select. review.criteria.for.clinical.audit. By.Hearnshaw.H,.Harker.R,. Cheater.F,.Baker.R,.Grimshaw.G. No. 2 Fludarabine.as.second-line.therapy.for. B.cell.chronic.lymphocytic.leukaemia:.a. technology.assessment. By.Hyde.C,.Wake.B,.Bryan.S,.Barton. P,.Fry-Smith.A,.Davenport.C,.et al. No. 3 Rituximab.as.third-line.treatment.for. refractory.or.recurrent.Stage.III.or.IV. follicular.non-Hodgkin\u2019s.lymphoma:. a.systematic.review.and.economic. evaluation. By.Wake.B,.Hyde.C,.Bryan.S,.Barton. P,.Song.F,.Fry-Smith.A,.et al. No. 4 A.systematic.review.of.discharge. arrangements.for.older.people. By.Parker.SG,.Peet.SM,.McPherson. A,.Cannaby.AM,.Baker.R,.Wilson.A,.et al. No. 5 The.clinical.effectiveness.and.costeffectiveness.of.inhaler.devices.used. in.the.routine.management.of.chronic. asthma.in.older.children:.a.systematic. review.and.economic.evaluation. By.Peters.J,.Stevenson.M,.Beverley.C,. Lim.J,.Smith.S. No. 6 The.clinical.effectiveness.and.costeffectiveness.of.sibutramine.in.the. management.of.obesity:.a.technology. assessment. By.O\u2019Meara.S,.Riemsma.R,.Shirran. L,.Mather.L,.ter.Riet.G. No. 7 The.cost-effectiveness.of.magnetic. resonance.angiography.for.carotid. artery.stenosis.and.peripheral.vascular. disease:.a.systematic.review. By.Berry.E,.Kelly.S,.Westwood.ME,. Davies.LM,.Gough.MJ,.Bamford.JM,. et al. No. 8 Promoting.physical.activity.in.South. Asian.Muslim.women.through.\u2018exercise. on.prescription\u2019. By.Carroll.B,.Ali.N,.Azam.N. No. 9 Zanamivir.for.the.treatment.of. influenza.in.adults:.a.systematic.review. and.economic.evaluation. By.Burls.A,.Clark.W,.Stewart.T,. Preston.C,.Bryan.S,.Jefferson.T,.et al. No. 10 A.review.of.the.natural.history.and. epidemiology.of.multiple.sclerosis:. implications.for.resource.allocation.and. health.economic.models. By.Richards.RG,.Sampson.FC,. Beard.SM,.Tappenden.P. No. 11 Screening.for.gestational.diabetes:. a.systematic.review.and.economic. evaluation. By.Scott.DA,.Loveman.E,.McIntyre. L,.Waugh.N. No. 12 The.clinical.effectiveness.and.costeffectiveness.of.surgery.for.people.with. morbid.obesity:.a.systematic.review.and. economic.evaluation. By.Clegg.AJ,.Colquitt.J,.Sidhu.MK,. Royle.P,.Loveman.E,.Walker.A. No. 13 The.clinical.effectiveness.of. trastuzumab.for.breast.cancer:.a. systematic.review. By.Lewis.R,.Bagnall.A-M,.Forbes.C,. Shirran.E,.Duffy.S,.Kleijnen.J,.et al. No. 14 The.clinical.effectiveness.and.costeffectiveness.of.vinorelbine.for.breast. cancer:.a.systematic.review.and. economic.evaluation.","cites":null},{"id":6013203,"title":"Woolacott.N,.Forbes.C,.Shirran.L,.et al.Health Technology Assessment reports published to date 136","authors":[],"date":"2003","doi":null,"raw":"By.Lewis.R,.Bagnall.A-M,.King.S,. Woolacott.N,.Forbes.C,.Shirran.L,.et al.Health Technology Assessment reports published to date 136 No. 15 A.systematic.review.of.the.effectiveness. and.cost-effectiveness.of.metal-onmetal.hip.resurfacing.arthroplasty.for. treatment.of.hip.disease. By.Vale.L,.Wyness.L,.McCormack.K,. McKenzie.L,.Brazzelli.M,.Stearns.SC. No. 16 The.clinical.effectiveness.and.costeffectiveness.of.bupropion.and.nicotine. replacement.therapy.for.smoking. cessation:.a.systematic.review.and. economic.evaluation. By.Woolacott.NF,.Jones.L,.Forbes.CA,. Mather.LC,.Sowden.AJ,.Song.FJ,.et al. No. 17 A.systematic.review.of.effectiveness. and.economic.evaluation.of.new.drug. treatments.for.juvenile.idiopathic. arthritis:.etanercept. By.Cummins.C,.Connock.M,. Fry-Smith.A,.Burls.A. No. 18 Clinical.effectiveness.and.costeffectiveness.of.growth.hormone.in. children:.a.systematic.review.and. economic.evaluation. By.Bryant.J,.Cave.C,.Mihaylova.B,. Chase.D,.McIntyre.L,.Gerard.K,.et al. No. 19 Clinical.effectiveness.and.costeffectiveness.of.growth.hormone. in.adults.in.relation.to.impact.on. quality.of.life:.a.systematic.review.and. economic.evaluation. By.Bryant.J,.Loveman.E,.Chase.D,. Mihaylova.B,.Cave.C,.Gerard.K,.et al. No. 20 Clinical.medication.review.by.a. pharmacist.of.patients.on.repeat. prescriptions.in.general.practice:.a. randomised.controlled.trial. By.Zermansky.AG,.Petty.DR,.Raynor. DK,.Lowe.CJ,.Freementle.N,.Vail.A. No. 21 The.effectiveness.of.infliximab.and. etanercept.for.the.treatment.of. rheumatoid.arthritis:.a.systematic. review.and.economic.evaluation. By.Jobanputra.P,.Barton.P,.Bryan.S,. Burls.A. No. 22 A.systematic.review.and.economic. evaluation.of.computerised.cognitive. behaviour.therapy.for.depression.and. anxiety. By.Kaltenthaler.E,.Shackley.P,. Stevens.K,.Beverley.C,.Parry.G,. Chilcott.J. No. 23 A.systematic.review.and.economic. evaluation.of.pegylated.liposomal. doxorubicin.hydrochloride.for.ovarian. cancer. By.Forbes.C,.Wilby.J,.Richardson.G,. Sculpher.M,.Mather.L,.Reimsma.R. No. 24 A.systematic.review.of.the.effectiveness. of.interventions.based.on.a.stages-ofchange.approach.to.promote.individual. behaviour.change. By.Riemsma.RP,.Pattenden.J,.Bridle. C,.Sowden.AJ,.Mather.L,.Watt.IS,.et al. No. 25 A.systematic.review.update.of.the. clinical.effectiveness.and.costeffectiveness.of.glycoprotein.IIb\/IIIa. antagonists. By.Robinson.M,.Ginnelly.L,.Sculpher. M,.Jones.L,.Riemsma.R,.Palmer.S,.et al. No. 26 A.systematic.review.of.the.effectiveness,. cost-effectiveness.and.barriers.to. implementation.of.thrombolytic.and. neuroprotective.therapy.for.acute. ischaemic.stroke.in.the.NHS. By.Sandercock.P,.Berge.E,.Dennis.M,. Forbes.J,.Hand.P,.Kwan.J,.et al. No. 27 A.randomised.controlled.crossover.trial. of.nurse.practitioner.versus.doctorled.outpatient.care.in.a.bronchiectasis. clinic. By.Caine.N,.Sharples.LD,. Hollingworth.W,.French.J,.Keogan.M,. Exley.A,.et al. No. 28 Clinical.effectiveness.and.cost.\u2013. consequences.of.selective.serotonin. reuptake.inhibitors.in.the.treatment.of. sex.offenders. By.Adi.Y,.Ashcroft.D,.Browne.K,. Beech.A,.Fry-Smith.A,.Hyde.C. No. 29 Treatment.of.established.osteoporosis:. a.systematic.review.and.cost\u2013utility. analysis. By.Kanis.JA,.Brazier.JE,.Stevenson. M,.Calvert.NW,.Lloyd.Jones.M. No. 30 Which.anaesthetic.agents.are.costeffective.in.day.surgery?.Literature. review,.national.survey.of.practice.and. randomised.controlled.trial. By.Elliott.RA.Payne.K,.Moore.JK,. Davies.LM,.Harper.NJN,.St.Leger.AS,. et al. No. 31 Screening.for.hepatitis.C.among. injecting.drug.users.and.in. genitourinary.medicine.clinics:. systematic.reviews.of.effectiveness,. modelling.study.and.national.survey.of. current.practice. By.Stein.K,.Dalziel.K,.Walker.A,. McIntyre.L,.Jenkins.B,.Horne.J, et al. No. 32 The.measurement.of.satisfaction.with. healthcare:.implications.for.practice. from.a.systematic.review.of.the. literature. By.Crow.R,.Gage.H,.Hampson.S,. Hart.J,.Kimber.A,.Storey.L,.et al. No. 33 The.effectiveness.and.cost-effectiveness. of.imatinib.in.chronic.myeloid. leukaemia:.a.systematic.review. By.Garside.R,.Round.A,.Dalziel.K,. Stein.K,.Royle.R. No. 34 A.comparative.study.of.hypertonic. saline,.daily.and.alternate-day.rhDNase. in.children.with.cystic.fibrosis. By.Suri.R,.Wallis.C,.Bush.A,. Thompson.S,.Normand.C,.Flather.M,. et al. No. 35 A.systematic.review.of.the.costs.and. effectiveness.of.different.models.of. paediatric.home.care. By.Parker.G,.Bhakta.P,.Lovett.CA,. Paisley.S,.Olsen.R,.Turner.D,.et al. Volume 7, 2003 No. 1 How.important.are.comprehensive. literature.searches.and.the.assessment. of.trial.quality.in.systematic.reviews?. Empirical.study. By.Egger.M,.Ju\u0308ni.P,.Bartlett.C,. Holenstein.F,.Sterne.J. No. 2 Systematic.review.of.the.effectiveness. and.cost-effectiveness,.and.economic. evaluation,.of.home.versus.hospital.or. satellite.unit.haemodialysis.for.people. with.end-stage.renal.failure. By.Mowatt.G,.Vale.L,.Perez.J,.Wyness. L,.Fraser.C,.MacLeod.A,.et al. No. 3 Systematic.review.and.economic. evaluation.of.the.effectiveness.of. infliximab.for.the.treatment.of.Crohn\u2019s. disease. By.Clark.W,.Raftery.J,.Barton.P,. Song.F,.Fry-Smith.A,.Burls.A. No. 4 A.review.of.the.clinical.effectiveness. and.cost-effectiveness.of.routine.anti-D. prophylaxis.for.pregnant.women.who. are.rhesus.negative. By.Chilcott.J,.Lloyd.Jones.M,.Wight. J,.Forman.K,.Wray.J,.Beverley.C,.et al. No. 5 Systematic.review.and.evaluation.of.the. use.of.tumour.markers.in.paediatric. oncology:.Ewing\u2019s.sarcoma.and. neuroblastoma. By.Riley.RD,.Burchill.SA,. Abrams.KR,.Heney.D,.Lambert.PC,. Jones.DR,.et al. No. 6 The.cost-effectiveness.of.screening.for. Helicobacter pylori to.reduce.mortality. and.morbidity.from.gastric.cancer.and. peptic.ulcer.disease:.a.discrete-event. simulation.model.","cites":null},{"id":6013204,"title":"Crabbe.D,.Pearce.R,.Bhandari.P,.et al.DOI: 10.3310\/hta13470 Health Technology Assessment","authors":[],"date":"2009","doi":null,"raw":"By.Roderick.P,.Davies.R,.Raftery.J,. Crabbe.D,.Pearce.R,.Bhandari.P,.et al.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 137 No. 7 The.clinical.effectiveness.and.costeffectiveness.of.routine.dental.checks:. a.systematic.review.and.economic. evaluation. By.Davenport.C,.Elley.K,.Salas. C,.Taylor-Weetman.CL,.Fry-Smith.A,. Bryan.S,.et al. No. 8 A.multicentre.randomised.controlled. trial.assessing.the.costs.and.benefits. of.using.structured.information.and. analysis.of.women\u2019s.preferences.in.the. management.of.menorrhagia. By.Kennedy.ADM,.Sculpher.MJ,. Coulter.A,.Dwyer.N,.Rees.M,.Horsley.S,. et al. No. 9 Clinical.effectiveness.and.cost\u2013utility. of.photodynamic.therapy.for.wet. age-related.macular.degeneration:. a.systematic.review.and.economic. evaluation. By.Meads.C,.Salas.C,.Roberts.T,. Moore.D,.Fry-Smith.A,.Hyde.C. No. 10 Evaluation.of.molecular.tests.for. prenatal.diagnosis.of.chromosome. abnormalities. By.Grimshaw.GM,.Szczepura.A,. Hult\u00e9n.M,.MacDonald.F,.Nevin.NC,. Sutton.F,.et al. No. 11 First.and.second.trimester.antenatal. screening.for.Down\u2019s.syndrome:. the.results.of.the.Serum,.Urine.and. Ultrasound.Screening.Study.(SURUSS). By.Wald.NJ,.Rodeck.C,.Hackshaw. AK,.Walters.J,.Chitty.L,.Mackinson.AM. No. 12 The.effectiveness.and.cost-effectiveness. of.ultrasound.locating.devices.for. central.venous.access:.a.systematic. review.and.economic.evaluation. By.Calvert.N,.Hind.D,.McWilliams. RG,.Thomas.SM,.Beverley.C,. Davidson.A. No. 13 A.systematic.review.of.atypical. antipsychotics.in.schizophrenia. By.Bagnall.A-M,.Jones.L,.Lewis.R,. Ginnelly.L,.Glanville.J,.Torgerson.D, et al. No. 14 Prostate.Testing.for.Cancer.and. Treatment.(ProtecT).feasibility.study. By.Donovan.J,.Hamdy.F,.Neal.D,. Peters.T,.Oliver.S,.Brindle.L,.et al. No. 15 Early.thrombolysis.for.the.treatment. of.acute.myocardial.infarction:.a. systematic.review.and.economic. evaluation. By.Boland.A,.Dundar.Y,.Bagust.A,. Haycox.A,.Hill.R,.Mujica.Mota.R,.et al. No. 16 Screening.for.fragile.X.syndrome:.a. literature.review.and.modelling. By.Song.FJ,.Barton.P,.Sleightholme. V,.Yao.GL,.Fry-Smith.A. No. 17 Systematic.review.of.endoscopic.sinus. surgery.for.nasal.polyps. By.Dalziel.K,.Stein.K,.Round.A,. Garside.R,.Royle.P. No. 18 Towards.efficient.guidelines:.how.to. monitor.guideline.use.in.primary.care. By.Hutchinson.A,.McIntosh.A,. Cox.S,.Gilbert.C. No. 19 Effectiveness.and.cost-effectiveness. of.acute.hospital-based.spinal.cord. injuries.services:.systematic.review. By.Bagnall.A-M,.Jones.L,.Richardson. G,.Duffy.S,.Riemsma.R. No. 20 Prioritisation.of.health.technology. assessment..The.PATHS.model:. methods.and.case.studies. By.Townsend.J,.Buxton.M,. Harper.G. No. 21 Systematic.review.of.the.clinical. effectiveness.and.cost-effectiveness.of. tension-free.vaginal.tape.for.treatment. of.urinary.stress.incontinence. By.Cody.J,.Wyness.L,.Wallace.S,. Glazener.C,.Kilonzo.M,.Stearns.S,.et al. No. 22 The.clinical.and.cost-effectiveness.of. patient.education.models.for.diabetes:. a.systematic.review.and.economic. evaluation. By.Loveman.E,.Cave.C,.Green.C,. Royle.P,.Dunn.N,.Waugh.N. No. 23 The.role.of.modelling.in.prioritising. and.planning.clinical.trials. By.Chilcott.J,.Brennan.A,.Booth.A,. Karnon.J,.Tappenden.P. No. 24 Cost\u2013benefit.evaluation.of.routine. influenza.immunisation.in.people. 65\u201374.years.of.age. By.Allsup.S,.Gosney.M,.Haycox.A,. Regan.M. No. 25 The.clinical.and.cost-effectiveness.of. pulsatile.machine.perfusion.versus.cold. storage.of.kidneys.for.transplantation. retrieved.from.heart-beating.and.nonheart-beating.donors. By.Wight.J,.Chilcott.J,.Holmes.M,. Brewer.N. No. 26 Can.randomised.trials.rely.on.existing. electronic.data?.A.feasibility.study.to. explore.the.value.of.routine.data.in. health.technology.assessment. By.Williams.JG,.Cheung.WY,. Cohen.DR,.Hutchings.HA,.Longo.MF,. Russell.IT. No. 27 Evaluating.non-randomised. intervention.studies. By.Deeks.JJ,.Dinnes.J,.D\u2019Amico.R,. Sowden.AJ,.Sakarovitch.C,.Song.F,.et al. No. 28 A.randomised.controlled.trial.to.assess. the.impact.of.a.package.comprising.a. patient-orientated,.evidence-based.self-. help.guidebook.and.patient-centred. consultations.on.disease.management. and.satisfaction.in.inflammatory.bowel. disease. By.Kennedy.A,.Nelson.E,.Reeves.D,. Richardson.G,.Roberts.C,.Robinson.A,. et al. No. 29 The.effectiveness.of.diagnostic.tests.for. the.assessment.of.shoulder.pain.due. to.soft.tissue.disorders:.a.systematic. review. By.Dinnes.J,.Loveman.E,.McIntyre.L,. Waugh.N. No. 30 The.value.of.digital.imaging.in.diabetic. retinopathy. By.Sharp.PF,.Olson.J,.Strachan.F,. Hipwell.J,.Ludbrook.A,.O\u2019Donnell.M,. et al. No. 31 Lowering.blood.pressure.to.prevent. myocardial.infarction.and.stroke:.a.new. preventive.strategy. By.Law.M,.Wald.N,.Morris.J. No. 32 Clinical.and.cost-effectiveness.of. capecitabine.and.tegafur.with.uracil.for. the.treatment.of.metastatic.colorectal. cancer:.systematic.review.and.economic. evaluation. By.Ward.S,.Kaltenthaler.E,.Cowan.J,. Brewer.N. No. 33 Clinical.and.cost-effectiveness.of.new. and.emerging.technologies.for.early. localised.prostate.cancer:.a.systematic. review. By.Hummel.S,.Paisley.S,.Morgan.A,. Currie.E,.Brewer.N. No. 34 Literature.searching.for.clinical.and. cost-effectiveness.studies.used.in.health. technology.assessment.reports.carried. out.for.the.National.Institute.for. Clinical.Excellence.appraisal.system.","cites":null},{"id":6013206,"title":"Assessment reports published to date 138","authors":[],"date":"2004","doi":"10.1017\/s0266462305230192","raw":"By.Royle.P,.Waugh.N.Health Technology Assessment reports published to date 138 No. 35 Systematic.review.and.economic. decision.modelling.for.the.prevention. and.treatment.of.influenza.A.and.B. By.Turner.D,.Wailoo.A,.Nicholson.K,. Cooper.N,.Sutton.A,.Abrams.K. No. 36 A.randomised.controlled.trial. to.evaluate.the.clinical.and.costeffectiveness.of.Hickman.line.insertions. in.adult.cancer.patients.by.nurses. By.Boland.A,.Haycox.A,.Bagust.A,. Fitzsimmons.L. No. 37 Redesigning.postnatal.care:.a. randomised.controlled.trial.of.protocolbased.midwifery-led.care.focused. on.individual.women\u2019s.physical.and. psychological.health.needs. By.MacArthur.C,.Winter.HR,. Bick.DE,.Lilford.RJ,.Lancashire.RJ,. Knowles.H,.et al. No. 38 Estimating.implied.rates.of.discount.in. healthcare.decision-making. By.West.RR,.McNabb.R,.Thompson. AGH,.Sheldon.TA,.Grimley.Evans.J. No. 39 Systematic.review.of.isolation.policies. in.the.hospital.management.of. methicillin-resistant.Staphylococcus aureus:.a.review.of.the.literature. with.epidemiological.and.economic. modelling. By.Cooper.BS,.Stone.SP,.Kibbler.CC,. Cookson.BD,.Roberts.JA,.Medley.GF,. et al. No. 40 Treatments.for.spasticity.and.pain.in. multiple.sclerosis:.a.systematic.review. By.Beard.S,.Hunn.A,.Wight.J. No. 41 The.inclusion.of.reports.of.randomised. trials.published.in.languages.other.than. English.in.systematic.reviews. By.Moher.D,.Pham.B,.Lawson.ML,. Klassen.TP. No. 42 The.impact.of.screening.on.future. health-promoting.behaviours.and. health.beliefs:.a.systematic.review. By.Bankhead.CR,.Brett.J,.Bukach.C,. Webster.P,.Stewart-Brown.S,.Munafo.M,. et al. Volume 8, 2004 No. 1 What.is.the.best.imaging.strategy.for. acute.stroke? By.Wardlaw.JM,.Keir.SL,.Seymour.J,. Lewis.S,.Sandercock.PAG,.Dennis.MS,. et al. No. 2 Systematic.review.and.modelling.of.the. investigation.of.acute.and.chronic.chest. pain.presenting.in.primary.care. By.Mant.J,.McManus.RJ,.Oakes.RAL,. Delaney.BC,.Barton.PM,.Deeks.JJ,.et al. No. 3 The.effectiveness.and.cost-effectiveness. of.microwave.and.thermal.balloon. endometrial.ablation.for.heavy. menstrual.bleeding:.a.systematic.review. and.economic.modelling. By.Garside.R,.Stein.K,.Wyatt.K,. Round.A,.Price.A. No. 4 A.systematic.review.of.the.role.of. bisphosphonates.in.metastatic.disease. By.Ross.JR,.Saunders.Y,. Edmonds.PM,.Patel.S,.Wonderling.D,. Normand.C,.et al. No. 5 Systematic.review.of.the.clinical. effectiveness.and.cost-effectiveness. of.capecitabine.(Xeloda\u00ae).for.locally. advanced.and\/or.metastatic.breast. cancer. By.Jones.L,.Hawkins.N,.Westwood.M,. Wright.K,.Richardson.G,.Riemsma.R. No. 6 Effectiveness.and.efficiency.of.guideline. dissemination.and.implementation. strategies. By.Grimshaw.JM,.Thomas.RE,. MacLennan.G,.Fraser.C,.Ramsay.CR,. Vale.L,.et al. No. 7 Clinical.effectiveness.and.costs.of.the. Sugarbaker.procedure.for.the.treatment. of.pseudomyxoma.peritonei. By.Bryant.J,.Clegg.AJ,.Sidhu.MK,. Brodin.H,.Royle.P,.Davidson.P. No. 8 Psychological.treatment.for.insomnia. in.the.regulation.of.long-term.hypnotic. drug.use. By.Morgan.K,.Dixon.S,.Mathers.N,. Thompson.J,.Tomeny.M. No. 9 Improving.the.evaluation.of. therapeutic.interventions.in.multiple. sclerosis:.development.of.a.patientbased.measure.of.outcome. By.Hobart.JC,.Riazi.A,.Lamping.DL,. Fitzpatrick.R,.Thompson.AJ. No. 10 A.systematic.review.and.economic. evaluation.of.magnetic.resonance. cholangiopancreatography.compared. with.diagnostic.endoscopic.retrograde. cholangiopancreatography. By.Kaltenthaler.E,.Bravo.Vergel.Y,. Chilcott.J,.Thomas.S,.Blakeborough.T,. Walters.SJ,.et al. No. 11 The.use.of.modelling.to.evaluate. new.drugs.for.patients.with.a.chronic. condition:.the.case.of.antibodies. against.tumour.necrosis.factor.in. rheumatoid.arthritis. By.Barton.P,.Jobanputra.P,.Wilson.J,. Bryan.S,.Burls.A. No. 12 Clinical.effectiveness.and.costeffectiveness.of.neonatal.screening. for.inborn.errors.of.metabolism.using. tandem.mass.spectrometry:.a.systematic. review. By.Pandor.A,.Eastham.J,.Beverley.C,. Chilcott.J,.Paisley.S. No. 13 Clinical.effectiveness.and.costeffectiveness.of.pioglitazone.and. rosiglitazone.in.the.treatment.of.type. 2.diabetes:.a.systematic.review.and. economic.evaluation. By.Czoski-Murray.C,.Warren.E,. Chilcott.J,.Beverley.C,.Psyllaki.MA,. Cowan.J. No. 14 Routine.examination.of.the.newborn:. the.EMREN.study..Evaluation.of.an. extension.of.the.midwife.role.including. a.randomised.controlled.trial.of. appropriately.trained.midwives.and. paediatric.senior.house.officers. By.Townsend.J,.Wolke.D,.Hayes.J,. Dav\u00e9.S,.Rogers.C,.Bloomfield.L,.et al. No. 15 Involving.consumers.in.research.and. development.agenda.setting.for.the. NHS:.developing.an.evidence-based. approach. By.Oliver.S,.Clarke-Jones.L,.Rees.R,. Milne.R,.Buchanan.P,.Gabbay.J,.et al. No. 16 A.multi-centre.randomised.controlled. trial.of.minimally.invasive.direct. coronary.bypass.grafting.versus. percutaneous.transluminal.coronary. angioplasty.with.stenting.for.proximal. stenosis.of.the.left.anterior.descending. coronary.artery. By.Reeves.BC,.Angelini.GD,.Bryan. AJ,.Taylor.FC,.Cripps.T,.Spyt.TJ,.et al. No. 17 Does.early.magnetic.resonance.imaging. influence.management.or.improve. outcome.in.patients.referred.to. secondary.care.with.low.back.pain?.A. pragmatic.randomised.controlled.trial. By.Gilbert.FJ,.Grant.AM,.Gillan. MGC,.Vale.L,.Scott.NW,.Campbell.MK,. et al. No. 18 The.clinical.and.cost-effectiveness. of.anakinra.for.the.treatment.of. rheumatoid.arthritis.in.adults:.a. systematic.review.and.economic. analysis.","cites":null},{"id":6013207,"title":"Assessment reports published to date 140","authors":[],"date":"2005","doi":null,"raw":"Chilcott.J,.Beverley.C.Health Technology Assessment reports published to date 140 No. 46 Supplementation.of.a.home-based. exercise.programme.with.a.classbased.programme.for.people. with.osteoarthritis.of.the.knees:.a. randomised.controlled.trial.and.health. economic.analysis. By.McCarthy.CJ,.Mills.PM,.Pullen.R,. Richardson.G,.Hawkins.N,.Roberts.CR,. et al. No. 47 Clinical.and.cost-effectiveness.of.oncedaily.versus.more.frequent.use.of.same. potency.topical.corticosteroids.for. atopic.eczema:.a.systematic.review.and. economic.evaluation. By.Green.C,.Colquitt.JL,.Kirby.J,. Davidson.P,.Payne.E. No. 48 Acupuncture.of.chronic.headache. disorders.in.primary.care:.randomised. controlled.trial.and.economic.analysis. By.Vickers.AJ,.Rees.RW,.Zollman.CE,. McCarney.R,.Smith.CM,.Ellis.N,.et al. No. 49 Generalisability.in.economic.evaluation. studies.in.healthcare:.a.review.and.case. studies. By.Sculpher.MJ,.Pang.FS,.Manca.A,. Drummond.MF,.Golder.S,.Urdahl.H,. et al. No. 50 Virtual.outreach:.a.randomised. controlled.trial.and.economic. evaluation.of.joint.teleconferenced. medical.consultations. By.Wallace.P,.Barber.J,.Clayton.W,. Currell.R,.Fleming.K,.Garner.P,.et al. Volume 9, 2005 No. 1 Randomised.controlled.multiple. treatment.comparison.to.provide.a.costeffectiveness.rationale.for.the.selection. of.antimicrobial.therapy.in.acne. By.Ozolins.M,.Eady.EA,.Avery.A,. Cunliffe.WJ,.O\u2019Neill.C,.Simpson.NB,. et al. No. 2 Do.the.findings.of.case.series.studies. vary.significantly.according.to. methodological.characteristics? By.Dalziel.K,.Round.A,.Stein.K,. Garside.R,.Castelnuovo.E,.Payne.L. No. 3 Improving.the.referral.process. for.familial.breast.cancer.genetic. counselling:.findings.of.three. randomised.controlled.trials.of.two. interventions. By.Wilson.BJ,.Torrance.N,. Mollison.J,.Wordsworth.S,.Gray.JR,. Haites.NE,.et al. No. 4 Randomised.evaluation.of.alternative. electrosurgical.modalities.to.treat. bladder.outflow.obstruction.in.men. with.benign.prostatic.hyperplasia. By.Fowler.C,.McAllister.W,.Plail.R,. Karim.O,.Yang.Q. No. 5 A.pragmatic.randomised.controlled. trial.of.the.cost-effectiveness.of. palliative.therapies.for.patients.with. inoperable.oesophageal.cancer. By.Shenfine.J,.McNamee.P,.Steen.N,. Bond.J,.Griffin.SM. No. 6 Impact.of.computer-aided.detection. prompts.on.the.sensitivity.and. specificity.of.screening.mammography. By.Taylor.P,.Champness.J,.Given-. Wilson.R,.Johnston.K,.Potts.H. No. 7 Issues.in.data.monitoring.and.interim. analysis.of.trials. By.Grant.AM,.Altman.DG,.Babiker. AB,.Campbell.MK,.Clemens.FJ,. Darbyshire.JH,.et al. No. 8 Lay.public\u2019s.understanding.of.equipoise. and.randomisation.in.randomised. controlled.trials. By.Robinson.EJ,.Kerr.CEP,. Stevens.AJ,.Lilford.RJ,.Braunholtz.DA,. Edwards.SJ,.et al. No. 9 Clinical.and.cost-effectiveness.of. electroconvulsive.therapy.for.depressive. illness,.schizophrenia,.catatonia. and.mania:.systematic.reviews.and. economic.modelling.studies. By.Greenhalgh.J,.Knight.C,.Hind.D,. Beverley.C,.Walters.S. No. 10 Measurement.of.health-related.quality. of.life.for.people.with.dementia:. development.of.a.new.instrument. (DEMQOL).and.an.evaluation.of. current.methodology. By.Smith.SC,.Lamping.DL,.Banerjee. S,.Harwood.R,.Foley.B,.Smith.P,.et al. No. 11 Clinical.effectiveness.and.costeffectiveness.of.drotrecogin.alfa. (activated).(Xigris\u00ae).for.the.treatment. of.severe.sepsis.in.adults:.a.systematic. review.and.economic.evaluation. By.Green.C,.Dinnes.J,.Takeda.A,. Shepherd.J,.Hartwell.D,.Cave.C,.et al. No. 12 A.methodological.review.of.how. heterogeneity.has.been.examined.in. systematic.reviews.of.diagnostic.test. accuracy. By.Dinnes.J,.Deeks.J,.Kirby.J,. Roderick.P. No. 13 Cervical.screening.programmes:.can. automation.help?.Evidence.from. systematic.reviews,.an.economic. analysis.and.a.simulation.modelling. exercise.applied.to.the.UK. By.Willis.BH,.Barton.P,.Pearmain.P,. Bryan.S,.Hyde.C. No. 14 Laparoscopic.surgery.for.inguinal. hernia.repair:.systematic.review.of. effectiveness.and.economic.evaluation. By.McCormack.K,.Wake.B,.Perez.J,. Fraser.C,.Cook.J,.McIntosh.E,.et al. No. 15 Clinical.effectiveness,.tolerability.and. cost-effectiveness.of.newer.drugs.for. epilepsy.in.adults:.a.systematic.review. and.economic.evaluation. By.Wilby.J,.Kainth.A,.Hawkins.N,. Epstein.D,.McIntosh.H,.McDaid.C,.et al. No. 16 A.randomised.controlled.trial.to. compare.the.cost-effectiveness.of. tricyclic.antidepressants,.selective. serotonin.reuptake.inhibitors.and. lofepramine. By.Peveler.R,.Kendrick.T,.Buxton.M,. Longworth.L,.Baldwin.D,.Moore.M,.et al. No. 17 Clinical.effectiveness.and.costeffectiveness.of.immediate.angioplasty. for.acute.myocardial.infarction:. systematic.review.and.economic. evaluation. By.Hartwell.D,.Colquitt.J,.Loveman. E,.Clegg.AJ,.Brodin.H,.Waugh.N,.et al. No. 18 A.randomised.controlled.comparison.of. alternative.strategies.in.stroke.care. By.Kalra.L,.Evans.A,.Perez.I,. Knapp.M,.Swift.C,.Donaldson.N. No. 19 The.investigation.and.analysis.of. critical.incidents.and.adverse.events.in. healthcare. By.Woloshynowych.M,.Rogers.S,. Taylor-Adams.S,.Vincent.C. No. 20 Potential.use.of.routine.databases.in. health.technology.assessment. By.Raftery.J,.Roderick.P,.Stevens.A. No. 21 Clinical.and.cost-effectiveness.of.newer. immunosuppressive.regimens.in.renal. transplantation:.a.systematic.review.and. modelling.study. By.Woodroffe.R,.Yao.GL,.Meads.C,. Bayliss.S,.Ready.A,.Raftery.J,.et al. No. 22 A.systematic.review.and.economic. evaluation.of.alendronate,.etidronate,. risedronate,.raloxifene.and.teriparatide. for.the.prevention.and.treatment.of. postmenopausal.osteoporosis. By.Stevenson.M,.Lloyd.Jones.M,.De.","cites":null},{"id":6013209,"title":"Thomas.S,.Lamb.J,.Bain.L,.et al.Health Technology Assessment reports published to date 142","authors":[],"date":"2006","doi":null,"raw":"By.Clar.C,.Cummins.E,.McIntyre.L,. Thomas.S,.Lamb.J,.Bain.L,.et al.Health Technology Assessment reports published to date 142 No. 48 Systematic.review.of.effectiveness.of. different.treatments.for.childhood. retinoblastoma. By.McDaid.C,.Hartley.S,.Bagnall. A-M,.Ritchie.G,.Light.K,.Riemsma.R. No. 49 Towards.evidence-based.guidelines. for.the.prevention.of.venous. thromboembolism:.systematic. reviews.of.mechanical.methods,.oral. anticoagulation,.dextran.and.regional. anaesthesia.as.thromboprophylaxis. By.Roderick.P,.Ferris.G,.Wilson.K,. Halls.H,.Jackson.D,.Collins.R,.et al. No. 50 The.effectiveness.and.cost-effectiveness. of.parent.training\/education. programmes.for.the.treatment. of.conduct.disorder,.including. oppositional.defiant.disorder,.in. children. By.Dretzke.J,.Frew.E,.Davenport.C,. Barlow.J,.Stewart-Brown.S,.Sandercock.J,. et al. Volume 10, 2006 No. 1 The.clinical.and.cost-effectiveness.of. donepezil,.rivastigmine,.galantamine. and.memantine.for.Alzheimer\u2019s. disease. By.Loveman.E,.Green.C,.Kirby.J,. Takeda.A,.Picot.J,.Payne.E,.et al. No. 2 FOOD:.a.multicentre.randomised.trial. evaluating.feeding.policies.in.patients. admitted.to.hospital.with.a.recent. stroke. By.Dennis.M,.Lewis.S,.Cranswick.G,. Forbes.J. No. 3 The.clinical.effectiveness.and.costeffectiveness.of.computed.tomography. screening.for.lung.cancer:.systematic. reviews. By.Black.C,.Bagust.A,.Boland.A,. Walker.S,.McLeod.C,.De.Verteuil.R,.et al. No. 4 A.systematic.review.of.the.effectiveness. and.cost-effectiveness.of.neuroimaging. assessments.used.to.visualise.the.seizure. focus.in.people.with.refractory.epilepsy. being.considered.for.surgery. By.Whiting.P,.Gupta.R,.Burch.J,. Mujica.Mota.RE,.Wright.K,.Marson.A,. et al. No. 5 Comparison.of.conference.abstracts. and.presentations.with.full-text.articles. in.the.health.technology.assessments.of. rapidly.evolving.technologies. By.Dundar.Y,.Dodd.S,.Dickson.R,. Walley.T,.Haycox.A,.Williamson.PR. No. 6 Systematic.review.and.evaluation. of.methods.of.assessing.urinary. incontinence. By.Martin.JL,.Williams.KS,.Abrams. KR,.Turner.DA,.Sutton.AJ,.Chapple.C,. et al. No. 7 The.clinical.effectiveness.and.costeffectiveness.of.newer.drugs.for. children.with.epilepsy..A.systematic. review. By.Connock.M,.Frew.E,.Evans.B-W,. Bryan.S,.Cummins.C,.Fry-Smith.A,.et al. No. 8 Surveillance.of.Barrett\u2019s.oesophagus:. exploring.the.uncertainty.through. systematic.review,.expert.workshop.and. economic.modelling. By.Garside.R,.Pitt.M,.Somerville.M,. Stein.K,.Price.A,.Gilbert.N. No. 9 Topotecan,.pegylated.liposomal. doxorubicin.hydrochloride.and. paclitaxel.for.second-line.or.subsequent. treatment.of.advanced.ovarian.cancer:. a.systematic.review.and.economic. evaluation. By.Main.C,.Bojke.L,.Griffin.S,. Norman.G,.Barbieri.M,.Mather.L,.et al. No. 10 Evaluation.of.molecular.techniques. in.prediction.and.diagnosis. of.cytomegalovirus.disease.in. immunocompromised.patients. By.Szczepura.A,.Westmoreland.D,. Vinogradova.Y,.Fox.J,.Clark.M. No. 11 Screening.for.thrombophilia.in.highrisk.situations:.systematic.review. and.cost-effectiveness.analysis..The. Thrombosis:.Risk.and.Economic. Assessment.of.Thrombophilia. Screening.(TREATS).study. By.Wu.O,.Robertson.L,.Twaddle.S,. Lowe.GDO,.Clark.P,.Greaves.M,.et al. No. 12 A.series.of.systematic.reviews.to.inform. a.decision.analysis.for.sampling.and. treating.infected.diabetic.foot.ulcers. By.Nelson.EA,.O\u2019Meara.S,.Craig.D,. Iglesias.C,.Golder.S,.Dalton.J,.et al. No. 13 Randomised.clinical.trial,.observational. study.and.assessment.of.costeffectiveness.of.the.treatment.of. varicose.veins.(REACTIV.trial). By.Michaels.JA,.Campbell.WB,. Brazier.JE,.MacIntyre.JB,.Palfreyman.SJ,. Ratcliffe.J,.et al. No. 14 The.cost-effectiveness.of.screening.for. oral.cancer.in.primary.care. By.Speight.PM,.Palmer.S,.Moles.DR,. Downer.MC,.Smith.DH,.Henriksson.M,. et al. No. 15 Measurement.of.the.clinical.and.costeffectiveness.of.non-invasive.diagnostic. testing.strategies.for.deep.vein. thrombosis. By.Goodacre.S,.Sampson.F,. Stevenson.M,.Wailoo.A,.Sutton.A,. Thomas.S,.et al. No. 16 Systematic.review.of.the.effectiveness. and.cost-effectiveness.of.HealOzone\u00ae. for.the.treatment.of.occlusal.pit\/fissure. caries.and.root.caries. By.Brazzelli.M,.McKenzie.L,.Fielding. S,.Fraser.C,.Clarkson.J,.Kilonzo.M,.et al. No. 17 Randomised.controlled.trials.of. conventional.antipsychotic.versus. new.atypical.drugs,.and.new.atypical. drugs.versus.clozapine,.in.people.with. schizophrenia.responding.poorly.to,.or. intolerant.of,.current.drug.treatment. By.Lewis.SW,.Davies.L,.Jones.PB,. Barnes.TRE,.Murray.RM,.Kerwin.R,. et al. No. 18 Diagnostic.tests.and.algorithms.used. in.the.investigation.of.haematuria:. systematic.reviews.and.economic. evaluation. By.Rodgers.M,.Nixon.J,.Hempel.S,. Aho.T,.Kelly.J,.Neal.D,.et al. No. 19 Cognitive.behavioural.therapy.in. addition.to.antispasmodic.therapy.for. irritable.bowel.syndrome.in.primary. care:.randomised.controlled.trial. By.Kennedy.TM,.Chalder.T,. McCrone.P,.Darnley.S,.Knapp.M,. Jones.RH,.et al. No. 20 A.systematic.review.of.the. clinical.effectiveness.and.costeffectiveness.of.enzyme.replacement. therapies.for.Fabry\u2019s.disease.and. mucopolysaccharidosis.type.1. By.Connock.M,.Juarez-Garcia.A,. Frew.E,.Mans.A,.Dretzke.J,.Fry-Smith.A,. et al. No. 21 Health.benefits.of.antiviral.therapy.for. mild.chronic.hepatitis.C:.randomised. controlled.trial.and.economic. evaluation. By.Wright.M,.Grieve.R,.Roberts.J,. Main.J,.Thomas.HC,.on.behalf.of.the. UK.Mild.Hepatitis.C.Trial.Investigators. No. 22 Pressure.relieving.support.surfaces:.a. randomised.evaluation.","cites":null},{"id":6013210,"title":"Iglesias.CP,.Hawkins.K,.Cullum.NA,.et al.DOI: 10.3310\/hta13470 Health Technology Assessment","authors":[],"date":"2009","doi":null,"raw":"By.Nixon.J,.Nelson.EA,.Cranny.G,. Iglesias.CP,.Hawkins.K,.Cullum.NA,.et al.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 143 No. 23 A.systematic.review.and.economic. model.of.the.effectiveness.and.costeffectiveness.of.methylphenidate,. dexamfetamine.and.atomoxetine. for.the.treatment.of.attention.deficit. hyperactivity.disorder.in.children.and. adolescents. By.King.S,.Griffin.S,.Hodges.Z,. Weatherly.H,.Asseburg.C,.Richardson.G,. et al. No. 24 The.clinical.effectiveness.and.costeffectiveness.of.enzyme.replacement. therapy.for.Gaucher\u2019s.disease:.a. systematic.review. By.Connock.M,.Burls.A,.Frew.E,. Fry-Smith.A,.Juarez-Garcia.A,.McCabe.C,. et al. No. 25 Effectiveness.and.cost-effectiveness. of.salicylic.acid.and.cryotherapy.for. cutaneous.warts..An.economic.decision. model. By.Thomas.KS,.Keogh-Brown.MR,. Chalmers.JR,.Fordham.RJ,.Holland.RC,. Armstrong.SJ,.et al. No. 26 A.systematic.literature.review.of.the. effectiveness.of.non-pharmacological. interventions.to.prevent.wandering.in. dementia.and.evaluation.of.the.ethical. implications.and.acceptability.of.their. use. By.Robinson.L,.Hutchings.D,.Corner. L,.Beyer.F,.Dickinson.H,.Vanoli.A,.et al. No. 27 A.review.of.the.evidence.on.the.effects. and.costs.of.implantable.cardioverter. defibrillator.therapy.in.different. patient.groups,.and.modelling.of.costeffectiveness.and.cost\u2013utility.for.these. groups.in.a.UK.context. By.Buxton.M,.Caine.N,.Chase.D,. Connelly.D,.Grace.A,.Jackson.C,.et al. No. 28 Adefovir.dipivoxil.and.pegylated. interferon.alfa-2a.for.the.treatment.of. chronic.hepatitis.B:.a.systematic.review. and.economic.evaluation. By.Shepherd.J,.Jones.J,.Takeda.A,. Davidson.P,.Price.A. No. 29 An.evaluation.of.the.clinical.and.costeffectiveness.of.pulmonary.artery. catheters.in.patient.management.in. intensive.care:.a.systematic.review.and.a. randomised.controlled.trial. By.Harvey.S,.Stevens.K,.Harrison.D,. Young.D,.Brampton.W,.McCabe.C,.et al. No. 30 Accurate,.practical.and.cost-effective. assessment.of.carotid.stenosis.in.the. UK. By.Wardlaw.JM,.Chappell.FM,. Stevenson.M,.De.Nigris.E,.Thomas.S,. Gillard.J,.et al. No. 31 Etanercept.and.infliximab.for.the. treatment.of.psoriatic.arthritis:.a. systematic.review.and.economic. evaluation. By.Woolacott.N,.Bravo.Vergel.Y,. Hawkins.N,.Kainth.A,.Khadjesari.Z,. Misso.K,.et al. No. 32 The.cost-effectiveness.of.testing.for. hepatitis.C.in.former.injecting.drug. users. By.Castelnuovo.E,.Thompson-Coon. J,.Pitt.M,.Cramp.M,.Siebert.U,.Price.A,. et al. No. 33 Computerised.cognitive.behaviour. therapy.for.depression.and.anxiety. update:.a.systematic.review.and. economic.evaluation. By.Kaltenthaler.E,.Brazier.J,. De.Nigris.E,.Tumur.I,.Ferriter.M,. Beverley.C,.et al. No. 34 Cost-effectiveness.of.using.prognostic. information.to.select.women.with.breast. cancer.for.adjuvant.systemic.therapy. By.Williams.C,.Brunskill.S,.Altman.D,. Briggs.A,.Campbell.H,.Clarke.M,.et al. No. 35 Psychological.therapies.including. dialectical.behaviour.therapy.for. borderline.personality.disorder:.a. systematic.review.and.preliminary. economic.evaluation. By.Brazier.J,.Tumur.I,.Holmes.M,. Ferriter.M,.Parry.G,.Dent-Brown.K,.et al. No. 36 Clinical.effectiveness.and.costeffectiveness.of.tests.for.the.diagnosis. and.investigation.of.urinary.tract. infection.in.children:.a.systematic. review.and.economic.model. By.Whiting.P,.Westwood.M,.Bojke.L,. Palmer.S,.Richardson.G,.Cooper.J,.et al. No. 37 Cognitive.behavioural.therapy. in.chronic.fatigue.syndrome:.a. randomised.controlled.trial.of.an. outpatient.group.programme. By.O\u2019Dowd.H,.Gladwell.P,.Rogers. CA,.Hollinghurst.S,.Gregory.A. No. 38 A.comparison.of.the.cost-effectiveness. of.five.strategies.for.the.prevention. of.nonsteroidal.anti-inflammatory. drug-induced.gastrointestinal.toxicity:. a.systematic.review.with.economic. modelling. By.Brown.TJ,.Hooper.L,.Elliott.RA,. Payne.K,.Webb.R,.Roberts.C,.et.al. No. 39 The.effectiveness.and.cost-effectiveness. of.computed.tomography.screening. for.coronary.artery.disease:.systematic. review. By.Waugh.N,.Black.C,.Walker.S,. McIntyre.L,.Cummins.E,.Hillis.G. No. 40 What.are.the.clinical.outcome.and.costeffectiveness.of.endoscopy.undertaken. by.nurses.when.compared.with.doctors?. A.Multi-Institution.Nurse.Endoscopy. Trial.(MINuET). By.Williams.J,.Russell.I,.Durai.D,. Cheung.W-Y,.Farrin.A,.Bloor.K,.et al. No. 41 The.clinical.and.cost-effectiveness.of. oxaliplatin.and.capecitabine.for.the. adjuvant.treatment.of.colon.cancer:. systematic.review.and.economic. evaluation. By.Pandor.A,.Eggington.S,.Paisley.S,. Tappenden.P,.Sutcliffe.P. No. 42 A.systematic.review.of.the.effectiveness. of.adalimumab,.etanercept.and. infliximab.for.the.treatment.of. rheumatoid.arthritis.in.adults.and. an.economic.evaluation.of.their.costeffectiveness. By.Chen.Y-F,.Jobanputra.P,.Barton.P,. Jowett.S,.Bryan.S,.Clark.W,.et al. No. 43 Telemedicine.in.dermatology:.a. randomised.controlled.trial. By.Bowns.IR,.Collins.K,.Walters.SJ,. McDonagh.AJG. No. 44 Cost-effectiveness.of.cell.salvage.and. alternative.methods.of.minimising. perioperative.allogeneic.blood. transfusion:.a.systematic.review.and. economic.model. By.Davies.L,.Brown.TJ,.Haynes.S,. Payne.K,.Elliott.RA,.McCollum.C. No. 45 Clinical.effectiveness.and.costeffectiveness.of.laparoscopic.surgery. for.colorectal.cancer:.systematic.reviews. and.economic.evaluation. By.Murray.A,.Lourenco.T,.de.Verteuil. R,.Hernandez.R,.Fraser.C,.McKinley.A,. et al. No. 46 Etanercept.and.efalizumab.for.the. treatment.of.psoriasis:.a.systematic. review. By.Woolacott.N,.Hawkins.N,. Mason.A,.Kainth.A,.Khadjesari.Z,.Bravo. Vergel.Y,.et al. No. 47 Systematic.reviews.of.clinical.decision. tools.for.acute.abdominal.pain. By.Liu.JLY,.Wyatt.JC,.Deeks.JJ,. Clamp.S,.Keen.J,.Verde.P,.et al. No. 48 Evaluation.of.the.ventricular.assist. device.programme.in.the.UK.","cites":null},{"id":6013211,"title":"Cafferty.F,.Demiris.N,.Dyer.M,.et al.Health Technology Assessment reports published to date 144","authors":[],"date":"2007","doi":null,"raw":"By.Sharples.L,.Buxton.M,.Caine.N,. Cafferty.F,.Demiris.N,.Dyer.M,.et al.Health Technology Assessment reports published to date 144 No. 49 A.systematic.review.and.economic. model.of.the.clinical.and.costeffectiveness.of.immunosuppressive. therapy.for.renal.transplantation.in. children. By.Yao.G,.Albon.E,.Adi.Y,.Milford.D,. Bayliss.S,.Ready.A,.et al. No. 50 Amniocentesis.results:.investigation.of. anxiety..The.ARIA.trial. By.Hewison.J,.Nixon.J,.Fountain.J,. Cocks.K,.Jones.C,.Mason.G,.et al. Volume 11, 2007 No. 1 Pemetrexed.disodium.for.the.treatment. of.malignant.pleural.mesothelioma:. a.systematic.review.and.economic. evaluation. By.Dundar.Y,.Bagust.A,.Dickson.R,. Dodd.S,.Green.J,.Haycox.A,.et al. No. 2 A.systematic.review.and.economic. model.of.the.clinical.effectiveness. and.cost-effectiveness.of.docetaxel. in.combination.with.prednisone.or. prednisolone.for.the.treatment.of. hormone-refractory.metastatic.prostate. cancer. By.Collins.R,.Fenwick.E,.Trowman.R,. Perard.R,.Norman.G,.Light.K,.et al. No. 3 A.systematic.review.of.rapid.diagnostic. tests.for.the.detection.of.tuberculosis. infection. By.Dinnes.J,.Deeks.J,.Kunst.H,. Gibson.A,.Cummins.E,.Waugh.N,.et al. No. 4 The.clinical.effectiveness.and.costeffectiveness.of.strontium.ranelate.for. the.prevention.of.osteoporotic.fragility. fractures.in.postmenopausal.women. By.Stevenson.M,.Davis.S,.Lloyd-Jones. M,.Beverley.C. No. 5 A.systematic.review.of.quantitative.and. qualitative.research.on.the.role.and. effectiveness.of.written.information. available.to.patients.about.individual. medicines. By.Raynor.DK,.Blenkinsopp. A,.Knapp.P,.Grime.J,.Nicolson.DJ,. Pollock.K,.et al. No. 6 Oral.naltrexone.as.a.treatment.for. relapse.prevention.in.formerly.opioiddependent.drug.users:.a.systematic. review.and.economic.evaluation. By.Adi.Y,.Juarez-Garcia.A,.Wang.D,. Jowett.S,.Frew.E,.Day.E,.et al. No. 7 Glucocorticoid-induced.osteoporosis:. a.systematic.review.and.cost\u2013utility. analysis. By.Kanis.JA,.Stevenson.M,. McCloskey.EV,.Davis.S,.Lloyd-Jones.M. No. 8 Epidemiological,.social,.diagnostic.and. economic.evaluation.of.population. screening.for.genital.chlamydial. infection. By.Low.N,.McCarthy.A,.Macleod.J,. Salisbury.C,.Campbell.R,.Roberts.TE,. et al. No. 9 Methadone.and.buprenorphine.for.the. management.of.opioid.dependence:. a.systematic.review.and.economic. evaluation. By.Connock.M,.Juarez-Garcia.A,. Jowett.S,.Frew.E,.Liu.Z,.Taylor.RJ,.et al. No. 10 Exercise.Evaluation.Randomised. Trial.(EXERT):.a.randomised.trial. comparing.GP.referral.for.leisure. centre-based.exercise,.community-based. walking.and.advice.only. By.Isaacs.AJ,.Critchley.JA,.See.Tai. S,.Buckingham.K,.Westley.D,.Harridge. SDR,.et al. No. 11 Interferon.alfa.(pegylated.and.nonpegylated).and.ribavirin.for.the. treatment.of.mild.chronic.hepatitis. C:.a.systematic.review.and.economic. evaluation. By.Shepherd.J,.Jones.J,.Hartwell.D,. Davidson.P,.Price.A,.Waugh.N. No. 12 Systematic.review.and.economic. evaluation.of.bevacizumab.and. cetuximab.for.the.treatment.of. metastatic.colorectal.cancer. By.Tappenden.P,.Jones.R,.Paisley.S,. Carroll.C. No. 13 A.systematic.review.and.economic. evaluation.of.epoetin.alfa,.epoetin. beta.and.darbepoetin.alfa.in.anaemia. associated.with.cancer,.especially.that. attributable.to.cancer.treatment. By.Wilson.J,.Yao.GL,.Raftery.J,. Bohlius.J,.Brunskill.S,.Sandercock.J,. et al. No. 14 A.systematic.review.and.economic. evaluation.of.statins.for.the.prevention. of.coronary.events. By.Ward.S,.Lloyd.Jones.M,.Pandor.A,. Holmes.M,.Ara.R,.Ryan.A,.et al. No. 15 A.systematic.review.of.the.effectiveness. and.cost-effectiveness.of.different. models.of.community-based.respite. care.for.frail.older.people.and.their. carers. By.Mason.A,.Weatherly.H,.Spilsbury. K,.Arksey.H,.Golder.S,.Adamson.J,.et al. No. 16 Additional.therapy.for.young. children.with.spastic.cerebral.palsy:.a. randomised.controlled.trial. By.Weindling.AM,.Cunningham.CC,. Glenn.SM,.Edwards.RT,.Reeves.DJ. No. 17 Screening.for.type.2.diabetes:.literature. review.and.economic.modelling. By.Waugh.N,.Scotland.G,.McNamee. P,.Gillett.M,.Brennan.A,.Goyder.E,.et al. No. 18 The.effectiveness.and.cost-effectiveness. of.cinacalcet.for.secondary. hyperparathyroidism.in.end-stage.renal. disease.patients.on.dialysis:.a.systematic. review.and.economic.evaluation. By.Garside.R,.Pitt.M,.Anderson.R,. Mealing.S,.Roome.C,.Snaith.A,.et al. No. 19 The.clinical.effectiveness.and.costeffectiveness.of.gemcitabine.for. metastatic.breast.cancer:.a.systematic. review.and.economic.evaluation. By.Takeda.AL,.Jones.J,.Loveman.E,. Tan.SC,.Clegg.AJ. No. 20 A.systematic.review.of.duplex. ultrasound,.magnetic.resonance. angiography.and.computed. tomography.angiography.for. the.diagnosis.and.assessment.of. symptomatic,.lower.limb.peripheral. arterial.disease. By.Collins.R,.Cranny.G,.Burch.J,. Aguiar-Ib\u00e1\u00f1ez.R,.Craig.D,.Wright.K,. et al. No. 21 The.clinical.effectiveness.and.costeffectiveness.of.treatments.for.children. with.idiopathic.steroid-resistant. nephrotic.syndrome:.a.systematic. review. By.Colquitt.JL,.Kirby.J,.Green.C,. Cooper.K,.Trompeter.RS. No. 22 A.systematic.review.of.the.routine. monitoring.of.growth.in.children.of. primary.school.age.to.identify.growthrelated.conditions. By.Fayter.D,.Nixon.J,.Hartley.S,. Rithalia.A,.Butler.G,.Rudolf.M,.et al. No. 23 Systematic.review.of.the.effectiveness.of. preventing.and.treating.Staphylococcus aureus carriage.in.reducing.peritoneal. catheter-related.infections. By.McCormack.K,.Rabindranath.K,.","cites":null},{"id":6013212,"title":"al.DOI: 10.3310\/hta13470 Health Technology Assessment","authors":[],"date":"2009","doi":null,"raw":"Kilonzo.M,.Vale.L,.Fraser.C,.McIntyre.L,. et al.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 145 No. 24 The.clinical.effectiveness.and.cost. of.repetitive.transcranial.magnetic. stimulation.versus.electroconvulsive. therapy.in.severe.depression:.a. multicentre.pragmatic.randomised. controlled.trial.and.economic.analysis. By.McLoughlin.DM,.Mogg.A,.Eranti. S,.Pluck.G,.Purvis.R,.Edwards.D,.et al. No. 25 A.randomised.controlled.trial.and. economic.evaluation.of.direct.versus. indirect.and.individual.versus.group. modes.of.speech.and.language.therapy. for.children.with.primary.language. impairment. By.Boyle.J,.McCartney.E,.Forbes.J,. O\u2019Hare.A. No. 26 Hormonal.therapies.for.early.breast. cancer:.systematic.review.and.economic. evaluation. By.Hind.D,.Ward.S,.De.Nigris.E,. Simpson.E,.Carroll.C,.Wyld.L. No. 27 Cardioprotection.against.the.toxic. effects.of.anthracyclines.given.to. children.with.cancer:.a.systematic. review. By.Bryant.J,.Picot.J,.Levitt.G,. Sullivan.I,.Baxter.L,.Clegg.A. No. 28 Adalimumab,.etanercept.and.infliximab. for.the.treatment.of.ankylosing. spondylitis:.a.systematic.review.and. economic.evaluation. By.McLeod.C,.Bagust.A,.Boland.A,. Dagenais.P,.Dickson.R,.Dundar.Y,.et al. No. 29 Prenatal.screening.and.treatment. strategies.to.prevent.group.B. streptococcal.and.other.bacterial. infections.in.early.infancy:.costeffectiveness.and.expected.value.of. information.analyses. By.Colbourn.T,.Asseburg.C,.Bojke.L,. Philips.Z,.Claxton.K,.Ades.AE,.et al. No. 30 Clinical.effectiveness.and.costeffectiveness.of.bone.morphogenetic. proteins.in.the.non-healing.of.fractures. and.spinal.fusion:.a.systematic.review. By.Garrison.KR,.Donell.S,.Ryder.J,. Shemilt.I,.Mugford.M,.Harvey.I,.et al. No. 31 A.randomised.controlled.trial.of. postoperative.radiotherapy.following. breast-conserving.surgery.in.a. minimum-risk.older.population..The. PRIME.trial. By.Prescott.RJ,.Kunkler.IH,.Williams. LJ,.King.CC,.Jack.W,.van.der.Pol.M,. et al. No. 32 Current.practice,.accuracy,.effectiveness. and.cost-effectiveness.of.the.school. entry.hearing.screen. By.Bamford.J,.Fortnum.H,.Bristow. K,.Smith.J,.Vamvakas.G,.Davies.L,.et al. No. 33 The.clinical.effectiveness.and.costeffectiveness.of.inhaled.insulin.in. diabetes.mellitus:.a.systematic.review. and.economic.evaluation. By.Black.C,.Cummins.E,.Royle.P,. Philip.S,.Waugh.N. No. 34 Surveillance.of.cirrhosis.for. hepatocellular.carcinoma:.systematic. review.and.economic.analysis. By.Thompson.Coon.J,.Rogers.G,. Hewson.P,.Wright.D,.Anderson.R,. Cramp.M,.et al. No. 35 The.Birmingham.Rehabilitation. Uptake.Maximisation.Study.(BRUM).. Homebased.compared.with.hospitalbased.cardiac.rehabilitation.in.a.multiethnic.population:.cost-effectiveness. and.patient.adherence. By.Jolly.K,.Taylor.R,.Lip.GYH,. Greenfield.S,.Raftery.J,.Mant.J,.et al. No. 36 A.systematic.review.of.the.clinical,. public.health.and.cost-effectiveness.of. rapid.diagnostic.tests.for.the.detection. and.identification.of.bacterial.intestinal. pathogens.in.faeces.and.food. By.Abubakar.I,.Irvine.L,.Aldus.CF,. Wyatt.GM,.Fordham.R,.Schelenz.S,.et al. No. 37 A.randomised.controlled.trial. examining.the.longer-term.outcomes. of.standard.versus.new.antiepileptic. drugs..The.SANAD.trial. By.Marson.AG,.Appleton.R,.Baker. GA,.Chadwick.DW,.Doughty.J,.Eaton.B,. et al. No. 38 Clinical.effectiveness.and.costeffectiveness.of.different.models. of.managing.long-term.oral.anticoagulation.therapy:.a.systematic. review.and.economic.modelling. By.Connock.M,.Stevens.C,.Fry-Smith. A,.Jowett.S,.Fitzmaurice.D,.Moore.D,. et al. No. 39 A.systematic.review.and.economic. model.of.the.clinical.effectiveness. and.cost-effectiveness.of.interventions. for.preventing.relapse.in.people.with. bipolar.disorder. By.Soares-Weiser.K,.Bravo.Vergel.Y,. Beynon.S,.Dunn.G,.Barbieri.M,.Duffy.S,. et al. No. 40 Taxanes.for.the.adjuvant.treatment.of. early.breast.cancer:.systematic.review. and.economic.evaluation. By.Ward.S,.Simpson.E,.Davis.S,.Hind. D,.Rees.A,.Wilkinson.A. No. 41 The.clinical.effectiveness.and.costeffectiveness.of.screening.for.open. angle.glaucoma:.a.systematic.review. and.economic.evaluation. By.Burr.JM,.Mowatt.G,.Hern\u00e1ndez. R,.Siddiqui.MAR,.Cook.J,.Lourenco.T,. et al. No. 42 Acceptability,.benefit.and.costs.of.early. screening.for.hearing.disability:.a.study. of.potential.screening.tests.and.models. By.Davis.A,.Smith.P,.Ferguson.M,. Stephens.D,.Gianopoulos.I. No. 43 Contamination.in.trials.of.educational. interventions. By.Keogh-Brown.MR,.Bachmann. MO,.Shepstone.L,.Hewitt.C,.Howe.A,. Ramsay.CR,.et al. No. 44 Overview.of.the.clinical.effectiveness.of. positron.emission.tomography.imaging. in.selected.cancers. By.Facey.K,.Bradbury.I,.Laking.G,. Payne.E. No. 45 The.effectiveness.and.cost-effectiveness. of.carmustine.implants.and. temozolomide.for.the.treatment.of. newly.diagnosed.high-grade.glioma:. a.systematic.review.and.economic. evaluation. By.Garside.R,.Pitt.M,.Anderson.R,. Rogers.G,.Dyer.M,.Mealing.S,.et al. No. 46 Drug-eluting.stents:.a.systematic.review. and.economic.evaluation. By.Hill.RA,.Boland.A,.Dickson.R,. Du\u0308ndar.Y,.Haycox.A,.McLeod.C,.et al. No. 47 The.clinical.effectiveness.and. cost-effectiveness.of.cardiac. resynchronisation.(biventricular.pacing). for.heart.failure:.systematic.review.and. economic.model. By.Fox.M,.Mealing.S,.Anderson.R,. Dean.J,.Stein.K,.Price.A,.et al. No. 48 Recruitment.to.randomised.trials:. strategies.for.trial.enrolment.and. participation.study..The.STEPS.study. By.Campbell.MK,.Snowdon.C,.","cites":null},{"id":6013213,"title":"Knight.R,.et al.Health Technology Assessment reports published to date 146","authors":[],"date":"2008","doi":null,"raw":"Francis.D,.Elbourne.D,.McDonald.AM,. Knight.R,.et al.Health Technology Assessment reports published to date 146 No. 49 Cost-effectiveness.of.functional. cardiac.testing.in.the.diagnosis.and. management.of.coronary.artery. disease:.a.randomised.controlled.trial.. The.CECaT.trial. By.Sharples.L,.Hughes.V,.Crean.A,. Dyer.M,.Buxton.M,.Goldsmith.K,.et al. No. 50 Evaluation.of.diagnostic.tests.when. there.is.no.gold.standard..A.review.of. methods. By.Rutjes.AWS,.Reitsma. JB,.Coomarasamy.A,.Khan.KS,. Bossuyt.PMM. No. 51 Systematic.reviews.of.the.clinical. effectiveness.and.cost-effectiveness.of. proton.pump.inhibitors.in.acute.upper. gastrointestinal.bleeding. By.Leontiadis.GI,.Sreedharan. A,.Dorward.S,.Barton.P,.Delaney.B,. Howden.CW,.et al. No. 52 A.review.and.critique.of.modelling.in. prioritising.and.designing.screening. programmes. By.Karnon.J,.Goyder.E,.Tappenden. P,.McPhie.S,.Towers.I,.Brazier.J,.et al. No. 53 An.assessment.of.the.impact.of.the. NHS.Health.Technology.Assessment. Programme. By.Hanney.S,.Buxton.M,.Green.C,. Coulson.D,.Raftery.J. Volume 12, 2008 No. 1 A.systematic.review.and.economic. model.of.switching.from. nonglycopeptide.to.glycopeptide. antibiotic.prophylaxis.for.surgery. By.Cranny.G,.Elliott.R,.Weatherly.H,. Chambers.D,.Hawkins.N,.Myers.L,.et al. No. 2 \u2018Cut.down.to.quit\u2019.with.nicotine. replacement.therapies.in.smoking. cessation:.a.systematic.review.of. effectiveness.and.economic.analysis. By.Wang.D,.Connock.M,.Barton.P,. Fry-Smith.A,.Aveyard.P,.Moore.D. No. 3 A.systematic.review.of.the.effectiveness. of.strategies.for.reducing.fracture.risk. in.children.with.juvenile.idiopathic. arthritis.with.additional.data.on.longterm.risk.of.fracture.and.cost.of.disease. management. By.Thornton.J,.Ashcroft.D,.O\u2019Neill.T,. Elliott.R,.Adams.J,.Roberts.C,.et al. No. 4 Does.befriending.by.trained.lay.workers. improve.psychological.well-being.and. quality.of.life.for.carers.of.people. with.dementia,.and.at.what.cost?.A. randomised.controlled.trial. By.Charlesworth.G,.Shepstone.L,. Wilson.E,.Thalanany.M,.Mugford.M,. Poland.F. No. 5 A.multi-centre.retrospective.cohort. study.comparing.the.efficacy,.safety. and.cost-effectiveness.of.hysterectomy. and.uterine.artery.embolisation.for. the.treatment.of.symptomatic.uterine. fibroids..The.HOPEFUL.study. By.Hirst.A,.Dutton.S,.Wu.O,.Briggs. A,.Edwards.C,.Waldenmaier.L,.et al. No. 6 Methods.of.prediction.and.prevention. of.pre-eclampsia:.systematic.reviews.of. accuracy.and.effectiveness.literature. with.economic.modelling. By.Meads.CA,.Cnossen.JS,.Meher.S,. Juarez-Garcia.A,.ter.Riet.G,.Duley.L,. et al. No. 7 The.use.of.economic.evaluations.in. NHS.decision-making:.a.review.and. empirical.investigation. By.Williams.I,.McIver.S,.Moore.D,. Bryan.S. No. 8 Stapled.haemorrhoidectomy. (haemorrhoidopexy).for.the.treatment. of.haemorrhoids:.a.systematic.review. and.economic.evaluation. By.Burch.J,.Epstein.D,.Baba-Akbari. A,.Weatherly.H,.Fox.D,.Golder.S,.et al. No. 9 The.clinical.effectiveness.of.diabetes. education.models.for.Type.2.diabetes:.a. systematic.review. By.Loveman.E,.Frampton.GK,. Clegg.AJ. No. 10 Payment.to.healthcare.professionals.for. patient.recruitment.to.trials:.systematic. review.and.qualitative.study. By.Raftery.J,.Bryant.J,.Powell.J,. Kerr.C,.Hawker.S. No. 11 Cyclooxygenase-2.selective.nonsteroidal.anti-inflammatory.drugs. (etodolac,.meloxicam,.celecoxib,. rofecoxib,.etoricoxib,.valdecoxib.and. lumiracoxib).for.osteoarthritis.and. rheumatoid.arthritis:.a.systematic. review.and.economic.evaluation. By.Chen.Y-F,.Jobanputra.P,.Barton.P,. Bryan.S,.Fry-Smith.A,.Harris.G,.et al. No. 12 The.clinical.effectiveness.and.costeffectiveness.of.central.venous.catheters. treated.with.anti-infective.agents.in. preventing.bloodstream.infections:. a.systematic.review.and.economic. evaluation. By.Hockenhull.JC,.Dwan.K,.Boland. A,.Smith.G,.Bagust.A,.Dundar.Y,.et al. No. 13 Stepped.treatment.of.older.adults.on. laxatives..The.STOOL.trial. By.Mihaylov.S,.Stark.C,.McColl.E,. Steen.N,.Vanoli.A,.Rubin.G,.et al. No. 14 A.randomised.controlled.trial.of. cognitive.behaviour.therapy.in. adolescents.with.major.depression. treated.by.selective.serotonin.reuptake. inhibitors..The.ADAPT.trial. By.Goodyer.IM,.Dubicka.B,. Wilkinson.P,.Kelvin.R,.Roberts.C,. Byford.S,.et al. No. 15 The.use.of.irinotecan,.oxaliplatin. and.raltitrexed.for.the.treatment.of. advanced.colorectal.cancer:.systematic. review.and.economic.evaluation. By.Hind.D,.Tappenden.P,.Tumur.I,. Eggington.E,.Sutcliffe.P,.Ryan.A. No. 16 Ranibizumab.and.pegaptanib.for. the.treatment.of.age-related.macular. degeneration:.a.systematic.review.and. economic.evaluation. By.Colquitt.JL,.Jones.J,.Tan.SC,. Takeda.A,.Clegg.AJ,.Price.A. No. 17 Systematic.review.of.the.clinical. effectiveness.and.cost-effectiveness. of.64-slice.or.higher.computed. tomography.angiography.as.an. alternative.to.invasive.coronary. angiography.in.the.investigation.of. coronary.artery.disease. By.Mowatt.G,.Cummins.E,.Waugh.N,. Walker.S,.Cook.J,.Jia.X,.et al. No. 18 Structural.neuroimaging.in.psychosis:. a.systematic.review.and.economic. evaluation. By.Albon.E,.Tsourapas.A,.Frew.E,. Davenport.C,.Oyebode.F,.Bayliss.S,.et al. No. 19 Systematic.review.and.economic. analysis.of.the.comparative. effectiveness.of.different.inhaled. corticosteroids.and.their.usage.with. long-acting.beta2.agonists.for.the. treatment.of.chronic.asthma.in.adults. and.children.aged.12.years.and.over. By.Shepherd.J,.Rogers.G,.Anderson.","cites":null},{"id":6013214,"title":"Hartwell.D,.et al.DOI: 10.3310\/hta13470 Health Technology Assessment","authors":[],"date":"2009","doi":null,"raw":"R,.Main.C,.Thompson-Coon.J,. Hartwell.D,.et al.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 147 No. 20 Systematic.review.and.economic. analysis.of.the.comparative. effectiveness.of.different.inhaled. corticosteroids.and.their.usage.with. long-acting.beta2.agonists.for.the. treatment.of.chronic.asthma.in.children. under.the.age.of.12.years. By.Main.C,.Shepherd.J,.Anderson.R,. Rogers.G,.Thompson-Coon.J,.Liu.Z,. et al. No. 21 Ezetimibe.for.the.treatment.of. hypercholesterolaemia:.a.systematic. review.and.economic.evaluation. By.Ara.R,.Tumur.I,.Pandor.A,. Duenas.A,.Williams.R,.Wilkinson.A,.et al. No. 22 Topical.or.oral.ibuprofen.for.chronic. knee.pain.in.older.people..The.TOIB. study. By.Underwood.M,.Ashby.D,.Carnes. D,.Castelnuovo.E,.Cross.P,.Harding.G,. et al. No. 23 A.prospective.randomised.comparison. of.minor.surgery.in.primary.and. secondary.care..The.MiSTIC.trial. By.George.S,.Pockney.P,.Primrose.J,. Smith.H,.Little.P,.Kinley.H,.et al. No. 24 A.review.and.critical.appraisal. of.measures.of.therapist\u2013patient. interactions.in.mental.health.settings. By.Cahill.J,.Barkham.M,.Hardy.G,. Gilbody.S,.Richards.D,.Bower.P,.et al. No. 25 The.clinical.effectiveness.and.costeffectiveness.of.screening.programmes. for.amblyopia.and.strabismus.in. children.up.to.the.age.of.4\u20135.years:. a.systematic.review.and.economic. evaluation. By.Carlton.J,.Karnon.J,.CzoskiMurray.C,.Smith.KJ,.Marr.J. No. 26 A.systematic.review.of.the.clinical. effectiveness.and.cost-effectiveness. and.economic.modelling.of.minimal. incision.total.hip.replacement. approaches.in.the.management.of. arthritic.disease.of.the.hip. By.de.Verteuil.R,.Imamura.M,.Zhu.S,. Glazener.C,.Fraser.C,.Munro.N,.et al. No. 27 A.preliminary.model-based.assessment. of.the.cost\u2013utility.of.a.screening. programme.for.early.age-related. macular.degeneration. By.Karnon.J,.Czoski-Murray.C,. Smith.K,.Brand.C,.Chakravarthy.U,. Davis.S,.et al. No. 28 Intravenous.magnesium.sulphate. and.sotalol.for.prevention.of.atrial. fibrillation.after.coronary.artery. bypass.surgery:.a.systematic.review.and. economic.evaluation. By.Shepherd.J,.Jones.J,.Frampton. GK,.Tanajewski.L,.Turner.D,.Price.A. No. 29 Absorbent.products.for.urinary\/faecal. incontinence:.a.comparative.evaluation. of.key.product.categories. By.Fader.M,.Cottenden.A,.Getliffe.K,. Gage.H,.Clarke-O\u2019Neill.S,.Jamieson.K,. et al. No. 30 A.systematic.review.of.repetitive. functional.task.practice.with.modelling. of.resource.use,.costs.and.effectiveness. By.French.B,.Leathley.M,.Sutton.C,. McAdam.J,.Thomas.L,.Forster.A,.et al. No. 31 The.effectiveness.and.cost-effectivness. of.minimal.access.surgery.amongst. people.with.gastro-oesophageal.reflux. disease.\u2013.a.UK.collaborative.study..The. reflux.trial. By.Grant.A,.Wileman.S,.Ramsay.C,. Bojke.L,.Epstein.D,.Sculpher.M,.et al. No. 32 Time.to.full.publication.of.studies.of. anti-cancer.medicines.for.breast.cancer. and.the.potential.for.publication.bias:.a. short.systematic.review. By.Takeda.A,.Loveman.E,.Harris.P,. Hartwell.D,.Welch.K. No. 33 Performance.of.screening.tests.for. child.physical.abuse.in.accident.and. emergency.departments. By.Woodman.J,.Pitt.M,.Wentz.R,. Taylor.B,.Hodes.D,.Gilbert.RE. No. 34 Curative.catheter.ablation.in.atrial. fibrillation.and.typical.atrial.flutter:. systematic.review.and.economic. evaluation. By.Rodgers.M,.McKenna.C,.Palmer. S,.Chambers.D,.Van.Hout.S,.Golder.S,. et al. No. 35 Systematic.review.and.economic. modelling.of.effectiveness.and.cost. utility.of.surgical.treatments.for.men. with.benign.prostatic.enlargement. By.Lourenco.T,.Armstrong.N,.N\u2019Dow. J,.Nabi.G,.Deverill.M,.Pickard.R,.et al. No. 36 Immunoprophylaxis.against.respiratory. syncytial.virus.(RSV).with.palivizumab. in.children:.a.systematic.review.and. economic.evaluation. By.Wang.D,.Cummins.C,.Bayliss.S,. Sandercock.J,.Burls.A. Volume 13, 2009 No. 1 Deferasirox.for.the.treatment.of.iron. overload.associated.with.regular. blood.transfusions.(transfusional. haemosiderosis).in.patients.suffering. with.chronic.anaemia:.a.systematic. review.and.economic.evaluation. By.McLeod.C,.Fleeman.N,.Kirkham. J,.Bagust.A,.Boland.A,.Chu.P,.et al. No. 2 Thrombophilia.testing.in.people.with. venous.thromboembolism:.systematic. review.and.cost-effectiveness.analysis. By.Simpson.EL,.Stevenson.MD,. Rawdin.A,.Papaioannou.D. No. 3 Surgical.procedures.and.non-surgical. devices.for.the.management.of.nonapnoeic.snoring:.a.systematic.review.of. clinical.effects.and.associated.treatment. costs. By.Main.C,.Liu.Z,.Welch.K,.Weiner. G,.Quentin.Jones.S,.Stein.K. No. 4 Continuous.positive.airway.pressure. devices.for.the.treatment.of.obstructive. sleep.apnoea\u2013hypopnoea.syndrome:.a. systematic.review.and.economic.analysis. By.McDaid.C,.Griffin.S,.Weatherly.H,. Dur\u00e9e.K,.van.der.Burgt.M,.van.Hout.S,. Akers.J,.et al. No. 5 Use.of.classical.and.novel.biomarkers. as.prognostic.risk.factors.for.localised. prostate.cancer:.a.systematic.review. By.Sutcliffe.P,.Hummel.S,.Simpson.E,. Young.T,.Rees.A,.Wilkinson.A,.et al. No. 6 The.harmful.health.effects.of. recreational.ecstasy:.a.systematic.review. of.observational.evidence. By.Rogers.G,.Elston.J,.Garside.R,. Roome.C,.Taylor.R,.Younger.P,.et al. No. 7 Systematic.review.of.the.clinical. effectiveness.and.cost-effectiveness. of.oesophageal.Doppler.monitoring. in.critically.ill.and.high-risk.surgical. patients. By.Mowatt.G,.Houston.G,.Hern\u00e1ndez. R,.de.Verteuil.R,.Fraser.C,.Cuthbertson. B,.et al. No. 8 The.use.of.surrogate.outcomes.in. model-based.cost-effectiveness.analyses:. a.survey.of.UK.Health.Technology. Assessment.reports. By.Taylor.RS,.Elston.J. No. 9 Controlling.Hypertension.and. Hypotension.Immediately.Post.Stroke. (CHHIPS).\u2013.a.randomised.controlled. trial. By.Potter.J,.Mistri.A,.Brodie.F,. Chernova.J,.Wilson.E,.Jagger.C,.et al.Health Technology Assessment reports published to date 148 No. 10 Routine.antenatal.anti-D.prophylaxis. for.RhD-negative.women:.a.systematic. review.and.economic.evaluation. By.Pilgrim.H,.Lloyd-Jones.M,.Rees.A. No. 11 Amantadine,.oseltamivir.and.zanamivir. for.the.prophylaxis.of.influenza. (including.a.review.of.existing.guidance. no..67):.a.systematic.review.and. economic.evaluation. By.Tappenden.P,.Jackson.R,.Cooper. K,.Rees.A,.Simpson.E,.Read.R,.et al. No. 12 Improving.the.evaluation.of. therapeutic.interventions.in.multiple. sclerosis:.the.role.of.new.psychometric. methods. By.Hobart.J,.Cano.S. No. 13 Treatment.of.severe.ankle.sprain:.a. pragmatic.randomised.controlled.trial. comparing.the.clinical.effectiveness. and.cost-effectiveness.of.three.types.of. mechanical.ankle.support.with.tubular. bandage..The.CAST.trial. By.Cooke.MW,.Marsh.JL,.Clark.M,. Nakash.R,.Jarvis.RM,.Hutton.JL,.et al.,. on.behalf.of.the.CAST.trial.group. No. 14 Non-occupational.postexposure. prophylaxis.for.HIV:.a.systematic. review. By.Bryant.J,.Baxter.L,.Hird.S. No. 15 Blood.glucose.self-monitoring.in.type.2. diabetes:.a.randomised.controlled.trial. By.Farmer.AJ,.Wade.AN,.French.DP,. Simon.J,.Yudkin.P,.Gray.A,.et al. No. 16 How.far.does.screening.women.for. domestic.(partner).violence.in.different. health-care.settings.meet.criteria.for. a.screening.programme?.Systematic. reviews.of.nine.UK.National.Screening. Committee.criteria. By.Feder.G,.Ramsay.J,.Dunne.D,. Rose.M,.Arsene.C,.Norman.R,.et al. No. 17 Spinal.cord.stimulation.for.chronic. pain.of.neuropathic.or.ischaemic. origin:.systematic.review.and.economic. evaluation. By.Simpson,.EL,.Duenas.A,.Holmes. MW,.Papaioannou.D,.Chilcott.J. No. 18 The.role.of.magnetic.resonance. imaging.in.the.identification.of. suspected.acoustic.neuroma:.a. systematic.review.of.clinical.and.costeffectiveness.and.natural.history. By.Fortnum.H,.O\u2019Neill.C,.Taylor.R,. Lenthall.R,.Nikolopoulos.T,.Lightfoot. G,.et al. No. 19 Dipsticks.and.diagnostic.algorithms.in. urinary.tract.infection:.development. and.validation,.randomised.trial,. economic.analysis,.observational.cohort. and.qualitative.study. By.Little.P,.Turner.S,.Rumsby.K,. Warner.G,.Moore.M,.Lowes.JA, et al. No. 20 Systematic.review.of.respite.care.in.the. frail.elderly. By.Shaw.C,.McNamara.R,.Abrams. K,.Cannings-John.R,.Hood.K,.Longo. M, et al. No. 21 Neuroleptics.in.the.treatment.of. aggressive.challenging.behaviour.for. people.with.intellectual.disabilities:. a.randomised.controlled.trial. (NACHBID). By.Tyrer.P,.Oliver-Africano.P,.Romeo. R,.Knapp.M,.Dickens.S,.Bouras.N, et al. No. 22 Randomised.controlled.trial.to. determine.the.clinical.effectiveness. and.cost-effectiveness.of.selective. serotonin.reuptake.inhibitors.plus. supportive.care,.versus.supportive.care. alone,.for.mild.to.moderate.depression. with.somatic.symptoms.in.primary. care:.the.THREAD.(THREshold.for. AntiDepressant.response).study. By.Kendrick.T,.Chatwin.J,.Dowrick.C,. Tylee.A,.Morriss.R,.Peveler.R, et al. No. 23 Diagnostic.strategies.using.DNA.testing. for.hereditary.haemochromatosis.in. at-risk.populations:.a.systematic.review. and.economic.evaluation. By.Bryant.J,.Cooper.K,.Picot.J,.Clegg. A,.Roderick.P,.Rosenberg.W,.et al. No. 24 Enhanced.external.counterpulsation. for.the.treatment.of.stable.angina.and. heart.failure:.a.systematic.review.and. economic.analysis. By.McKenna.C,.McDaid.C,. Suekarran.S,.Hawkins.N,.Claxton.K,. Light.K,.et al. No. 25 Development.of.a.decision.support. tool.for.primary.care.management.of. patients.with.abnormal.liver.function. tests.without.clinically.apparent.liver. disease:.a.record-linkage.population. cohort.study.and.decision.analysis. (ALFIE). By.Donnan.PT,.McLernon.D,.Dillon. JF,.Ryder.S,.Roderick.P,.Sullivan.F,.et al. No. 26 A.systematic.review.of.presumed. consent.systems.for.deceased.organ. donation. By.Rithalia.A,.McDaid.C,.Suekarran. S,.Norman.G,.Myers.L,.Sowden.A. No. 27 Paracetamol.and.ibuprofen.for.the. treatment.of.fever.in.children:.the. PITCH.randomised.controlled.trial. By.Hay.AD,.Redmond.NM,.Costelloe. C,.Montgomery.AA,.Fletcher.M,. Hollinghurst..S,.et al. No. 28 A.randomised.controlled.trial.to. compare.minimally.invasive.glucose. monitoring.devices.with.conventional. monitoring.in.the.management.of. insulin-treated.diabetes.mellitus. (MITRE). By.Newman.SP,.Cooke.D,.Casbard.A,. Walker.S,.Meredith.S,.Nunn.A,.et al. No. 29 Sensitivity.analysis.in.economic. evaluation:.an.audit.of.NICE.current. practice.and.a.review.of.its.use.and. value.in.decision-making. By.Andronis.L,.Barton.P,.Bryan.S. Suppl. 1 Trastuzumab.for.the.treatment.of. primary.breast.cancer.in.HER2-positive. women:.a.single.technology.appraisal. By.Ward.S,.Pilgrim.H,.Hind.D. Docetaxel.for.the.adjuvant.treatment. of.early.node-positive.breast.cancer:.a. single.technology.appraisal. By.Chilcott.J,.Lloyd.Jones.M,. Wilkinson.A. The.use.of.paclitaxel.in.the. management.of.early.stage.breast. cancer. By.Griffin.S,.Dunn.G,.Palmer.S,. Macfarlane.K,.Brent.S,.Dyker.A,.et al. Rituximab.for.the.first-line.treatment. of.stage.III\/IV.follicular.non-Hodgkin\u2019s. lymphoma. By.Dundar.Y,.Bagust.A,.Hounsome.J,. McLeod.C,.Boland.A,.Davis.H,.et al. Bortezomib.for.the.treatment.of. multiple.myeloma.patients. By.Green.C,.Bryant.J,.Takeda.A,. Cooper.K,.Clegg.A,.Smith.A,.et al. Fludarabine.phosphate.for.the.firstline.treatment.of.chronic.lymphocytic. leukaemia. By.Walker.S,.Palmer.S,.Erhorn.S,. Brent.S,.Dyker.A,.Ferrie.L,.et al. Erlotinib.for.the.treatment.of.relapsed. non-small.cell.lung.cancer. By.McLeod.C,.Bagust.A,.Boland.A,. Hockenhull.J,.Dundar.Y,.Proudlove.C,. et al. Cetuximab.plus.radiotherapy.for.the. treatment.of.locally.advanced.squamous. cell.carcinoma.of.the.head.and.neck. By.Griffin.S,.Walker.S,.Sculpher.M,. White.S,.Erhorn.S,.Brent.S,.et al. Infliximab.for.the.treatment.of.adults. with.psoriasis. By.Loveman.E,.Turner.D,.Hartwell.","cites":null},{"id":6013217,"title":"Queen\u2019s Printer and Controller of HMSO. All rights reserved. 153 Therapeutic.Procedures.Panel Members Chair, Dr","authors":[],"date":"2009","doi":null,"raw":"Department.of.HealthDOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47 \u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved. 153 Therapeutic.Procedures.Panel Members Chair, Dr John C Pounsford, Consultant.Physician,.North. Bristol.NHS.Trust Deputy Chair, Professor Scott Weich, Professor.of.Psychiatry,.Division. of.Health.in.the.Community,. University.of.Warwick,. Coventry Professor.Jane.Barlow, Professor.of.Public.Health.in. the.Early.Years,.Health.Sciences. Research.Institute,.Warwick. Medical.School,.Coventry Ms.Maree.Barnett, Acting.Branch.Head.of.Vascular. Programme,.Department.of. Health Mrs.Val.Carlill, Service.User.Representative Mrs.Anthea.De.Barton-Watson, Service.User.Representative Mr.Mark.Emberton, Senior.Lecturer.in.Oncological. Urology,.Institute.of.Urology,. University.College.Hospital,. London Professor.Steve.Goodacre, Professor.of.Emergency. Medicine,.University.of. Sheffield Professor.Christopher.Griffiths, Professor.of.Primary.Care,.Barts. and.The.London.School.of. Medicine.and.Dentistry Mr.Paul.Hilton, Consultant.Gynaecologist. and.Urogynaecologist,.Royal. Victoria.Infirmary,.Newcastle. upon.Tyne Professor.Nicholas.James,. Professor.of.Clinical.Oncology,. University.of.Birmingham,. and.Consultant.in.Clinical. Oncology,.Queen.Elizabeth. Hospital Dr.Peter.Martin, Consultant.Neurologist,. Addenbrooke\u2019s.Hospital,. Cambridge Dr.Kate.Radford, Senior.Lecturer.(Research),. Clinical.Practice.Research. Unit,.University.of.Central. Lancashire,.Preston Mr.Jim.Reece Service.User.Representative Dr.Karen.Roberts, Nurse.Consultant,.Dunston.Hill. Hospital.Cottages Observers Dr.Phillip.Leech, Principal.Medical.Officer.for. Primary.Care,.Department.of. Health Ms.Kay.Pattison, Section.Head,.NHS.R&D. Programme,.Department.of. Health Dr.Morven.Roberts, Clinical.Trials.Manager,. Medical.Research.Council Professor.Tom.Walley, Director,.NIHR.HTA. programme,.Professor.of. Clinical.Pharmacology,. University.of.Liverpool Disease.Prevention.Panel Members Chair, Dr Edmund Jessop, Medical.Adviser,.National. Specialist,.National. Commissioning.Group.(NCG),. London Deputy Chair, Dr David Pencheon, Director,.NHS.Sustainable. Development.Unit,.Cambridge Dr.Elizabeth.Fellow-Smith, Medical.Director,.West.London. Mental.Health.Trust,.Middlesex Dr.John.Jackson, General.Practitioner,.Parkway. Medical.Centre,.Newcastle. upon.Tyne Professor.Mike.Kelly, Director,.Centre.for.Public. Health.Excellence,.NICE,. London Dr.Chris.McCall, General.Practitioner,.The. Hadleigh.Practice,.Corfe. Mullen,.Dorset Ms.Jeanett.Martin, Director.of.Nursing,..BarnDoc. Limited,.Lewisham.Primary. Care.Trust Dr.Julie.Mytton, Locum.Consultant.in.Public. Health.Medicine,.Bristol. Primary.Care.Trust Miss.Nicky.Mullany, Service.User.Representative Professor.Ian.Roberts, Professor.of.Epidemiology.and. Public.Health,.London.School. of.Hygiene.&.Tropical.Medicine Professor.Ken.Stein, Senior.Clinical.Lecturer.in. Public.Health,.University.of. Exeter Observers Ms.Christine.McGuire, Research.&.Development,. Department.of.Health Dr.Caroline.Stone, Programme.Manager,.Medical. Research.Council Dr.Ursula.Wells, Principal.Research.Officer,. Department.of.Health Dr.Kieran.Sweeney, Honorary.Clinical.Senior. Lecturer,.Peninsula.College. of.Medicine.and.Dentistry,. Universities.of.Exeter.and. Plymouth Professor.Carol.Tannahill, Glasgow.Centre.for.Population. Health Professor.Margaret.Thorogood, Professor.of.Epidemiology,. University.of.Warwick.Medical. School,.CoventryHealth Technology Assessment programme 154 Current and past membership details of all HTA programme \u2018committees\u2019 are available from the HTA website (www.hta.ac.uk) Expert.Advisory.Network Members Professor.Douglas.Altman, Professor.of.Statistics.in. Medicine,.Centre.for.Statistics. in.Medicine,.University.of. Oxford Professor.John.Bond, Professor.of.Social.Gerontology. &.Health.Services.Research,. University.of.Newcastle.upon. Tyne Professor.Andrew.Bradbury, Professor.of.Vascular.Surgery,. Solihull.Hospital,.Birmingham Mr.Shaun.Brogan, Chief.Executive,.Ridgeway. Primary.Care.Group,.Aylesbury Mrs.Stella.Burnside.OBE, Chief.Executive,.Regulation. and.Improvement.Authority,. Belfast Ms.Tracy.Bury, Project.Manager,.World. Confederation.for.Physical. Therapy,.London Professor.Iain.T.Cameron, Professor.of.Obstetrics.and. Gynaecology.and.Head.of.the. School.of.Medicine,.University. of.Southampton Dr.Christine.Clark, Medical.Writer.and.Consultant. Pharmacist,.Rossendale Professor.Collette.Clifford, Professor.of.Nursing.and. Head.of.Research,.The. Medical.School,.University.of. Birmingham Professor.Barry.Cookson, Director,.Laboratory.of.Hospital. Infection,.Public.Health. Laboratory.Service,.London Dr.Carl.Counsell, Clinical.Senior.Lecturer.in. Neurology,.University.of. Aberdeen Professor.Howard.Cuckle, Professor.of.Reproductive. Epidemiology,.Department. of.Paediatrics,.Obstetrics.&. Gynaecology,.University.of. Leeds Dr.Katherine.Darton, Information.Unit,.MIND.\u2013.The. Mental.Health.Charity,.London Professor.Carol.Dezateux, Professor.of.Paediatric. Epidemiology,.Institute.of.Child. Health,.London Mr.John.Dunning,. Consultant.Cardiothoracic. Surgeon,.Papworth.Hospital. NHS.Trust,.Cambridge Mr.Jonothan.Earnshaw, Consultant.Vascular.Surgeon,. Gloucestershire.Royal.Hospital,. Gloucester Professor.Martin.Eccles, Professor.of.Clinical. Effectiveness,.Centre.for.Health. Services.Research,.University.of. Newcastle.upon.Tyne Professor.Pam.Enderby, Dean.of.Faculty.of.Medicine,. Institute.of.General.Practice. and.Primary.Care,.University.of. Sheffield Professor.Gene.Feder, Professor.of.Primary.Care. Research.&.Development,. Centre.for.Health.Sciences,. Barts.and.The.London.School. of.Medicine.and.Dentistry Mr.Leonard.R.Fenwick, Chief.Executive,.Freeman. Hospital,.Newcastle.upon.Tyne Mrs.Gillian.Fletcher, Antenatal.Teacher.and.Tutor. and.President,.National. Childbirth.Trust,.Henfield Professor.Jayne.Franklyn, Professor.of.Medicine,. University.of.Birmingham Mr.Tam.Fry, Honorary.Chairman,.Child. Growth.Foundation,.London Professor.Fiona.Gilbert, Consultant.Radiologist.and. NCRN.Member,.University.of. Aberdeen Professor.Paul.Gregg, Professor.of.Orthopaedic. Surgical.Science,.South.Tees. Hospital.NHS.Trust Bec.Hanley, Co-director,.TwoCan.Associates,. West.Sussex Dr.Maryann.L.Hardy, Senior.Lecturer,.University.of. Bradford Mrs.Sharon.Hart, Healthcare.Management. Consultant,.Reading Professor.Robert.E.Hawkins, CRC.Professor.and.Director. of.Medical.Oncology,.Christie. CRC.Research.Centre,. Christie.Hospital.NHS.Trust,. Manchester Professor.Richard.Hobbs, Head.of.Department.of.Primary. Care.&.General.Practice,. University.of.Birmingham Professor.Alan.Horwich, Dean.and.Section.Chairman,. The.Institute.of.Cancer. Research,.London Professor.Allen.Hutchinson, Director.of.Public.Health.and. Deputy.Dean.of.ScHARR,. University.of.Sheffield Professor.Peter.Jones, Professor.of.Psychiatry,. University.of.Cambridge,. Cambridge Professor.Stan.Kaye, Cancer.Research.UK.Professor. of.Medical.Oncology,.Royal. Marsden.Hospital.and.Institute. of.Cancer.Research,.Surrey Dr.Duncan.Keeley, General.Practitioner.(Dr.Burch. &.Ptnrs),.The.Health.Centre,. Thame Dr.Donna.Lamping, Research.Degrees.Programme. Director.and.Reader.in. Psychology,.Health.Services. Research.Unit,.London.School. of.Hygiene.and.Tropical. Medicine,.London Mr.George.Levvy, Chief.Executive,.Motor. Neurone.Disease.Association,. Northampton Professor.James.Lindesay, Professor.of.Psychiatry.for.the. Elderly,.University.of.Leicester Professor.Julian.Little, Professor.of.Human.Genome. Epidemiology,.University.of. Ottawa Professor.Alistaire.McGuire, Professor.of.Health.Economics,. London.School.of.Economics Professor.Rajan.Madhok, Medical.Director.and.Director. of.Public.Health,.Directorate. of.Clinical.Strategy.&.Public. Health,.North.&.East.Yorkshire. &.Northern.Lincolnshire. Health.Authority,.York Professor.Alexander.Markham, Director,.Molecular.Medicine. Unit,.St.James\u2019s.University. Hospital,.Leeds Dr.Peter.Moore, Freelance.Science.Writer,. Ashtead Dr.Andrew.Mortimore, Public.Health.Director,. Southampton.City.Primary. Care.Trust Dr.Sue.Moss, Associate.Director,.Cancer. Screening.Evaluation.Unit,. Institute.of.Cancer.Research,. Sutton Professor.Miranda.Mugford, Professor.of.Health.Economics. and.Group.Co-ordinator,. University.of.East.Anglia Professor.Jim.Neilson, Head.of.School.of.Reproductive. &.Developmental.Medicine. and.Professor.of.Obstetrics. and.Gynaecology,.University.of. Liverpool Mrs.Julietta.Patnick, National.Co-ordinator,.NHS. Cancer.Screening.Programmes,. Sheffield Professor.Robert.Peveler, Professor.of.Liaison.Psychiatry,. Royal.South.Hants.Hospital,. Southampton Professor.Chris.Price, Director.of.Clinical.Research,. Bayer.Diagnostics.Europe,. Stoke.Poges Professor.William.Rosenberg, Professor.of.Hepatology. and.Consultant.Physician,. University.of.Southampton Professor.Peter.Sandercock, Professor.of.Medical.Neurology,. Department.of.Clinical. Neurosciences,.University.of. Edinburgh Dr.Susan.Schonfield, Consultant.in.Public.Health,. Hillingdon.Primary.Care.Trust,. Middlesex Dr.Eamonn.Sheridan, Consultant.in.Clinical.Genetics,. St.James\u2019s.University.Hospital,. Leeds Dr.Margaret.Somerville, Director.of.Public.Health. Learning,.Peninsula.Medical. School,.University.of.Plymouth Professor.Sarah.Stewart-Brown, Professor.of.Public.Health,. Division.of.Health.in.the. Community,.University.of. Warwick,.Coventry Professor.Ala.Szczepura, Professor.of.Health.Service. Research,.Centre.for.Health. Services.Studies,.University.of. Warwick,.Coventry Mrs.Joan.Webster, Consumer.Member,.Southern. Derbyshire.Community.Health. Council Professor.Martin.Whittle, Clinical.Co-director,.National. Co-ordinating.Centre.for. Women\u2019s.and.Children\u2019s.","cites":null}],"documentType":{"type":null}},"contributors":["University of Aberdeen, School of Medicine & Dentistry, Division of Applied Health Sciences"],"datePublished":"2009-10","abstract":"Objective: To determine whether oral prednisolone or aciclovir, used separately or in combination, early in the course of Bell\u2019s palsy, improves the chances of recovery at 3 and 9 months. Design: A 2 \u00d7 2 factorial randomised double-blind trial. Patients were randomly assigned to treatment by an automated telephone service using a permuted block randomisation technique with block sizes of four or eight, and no stratification. Setting: Mainland Scotland, with referrals mainly from general practice to 17 hospital trial sites. Participants: Adults (aged 16 years or older) with unilateral facial nerve weakness of no identifiable cause presenting to primary care, the emergency department or NHS24 within 72 hours of symptom onset. Interventions: Patients were randomised to receive active preparations or placebo for 10 days: (1) prednisolone (50 mg per day, 2 \u00d7 25-mg capsules) and aciclovir (2000 mg per day, 5 \u00d7 400-mg capsules); (2) prednisolone and placebo (lactose, indistinguishable); (3) aciclovir and placebo; and (4) placebo and placebo. Outcome measures: The primary outcome was recovery of facial function assessed by the House\u2013 Brackmann scale. Secondary outcomes included health status, pain, self-perceived appearance and costeffectivenes Results: Final outcomes were available for 496 patients, balanced for gender; mean age 44 years; initial facial paralysis moderate to severe. One half of patients initiated treatment within 24 hours of onset of symptoms, one-third within 24\u201348 hours and the remainder within 48\u201372 hours. Of the completed patients, 357 had recovered by 3 months and 80 at 9 months, leaving 59 with a residual deficit. There were significant differences in complete recovery at 3 months between the prednisolone comparison groups\\ud\n(83.0% for prednisolone, 63.6% for no prednisolone, a difference of + 19.4%; 95% confidence interval (CI): + 11.7% to + 27.1%, p < 0.001). The number needed to treat (NNT) in order to achieve one additional complete recovery was 6 (95% CI: 4 to 9). There was no significant difference between the acyclovir comparison groups (71.2% for aciclovir and 75.7% for no aciclovir). Nine-month assessments of patients recovered were 94.4% for prednisolone compared with 81.6% for no prednisolone, a difference of + 12.8% (95% CI: + 7.2% to + 18.4%, p < 0.001); the NNT was 8 (95% CI: 6 to 14). Proportions recovered at 9 months were 85.4% for aciclovir and 90.8% for no aciclovir, a difference of \u2013 5.3%. There was no significant prednisolone\u2013aciclovir interaction at 3 months or at 9 months. Outcome differences by individual treatment (the four-arm model) showed significant differences. At 3 months the recovery rate was 86.3% in the prednisolone treatment group, 79.7% in the aciclovir\u2013 prednisolone group, 64.7% in the placebo group and 62.5% in the aciclovir group. At 9 months the recovery rates were respectively 96.1%, 92.7%, 85.3% and 78.1%. The increase in recovery rate conferred by the addition of prednisolone (both for prednisolone over placebo and for aciclovir\u2013prednisolone over aciclovir) is highly statistically significant (p < 0.001). There were no significant differences in secondary measures apart from Health Utilities Index Mark 3 (HUI3) at 9 months in those treated with prednisolone. Conclusions: This study provided robust evidence to support the early use of oral prednisolone in Bell\u2019s palsy as an effective treatment which may be considered costeffective. Treatment with aciclovir, either alone or with steroids, had no effect on outcome. Trial registration: Current Controlled Trials ISRCTN71548196.The Chief Scientist Office of the Scottish Government Health Directorates. The University of Dundee.Peer reviewedPublisher PD","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":"Gray Publications","rawRecordXml":"<record><header><identifier>\n        \n            \n                oai:aura.abdn.ac.uk:2164\/291<\/identifier><datestamp>\n                2010-12-20T12:15:57Z<\/datestamp><setSpec>\n                com_2164_632<\/setSpec><setSpec>\n                com_2164_364<\/setSpec><setSpec>\n                com_2164_330<\/setSpec><setSpec>\n                com_2164_705<\/setSpec><setSpec>\n                col_2164_633<\/setSpec><setSpec>\n                col_2164_706<\/setSpec>\n            <\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:doc=\"http:\/\/www.lyncode.com\/xoai\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:title>\n            \nA randomised controlled trial of the use of aciclovir and\/or prednisolone for the early treatment of Bell\u2019s palsy: the BELLS study<\/dc:title><dc:creator>\nSullivan, F.M.<\/dc:creator><dc:creator>\nSwan, I.R.C<\/dc:creator><dc:creator>\nDonnan, P.T.<\/dc:creator><dc:creator>\nMorrison, J.M.<\/dc:creator><dc:creator>\nSmith, Blair Hamilton<\/dc:creator><dc:creator>\nMcKinstry, B<\/dc:creator><dc:creator>\nDavenport, R.J.<\/dc:creator><dc:creator>\nVale, Luke David<\/dc:creator><dc:creator>\nClarkson, J.E.<\/dc:creator><dc:creator>\nHern\u00e1ndez, Rodolfo Andr\u00e9s<\/dc:creator><dc:creator>\nStewart, K<\/dc:creator><dc:creator>\nHammersley, V<\/dc:creator><dc:creator>\nHayavi, S<\/dc:creator><dc:creator>\nMcAteer, Anne<\/dc:creator><dc:creator>\nGray, Denise Ann<\/dc:creator><dc:creator>\nDaley, F<\/dc:creator><dc:contributor>\nUniversity of Aberdeen, School of Medicine & Dentistry, Division of Applied Health Sciences<\/dc:contributor><dc:subject>\nAnti-inflammatory Agents<\/dc:subject><dc:subject>\nAntiviral Agents<\/dc:subject><dc:subject>\nBells Palsy<\/dc:subject><dc:subject>\nRC Internal medicine<\/dc:subject><dc:description>\nObjective: To determine whether oral prednisolone or aciclovir, used separately or in combination, early in the course of Bell\u2019s palsy, improves the chances of recovery at 3 and 9 months. Design: A 2 \u00d7 2 factorial randomised double-blind trial. Patients were randomly assigned to treatment by an automated telephone service using a permuted block randomisation technique with block sizes of four or eight, and no stratification. Setting: Mainland Scotland, with referrals mainly from general practice to 17 hospital trial sites. Participants: Adults (aged 16 years or older) with unilateral facial nerve weakness of no identifiable cause presenting to primary care, the emergency department or NHS24 within 72 hours of symptom onset. Interventions: Patients were randomised to receive active preparations or placebo for 10 days: (1) prednisolone (50 mg per day, 2 \u00d7 25-mg capsules) and aciclovir (2000 mg per day, 5 \u00d7 400-mg capsules); (2) prednisolone and placebo (lactose, indistinguishable); (3) aciclovir and placebo; and (4) placebo and placebo. Outcome measures: The primary outcome was recovery of facial function assessed by the House\u2013 Brackmann scale. Secondary outcomes included health status, pain, self-perceived appearance and costeffectivenes Results: Final outcomes were available for 496 patients, balanced for gender; mean age 44 years; initial facial paralysis moderate to severe. One half of patients initiated treatment within 24 hours of onset of symptoms, one-third within 24\u201348 hours and the remainder within 48\u201372 hours. Of the completed patients, 357 had recovered by 3 months and 80 at 9 months, leaving 59 with a residual deficit. There were significant differences in complete recovery at 3 months between the prednisolone comparison groups\\ud\n(83.0% for prednisolone, 63.6% for no prednisolone, a difference of + 19.4%; 95% confidence interval (CI): + 11.7% to + 27.1%, p < 0.001). The number needed to treat (NNT) in order to achieve one additional complete recovery was 6 (95% CI: 4 to 9). There was no significant difference between the acyclovir comparison groups (71.2% for aciclovir and 75.7% for no aciclovir). Nine-month assessments of patients recovered were 94.4% for prednisolone compared with 81.6% for no prednisolone, a difference of + 12.8% (95% CI: + 7.2% to + 18.4%, p < 0.001); the NNT was 8 (95% CI: 6 to 14). Proportions recovered at 9 months were 85.4% for aciclovir and 90.8% for no aciclovir, a difference of \u2013 5.3%. There was no significant prednisolone\u2013aciclovir interaction at 3 months or at 9 months. Outcome differences by individual treatment (the four-arm model) showed significant differences. At 3 months the recovery rate was 86.3% in the prednisolone treatment group, 79.7% in the aciclovir\u2013 prednisolone group, 64.7% in the placebo group and 62.5% in the aciclovir group. At 9 months the recovery rates were respectively 96.1%, 92.7%, 85.3% and 78.1%. The increase in recovery rate conferred by the addition of prednisolone (both for prednisolone over placebo and for aciclovir\u2013prednisolone over aciclovir) is highly statistically significant (p < 0.001). There were no significant differences in secondary measures apart from Health Utilities Index Mark 3 (HUI3) at 9 months in those treated with prednisolone. Conclusions: This study provided robust evidence to support the early use of oral prednisolone in Bell\u2019s palsy as an effective treatment which may be considered costeffective. Treatment with aciclovir, either alone or with steroids, had no effect on outcome. Trial registration: Current Controlled Trials ISRCTN71548196.<\/dc:description><dc:description>\nThe Chief Scientist Office of the Scottish Government Health Directorates. The University of Dundee.<\/dc:description><dc:description>\nPeer reviewed<\/dc:description><dc:description>\nPublisher PDF<\/dc:description><dc:date>\n2009-11-24T15:34:46Z<\/dc:date><dc:date>\n2009-11-24T15:34:46Z<\/dc:date><dc:date>\n2009-10<\/dc:date><dc:type>\nJournal Article<\/dc:type><dc:type>\nText<\/dc:type><dc:identifier>\nSullivan, F.M., Swan, I.R.C., Donnan, P.T., Morrison, J.M., Smith, B.H., McKinstry, B., Davenport, R.J., Vale, L.D., Clarkson, J.E., Hernandez, R., Stewart, K., Hammersley, V., Hayavi, S., McAteer, A., Gray, D., and Daley, F., (2009) A randomised controlled trial of the use of aciclovir and\/or prednisolone for the early treatment of Bell\u2019s palsy: the BELLS study. Health Technology Assessment, 13 (47), pp. 1-151.<\/dc:identifier><dc:identifier>\n1366-5278<\/dc:identifier><dc:identifier>\nPURE: 847386<\/dc:identifier><dc:identifier>\nhttp:\/\/hdl.handle.net\/2164\/291<\/dc:identifier><dc:identifier>\nhttp:\/\/dx.doi.org\/10.3310\/hta13470<\/dc:identifier><dc:language>\nen<\/dc:language><dc:format>\n2193472 bytes<\/dc:format><dc:format>\n151 p.<\/dc:format><dc:format>\napplication\/pdf<\/dc:format><dc:publisher>\nGray Publications<\/dc:publisher>\n<\/oai_dc:dc>\n<\/metadata>\n        <\/record>","journals":[{"title":null,"identifiers":["issn:1366-5278","1366-5278"]}],"language":{"code":"en","id":9,"name":"English"},"relations":[],"year":2009,"topics":["Anti-inflammatory Agents","Antiviral Agents","Bells Palsy","RC Internal medicine"],"subject":["Journal Article","Text"],"fullText":"Health Technology Assessment 2009; Vol. 13: No. 47\nHealth Technology Assessment\nNIHR HTA programme\nwww.hta.ac.uk\nOctober 2009\nDOI: 10.3310\/hta13470\nA randomised controlled trial of the \nuse of aciclovir and\/or prednisolone for \nthe early treatment of Bell\u2019s palsy: the \nBELLS study\nFM Sullivan, IRC Swan, PT Donnan,  \nJM Morrison, BH Smith, B McKinstry,  \nRJ Davenport, LD Vale, JE Clarkson,  \nR Hern\u00e1ndez, K Stewart, V Hammersley, \nS Hayavi, A McAteer, D Gray and F DalyHow to obtain copies of this and other HTA programme reports\nAn electronic version of this publication, in Adobe Acrobat format, is available for downloading free of \ncharge for personal use from the HTA website (www.hta.ac.uk). A fully searchable CD-ROM is also \navailable (see below). \nPrinted copies of HTA monographs cost \u00a320 each (post and packing free in the UK) to both public and \nprivate sector purchasers from our Despatch Agents.\nNon-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is \n\u00a32 per monograph and for the rest of the world \u00a33 per monograph.\nYou can order HTA monographs from our Despatch Agents:\n\u2013 fax (with credit card or official purchase order) \n\u2013 post (with credit card or official purchase order or cheque)\n\u2013 phone during office hours (credit card only).\nAdditionally the HTA website allows you either to pay securely by credit card or to print out your \norder and then post or fax it.\nContact details are as follows:\nHTA Despatch  Email: orders@hta.ac.uk\nc\/o Direct Mail Works Ltd  Tel: 02392 492 000\n4 Oakwood Business Centre  Fax: 02392 478 555\nDownley, HAVANT PO9 2NP, UK  Fax from outside the UK: +44 2392 478 555\nNHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of  \n\u00a3100 for each volume (normally   comprising 30\u201340 titles). The commercial subscription rate is \u00a3300  \nper volume. Please see our website for details. Subscriptions can be purchased only for the current or \n  forthcoming volume.\nPayment methods\nPaying by cheque\nIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd \nand drawn on a bank with a UK address.\nPaying by credit card \nThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, \nMastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.\nPaying by official purchase order \nYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. \nWe cannot at present accept purchase orders from commercial companies or from outside the UK.\nHow do I get a copy of HTA on CD?\nPlease use the form on the HTA website (www.hta.ac.uk\/htacd.htm). Or contact Direct Mail Works (see \ncontact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.\nThe website also provides information about the HTA programme and lists the membership of the   various \n  committees.\nHTAA randomised controlled trial of the \nuse of aciclovir and\/or prednisolone for \nthe early treatment of Bell\u2019s palsy: the \nBELLS study\nFM Sullivan,1* IRC Swan,2 PT Donnan,3 \nJM Morrison,4 BH Smith,5 B McKinstry,6 \nRJ Davenport,7 LD Vale,8,9 JE Clarkson,10 \nR Hern\u00e1ndez,9 K Stewart,11 V Hammersley,6 \nS Hayavi,4 A McAteer,5 D Gray5 and F Daly3 \n1Scottish School of Primary Care, University of Dundee, UK\n2Department of Otolaryngology, University of Glasgow, UK\n3Community Health Sciences, University of Dundee, UK\n4Division of Community Based Sciences, University of Glasgow, UK\n5Centre of Academic Primary Care, University of Aberdeen, UK\n6Community Health Sciences, University of Edinburgh, UK\n7Department of Clinical Neurosciences, University of Edinburgh, UK\n8Health Services Research Unit, University of Aberdeen, UK\n9Health Economics Research Unit, University of Aberdeen, UK\n10Dental Health Services Research Unit, University of Dundee, UK\n11St John\u2019s Hospital, Livingston, UK\n*Corresponding author\nDeclared competing interests of authors: none\nPublished October 2009\nDOI: 10.3310\/hta13470\nThis report should be referenced as follows:\nSullivan FM, Swan IRC, Donnan PT, Morrison JM, Smith BH, McKinstry B, et al. A \nrandomised controlled trial of the use of aciclovir and\/or prednisolone for the early \ntreatment of Bell\u2019s palsy: the BELLS study. Health Technol Assess 2009;13(47).\nHealth Technology Assessment is indexed and abstracted in Index Medicus\/MEDLINE, \nExcerpta Medica\/EMBASE, Science Citation Index Expanded (SciSearch\uf8e8) and Current \nContents\uf8e8\/Clinical Medicine.\nAbstract  ............................................................. iii\nContents  . ............................................................ v\nList of abbreviations  . .......................................... vii\nExecutive summary  . ........................................... ix\nChapter 1  \nBackground  ................................................. 1\nDisease.condition. . ........................................ 1\nProvenance.of.the.Scottish.Bell\u2019s.Palsy.Study. . . 1\nGovernance. . ................................................. 1\nApprovals. ..................................................... 1\nStudy.calendar. ............................................. 2\nChapter 2  \nMethods  ....................................................... 3\nReferrers. ...................................................... 3\nRecruiters. . .................................................... 5\nPatients. . ........................................................ 6\nInterventions. ............................................... 6\nIdentification.of.coded.treatments. .............. 7\nResearchers. .................................................. 7\nAssessors. ...................................................... 9\nObjectives. . .................................................... 9\nPrimary.outcomes. ........................................ 9\nSecondary.outcomes. .................................... 10\nMethods.used.to.enhance.the.quality.of.measurements. .\n. .............................................................11\nChapter 3  \nStudy design  ................................................ 13\nSample.size. .................................................. 13\nExplanation.of.any.interim.analyses.and.stopping.rules. .\n. .............................................................13\nRandomisation. . ............................................ 13\nSubgroup.analyses. ....................................... 14\nChapter 4  \nResults  ......................................................... 15\nParticipant.flow. ............................................ 15\nProtocol.deviations.from.study.as.planned,.together.with.\nreasons. . .................................................... 15\nRecruitment. ................................................. 15\nBaseline.data. . ............................................... 18\nOutcomes.and.estimation. ............................ 18\nAncillary.analyses. . ........................................ 25\nAdverse.events.and.side.effects. ................... 26\nChapter 5  \nEconomic evaluation of treatments  ............ 27\nIntroduction. . ................................................ 27\nAim. .............................................................. 27\nMethods. ....................................................... 28\nHealth-care.resource.use.and.costs. . ............. 28\nEstimation.of.utilities. . .................................. 35\nResults. .......................................................... 37\nChapter 6  \nSubgroup analyses  . ...................................... 43\nOutcome.dependent.on.the.time.delay.to.\ncommencement.of.treatment. .................. 43\nOutcome.dependent.on.severity.at.onset. .... 44\nAssessors\u2019.concordance. ................................ 44\nChapter 7  \nDiscussion  .................................................... 47\nStrengths.and.limitations.of.the.study. . ........ 47\nImplications.for.practice. . ............................. 48\nChapter 8  \nConclusion  ................................................... 49\nChapter 9  \nOpportunities for further research  . ............ 51\nPrimary.research. .......................................... 51\nEvidence.synthesis. ....................................... 51\nAcknowledgements  ........................................... 53\nReferences  . ......................................................... 55\nAppendix 1  \nBELLS protocol  . ........................................... 57\nAppendix 2  \nTrial Steering Committee  ........................... 67\nAppendix 3  \nData Monitoring and Ethics Committee (DMEC)  . .\n69\nDATA.MONITORING.AND.ETHICS.COMMITTEE. .\n. .............................................................71\nREPORT.TEMPLATE.1. .............................. 71\nDATA.MONITORING.AND.ETHICS.COMMITTEE. .\n. .............................................................72\nREPORT.TEMPLATE.2. .............................. 72\nAppendix 4  \nBELLS Study Management Committee  . ..... 75\nAppendix 5  \nTimetable of approvals  . ............................... 77\nAppendix 6  \nHow cruel to call it Bell\u2019s palsy \nby Graeme Garden   ..............  81\nAppendix 7  \nLocal Principal Investigators  ....................... 83\nAppendix 8  \nScottish Bell\u2019s Palsy Study: \u2018BELLS\u2019  ............. 85\nAppendix 9  \nForm A  . ........................................................ 87\nAppendix 10  \nConsent form  . .............................................. 91\nAppendix 11  \nRandomisation Service User Guide  ............ 93\nAppendix 12  \nRecruiters\u2019 notes  ......................................... 97\nAppendix 13  \nWeekly recruitment update (example)  ...... 99\nAppendix 14  \nBriefing notes for researchers  ....................103\nAppendix 15  \nForm C  .........................................................107\nAppendix 16  \nForm B  .........................................................109\nAppendix 17  \nHouse\u2013Brackmann Assessors  .....................111\nAppendix 18  \nHealth Utilities Index Mark 3  .....................113\nAppendix 19  \nBrief Pain Inventory  ....................................119\nAppendix 20  \nDerriford Appearance Scale (DAS59)  ........123\nAppendix 21  \nPatient deaths on the BELLS study  ............127\nAppendix 22  \nCONSORT Checklist of items to include when \nreporting a randomised trial  . ......................129\nHealth Technology Assessment reports published to \ndate  . .............................................................131\nHealth Technology Assessment  \nprogramme  . .................................................151NIHR Health Technology Assessment programme\nT\nhe.Health.Technology.Assessment.(HTA).programme,.part.of.the.National.Institute.for.Health.\nResearch.(NIHR),.was.set.up.in.1993..It.produces.high-quality.research.information.on.the.\neffectiveness,.costs.and.broader.impact.of.health.technologies.for.those.who.use,.manage.and.provide.care.\nin.the.NHS..\u2018Health.technologies\u2019.are.broadly.defined.as.all.interventions.used.to.promote.health,.prevent.\nand.treat.disease,.and.improve.rehabilitation.and.long-term.care.\nThe.research.findings.from.the.HTA.programme.directly.influence.decision-making.bodies.such.as.the.\nNational.Institute.for.Health.and.Clinical.Excellence.(NICE).and.the.National.Screening.Committee.\n(NSC)..HTA.findings.also.help.to.improve.the.quality.of.clinical.practice.in.the.NHS.indirectly.in.that.they.\nform.a.key.component.of.the.\u2018National.Knowledge.Service\u2019.\nThe.HTA.programme.is.needs.led.in.that.it.fills.gaps.in.the.evidence.needed.by.the.NHS..There.are.three.\nroutes.to.the.start.of.projects.\nFirst.is.the.commissioned.route..Suggestions.for.research.are.actively.sought.from.people.working.in.the.\nNHS,.from.the.public.and.consumer.groups.and.from.professional.bodies.such.as.royal.colleges.and.NHS.\ntrusts..These.suggestions.are.carefully.prioritised.by.panels.of.independent.experts.(including.NHS.service.\nusers)..The.HTA.programme.then.commissions.the.research.by.competitive.tender.\nSecond,.the.HTA.programme.provides.grants.for.clinical.trials.for.researchers.who.identify.research.\nquestions..These.are.assessed.for.importance.to.patients.and.the.NHS,.and.scientific.rigour.\nThird,.through.its.Technology.Assessment.Report.(TAR).call-off.contract,.the.HTA.programme.\ncommissions.bespoke.reports,.principally.for.NICE,.but.also.for.other.policy-makers..TARs.bring.together.\nevidence.on.the.value.of.specific.technologies.\nSome.HTA.research.projects,.including.TARs,.may.take.only.months,.others.need.several.years..They.\ncan.cost.from.as.little.as.\u00a340,000.to.over.\u00a31.million,.and.may.involve.synthesising.existing.evidence,.\nundertaking.a.trial,.or.other.research.collecting.new.data.to.answer.a.research.problem.\nThe.final.reports.from.HTA.projects.are.peer.reviewed.by.a.number.of.independent.expert.referees.before.\npublication.in.the.widely.read.journal.series.Health Technology Assessment.\nCriteria for inclusion in the HTA journal series\nReports.are.published.in.the.HTA.journal.series.if.(1).they.have.resulted.from.work.for.the.HTA.\nprogramme,.and.(2).they.are.of.a.sufficiently.high.scientific.quality.as.assessed.by.the.referees.and.\neditors.\nReviews.in.Health Technology Assessment are.termed.\u2018systematic\u2019.when.the.account.of.the.search,.appraisal.\nand.synthesis.methods.(to.minimise.biases.and.random.errors).would,.in.theory,.permit.the.replication.\nof.the.review.by.others.\nThe.research.reported.in.this.issue.of.the.journal.was.commissioned.by.the.HTA.programme.as.project.\nnumber.02\/09\/04..The.contractual.start.date.was.in.November.2003..The.draft.report.began.editorial.\nreview.in.September.2007.and.was.accepted.for.publication.in.March.2009..As.the.funder,.by.devising.a.\ncommissioning.brief,.the.HTA.programme.specified.the.research.question.and.study.design..The.authors.\nhave.been.wholly.responsible.for.all.data.collection,.analysis.and.interpretation,.and.for.writing.up.their.\nwork..The.HTA.editors.and.publisher.have.tried.to.ensure.the.accuracy.of.the.authors\u2019.report.and.would.\nlike.to.thank.the.referees.for.their.constructive.comments.on.the.draft.document..However,.they.do.not.\naccept.liability.for.damages.or.losses.arising.from.material.published.in.this.report.\nThe.views.expressed.in.this.publication.are.those.of.the.authors.and.not.necessarily.those.of.the.HTA.\nprogramme.or.the.Department.of.Health.\nEditor-in-Chief: Professor.Tom.Walley.CBE\nSeries.Editors: Dr.Aileen.Clarke,.Professor.Chris.Hyde,.Dr.John.Powell,.\nDr.Rob.Riemsma.and.Professor.Ken.Stein\nISSN 1366-5278\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO\nThis monograph may be freely reproduced for the purposes of private research and study and may be included in professional journals provided \nthat suitable acknowledgement is made and the reproduction is not associated with any form of advertising.\nApplications for commercial reproduction should be addressed to: NETSCC, Health Technology Assessment, Alpha House, University of \nSouthampton Science Park, Southampton SO16 7NS, UK.\nPublished by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk), on behalf of NETSCC, HTA.\nPrinted on acid-free paper in the UK by Henry Ling Ltd, The Dorset Press, Dorchester.  GDOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\niii\nObjective: To determine whether oral prednisolone or \naciclovir, used separately or in combination, early in the \ncourse of Bell\u2019s palsy, improves the chances of recovery \nat 3 and 9 months.\nDesign: A 2 \u00d7 2 factorial randomised double-blind trial. \nPatients were randomly assigned to treatment by an \nautomated telephone service using a permuted block \nrandomisation technique with block sizes of four or \neight, and no stratification.\nSetting: Mainland Scotland, with referrals mainly from \ngeneral practice to 17 hospital trial sites.\nParticipants: Adults (aged 16 years or older) with \nunilateral facial nerve weakness of no identifiable cause \npresenting to primary care, the emergency department \nor NHS24 within 72 hours of symptom onset.\nInterventions: Patients were randomised to receive \nactive preparations or placebo for 10 days: (1) \nprednisolone (50 mg per day, 2 \u00d7 25-mg capsules) and \naciclovir (2000 mg per day, 5 \u00d7 400-mg capsules); (2) \nprednisolone and placebo (lactose, indistinguishable); (3) \naciclovir and placebo; and (4) placebo and placebo. \nOutcome measures: The primary outcome was \nrecovery of facial function assessed by the House\u2013\nBrackmann scale. Secondary outcomes included health \nstatus, pain, self-perceived appearance and cost-\neffectiveness.\nAbstract\nA randomised controlled trial of the use of aciclovir \nand\/or prednisolone for the early treatment of Bell\u2019s \npalsy: the BELLS study\nFM Sullivan,1* IRC Swan,2 PT Donnan,3 JM Morrison,4 BH Smith,5 \nB McKinstry,6 RJ Davenport,7 LD Vale,8,9 JE Clarkson,10 R Hern\u00e1ndez,9 \nK Stewart,11 V Hammersley,6 S Hayavi,4 A McAteer,5 D Gray5 and F Daly3 \n1Scottish School of Primary Care, University of Dundee, UK\n2Department of Otolaryngology, University of Glasgow, UK\n3Community Health Sciences, University of Dundee, UK\n4Division of Community Based Sciences, University of Glasgow, UK\n5Centre of Academic Primary Care, University of Aberdeen, UK\n6Community Health Sciences, University of Edinburgh, UK\n7Department of Clinical Neurosciences, University of Edinburgh, UK\n8Health Services Research Unit, University of Aberdeen, UK\n9Health Economics Research Unit, University of Aberdeen, UK\n10Dental Health Services Research Unit, University of Dundee, UK\n11St John\u2019s Hospital, Livingston, UK\n*Corresponding author\nResults: Final outcomes were available for 496 \npatients, balanced for gender; mean age 44 years; \ninitial facial paralysis moderate to severe. One half of \npatients initiated treatment within 24 hours of onset \nof symptoms, one-third within 24\u201348 hours and the \nremainder within 48\u201372 hours. Of the completed \npatients, 357 had recovered by 3 months and 80 at \n9 months, leaving 59 with a residual deficit. There \nwere significant differences in complete recovery at 3 \nmonths between the prednisolone comparison groups \n(83.0% for prednisolone, 63.6% for no prednisolone, \na difference of + 19.4%; 95% confidence interval (CI): \n+ 11.7% to + 27.1%, p < 0.001). The number needed \nto treat (NNT) in order to achieve one additional \ncomplete recovery was 6 (95% CI: 4 to 9). There \nwas no significant difference between the aciclovir \ncomparison groups (71.2% for aciclovir and 75.7% \nfor no aciclovir). Nine-month assessments of patients \nrecovered were 94.4% for prednisolone compared with \n81.6% for no prednisolone, a difference of + 12.8% \n(95% CI: + 7.2% to + 18.4%, p < 0.001); the NNT \nwas 8 (95% CI: 6 to 14). Proportions recovered at 9 \nmonths were 85.4% for aciclovir and 90.8% for no \naciclovir, a difference of \u2013 5.3%. There was no significant \nprednisolone\u2013aciclovir interaction at 3 months or at 9 \nmonths. Outcome differences by individual treatment Abstract\niv\n(the four-arm model) showed significant differences. \nAt 3 months the recovery rate was 86.3% in the \nprednisolone treatment group, 79.7% in the aciclovir\u2013\nprednisolone group, 64.7% in the placebo group and \n62.5% in the aciclovir group. At 9 months the recovery \nrates were respectively 96.1%, 92.7%, 85.3% and \n78.1%. The increase in recovery rate conferred by the \naddition of prednisolone (both for prednisolone over \nplacebo and for aciclovir\u2013prednisolone over aciclovir) \nis highly statistically significant (p < 0.001). There were \nno significant differences in secondary measures apart \nfrom Health Utilities Index Mark 3 (HUI3) at 9 months \nin those treated with prednisolone. \nConclusions: This study provided robust evidence to \nsupport the early use of oral prednisolone in Bell\u2019s palsy \nas an effective treatment which may be considered cost-\neffective. Treatment with aciclovir, either alone or with \nsteroids, had no effect on outcome.\nTrial registration: Current Controlled Trials \nISRCTN71548196.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\nv\nContents\n  List of abbreviations  .................................... vii\n  Executive summary  ..................................... ix\n1  Background  ................................................. 1\nDisease.condition. . ........................................ 1\nProvenance.of.the.Scottish.Bell\u2019s.Palsy..\nStudy. . ....................................................... 1\nGovernance. . ................................................. 1\nApprovals. ..................................................... 1\nStudy.calendar. ............................................. 2\n2  Methods  ....................................................... 3\nReferrers. ...................................................... 3\nRecruiters. . .................................................... 5\nPatients. . ........................................................ 6\nInterventions. ............................................... 6\nIdentification.of.coded.treatments. .............. 7\nResearchers. .................................................. 7\nAssessors. ...................................................... 9\nObjectives. . .................................................... 9\nPrimary.outcomes. ........................................ 9\nSecondary.outcomes. .................................... 10\nMethods.used.to.enhance.the.quality.of.\nmeasurements. . ......................................... 11\n3  Study design  ................................................ 13\nSample.size. .................................................. 13\nExplanation.of.any.interim.analyses.and.\nstopping.rules. . ......................................... 13\nRandomisation. . ............................................ 13\nSubgroup.analyses. ....................................... 14\n4  Results  ......................................................... 15\nParticipant.flow. ............................................ 15\nProtocol.deviations.from.study.as.planned,.\ntogether.with.reasons. .............................. 15\nRecruitment. ................................................. 15\nBaseline.data. . ............................................... 18\nOutcomes.and.estimation. ............................ 18\nAncillary.analyses. . ........................................ 25\nAdverse.events.and.side.effects. ................... 26\n5  Economic evaluation of treatments  ............ 27\nIntroduction. . ................................................ 27\nAim. .............................................................. 27\nMethods. ....................................................... 28\nHealth-care.resource.use.and.costs. . ............. 28\nEstimation.of.utilities. . .................................. 35\nResults. .......................................................... 37\n6  Subgroup analyses  . ...................................... 43\nOutcome.dependent.on.the.time.delay.to.\ncommencement.of.treatment. .................. 43\nOutcome.dependent.on.severity.at.onset. .... 44\nAssessors\u2019.concordance. ................................ 44\n7  Discussion  .................................................... 47\nStrengths.and.limitations.of.the.study. . ........ 47\nImplications.for.practice. . ............................. 48\n8  Conclusion  ................................................... 49\n9  Opportunities for further research  . ............ 51\nPrimary.research. .......................................... 51\nEvidence.synthesis. ....................................... 51\n  Acknowledgements  ..................................... 53\n  References  ................................................... 55\n  Appendix 1  BELLS.protocol. . ...................... 57\n  Appendix 2  Trial.Steering.Committee. ....... 67\n  Appendix 3  Data.Monitoring.and.Ethics.\nCommittee.(DMEC). . .................................... 69\n  Appendix 4  BELLS.Study.Management.\nCommittee. ................................................... 75\n  Appendix 5  Timetable.of.approvals. ........... 77\n  Appendix 6  How.cruel.to.call.it.Bell\u2019s.\npalsy............................................................... 81\n  Appendix 7  Local.Principal.Investigators. .. 83\n  Appendix 8  Scottish.Bell\u2019s.Palsy.Study:.\n\u2018BELLS\u2019. ........................................................ 85\n  Appendix 9  Form.A. . .................................... 87\n  Appendix 10  Consent.form. ........................ 91\n  Appendix 11  Randomisation.Service.User.\nGuide. ........................................................... 93Contents\nvi\n  Appendix 12  Recruiters\u2019.notes. . ................... 97\n  Appendix 13  Weekly.recruitment.\nupdate.(example). . ........................................ 99\n  Appendix 14  Briefing.notes.for.\nresearchers. ...................................................103\n  Appendix 15  Form.C. ..................................107\n  Appendix 16  Form.B. . ..................................109\n  Appendix 17  House\u2013Brackmann.\nAssessors. ......................................................111\n  Appendix 18  Health.Utilities.Index.\nMark.3. .........................................................113\n  Appendix 19  Brief.Pain.Inventory. ..............119\n  Appendix 20  Derriford.Appearance.\nScale.(DAS59). ..............................................123\n  Appendix 21  Patient.deaths.on.the.\nBELLS.study. ................................................127\n  Appendix 22  CONSORT.Checklist.of.items.\nto.include.when.reporting.a.randomised..\ntrial. ..............................................................129\nHealth Technology Assessment reports  \npublished to date  . ........................................131\nHealth Technology Assessment  \nprogramme  . .................................................151DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\nvii\nStudy-related abbreviations\nAP aciclovir\u2013prednisolone.group\nAO aciclovir\u2013placebo.group\nOP placebo\u2013prednisolone.group\nOO placebo\u2013placebo.group\nA aciclovir.group.(i.e..AP.+.AO)\nA\u2032 no-aciclovir.group.(i.e..OP.+.\nOO)\nP prednisolone.group.(i.e..AP.+.\nOP)\nP\u2032 no-prednisolone.group.(i.e..AO.\n+.OO)\nHB House\u2013Brackmann\nPrior.to.decoding,.the.four.treatments.were.labelled.\nTrt.1,.Trt.2,.Trt.3,.Trt.4,.and.after.decoding.these.\nwere.revealed.to.be:\nOP. Trt.1 (prednisolone.+.placebo)\nAP. Trt.3 (aciclovir.+.prednisolone)\nOO. Trt.2 (placebo.+.placebo)\nAO. Trt.4 (aciclovir.+.placebo)\nOther abbreviations\nA&E accident.and.emergency\nBNF British National Formulary\nBPI Brief.Pain.Inventory\nCEAC cost-effectiveness.acceptability.\ncurves.\nCI confidence.interval\nCSO Chief.Scientist.Office.(of.the.\nScottish.Government)\nDAS59 Derriford.Appearance.Scale\nDDX Doctors\u2019.and.Dentists\u2019.Exemption\nDMEC Data.Monitoring.and.Ethics.\nCommittee.\nENT ear,.nose.and.throat\nGPRD General.Practice.Research.\nDatabase\nHSRU Health.Services.Research.Unit.\nHUI3 Health.Utilities.Index.Mark.3\nICER incremental.cost-effectiveness.\nratio\nIQR interquartile.range\nISD Information.Services.Department\nLREC Local.Research.Ethics.Committee.\nMREC Multicentre.Research.Ethics.\nCommittee\nNNT number.needed.to.treat\nOR odds.ratio\nQALY quality-adjusted.life-year\nQoL quality.of.life\nSD standard.deviation\nSE standard.error\nSPCRN Scottish.Primary.Care.Research.\nNetwork\nSPPIRe Scottish.Professionals.and.\nPractices.Interested.in.Research\nTSC Trial.Steering.Committee.\nList of abbreviations\nAll.abbreviations.that.have.been.used.in.this.report.are.listed.here.unless.the.abbreviation.is.well.\nknown.(e.g..NHS),.or.it.has.been.used.only.once,.or.it.is.a.non-standard.abbreviation.used.only.in.\nfigures\/tables\/appendices,.in.which.case.the.abbreviation.is.defined.in.the.figure.legend.or.in.the.\nnotes.at.the.end.of.the.table.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\nix\nT\nhe.cause.of.Bell\u2019s.palsy.is.unknown.although.\nvascular,.inflammatory.and.viral.aetiologies.\nhave.been.suggested..There.are.11.to.40.cases.\nper.100,000.people.each.year,.most.commonly.in.\nthe.age.range.30\u201345..Up.to.30%.of.patients.have.\ncontinuing.facial.disfigurement,.psychological.\ndifficulties.and.sometimes.facial.pain..Treatment.\nhas.been.controversial.and.highly.variable.\nMethods\nWe.conducted.a.2.\u00d7.2.factorial.randomised.double-\nblind.trial..The.primary.outcome.was.recovery.of.\nfacial.function.assessed.by.the.House\u2013Brackmann.\nscale..Secondary.outcomes.included.health.\nstatus,.pain,.self-perceived.appearance.and.cost-\neffectiveness.\nPatients\nWe.recruited.adults.(aged.16.years.or.older).with.\nunilateral.facial.nerve.weakness.of.no.identifiable.\ncause.presenting.to.primary.care,.the.accident.and..\nemergency.department.(A&E).or.NHS24.within.72.\nhours.of.symptom.onset.\nStudy design\nThe.study.was.conducted.throughout.\nmainland.Scotland.with.referrals.mainly.from.\ngeneral.practice.to.17.hospital.trial.sites..An.\notolaryngologist.confirmed.eligibility,.and.\npatients.were.randomly.assigned.to.treatment.by.\nan.independent,.secure,.automated.telephone.\nservice.using.a.permuted.block.randomisation.\ntechnique.with.block.sizes.of.four.or.eight,.and.no.\nstratification.\nPatients.were.randomised.into.four.groups.to.\nreceive.active.preparations.or.placebo.for.10.\ndays:.(1).prednisolone.(50.mg.per.day,.2.\u00d7.25-mg.\ncapsules).and.aciclovir.(2000.mg.per.day,.5.\u00d7.400-\nmg.capsules);.(2).prednisolone.and.placebo.\n(lactose,.indistinguishable);.(3).aciclovir.and.\nplacebo;.and.(4).placebo.and.placebo..The.patient.\ntook.the.first.dose.before.leaving.hospital,.and.the.\nremaining.doses.at.home.over.the.next.10.days.\nA.researcher.visited.patients.at.their.home.or.\ntheir.doctor\u2019s.surgery.within.the.next.3\u20135.days.\nto.complete.the.baseline.assessments,.record.any.\nadverse.events.and.arrange.follow-up..Repeat.\npatient.visits.to.assess.recovery.occurred.at.3.\nmonths.and,.if.recovery.was.incomplete.at.this.visit,.\nagain.at.9.months.\nOutcome measurements\nThe.primary.outcome.measure.was.the.House\u2013\nBrackmann.grading.system.for.facial.nerve.\nfunction..It.assigns.patients.to.six.categories.(I.to.\nVI).on.the.basis.of.their.degree.of.facial.function:.\ngrade.I.indicates.normal.function..Assessment.\nwas.based.on.digital.photographic.images.in.four.\nstandard.portrait.poses,.graded.independently.by.\nthree.experts.masked.to.treatment.allocation.\nSecondary.outcomes.were.quality.of.life.(QoL).\nmeasured.by.the.Health.Utilities.Index.Mark.3.\n(HUI3),.the.Derriford.Appearance.Scale.(DAS59),.\nthe.Brief.Pain.Inventory.(BPI).and.incremental.cost.\nper.cure.and.incremental.cost.per.quality-adjusted.\nlife-year.(QALY),.with.QALYs.based.on.patient.\nresponses.to.HUI3.\nSubgroup.analyses.included.outcome.dependent.\non.delay.between.onset.of.symptoms.and.\ncommencement.of.treatment,.and.on.severity.\nat.onset;.there.was.an.additional.analysis.of.\nconcordance.between.expert.assessors.\nSafety evaluation and compliance\nMedication.use.was.reviewed.at.the.first.visit.and.\nduring.two.subsequent.telephone.calls..Adverse.\nevents.were.reviewed.then.and.at.subsequent.visits.\nStatistical analysis\nPrimary.and.secondary.analyses.were.based.on.\nintention-to-treat..Subgroup.and.additional.\nanalyses.were.made.post.hoc.\nComplete.recovery.(House\u2013Brackmann.grade.I).\nat.3.and.9.months.was.compared.initially.between.\nthose.who.did.and.did.not.receive.prednisolone.\nusing.a.two-sided.Fisher\u2019s.exact.test..This.was.\nExecutive summaryExecutive summary\nx\nrepeated.for.aciclovir..We.tested.the.data.for.any.\ninteraction.between.the.groups.prior.to.these.\ntests..Pre-specified.secondary.analyses.compared.\nHUI3,.DAS59.and.BPI.scores..Our.analysis.was.\nadjusted.for.all.baseline.characteristics.measured:.\nage,.gender,.interval.between.onset.and.receiving.\ntreatment,.and.scores.on.the.House\u2013Brackmann.\nscale,.HUI3,.DAS59.and.BPI.\nDecision.economic.modelling.was.used.to.compare.\ncost-effectiveness..The.time.horizon.of.the.model.\nwas.9.months,.and.outcomes.were.the.cumulative.\nproportion.of.cases.cured,.mean.QALYs.gained.\nand.mean.costs..Costs.were.reported.in.2006\u20137.\npounds.sterling..NHS.costs.were.based.on.costs.of.\ntreatments.and.costs.of.subsequent.health.services.\ncollected.from.general.practice.notes..QALYs.were.\nbased.on.responses.to.HUI3.with.the.assumption.\nthat.the.3-month.score.of.those.cured.at.3.months.\nwas.carried.forward.to.the.9-month.assessment..\nTwo-arm.models.were.developed.for.prednisolone.\nversus.no.prednisolone.and.aciclovir.versus.no.\naciclovir.comparisons,.respectively..A.further.four-\narm.model.was.developed.to.compare.prednisolone.\nalone,.aciclovir.alone,.aciclovir.and.prednisolone,.\nand.no.treatment.(placebo).strategies.\nPower calculation\nA.difference.in.complete.recovery.of.10%.or.\nmore.was.considered.to.be.clinically.meaningful..\nRandomising.240.patients.per.treatment.(a.total.\nof.480).would.provide.80%.power.to.detect.a.\ndifference.of.the.order.of.12%.at.the.5%.level..\nSince.the.study.design.was.factorial.the.power.is.the.\nsame.for.each.pair-wise.comparison.of.treatments.\nResults\nStudy population\nOf.752.patients.referred,.132.were.ineligible.and.\n551.of.the.620.patients.eligible.were.randomised..\nFifty-five.patients.dropped.out.of.the.study.before.\na.final.determination.of.their.House\u2013Brackmann.\nstatus..Thus.final.outcomes.were.available.for.496.\npatients.\nThe.study.was.balanced.for.gender;.the.mean.age.\nof.patients.was.44.years;.and.the.degree.of.initial.\nfacial.paralysis.was.moderate.to.severe..One.half.\nof.patients.initiated.treatment.within.24.hours.of.\nonset.of.symptoms,.one-third.within.24\u201348.hours.\nand.the.remainder.within.48\u201372.hours.\nOf.496.completed.patients,.357.had.recovered.by.\n3.months..A.further.80.had.recovered.at.9.months,.\nleaving.59.with.a.residual.facial.nerve.deficit.\nThere.was.no.significant.prednisolone\u2013aciclovir.\ninteraction.at.3.months.or.at.9.months.(p.=.0.32,.\np.=.0.72.respectively).\nThere.were.significant.differences.in.complete.\nrecovery.at.3.months.between.the.prednisolone.\ncomparison.groups.(83.0%.for.prednisolone,.63.6%.\nfor.no.prednisolone,.a.difference.of.+.19.4%;.95%.\nconfidence.interval.(CI):.+.11.7%.to.+.27.1%,.p.\n<.0.001)..The.number.needed.to.treat.(NNT).in.\norder.to.achieve.one.additional.complete.recovery.\nwas.6.(95%.CI:.4.to.9)..There.was.no.significant.\ndifference.between.the.aciclovir.comparison.groups.\n(71.2%.for.aciclovir.and.75.7%.for.no.aciclovir,.a.\ndifference.of.\u2013.4.5%.(95%.CI:.\u2013.12.4%.to.+.3.3%,.\np.=.0.30,.adjusted.0.50)..Nine-month.assessments.\nof.patients.recovered.were.94.4%.for.prednisolone.\ncompared.with.81.6%.for.no.prednisolone,.a.\ndifference.of.+.12.8%.(95%.CI:.+.7.2%.to.+.18.4%,.\np.<.0.001);.the.NNT.is.8.(95%.CI:.6.to.14)..\nProportions.recovered.at.9.months.were.85.4%.for.\naciclovir.and.90.8%.for.no.aciclovir,.a.difference.\nof.\u2013.5.3%.(95%.CI:.\u2013.11.0%.to.+.0.3%,.p.=.0.07,.\nadjusted.0.10).\nThe.formally.correct.analysis.for.the.2.\u00d7.2.factorial.\ndesign.is.to.follow.two.independent.(two-arm).\ncomparisons,.being.(1).study.outcomes.for.those.\npatients.treated.with.prednisolone,.and.those.not;.\nand.(2).study.outcomes.for.those.patients.treated.\nwith.aciclovir,.and.those.not.\nHowever,.it.is.helpful.for.clinicians.to.be.provided.\nwith.a.single.simple.comparison.of.the.four.\ntreatment.options.available.to.trial.participants.\n(prednisolone.with.aciclovir,.prednisolone.alone,.\naciclovir.alone,.and.placebo).supported.by.an.\nexpression.of.prednisolone\u2013aciclovir.interaction..\nThis.four-arm.analysis.does.not.provide.the.most.\npowerful.scrutiny.of.the.data,.but.it.does.provide.\nan.easily.interpreted.assessment.of.treatment.\noptions..For.this.study,.the.results.of.the.four-arm.\nanalysis.are.included.to.support.and.confirm.those.\nof.the.two-arm.analyses.\nWhen.we.explored.outcome.differences.by.\nindividual.treatment.(the.four-arm.model).there.\nwere.significant.differences.at.3.and.9.months..\nAt.3.months.the.recovery.rate.was.86.3%.in.the.\nprednisolone.treatment.group,.79.7%.in.the.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\nxi\naciclovir\u2013prednisolone.group,.64.7%.in.the.placebo.\ngroup.and.62.5%.in.the.aciclovir.group..At.9.\nmonths.the.recovery.rates.were.respectively.96.1%,.\n92.7%,.85.3%.and.78.1%..The.increase.in.recovery.\nrate.conferred.by.the.addition.of.the.treatment.\nprednisolone.(both.for.prednisolone.over.placebo.\nand.for.aciclovir\u2013prednisiolone.over.aciclovir).is.\nhighly.statistically.significant.(p <.0.001).\nThere.were.no.significant.differences.in.our.\nsecondary.measures.apart.from.HUI3.at.9.months.\nin.those.treated.with.prednisolone.\nFrom.the.two-arm.model,.the.mean.cost.of.\nprednisolone.was.\u00a3232.and.the.mean.cost.of.no.\nprednisolone.was.\u00a3248..Prednisolone.was.more.\neffective.in.terms.of.cure.and.provided.on.average.\nslightly.more.QALYs.(0.718.versus.0.717)..A.\nprobabilistic.analysis.suggested.that.prednisolone.\nwas.likely.(over.70%).to.be.considered.cost-\neffective.at.a.\u00a320,000.or.\u00a330,000.cost.per.QALY.\nthreshold..The.aciclovir.versus.no.aciclovir.two-\narm.model.showed.that.aciclovir.was.on.average.\nmore.costly.than.no.aciclovir.(\u00a3253.versus.\u00a3246).\nand.not.likely.to.be.more.effective.in.terms.of.cure.\nand.QALYs.(0.717.versus.0.718)..It.was.unlikely.\nto.be.considered.cost-effective.at.a.\u00a320,000.or.\n\u00a330,000.cost.per.QALY.threshold.(15%.and.\n18%,.respectively)..The.four-arm.model.showed.\nprednisolone.alone.to.be.more.effective.and.\nless.costly.than.the.other.strategies.(over.70%.\nprobability.of.being.cost-effective.for.\u00a320,000.and.\n\u00a330,000.thresholds).\nAdverse.events.included.the.expected.range.of.\nminor.side.effects.with.the.drugs.used.(nausea,.\ndyspepsia,.constipation,.rash)..There.were.three.\ndeaths.during.follow-up.(two.in.the.placebo-\nplacebo.group.and.one.in.the.aciclovir-placebo.\ngroup).all.unrelated.to.treatment..No.serious.\nadverse.events.were.reported..No.suspected.\nunexpected.serious.adverse.reactions.were.\nreported..There.was.no.instance.of.a.requirement.\nfor.unblinding.of.patients.or.their.practitioners.or.\nof.study.personnel..An.analysis.of.the.frequency.of.\nadverse.events.showed.no.differences.whatsoever.\nbetween.the.treatment.groups.\nDiscussion\nThis.is.the.largest.randomised.controlled.trial.of.\nthe.effectiveness.of.treatment.for.Bell\u2019s.palsy..We.\nhave.confirmed.the.generally.favourable.outcome.\nfor.Bell\u2019s.palsy,.with.63%.of.patients.recovered.with.\nno.treatment.at.3.months,.increasing.to.85%.after.\n9.months..Treatment.within.72.hours.of.onset.with.\nprednisolone.increased.these.rates.to.83%.and.94%.\nrespectively..Aciclovir.alone.produced.no.benefit.\nover.placebo.and.there.was.no.benefit.from.its.\naddition.to.prednisolone.\nThis.study.provided.robust.evidence.to.support.\nthe.early.use.of.oral.prednisolone.in.Bell\u2019s.palsy.\nas.an.effective.treatment.which.may.be.considered.\ncost-effective.by.NHS.commissioners..Most.patients.\nrecover.fully.without.any.treatment..Therefore,.for.\nsome.clinicians.and.their.patients,.the.option.of.\noffering.\u2018no.treatment\u2019.may.remain.an.appropriate.\nstrategy,.but.they.can.now.have.a.more.fully.\ninformed.discussion.regarding.the.use.of.steroids..\nTreatment.with.aciclovir,.either.alone.or.with.\nsteroids,.had.no.effect.on.outcome..\nTrial registration\nThis.trial.is.registered.as.ISRCTN71548196.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n1\nDisease condition\nBell\u2019s.palsy.is.an.acute.unilateral.paralysis.of.\nthe.facial.nerve.first.described.by.the.Scottish.\nsurgeon.Sir.Charles.Bell.(1774\u20131842).1.Its.cause.\nis.unknown.but.animal.studies.have.suggested.\nthe.possibility.that.reactivation.of.herpes.viruses.\nmay.be.responsible.for.demyelination.2,3.It.affects.\n11\u201340.people.per.100,000.in.the.population.per.\nannum,.most.commonly.in.the.age.group.30\u201345.4.\nThe.condition.presents.disproportionately.among.\npregnant.women.and.people.who.have.diabetes,.\ninfluenza,.a.cold.or.some.other.upper.respiratory.\nailment..On.average.every.year.a.general.\npractitioner.will.see.one.or.two.patients.who.have.\ndeveloped.the.condition..A.recent.UK.study.using.\nthe.General.Practice.Research.Database.(GPRD).\nshowed.that.36%.of.patients.were.treated.with.\noral.steroids.and.19%.were.referred.to.hospital.5.\nAlthough.most.patients.recover.well,.30%.have.a.\npoor.recovery.with.continuing.facial.disfigurement,.\npsychological.difficulties.and.sometimes.facial.\npain.(though.the.presence.and.course.of.pain.is.\nunclear.from.current.knowledge).6.In.the.absence.\nof.an.established.aetiology,.treatment.continues.to.\nbe.based.upon.the.established.pathophysiology:.\nswelling.and.entrapment.of.the.nerve.\nTwo.recent.Cochrane.reviews.concerning.the.\ntreatment.of.Bell\u2019s.palsy.have.examined.the.\neffectiveness.of.oral.prednisolone.and.aciclovir.7,8.\nThese.found.that.insufficient.data.exist.to.conclude.\nthat.either.or.both.therapies.are.effective..Many.of.\nthe.studies.included.in.the.reviews.either.failed.to.\nrandomise.patients.or,.when.correctly.randomised,.\nwere.erroneously.interpreted.in.a.favourable.\nlight.9,10.In.addition,.high-dose.steroid.therapy.\nhas.numerous.potential.side.effects.including.\npeptic.ulceration,.hypertension.and.confusional.\nstates..Antiviral.therapy.is.expensive.and.should.be.\nreserved.for.circumstances.where.definite.benefits.\nare.likely.to.be.obtained..Current.recommendations.\nsuggest.that.aciclovir.needs.to.be.started.within.\n48.hours,.though.more.recent.studies.of.viral.\nreplication.in.patients.with.Bell\u2019s.palsy.suggest.that.\nthis.might.be.extended.11\nProvenance of the Scottish \nBell\u2019s Palsy Study\nGiven.this.lack.of.evidence.the.UK.National.\nInstitute.for.Health.Research.(NIHR).Health.\nTechnology.Assessment.programme.commissioned.\nan.independent.academic.group.to.conduct.a.\nrandomised.clinical.trial.to.determine.whether.\nprednisolone.or.aciclovir,.used.separately.or.in.\ncombination.and.used.early.in.the.course.of.Bell\u2019s.\npalsy,.improved.the.chances.of.recovery.at.3.and.9.\nmonths.\nWith.this.defined.as.the.primary.research.question,.\nthe.protocol.for.the.Scottish.Bell\u2019s.Palsy.Study.\nwas.developed.and.submitted.and.is.provided.as.\nAppendix.1..A.small.number.of.variations.to.the.\nprotocol.are.summarised.where.they.arise.\nGovernance\nWe.established.three.committees.for.the.oversight.\nof.the.study.\u2013.a.Trial.Steering.Committee.(TSC:.\nconstitution.and.personnel.listed.in.Appendix.2);.\na.Data.Monitoring.and.Ethics.Committee.(DMEC:.\nconstitution.and.personnel.listed.in.Appendix.3);.\nand.a.Management.Committee.for.the.day-to-day.\nmonitoring.of.the.progress.of.the.trial,.comprising.\nthe.nine.Principal.Investigators,.Trial.Co-ordinator.\nand.three.Researchers.(personnel.listed.in.\nAppendix.4).\nThe.lead.host.organisation.and.the.sponsor.of.the.\nstudy.was.the.University.of.Dundee.\nAssociate.host.organisations.(trial.centres).were.the.\nUniversities.of.Glasgow,.Edinburgh.and.Aberdeen.\nApprovals\nIn.common.with.many.researchers.and.triallists.\nsetting.up.studies.during.2003\u20134.raising.\nquestions.in.the.clinical.arena.and.requiring.the.\nparticipation.of.patient.groups,.we.found.the.\nprocesses.for.obtaining.approvals.demanding.\nChapter 1  \nBackgroundBackground\n2\nand.time-consuming.in.a.way.that.they.had.not.\nbeen.previously..With.other.research.teams.we.\nwere.invited.to.summarise.our.experience.for.an.\ninvestigative.commission.headed.by.Professor.\nAdrian.Grant.on.behalf.of.Scotland\u2019s.Chief.\nScientist.Office.(CSO),.and.did.so.as.outlined.in.\nAppendix.5..We.recognise.that.our.experience.was.\nnot.untypical.of.that.of.other.researchers.at.the.\ntime,.but.we.include.our.report.to.the.CSO.and.this.\naccount.of.it.because.of.the.depth.of.feeling.that.\nwas.then.commonly.reported.by.researchers.\nEthical.approval.for.the.study.was.provided.by.\nthe.lead.research.ethics.committee,.Multicentre.\nResearch.Ethics.Committee.(MREC).Scotland.\n(Edinburgh).reference.MREC.03\/0\/74,.and.by.\nLocal.Research.Ethics.Committees.(LRECs).\nwhere.patients.were.referred.to.local.sites,.or.\nwhere.the.study.recruited.patients..Research.and.\nDevelopment.(R&D).approval.was.provided.by.\nlocal.R&D.offices.likewise..The.Clinical.Trials.\nAuthority.to.use.prednisolone,.aciclovir.and.\nlactose.placebo.was.provided.by.the.Medicines.and.\nHealthcare.Products.Regulatory.Agency.(MHRA),.\nreferences.MF8000\/13139.and.13140.respectively..\nThe.study.was.registered.with.Current.Controlled.\nTrials.reference.ISRCTN.71548196.under.the.title.\nBell\u2019s.palsy:.Early.acicLovir.and\/or.prednisoLone.\nin.Scotland.(\u2018BELLS\u2019).and.from.07\/08\/2007.its.\nregistered.status.is.\u2018Completed\u2019.\nStudy calendar\nThe.study.calendar.is.shown.in.Table 1..The.total.\nduration.of.the.study.was.44.months.of.which.\n25.months.were.dedicated.to.patient.recruitment.\nThe.calendar.represents.an.amendment.to.the.\noriginal.timetable,.being.an.8-month.extension.to.\nthe.study.overall,.which.had.comprised.3.months.\nfor.approvals,.18.months.for.patient.recruitment,.\n9.months.for.patient.follow-up.and.6.months.for.\nanalysis.(i.e..36.months.altogether).\nSubmission.of.a.paper.describing.the.results.of.the.\nstudy.to.an.appropriate.journal,.and.of.a.draft.final.\nreport.to.the.funder.were.scheduled.to.take.place.\nas.soon.as.possible.following.completion.of.the.\nanalysis.of.results.\nTABLE 1  Study calendar \nDates Duration Activity\nNov 2003\u2013May 2004 7 months Approvals, staff recruitment and training\nJun 2004\u2013Jun 2006 25 months Recruitment of patients\nJul 2006\u2013Mar 2007 9 months Follow-up of patients\nApr 2007\u2013Jun 2007 3 months Analysis of resultsDOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n3\nReferrers\nPatients.identified.in.primary.medical.and.\ndental.care.or.accident.and.emergency.(A&E).\ndepartments.and.those.who.approached.NHS24.\n(a.24-hour.medical.advice.line.in.Scotland.similar.\nto.NHS.Direct.in.England.and.Wales,.which.also.\nco-ordinates.all.general.practice.out-of-hours.\nconsultations).with.an.appropriate.description.of.\nsymptoms,.were.asked.to.attend.1.of.17.hospital.\nsites.where.trial.arrangements.were.in.place..The.\ngeographical.coverage.of.the.BELLS.study.is.shown.\nin.Figure 1..The.contributing.sites.are.listed.in.Table \n2..\nWe.recognised.that.not.all.of.these.patients.would.\nbe.notified.to.the.study.or.recruited.to.it..It.was.\nimportant.therefore.to.pilot.notification.of.the.\ncondition.prior.to.running.the.study.to.determine.\nif.general.practitioners.considered.the.condition.to.\nbe.of.sufficiently.significant.importance.to.become.\ninvolved.in.a.trial,.and.what.proportion.of.patients.\nwould.be.recruited.\nIn.order.to.test.this.we.piloted.a.notification.\nprocess.in.one.region.of.Scotland..With.the.\nco-operation.of.the.local.research.networks.in.\nTayside.and.Fife.we.asked.general.practitioners.\nto.notify.us.of.all.patients.presenting.with.Bell\u2019s.\npalsy.over.a.period.of.1.month..As.a.result.of.this.\nexercise.we.determined.that.we.would.be.able.to.\nrecruit.one-third.of.those.presenting.within.48.\nhours.of.diagnosis..Of.those,.we.assumed.that.\ntwo-thirds.would.remain.in.the.trial.for.review.at.9.\nmonths..In.order.therefore.to.recruit.and.retain.the.\n480.patients.necessary.to.detect.a.12%.difference.\nin.treatment.effect.from.Scottish.recruitment,.we.\nneeded.to.recruit.continuously.for.25.months.\nAs.it.was.unlikely.that.individual.general.\npractitioners.or.A&E.doctors.would.be.involved.\nmore.than.once.in.the.trial.it.was.essential.that.\ntheir.role.should.be.clearly.delineated.and.\nrelatively.simple.to.carry.out,.and.that.instruction.\nshould.be.available.relatively.easily..The.\ninvolvement.of.recruiting.doctors.was.restricted.\nto.diagnosis.followed.by.determination.of.the.\npatients\u2019.interest.in.participating,.exclusion.of.\nineligible.patients,.and.a.telephone.referral.to.the.\non-call.otolaryngology.specialist..The.trial.process.\nactually.constituted.a.reduction.in.clinical.workload.\nfor.most.general.pratitioners,.who.would.normally.\nChapter 2  \nMethods\nCactus Design and Illustration Ltd\nFigure Number: 01.ai   Title: 02-09-04 Proof Stage:  1\nFIGURE 1  Map of hospital sites contributing to the BELLS study.Methods\n4\nundertake.follow-up.of.patients.without.input.\nfrom.hospital.colleagues.12.The.trial.also.offered.\nimmediate.access.to.specialist.assessment,.which.\nwould.not.be.provided.under.normal.care..Both.\nof.these.attributes.were.found.to.be.very.attractive.\nto.general.practitioners.and.patients.during.the.\nplanning.phase.of.the.trial.\nDoctors.need.to.be.reminded.regularly.of.an.\nongoing.trial.of.a.condition.that.occurs.relatively.\nsporadically.13.In.addition,.there.is.a.high.turnover.\namong.staff.in.A&E.departments.and.training.\ngrades.in.general.practice.and.otolaryngology..A.\nvariety.of.strategies.publicising.the.trial.were.set.in.\nmotion.\nMailshots\nThe.responsibility.for.keeping.doctors.informed.\nabout.the.on-going.trial.was.taken.on.by.SPPIRe14.\n(Scottish.Professionals.and.Practices.Interested.\nin.Research,.since.renamed.SPCRN,.the.Scottish.\nPrimary.Care.Research.Network,.to.fit.the.SPCRN.\nmodel)..All.general.practitioners.in.the.four.\nparticipating.regions.of.Scotland.were.sent.a.\nmailshot.outlining.the.trial.and.explaining.how.\nto.take.part..We.emphasised.the.importance.of.\nthe.condition.and.the.simplicity.of.involvement..\nThe.mailshots.were.in.colour.and.designed.to.be.\nattractive;.further,.based.on.evidence.from.the.\nliterature,.we.highlighted.the.benefits.to.patients15.\nand.remuneration.to.general.practitioners16.for.\ntaking.part,.and.letters.were.signed.by.well-known.\nlocal.general.practitioner.\u2018champions\u2019.17.Separate.\nmailshots.went.out.to.non-principal.doctors.and.\nregistrars.\nThe.trial.was.also.highlighted.in.Local.Medical.\nCommittee.briefings.to.general.practitioners.\nthroughout.the.country..We.estimate.that.each.\nquarterly.mailshot.took.about.a.day.of.researcher.\ntime.in.each.of.the.four.participating.regions..A&E.\ndepartments.were.kept.informed.by.literature.and.\nposters.from.the.centre;.similarly,.general.practice.\nco-operatives.were.informed.through.literature.\nand.posters.distributed.with.SPPIRe\u2019s.help,.while.\nNHS24.was.in.direct.contact.with.the.study.centre..\nWe.found.that.the.most.attention-grabbing.poster.\nwas.one.showing.photographs.of.a.patient.at.onset.\n(see.Figure 2)..Every.mailshot.included.the.project\u2019s.\nweb.address.and.telephone.contact.details.\nProject website\nThe.project.website18.had.a.simple.web.address,.was.\nclear.and.easy.to.navigate,.with.instructions.on.how.\nto.take.part.in.the.trial,.and.was.regularly.updated.\nat.its.Stop.Press.page19.with.information.on.the.\nprogress.of.the.trial..The.site.was.easily.found.with.\nsimple.Google.terms.\nMedia\nIn.order.to.heighten.and.maintain.the.profile.of.\nthe.study.we.contacted.professional.magazines,.\nnational.press.and.radio..We.were.fortunate.that.\na.medical.graduate.and.former.sufferer.who.\nregularly.works.in.a.variety.of.media,.Graeme.\nGarden,.offered.to.speak.to.media.colleagues.on.\nour.behalf.to.provide.his.insight.into.the.condition..\n(See.Appendix.6.for.Graeme\u2019s.story.)\nIn.all.we.had.one.professional.magazine.article,20.\nseveral.newspaper.articles,21,22.a.radio.programme23.\nand.a.BBC.Health.website24.dealing.with.the.topic.\nduring.recruitment.\nWe.took.advantage.of.two.articles.in.the.British \nMedical Journal.about.Bell\u2019s.palsy25,26.and.the.\nresultant.correspondence.of.48.rapid.responses.\nFIGURE 2  Posed portrait photographs (at rest, smiling, eyes tight shut, eyebrows raised). Note: This patient was graded HB5 by the \npanel of assessors.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n5\nTABLE 2  Trial sites for the BELLS study\nRaigmore Hospital, Inverness\nAberdeen Royal Infirmary\nNinewells Hospital, Dundee (two sites: ward and clinic)\nPerth Royal Infirmary\nVictoria Hospital, Kirkcaldy\nRoyal Infirmary, Edinburgh\nWestern General Hospital, Edinburgh\nSt John\u2019s Hospital, Livingston\nBorders General Hospital, Melrose\nCrosshouse Hospital, Kilmarnock\nRoyal Alexandra Hospital, Paisley (two sites: ward and \nannex)\nMonklands Hospital, Airdrie\nGartnavel General Hospital, Glasgow\nVictoria Infirmary, Glasgow\nStobhill Hospital, Glasgow\nGlasgow Royal Infirmary\nSouthern General Hospital, Glasgow\n(with.potentially.problematic.influences.on.referral.\nof.patients.into.the.study).to.respond.with.details.\nof.the.study..All.of.these.activities.may.have.helped.\nto.keep.the.study.in.the.eye.of.our.target.group.for.\nrecruitment..Such.activities.did.take.several.days.in.\nterms.of.planning,.writing.and.interviews.but.could.\nreasonably.be.fitted.in.around.the.general.work.of.\nthe.project.\nEducational meetings\nWe.took.every.opportunity.to.raise.awareness.and.\nbuild.the.profile.of.the.study.including.conference.\npresentations.and.workshops..However,.these.\nexercises.connected.with.relatively.few.recruiting.\ngeneral.practitioners.and.emergency.room.staff,.\nand.it.is.hard.to.know.what.impact,.if.any,.they.had.\non.recruitment.\nRegular feedback on the trial\nIn.the.quarterly.mailings.to.general.practitioners.\norganised.by.the.SPPIRe.nodes.we.took.the.\nopportunity.both.to.let.them.know.that.the.study.\nwas.still.ongoing.and.the.current.recruiting.status.\nRemuneration\nFollowing.negotiation.with.primary.care.R&D.\ndepartments,.general.practices.were.offered.\u00a351.\nper.patient.for.recruiting.patients.into.the.trial.and.\nfor.any.ongoing.explanation.and.care.that.might.\nbe.required..This.fee.was.intended.additionally.to.\ncover.the.situation.where.in.rare.cases.a.patient.\npreferred.to.use.their.general.practitioner.surgery.\nrather.than.their.home.for.the.researcher\u2019s.visits.\nRecruiters\nHeads.of.ear,.nose.and.throat.(ENT).departments.\nat.20.hospitals.in.Scotland.that.could.contribute.\nto.the.trial.as.recruiting.sites.were.approached,.\nand.17.agreed.to.join..It.was.never.anticipated.\nthat.the.trial.would.recruit.in.the.island.regions;.\nhowever,.both.potential.centres.in.NHS.Forth.\nValley.(Stirling.Royal.Infirmary,.Falkirk.&.District.\nRoyal.Infirmary).and.also.that.for.NHS.Dumfries.\n&.Galloway.(Dumfries.&.Galloway.Royal.Infirmary).\ndeclined.to.join,.reducing.the.national.coverage.to.\nan.estimated.88%.of.the.Scottish.population..In.all.\ncases,.staffing.difficulties.were.cited.as.the.reason.\nfor.non-participation..The.three.main.Scottish.\ndental.institutions.(Dundee.Dental.Hospital,.\nGlasgow.Dental.Hospital.and.Edinburgh.Dental.\nInstitute).were.also.approached.but.rather.than.\nact.as.recruiting.sites.agreed.to.refer.potential.\npatients.to.the.nearest.site..The.17.sites.(with.\nadditional.premises.at.Ninewells.Hospital.and.\nRoyal.Alexandra.Hospital).finally.organised.\nand.provisioned.with.study.medications.and.\nstationery.were.the.ENT.wards.and.clinics.listed.\nin.Table 2..The.head.of.each.contributing.clinic.\nor.department.was.formally.designated.Local.\nPrincipal.Investigator.with.site-specific.approvals.\nfrom.their.LREC.and.R&D.division;.these.are.listed.\nin.Appendix.7.\nEach.trial.site.was.supplied.with.stationery.(site.\nfolders;.patient.information.sheets,.consent.\nforms.and.case.record.forms.\u2013.see.Appendices.\nreferred.to.later);.instructions.for.the.process.of.\nrandomisation;.and.patient.packs.comprising.the.\ntrial.medications.in.appropriate.storage.locations.\n(e.g..drugs.cupboards).\nPrior.to.the.start.of.recruitment.all.sites.were.\nbriefed.by.the.Local.Principal.Investigator.or.a.\nmember.of.the.BELLS.team.or.both..The.briefing.\nwas.provided.as.part.of.the.standard.educational.\nprogramme.and.potential.recruiters.were.taken.\nstep-by-step.through.the.processes.of.recruitment.\nas.follows.\nRecruitment step 1: Patient awareness\nStaff.were.requested.to.explain.the.condition.to.the.\npatient.and.the.options.for.treatment,.and.to.bring.Methods\n6\nto.the.patient\u2019s.attention.the.ongoing.Scottish.\nBell\u2019s.Palsy.Study..Potential.patients.were.presented.\nwith.the.site-specific.study.Patient.Information.\nSheet,.an.example.of.which.is.provided.in.\nAppendix.8.\nRecruitment step 2: Data collection\nAll.patients.and.recruiting.staff.provided.a.\ncompleted.site-specific.patient.case.record.form,.\nirrespective.of.final.recruitment.status..An.example.\nis.provided.in.Appendix.9.\nRecruitment step 3: Consent\nFor.eligible.patients.consenting.to.join.the.study,.\nthe.BELLS.consent.form.was.then.completed..The.\npatient.consent.form.was.health.region.specific..An.\nexample.is.provided.in.Appendix.10.\nRecruitment step 4: Randomisation to \ntreatment\nThe.patient.was.then.randomised.to.treatment.\naccording.to.the.following.schedule,.and.utilising.\nthe.services.of.the.Health.Services.Research.Unit.\n(HSRU).randomisation.facility.at.the.University.\nof.Aberdeen..The.randomisation.scheme.was.site-\nspecific..An.example.is.provided.in.Appendix.11.\nRecruitment step 5: Initiation of \ntreatment\nFinally,.staff.were.instructed.to.request.the.patient.\nto.commence.treatment.immediately.by.taking.the.\nfirst.dose..Staff.at.the.recruiting.sites.changed.twice.\na.year:.briefing.of.new.staff.was.handled.by.the.\nlocal.principal.investigator,.who.supplied.briefing.\nnotes,.including.expanded.instructions.on.what.\nto.do.if.any.aspect.of.the.randomisation.process.\ndiffered.from.that.expected.(see.Appendix.12).\nRemuneration\nDepartments.were.paid.\u00a350.for.each.recruitment.\nirrespective.of.the.patient\u2019s.completion.status,.paid.\nfrom.study.funds.\nFeedback\nLocal.principal.investigators.were.advised.\nmonthly.by.email.of.the.current.status.of.the.study.\n(recruitment.figures,.retention.figures,.adherence.\nto.target)..The.Management.Committee.were.\nupdated.weekly.by.email:.see.Appendix.13.for.a.\ntypical.example.\nPatients\nPatients.were.referred.to.participating.sites.after.\npresentation.at.GP.surgeries,.A&E,.NHS24.or.\n(rarely).their.dentist..After.the.diagnosis.of.Bell\u2019s.\npalsy.was.confirmed.then.inclusion.and.exclusion.\ncriteria.were.examined..See.Table 3.for.a.full.listing.\nof.inclusion.and.exclusion.criteria.\nInterventions\nPatients.satisfying.the.criteria.for.entry.into.the.\nScottish.Bell\u2019s.Palsy.Study.and.who.were.willing.\nTABLE 3  Inclusion and exclusion criteria for the BELLS study\nInclusion criteria\nAdults (16 or older)\nUnilateral facial nerve weakness of no identifiable cause \nconfirmed as Bell\u2019s palsy\nSeen within 72 hours of the onset of weakness\nExclusion criteria\nPregnancy\nUncontrolled diabetes (HbA1c > 8%)\nPeptic ulcer disease\nSuppurative otitis media\nHerpes zoster\nMultiple sclerosis\nSarcoidosis and other rarer conditions\nInability to give informed consent\nBreast-feeding\nPatients with systemic infection\nHbA1c, glycated haemoglobin.\nTABLE 4  BELLS study: factorial trial design\nTreatment Prednisolone P Placebo P\u2032\nAciclovir A aciclovir\u2013\nprednisolone AP\naciclovir\u2013placebo AO\nPlacebo A\u2032 placebo\u2013\nprednisolone OP\nplacebo\u2013placebo OO\nTABLE 5  Dosing regime for the BELLS study\nPrednisolone 2 \u00d7 25 mg\/day = 50 mg\/day for  \n10 days, starting immediately\nPlacebo equivalent Indistinguishable capsules (red)\nAciclovir 5 \u00d7 400 mg\/day = 2000 mg\/day for \n10 days, starting immediately\nPlacebo equivalent Indistinguishable capsules (green)DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n7\nFIGURE 3  (a) Study medications: bottles (ten days\u2019 treatment). (b) Study medications: capsules (one day\u2019s dose).\n(a) (b)\nto.join.it,.and.who.had.provided.signed.witnessed.\nconsent,.were.immediately.randomised.into.the.\ntrial.as.follows..In.order.to.accommodate.the.\nintended.2.\u00d7.2.factorial.design.(see.Table 4).patients.\nwere.randomised.to.prednisolone\/placebo.and.\nto.aciclovir\/placebo.as.follows,.with.all.processes.\nnecessary.to.achieve.balance.attended.to.by.the.\nrandomisation.unit.at.HSRU.\nIn.Table 4.we.use.the.shorthand.abbreviations.that.\nwill.be.used.throughout.this.report.to.distinguish.\nbetween.the.treatment.groups,.specifically:\naciclovir\u2013prednisolone. AP\naciclovir\u2013placebo. AO\nplacebo\u2013prednisolone. OP\nplacebo\u2013placebo. OO\nand\naciclovir. A. AP.+.AO\nno.aciclovir. A\u2032. OP.+.OO\nprednisolone. P. AP.+.OP\nno.prednisolone. P\u2032. AO.+.OO\nMedications.were.prescribed.according.to.the.doses.\ndescribed.in.Table 5.\nThe.four.treatment.combinations.were.provided.\nin.packs.labelled.Treatment.1,.2,.3,.4.with.all.\nparticipants.masked.(referrers,.recruiters,.patients.\nand.researchers,.and,.later,.assessors)..The.bottles,.\nlabelling.and.capsules.are.shown.in.Figure 3.\nPatients.were.requested.to.commence.the.first.dose.\non.site,.even.if.there.was.sufficient.time.only.to.\ncomplete.a.half-day\u2019s.dose.\nTABLE 6  Identification of masked treatments\nTreatment \n(code)\nTreatment  \n(actual)\nTreatment \n(shorthand)\n1 placebo\u2013prednisolone OP\n2 placebo\u2013placebo OO\n3 aciclovir\u2013prednisolone AP\n4 aciclovir\u2013placebo AO\nIdentification of coded \ntreatments\nThe.identification.of.treatments.was.established.\nby.code.break.in.the.presence.of.the.Chief.\nInvestigator,.Trial.Statistician.and.Trial.Co-\nordinator.on.20.March.2007.by.agreement.with.the.\nTSC.and.DMEC,.after.the.last.patient.was.followed.\nup.and.all.primary.and.secondary.outcomes.\nobtained.\nFor.clarity.in.the.sequel,.the.identification.of.\ntreatments.is.provided.in.Table 6.\nResearchers\nThe.geographical.coverage.of.the.study.was.split.\ninto.four.regions,.each.staffed.by.one.researcher.as.\nshown.in.Table 7.\nAfter.interview.and.appointment.researchers.\nwere.briefed.to.practise.as.outlined.in.Appendix.\n14,.in.order.to.achieve.as.uniform.an.approach.\nas.possible..During.the.first.patient.visit.(as.well.Methods\n8\nTABLE 7  Coverage of the BELLS study, showing the proportion of coverage achieved in each region\nRegion Coverage Proportion\nNorth NHS Highland, NHS Grampian 16.4%\nEast and South-East NHS Tayside, NHS Fife 16.6%\nSouth NHS Lothian, NHS Lothian West NHS Borders, NHS Dumfries and \nGalloway\n17.5%\nWest NHS Argyll & Clyde, NHS Forth Valley, NHS Greater Glasgow, NHS \nAyrshire & Arran, NHS Lanarkshire\n49.5%\nas.completing.study.instruments;.see.later).the.\nresearcher.completed.Form.C.(checklist,.see.\nAppendix.15).and.Form.B.(patient.details,.see.\nAppendix.16)..In.particular,.Form.C.contains.the.\ncheck.item.that.the.treatment.dispensed.to.the.\npatient.was.that.allocated.\nPatients.were.assessed.during.a.home.visit.3\u20135.days.\nafter.randomisation,.i.e..up.to.8.days.after.onset.\nof.symptoms;.again.after.3.months;.and.finally.at.\na.third.assessment.after.9.months,.if.they.were.still.\nunrecovered.(House\u2013Brackmann.grade.II\u2013VI).at.3.\nmonths.\nThe.preceding.paragraph.encapsulates.two.\nvariations.to.protocol.made.on.clinical.grounds.\nwithin.weeks.of.the.commencement.of.patient.\nrandomisation..These.were:\nDefinition of \u2018complete recovery\u2019\nOur.definition.of.recovery.stated.in.the.trial.\nprotocol.is.attainment.of.House\u2013Brackmann.grade.\nI.or.II.(HBI.or.HBII).\nWithin.a.few.weeks.of.commencing.3-month.\nassessment.visits.to.BELLS.patients,.i.e..after.\nNovember.2004,.it.was.evident.to.investigators.and.\nfrom.the.patients\u2019.own.accounts.of.their.progress.\ntowards.recovery.that.patients.looked,.and.felt,.fully.\nrecovered.only.when.a.status.of.HBI.was.attained.\nResearchers.were.instructed.to.make.the.final.\nfollow-up.visit.at.9.months.only.to.patients.graded.\nHBII.or.higher..At.a.meeting.of.the.trial.DMEC.\non.24.August.2005.and.following.a.scheduled.\nanalysis.of.3-month.data.only.(independent.of.and.\nblind.to.investigators).the.Chair.of.the.Committee.\ndrew.to.the.attention.of.principal.investigators.the.\ndiscrepancy.between.the.definition.of.complete.\nrecovery.(HBI).and.the.definition.stated.in.the.\nprotocol.(HBI.or.II)..At.the.next.meeting.of.\nPrincipal.Investigators.on.2.December.2005.under.\nItem.2(ii).it.was.noted.as.follows:\n\u2022. the.opinion.of.the.meeting.was.that.HBI.at.\nV2.was.the.definition.of.\u2018recovery..\u2019.and.that.\nfurther.data.collection.on.recovered.patients.is.\nirrelevant;\n\u2022. the.comments.from.DMEC.that.the.definition.\nof.recovery.(HBI).differed.from.that.in.the.\nprotocol.(HBI-II);.the.feeling.of.the.meeting.\nwas.that.if.this.was.a.real.issue.then.it.could.be.\ncovered.by.discussion.in.the.final.report.[to.the.\nfunder].\nWe.did.not.alter.the.protocol.or.seek.an.\namendment.to.it.to.address.this.difference,.but.\nwe.determined.to.continue.to.use.the.definition.\nof.HBI.as.\u2018completely.recovered\u2019.to.impose.our.\nstrategy.for.9-month.visits,.and.finally.in.our.pre-\nspecified.primary.analysis.for.the.funder\u2019s.final.\nreport.\nA.supplementary.analysis.based.around.HBI-II.for.\nrecovery.(\u2018good\u2019.not.\u2018complete\u2019).is.included.in.this.\nfinal.report.\n Baseline visits\nAt.the.same.time.as.it.was.determined.to.\ndistinguish.between.\u2018good\u2019.and.\u2018complete\u2019.recovery.\n(HBI-II.and.HBI.respectively).and.for.the.same.\nreason.(clinical.response.to.patient.feedback).\nit.was.decided.to.extend.the.time.lag.between.\nnotification.of.a.new.randomisation.and.the.\nbaseline.assessment.visit.from.\u2018as.soon.as.possible\u2019.\nto.\u20183\u20135.days\u2019..Earlier,.patients.recruited.to.the.\ntrial.had.reported.with.regret.that.researchers.\nwere.visiting.\u2018too.soon\u2019.and.that.their.symptoms.\u2013.\nspecifically,.poor.appearance.and.pain.\u2013.worsened.\nafter.that.visit.had.been.made..In.order.to.capture.\nthe.patient.experience.adequately,.researchers.were.\ninstructed.to.negotiate.the.timing.of.the.baseline.\nvisit.with.the.greater.flexibility.indicated.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n9\nAssessors\nThe.fifth.and.final.group.of.participants.were.the.\nassessors,.whose.role.was.to.assess.the.patients\u2019.\nrecovery.status.(House\u2013Brackmann.grading.I.to.\nVI).on.the.basis.of.the.posed.photographs.taken.\nby.the.researcher.during.patient.visits..These.\nwere.experts.in.their.field.(one.otolaryngologist,.\none.neurosurgeon,.one.plastic.surgeon).and.were.\nblinded.to.the.patient.treatment.allocation,.and.\nto.the.timing.of.the.visit.(onset,.3.months.or.9.\nmonths).throughout.the.assessment.period..A.\ntypical.set.of.the.four.required.posed.photographs.\nis.shown.as.Figure 2..(This.patient\u2019s.signed.consent.\nfor.publication.is.available.on.file.)\nAssessors.provided.independent.gradings.for.each.\npatient.visit,.based.on.the.four.posed.portrait.\nphotographs.\nPatients.graded.\u2018well\u2019.at.3.months.(House\u2013\nBrackmann.grade.I).did.not.receive.a.9-month.\nvisit..\nThe.identities.of.the.members.of.the.panel.of.\nassessors.are.provided.in.Appendix.17.\nIn.order.to.achieve.a.clear.definition.of.the.\nattainment.of.recovery.we.wanted.to.make.the.\nassumption.that.in.Bell\u2019s.palsy.no.patient\u2019s.\ncondition.worsened.from.one.visit.to.the.next..\nIn.fact.there.were.just.four.cases.where.this.\nassumption.failed.(0.8%;.three.patients.were.\ngraded.I\u2013II\u2013I,.i.e..\u2018well\u2013ill\u2013well\u2019.at.the.respective.\nassessment.visits,.and.one.was.graded.III\u2013I\u2013II,.\ni.e..\u2018ill\u2013well\u2013ill\u2019)..Given.the.small.number.of.such.\ncases.and.the.comparatively.greater.variation.\nin.individual.gradings.by.experts,.we.elected.in.\nall.four.cases.to.allow.the.minority.judgement.\nto.over-rule.the.majority.or.median.judgement,.\nthe.patients.being.regraded.II\u2013II\u2013I.and.III\u2013II\u2013II.\nrespectively,.and.thus.we.achieved.a.trajectory.that,.\nfor.the.purposes.of.an.exploration.of.recovery.after.\nonset.of.Bell\u2019s.palsy,.is.satisfactorily.defined.\nObjectives\nThe.trial.objectives.are.listed.in.Table 8.\nPrimary outcomes\nHouse\u2013Brackmann grade\nOur.primary.disease.measurement.was.the.\ncommonly.used.and.easily.administered.House\u2013\nBrackmann.scale.for.facial.paralysis,.where.a.score.\nof.I.is.\u2018normal\u2019.(or.\u2018recovered\u2019,.in.the.language.\nof.the.trial).and.scores.II\u2013VI.reflect.increasing.\ndysfunction.from.\u2018minor.asymmetry.e.g..when.\nsmiling\u2019.(graded.II).to.\u2018no.perceptible.movement\u2019.\n(graded.VI)..The.complete.scale.is.provided.in.\nTable 9.\nPatients.were.assessed.during.a.home.visit.3\u20135.\ndays.after.randomisation,.i.e..up.to.8.days.after.\nonset.of.symptoms;.again.after.3.months;.and.\nfinally.at.a.third.assessment.after.9.months,.if.\nthey.were.still.unrecovered.(House\u2013Brackmann.\nII\u2013VI).at.3.months..Judgements.were.made.by.\nexpert.review.of.four.posed.portrait.photographs.\ntaken.during.the.assessment.visit.(at.rest,.smiling,.\neyebrows.raised,.eyes.tight.shut)..Three.clinicians.\n(one.otolaryngologist,.one.neurologist,.one.plastic.\nsurgeon).independently.reviewed.the.posed.\nphotographs.and.recorded.a.grading.I\u2013VI..If.there.\nwas.disagreement.by.more.than.one.point.on.the.\nscale,.a.revised.opinion.was.requested.from.all.\nthree.assessors..The.majority.or.median.judgement.\nwas.taken.as.providing.the.patient\u2019s.health.status.\non.the.day.of.the.visit.\nTABLE 8  Trial objectives for the BELLS study\n1. To describe the resolution of neurological deficit and cosmetic, psychological and functional recovery in each of four \ngroups of patients: those treated with prednisolone, aciclovir, both, or neither\n2. To determine which group of patients has the greatest reduction in neurological disability scores on the House\u2013\nBrackmann grading system at 3 and 9 months after randomisation\n3. To compare self-reported health status (including assessments of pain) at 3 and 9 months after randomisation\n4. To compare the incremental cost per neurological deficit resolved (case cured) and incremental cost per QALY in the \nstudy groupsMethods\n10\nTABLE 9  House\u2013Brackmann scale\nGrade Definition\nI Normal symmetrical function in all areas\nII Slight weakness noticeable only on close inspection. Complete eye closure with minimal effort. Slight asymmetry \nof smile with maximal effort. Synkinesis barely noticeable; contracture or spasm absent\nIII Obvious weakness, but not disfiguring. May not be able to lift eyebrow. Complete eye closure; strong but \nasymmetrical mouth movement with maximal effort. Obvious, but not disfiguring synkinesis, mass movement or \nspasm\nIV Obvious disfiguring weakness. Inability to lift brow. Incomplete eye closure and asymmetry of mouth with maximal \neffort. Severe synkinesis, mass movement, spasm\nV Motion barely perceptible. Incomplete eye closure; slight movement of corner of mouth. Synkinesis, contracture \nand spasm usually absent\nVI No movement; loss of tone; no synkinesis, contracture, or spasm\nPatients,.referrers,.recruiters,.research.visitors.and.\nassessors.were.all.blinded.to.treatment.throughout.\nthe.duration.of.the.study.\nSecondary outcomes\nThere.are.three.secondary.outcomes.for.patients.on.\nthe.BELLS.study,.measured.once.at.each.visit.\nHealth Utilities Index Mark 3 \n(HUI3)\nThe.Health.Utilities.Index.Mark.3.(HUI3)27.is.a.\nmulti-attribute.health.status.classification.system.\nproviding.an.aggregated.score.on.eight.variables,.\ni.e..vision,.hearing,.speech,.ambulation,.dexterity,.\nemotion,.cognition.and.pain..It.is.designed.for.\nuse.in.clinical.practice.and.research,.health.policy.\nevaluations,.and.general.population.surveys..It.\nis.constructed.for.self-administration.by.persons.\n14.years.of.age.and.older,.and.for.administration.\nby.a.trained.interviewer.in.person.or.by.telephone..\nIt.takes.about.5\u201310.minutes.to.administer..A.copy.\nof.the.form.for.the.collection.of.HUI3.data.is.\nprovided.in.Appendix.18..Scoring.is.achieved.\nthrough.the.HUI3.Multi-Attribute.Utility.Function.\non.the.Dead-Healthy.Scale28.as.shown.in.Table 10.\nHere.xn.is.the.attribute.level.and.bn.is.the.attribute.\nutility.score..Then.a.patient\u2019s.HUI3.score.on.the.\nDead-Healthy.scale.is.defined.by.the.formula.on.\nthe.Dead\u2013Perfect.Health.scale:\nu.=.1.371.(b1.\u00d7.b2.\u00d7.b3.\u00d7.b4.\u00d7.b5.\u00d7.b6.\u00d7.b7.\u00d7.b8).\u2013.0.371\nwhere.u.is.the.utility.of.a.chronic.health.state.on.a.\nutility.scale.where.\u2018dead\u2019.has.a.utility.of.0.00.and.\n\u2018healthy\u2019.has.a.utility.of.1.00..The.range.of.the.\nscore.is.\u2013.0.371.to.+.1.000.\nBrief Pain Inventory (BPI)\nThe.Brief.Pain.Inventory.(BPI).is.based.on.a.\nmeasure.known.as.the.Wisconsin.Brief.Pain.\nQuestionnaire29.and.was.developed.by.the.Pain.\nResearch.Group.to.provide.information.on.the.\nintensity.of.pain.(the.sensory.dimension).as.well.as.\nthe.degree.to.which.pain.interferes.with.function.\n(the.reactive.dimension)..The.BPI.also.asks.\nquestions.about.pain.relief,.pain.quality,.and.the.\npatient\u2019s.perception.of.the.cause.of.pain..It.uses.\nnumerical.rating.scales.of.0.to.10.for.item.ratings.\nbecause.of.their.simplicity,.lack.of.ambiguity.and.\nbecause.they.seemed.the.best.to.use.for.cross-\nlinguistic.pain.measurement..A.copy.of.the.form.\nfor.data.collection.is.provided.in.Appendix.19.\nThe.pain.score.is.obtained.by.adding.together.\nthe.scores.provided.by.the.patient\u2019s.responses.to.\nQuestions.2.to.12..The.range.of.scores.for.any.\nindividual.patient.visit.is.thus.0.to.110..The.higher.\nthe.score,.the.greater.the.impact.of.pain.on.the.\npatient\u2019s.daily.living.\nDerriford Appearance Scale \n(DAS59)\nThe.Derriford.Appearance.Scales.(DAS24.and.\nDAS59)30.are.psychological.measures.of.concern.\nabout.appearance,.developed.and.validated.in.the.\nUK.for.use.in.clinical.and.research.settings.(e.g..\nin.plastic.surgery,.oncology.and.psychology)..They.\nhave.excellent.validity.and.reliability,.and.have.\nbeen.independently.recommended.as.a.measure.\nof.choice..A.copy.of.the.DAS59.form.is.provided.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n11\nTABLE 10  HUI3 Multi-Attribute Utility Function on the Dead-Healthy Scale\nVision  \nx1  b1\nHearing \nx2  b2\nSpeech \nx3  b3\nAmbulation \nx4  b4\nDexterity \nx5  b5\nEmotion \nx6  b6\nCognition \nx7  b7\nPain  \nx8  b8\n1  1.00 1  1.00 1  1.00 1  1.00 1  1.00 1  1.00 1  1.00 1  1.00\n2  0.98 2  0.95 2  0.94 2  0.93 2  0.95 2  0.95 2  0.92 2  0.96\n3  0.89 3  0.89 3  0.89 3  0.86 3  0.88 3  0.85 3  0.95 3  0.90\n4  0.84 4  0.80 4  0.81 4  0.73 4  0.76 4  0.64 4  0.83 4  0.77\n5  0.75 5  0.74 5  0.68 5  0.65 5  0.65 5  0.46 5  0.60 5  0.55\n6  0.61 6  0.61   6  0.58 6  0.56   6  0.42  \nin.Appendix.20..We.obtained.permission.for.\nuse.of.the.form.from.the.copyright.owners,.who.\ngenerously.waived.copyright.charges.after.the.first.\n250.copies.were.obtained.\nScoring of the DAS59\nThe.score.for.the.DAS59.is.obtained.by.summing.\ndifferent.components.as.follows:\n\u2022. items.on.page.1.do.not.contribute;\n\u2022. throughout.the.scale.\u2018N\/A\u2019.scores.0;\n\u2022. items.52,.54,.55,.56,.57.have.their.score.values.\nreversed.(1.becomes.5,.2.becomes.4,.3.is.\nunchanged,.4.becomes.2,.5.becomes.1).\nThe.DAS59.generates.six.measures.of.\npsychological.distress.and.dysfunction.as.well.as.a.\nmeasure.of.physical.distress.and.dysfunction.(items.\n25.and.26)..Full-scale.and.factorial.sub-scale.scores.\nare.obtained.by.adding.the.scores.of.individual.\nitems.as.shown.in.Table 11.\nThe.range.of.DAS59.scores.is.8.to.262..The.higher.\nthe.score,.the.greater.the.patient\u2019s.level.of.distress.\nand.dysfunction.\nMethods used to enhance \nthe quality of measurements\nAll.participants.were.briefed.similarly.(including.\npatients,.through.the.medium.of.the.Patient.\nInformation.Sheet.and.discussion.with.the.\nreferring.and.recruiting.clinicians)..General.\npractitioners.were.provided.with.instructions.for.\nreferral.on.the.study.website..Referrers.followed.\nidentical.procedures.as.far.as.it.was.possible.to.\ncontrive.this..Researchers.used.the.same.model.of.\ncamera.(Sony.DSC\u2013P12),.with.the.same.settings,.\nand.requested.the.same.poses.of.their.patients;.\nfollow-up.procedures.(phone.calls,.visits).were.\nmanaged.identically..Assessors.calibrated.their.\nmeasurements.through.an.initial.training.period.\nwith.discussion.(assessment.of.10.sample.portrait.\nsets,.with.a.discussion.of.differences,.followed.by.\nassessment.of.a.further.20.sample.portrait.sets);.\nassessors.were.at.all.times.made.aware.of.any.\u2018large\u2019.\ndiscrepancies.in.their.grading.of.patient.recovery.\n(i.e..any.difference.in.grading.exceeding.one.grade.\npoint).and.in.all.such.cases.the.portrait.sets.were.\nreassessed.\nTABLE 11  DAS59 scoring system\nFactor Label Items\nFactor 1 General self-consciousness of appearance (GSC) 1, 8, 10, 12, 15, 17, 27, 28, 30, 31, \n34, 35, 36, 38, 41, 42, 58\nFactor 2 Social self-consciousness of appearance (SSC) 2, 3, 5, 6, 7, 13, 14, 16, 18, 19, 20, \n21, 22, 29, 32, 33, 39, 40, 47, 50\nFactor 3 Sexual and bodily self-consciousness of appearance (SBSC) 4, 9, 23, 24, 37, 43, 45, 46, 49\nFactor 4 Negative self-concept (NSC) 52, 54, 55, 56, 57\nFactor 5 Facial self-consciousness of appearance (FSC) 11, 44, 48, 51Methods\n12\nAt.the.centre.there.was.double.entry.of.data.and.\nall.discrepancies.were.identified,.discussed.and.\ncorrected.\nTwo.statisticians.independently.pursued.separate.\nanalyses.of.the.data.\nUnblinding.took.place.in.the.presence.of.the.Chief.\nInvestigator,.one.principal.investigator.and.the.\nstudy.co-ordinator,.who.independently.interpreted.\nthe.decoding.key.and.agreed.that.interpretation.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n13\nSample size\nThe.relevant.Cochrane.reviews.suggested.\npotential.effect.sizes.from.4%.to.17%..A.\ndifference.in.complete.recovery.of.10\u201312%.or.\nmore.was.considered.to.be.clinically.meaningful..\nRandomising.240.patients.per.active.treatment.\n(e.g..aciclovir.or.not;.a.total.of.480.patients).\nwas.calculated.to.provide.80%.power.to.detect.\na.difference.of.the.order.of.12%.at.the.5%.level..\nSince.the.study.design.is.factorial.the.attained.\npower.is.the.same.for.each.pair-wise.comparison.\nof.treatments.(assuming.no.interaction.between.\ntreatments.and.groups)..Assuming.an.incidence.\nrate.of.24.per.100,000.per.annum.based.on.\npopulation.access.and.age.range.we.would.have.\nanticipated.2235.cases.to.have.occurred.in.the.\nstudy.catchment.area.during.the.recruitment.\nperiod..We.therefore.aimed.to.refer.approximately.\none-third.of.all.cases.of.Bell\u2019s.palsy.arising.in.\nScotland.during.the.study.period,.and.after.\nexcluding.ineligible.cases,.to.recruit.approximately.\none-quarter.of.all.cases.\nThus.the.number.of.patients.required.to.achieve.\nthe.intended.design.is.240.per.treatment.arm,.as.\nshown.in.Table 12.(in.brackets.after.the.treatment.\ncode).\nWe.aimed,.therefore,.to.assess.720.patients.for.\neligibility.(approximately.one-third.of.all.cases.in.\nScotland.over.the.25-month.recruitment.period).\nand.to.randomise.540.of.those.to.treatment.(three-\nquarters:.in.other.words,.to.randomise.one-quarter.\nof.all.cases.in.Scotland).in.order.to.achieve.480.\ncompleted.patients.(about.nine-tenths.of.those.\nrandomised;.this.retention.rate.represents.a.very.\nhigh.proportion.but.one.that.was.realised.in.fact).\nExplanation of any interim \nanalyses and stopping rules\nNo.formal.interim.analysis.was.scheduled.or.\nrequested;.however,.as.part.of.a.quality.control.\nexercise.an.analysis.of.completed.data.was.carried.\nout.in.August.2005.at.the.request.of.the.Chair.\nof.the.study.DMEC,.and.managed.by.the.host.\ninstitution..A.statistician.co-opted.to.the.committee.\nto.analyse.the.partial.data.remained.blinded.to.\nthe.treatment.key,.having.been.made.aware.only.of.\nthe.contrasts.by.Tayside.Pharmaceuticals,.the.drug.\nmanufacturers..At.the.conclusion.of.this.analysis.\nthe.team.was.requested.to.continue.recruitment.\nand.follow-up;.no.other.illumination.of.progress.\nwas.provided.\nRandomisation\nAllocation to treatment\nThe.randomisation.processes.were.designed.\nand.managed.by.the.HSRU.at.the.University.\nof.Aberdeen..After.witnessing.signed.informed.\nconsent.from.an.intending.patient,.the.recruiting.\nclinician.telephoned.a.24-hour.automated.contact.\nat.HSRU..Telephone.key-presses.advised.HSRU.\nof.the.site,.and.the.HSRU.randomisation.service.\nresponded.with.a.unique.patient.ID.carrying.a.code.\nfor.the.recruiting.trial.site.and.patient.accession.\nnumber,.and.finally.with.a.decision.about.the.\ntreatment.allocation..The.allocated.treatment.was.\ntaken.from.local.storage.and.administration.of.the.\nallocated.medication.commenced.immediately.\nPharmaceutical stock control\nStock.control.was.managed.through.constant.\nmonitoring.of.the.treatment.supplies.at.each.of.\nthe.treatment.sites..When.supplies.were.noted.\nto.be.reducing,.stock.was.ordered.directly.from.\nTayside.Pharmaceuticals,.who.attended.to.the.\ndraw.from.stock.and.delivery.to.the.sites..Stocks.\nwere.replenished.by.instruction.to.Tayside.\nPharmaceuticals,.requesting.40.or.80.patient.packs.\n(10.or.20.packs.of.each.of.the.four.treatments).\nat.a.time..Quality.control,.batch.control.and.\nlabelling.were.all.attended.to.by.staff.at.Tayside.\nPharmaceuticals.\nSequence generation\nRandomisation.was.achieved.using.a.permuted.\nblock.randomisation.technique.with.block.sizes.of.\nfour.or.eight,.and.no.stratification..The.sequence.\nremained.entirely.concealed.until.the.intervention.\nwas.assigned.\nChapter 3  \nStudy designStudy design\n14\nTable 12  Target completed patient numbers in the Scottish Bell\u2019s Palsy Study\nTreatment  Prednisolone Placebo  Total \nAciclovir  AP (120) AO (120) 240\nPlacebo  OP (120) OO (120) 240\nTotal  240 240 480\nAO, aciclovir\u2013placebo group; AP , aciclovir\u2013prednisolone group; OO, placebo\u2013placebo group; OP , placebo\u2013prednisolone group.\nBlinding (masking)\nPatients,.referrers,.recruiters,.research.visitors.and.\nassessors.were.all.masked.to.treatment.throughout.\nthe.duration.of.the.study.\nHow the success of blinding was evaluated\nNo.formal.checks.of.the.quality.of.blinding.were.\nimplemented..However,.no.attempts.were.made.\nindividually.or.collectively,.formally.or.informally,.\nto.match.treatment.to.side.effects,.or.to.speed.of.\nrecovery,.or.to.extent.of.recovery..Where.masking.\nmight.have.been.threatened.(e.g..consideration.of.\nthe.three.deaths.that.occurred.during.follow-up,.\nor.during.the.quality-driven.analysis).the.opinion.\nof.independent.experts.was.sought.and.study.staff.\nremained.entirely.insulated.from.the.process..\nOccasionally.patients.hazarded.a.guess.(as.in.\u2018I\u2019m.\nsure.I\u2019m.on.placebo\u2019);.a.small.number.of.patients.\nclaimed.to.\u2018know\u2019.the.treatment.allocated,.through.\nmisinterpretation.of.the.labelling.on.the.patient.\npacks..Three.members.of.the.team.(the.Chief.\nInvestigator,.the.Trial.Statistician.and.the.Trial.Co-\nordinator).confirmed.the.decode.envelope.to.be.\nsealed.at.the.end.of.study,.and.it.was.opened.only.\nwhen.it.became.necessary.to.do.so.in.order.for.the.\ntreatments.to.be.identified,.the.analysis.having.\ntaken.place.masked..The.primary.statistical.analysis.\nwas.completed.before.decoding.took.place.\nStatistical methods\nAll.analyses.were.based.on.intention-to-treat.and.\nspecific.comparisons.were.pre-specified.in.the.\nprotocol.\nThe.primary.outcome.measure.of.complete.\nrecovery.(House\u2013Brackmann.I).at.3.and.9.months.\nwas.compared.initially.between.those.who.did.and.\ndid.not.receive.prednisolone.using.a.two-sided.\nFisher\u2019s.exact.test..This.was.repeated.for.aciclovir..\nWe.tested.the.data.for.any.interaction.between.the.\ngroups.prior.to.these.tests.\nPre-specified.secondary.analyses.compared.HUI3,.\nDAS59.and.BPI.scores..Then,.our.analysis.was.\nadjusted.for.all.baseline.characteristics.measured:.\nage,.gender,.interval.between.onset.and.receiving.\ntreatment,.and.scores.on.House\u2013Brackmann,.\nHUI3,.DAS59.and.BPI.\nThe.results.were.also.assessed.for.sensitivity.\nto.drop-out,.assuming.missing.at.random..A.\npropensity.score.for.drop-out.at.9.months.(Yes\/\nNo).was.estimated.using.logistic.regression,.and.a.\nfurther.analysis.carried.out.weighting.the.results.by.\nthe.reciprocal.of.the.probability.of.remaining.in.the.\nstudy.\nIf.there.is.a.significant.interaction.the.overall.\nefficiency.of.the.design.is.maintained.as.long.as.\nthe.two.drugs.do.not.act.antagonistically.to.cancel.\neach.other.out,.which.was.considered.unlikely.\nin.this.case..In.the.presence.of.an.interaction.it.\nis.still.possible.to.assess.each.drug.separately,.\nalbeit.with.reduced.power.(72%.instead.of.80%).\nfor.the.effect.size.(12%).or.alternatively.to.detect.\neffect.sizes.greater.than.15%.with.the.same.power..\nRandomisation.does.not.always.result.in.perfect.\nbalance.of.all.factors.that.may.affect.the.primary.\noutcome.and.it.is.important.to.adjust.even.for.\nminor.differences..The.differences.between.odds.\nratios.(ORs),.and.adjusted.odds.ratios.were.not.\nsubstantial;.nevertheless.the.odds.ratios.were.\nlowered.on.adjustment,.showing.that.crude.\nunadjusted.results.would.have.given.an.over-\noptimistic.impression.of.effect.size.\nEconomic.evaluation.was.an.integral.part.of.the.\ntrial..Furthermore,.a.series.of.subgroup.analyses.\nwere.also.considered..The.rationale,.methods.and.\nresults.of.these.analyses.are.presented.in.Chapters.\n7.and.8.respectively.\nSubgroup analyses\nPost.hoc.analyses.were.performed.of.(1).the.\neffectiveness.of.prednisolone.and.its.dependence.\non.the.time.of.commencement.of.administration.\nof.treatment.after.onset.of.symptoms,.and.(2).the.\neffectiveness.of.prednisolone.and.its.dependence.\non.the.severity.of.symptoms.at.onset..We.also.\nexamined.(3).the.inter-.and.intra-assessor.reliability.\nof.the.primary.outcome.measurement.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n15\nParticipant flow\nThe.flow.of.participants.through.each.stage.of.\nthe.study.is.shown.in.Figure 4..Specifically,.this.\nshows.for.each.treatment.group.the.numbers.of.\nparticipants.randomly.assigned,.how.many.received.\nthe.intended.treatment,.how.many.completed.the.\nstudy.protocol,.and.how.many.were.analysed.for.\nthe.primary.outcome.(\u2018Completed\u2019).\nProtocol deviations from \nstudy as planned, together \nwith reasons\nIn.two.cases.patients.were.recruited.to.the.study.\nbut.later.it.was.decided.that.the.diagnosis.of.Bell\u2019s.\npalsy.was.probably.mistaken.\nIn.one.case.a.patient.with.diabetes.was.recruited.to.\nthe.study..It.is.not.known.how.this.occurred.\nIn.a.small.number.of.cases,.it.became.apparent.\nduring.the.researchers\u2019.follow-up.visits.that.\nthe.delay.between.onset.of.symptoms.and.the.\ncommencement.of.treatment.probably.exceeded.72.\nhours..It.is.unlikely.that.this.aspect.of.the.consent.\nprocess.was.neglected:.in.fact,.patients\u2019.definition.\nof.the.onset.of.symptoms,.and.consequently.of.the.\ntime.of.onset.of.symptoms,.was.in.a.few.cases.very.\nvague.indeed.\nIt.is.our.belief.that.signed.consent.was.always.\nobtained.at.the.time.of.recruitment;.however,.the.\nsigned.consent.form.along.with.the.patient.case.\nrecord.form.was.occasionally.returned.to.hospital.\nnotes.rather.than.being.retained.in.the.site.folder..\nIn.these.cases.strenuous.efforts,.usually.successful,.\nwere.always.made.to.locate.and.retrieve.the.signed.\nconsent.form.\nIn.nine.cases,.patients.received.a.treatment.\ndifferent.to.that.allocated,.and.in.one.case.a.\npatient.was.sent.away.with.no.treatment.at.all..\nAlthough.stocks.were.monitored.and.maintained,.\noccasionally.they.were.not.available.for.issue.at.\nthe.site.(simply,.they.were.temporarily.mislaid)..\nIn.these.cases.an.alternative.was.offered.and.the.\nalternative.noted.\nIn.one.case,.a.patient.successfully.recruited.to.the.\nstudy.and.randomised.to.treatment.was.not.offered.\nthe.allocated.treatment:.instead.a.7-day.regime.\nof.prednisolone.and.aciclovir.in.combination.was.\nprescribed..It.is.not.known.how.this.breakdown.\nbetween.briefing.and.practice.occurred.\nUnder.intention.to.treat.(ITT).all.these.patients.\nwere.followed.up.and.their.data.retained.in.the.\nanalysis.of.results.\nRecruitment\nThe.study.ran.during.2003\u20137.and.included.\n25.months\u2019.recruitment.and.9.months\u2019.patient.\nfollow-up..At.an.estimated.30.cases\/100,000\/\nyear.(estimates.vary.from.11.to.40.cases\/100,000\/\nyear31).in.the.Scottish.population.(5.04.million,.of.\nwhom.4.10.million.are.aged.over.16,.the.minimum.\nage.for.recruitment.to.this.clinical.trial).and.with.\nan.estimated.geographical.trial.catchment.area.\nof.88%,.we.sought.to.refer.one-third.of.all.cases.\n(approximately.720).and.to.recruit.three-quarters.\nof.those.(approximately.540).to.achieve.our.target.\nof.480.completed.patients.(see.Table 12).\nIn.the.event.we.assessed.752.patients.for.eligibility.\nand.randomised.551.of.those.to.treatment,.of.\nwhom.496.patients.completed.follow-up,.as.shown.\nin.Table 13.\nThe.pattern.in.weekly.recruitment.and.overall.\nretention.to.target.over.the.108.weeks.of.\nrecruitment.to.the.BELLS.study.are.shown.in.\nFigures 5 and 6..Summary.totals.are.shown.in.Table \n13.\nDespite.a.very.flexible.and.convenient.system.\nfor.patient.appointments.and.assessment,.not.\nall.patients.were.assessed.at.all.the.required.\ntime.points:.altogether.there.were.19.missed.\nappointments.(of.course,.there.were.many.more.\nmissed.appointments.for.the.55.patients.of.the.551.\nrandomised.into.the.trial.who.did.not.complete.\nfollow-up,.chronic.missed.appointments.being.the.\nmost.common.reason.for.loss.to.follow-up)..The.\nnumber.of.attained.appointments.for.the.collection.\nof.data.on.the.BELLS.Study.is.shown.in.Table 14.\nChapter 4  \nResultsResults\n16\nCactus Design and Illustration Ltd\nFigure Number: 4.ai   Title: 02-09-04 Proof Stage:  2\nAssessed for eligibility\nn = 752\nNot meeting inclusion criteria    n = 132\nEligible but refused to participate   n = 59\nEnrolment failed (admin error)    n = 6\nClinician prescribed steroid\/aciclovir\/both  n = 4\nRandomised\nn = 551\nAciclovir\nn = 272\nPlacebo\nn = 279\nReceived allocation  n = 130\nReceived alternative  n = 4\n(human error, allocation n\/a)\nReceived allocation  n = 135\nReceived alternative  n = 3\n(human error, allocation n\/a)\nAP (coded treatment 3)\nLost to follow-up\n  n = 10\nNo contact achieved\n  n = 0\nPatient w\/d, trial intrusive\n  n = 2\nPatient w\/d to seek active\ntreatment\n    n = 2\nPatient w\/d by team\n  n = 0\nNo 1-year data provided\n  n = 0\nLost contact after V1\n  n = 6\nPatient died\n  n = 0\nTOTAL\n  n = 10\nCompleted n = 124\nAO (coded treatment 4)\nLost to follow-up\n  n = 15\nNo contact achieved\n  n = 1\nPatient w\/d, trial intrusive\n  n = 2\nPatient w\/d to seek active\ntreatment\n  n = 1\nPatient w\/d by team\n  n = 1\nNo 1-year data provided\n  n = 0\nLost contact after V1\n  n = 9\nPatient died\n  n = 1\nTOTAL\n  n = 15\nCompleted n = 123\nOP (coded treatment 1)\nLost to follow-up\n  n = 11\nNo contact achieved\n  n = 0\nPatient w\/d, trial intrusive\n  n = 4\nPatient w\/d to seek active\ntreatment\n  n = 2\nPatient w\/d by team\n  n = 0\nNo 1-year data provided\n  n = 1\nLost contact after V1\n  n = 4\nPatient died\n  n = 0\nTOTAL\n  n = 11\nCompleted n = 127\nOO (coded treatment 2)\nLost to follow-up\n  n = 19\nNo contact achieved\n  n = 3\nPatient w\/d, trial intrusive\n  n = 6\nPatient w\/d to seek active\ntreatment\n  n = 3\nPatient w\/d by team\n  n = 1\nNo 1-year data provided\n  n = 1\nLost contact after V1\n  n = 3\nPatient died\n  n = 2\nTOTAL\n  n = 19\nCompleted n = 122\nExcluded\nn = 201\nPrednisolone\nAllocated\nn = 134\nPlacebo\nAllocated\nn = 138\nReceived allocation  n = 135\nReceived alternative  n = 3\n(human error, allocation n\/a)\nPrednisolone\nAllocated\nn = 138\nReceived allocation  n = 141\nReceived alternative  n = 0\nPlacebo\nAllocated\nn = 141\nFIGURE 4  CONSORT Framework diagram, BELLS study. AO, aciclovir\u2013placebo group; AP , aciclovir\u2013prednisolone group; OO, placebo\u2013\nplacebo group; OP , placebo\u2013prednisolone group; n\/a, not available.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n17\nCactus Design and Illustration Ltd\nFigure Number:5.ai   Title: 02-09-04 Proof Stage:  2\nActual\nTrend\n0 12 24 36 48 72 84 96 108\nWeeks\nN\nu\nm\nb\ne\nr\n \no\nf\n \nr\ne\nc\nr\nu\ni\nt\ns\n60\n0\n1\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n2\nCactus Design and Illustration Ltd\nFigure Number: 6.ai   Title: 02-09-04 Proof Stage:  2\nActual\nTrend\nTarget\n0 12 24 36 48 72 84 96 108\nWeeks\nN\nu\nm\nb\ne\nr\n \no\nf\n \nr\ne\nc\nr\nu\ni\nt\ns\n60\n0\n1\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n2\nFIGURE 5  Weekly recruitment to the BELLS study.\nFIGURE 6  Retention to target on the BELLS study.\nTABLE 13  BELLS Study: attained completed patient numbers\nTreatment Prednisolone Placebo Total\nAciclovir AP (124) AO (123) A (247)\nPlacebo OP (127) OO (122) A\u2032 (249)\nTotal P (251) P\u2032 (245) (496)\nA, aciclovir group; A\u2032 no-aciclovir group; AO, aciclovir\u2013placebo group; AP , aciclovir\u2013prednisolone group; OO, placebo\u2013\nplacebo group; OP , placebo\u2013prednisolone group; P , prednisolone group; P\u2032, no-prednisolone group.Results\n18\nTABLE 14  Attained appointments for the collection of data\nPatient health status as defined by House\u2013Brackmann grade\nVisit 1  \n(soon after onset)\nVisit 2  \n(~ 3 months after onset)\nVisit 3  \n(~ 9 months after onset) Frequency\nMissed Missed Well 2\nMissed Missed Ill 0\nMissed Well 8\nMissed Ill Well 0\nMissed Ill Ill 1\nWell Missed Well 1\nIll Missed Well 4\nIll Missed Ill 1\nWell Well 30\nIll Well 319\nIll Ill Well 73\nIll Ill Ill 57\nTotal 496\n\u2018Well\u2019, House\u2013Brackmann I; \u2018Ill\u2019, House\u2013Brackmann II\u2013VI.\nWe.noted.a.small.number.of.cases.(31).where.the.\npatient.was.graded.well.(HBI).at.the.baseline.\nvisit..In.fact.this.is.not.clinically.very.remarkable..\nOne.of.several.characteristics.of.Bell\u2019s.palsy.is.\nthat.it.is.capable.of.very.rapid.recovery,.and.there.\nwere.many.anecdotal.reports.amongst.patients.\nvisited.soon.after.onset.commenting.that.they.felt.\n\u2018better.already\u2019.and.those.visited.at.3.months.who.\nreported.that.the.condition.\u2018cleared.up.soon.after.\nyou.came.to.see.me.the.first.time\u2019.\nEight.patients.received.their.first.visit.after.\ncompleting.the.10-day.course.of.treatment;.and.\nthree.patients.received.their.final.assessment.\na.year.after.onset..The.reasons.for.this.were.\nalways.related.to.the.difficulty.of.following.up.a.\nmobile.population.and.arranging.a.visit.that.was.\nconvenient.to.the.patient..\nBaseline data\nTable 15.shows.the.baseline.characteristics.of.\ngroups..The.patients.were.balanced.for.gender,.\nthe.mean.age.was.44.years,.and.the.degree.of.\ninitial.facial.paralysis.was.moderate.to.severe..Most.\npatients.(53%).initiated.treatment.within.24.hours.\nof.onset.of.symptoms,.32%.within.the.24\u201348-hour.\nperiod,.and.15%.from.48\u201372.hours.\nOutcomes and estimation\nAny.patient.graded.\u2018well\u2019.(i.e..House\u2013Brackmann.I).\nat.3.months.was.deemed.\u2018completed\u2019,.and.no.visit.\nwas.made.to.the.patient.at.9.months..Altogether.\n496.patients.(90%.of.all.those.recruited).completed.\nfollow-up.\nPrimary outcome\nFollowing.the.classical.procedure.for.a.factorial.\ndesign,.we.first.independently.assessed.outcome.in.\nthe.marginal.treatment.groups.prednisolone.versus.\nno.prednisolone.(P.vs.P\u2032;.i.e..AP.+.OP.vs.AO.+.\nOO).and.aciclovir.versus.no.aciclovir.(A.vs.A\u2032;.i.e..\nAP.+.AO.vs.OP.+.OO).\nTable 16.presents.the.unadjusted.and.adjusted.\noutcome.data.on.patients.who.completed.the.\nstudy..Altogether.357.patients.had.recovered.by.3.\nmonths.and.did.not.require.a.further.visit..Of.the.\nremainder,.80.had.recovered.at.9.months,.leaving.\n59.with.a.residual.facial.nerve.deficit.\nThe.analysis.in.this.section.was.pre-specified.and.\nall.analyses.were.based.on.intention-to-treat.\nThe.effect.of.adjustment.was.to.attenuate.\nodds.ratios.in.the.case.of.the.prednisolone.\ncomparison,.and.thus.adjustment.acted.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n19\nTABLE 15  Baseline characteristics of randomised treatment groups; mean (SD) or percent (n)\nPrednisolone  \nP (n = 251)\nNo prednisolone  \nP\u2032 (n = 245)\nAciclovir  \nA (n = 247)\nNo aciclovir  \nA\u2032 (n = 249)\nAll  \n(n = 496)\nDemography\nMale 53.8 (135) 48.2 (118) 48.2 (119) 53.8 (134) 51.0 (253)\nFemale 46.2 (116) 51.8 (127) 51.8 (128) 46.2 (115) 49.0 (243)\nAge 43.2 (16.2) 44.9 (16.6) 45.0 (16.6) 43.0 (16.1) 44.0 (16.4)\nPrimary oucome\nHouse\u2013Brackmann \ngradea\n3.5 (1.2) 3.8 (1.3) 3.6 (1.3) 3.7 (1.2) 3.6 (1.3)\nSecondary outcome\nHUI3b 0.796 (0.225) 0.775 (0.206) 0.792 (0.209) 0.779 (0.223) 0.786 (0.216)\nDAS59b 71 (37) 75 (41) 72 (39) 74 (38) 73 (39)\nBPIc 10 (18) 16 (21) 12 (18) 14 (21) 13 (20)\nTime to commencement of treatment\nWithin 24 h 47.8 (120) 60.0 (147) 55.5 (137) 52.2 (130) 53.8 (267)\n24\u201348 h 37.8 (95) 26.1 (64) 30.4 (75) 33.7 (84) 32.1 (159)\n48\u201372 h 10.0 (25) 7.3 (18) 10.1 (25) 7.2 (18) 8.7 (43)\nUnknown but \n< 72 h\n4.4 (11) 6.5 (16) 4.0 (10) 6.8 (17) 5.4 (27)\na  12 missing House\u2013Brackmann grade.\nb  13 missing HUI3 (Health Utilities Index Mark 3) and DAS59 (Derriford Appearance Scale 59).\nc  Seven missing BPI (Brief Pain Inventory) data.\nTABLE 16  Primary outcome at 3 and 9 months unadjusted (u)\/adjusted (a)a for baseline characteristics\nTreatment % (n) No treatment % (n) OR (95% CI) p value\nPrednisolone\nHB I at 3 months 83.0% (205\/247) 63.6% (152\/239) 2.79 (1.82 to 4.35) (u)\n2.44 (1.55 to 3.84) (a)\n< 0.001 (u)\n< 0.001 (a)\nHB I at 9 months 94.4% (237\/251) 81.6% (200\/245) 3.81 (2.01 to 7.56) (u)\n3.32 (1.72 to 6.44) (a)\n< 0.001 (u)\n< 0.001 (a)\nAciclovir\nHB I at 3 months 71.2% (173\/243) 75.7% (184\/243) 0.79 (0.53 to1.21) (u)\n0.86 (0.55 to 1.34) (a)\n0.304 (u)\n0.504 (a)\nHB I at 9 months 85.4% (211\/247) 90.8% (226\/249) 0.60 (0.34 to 1.07) (u)\n0.61 (0.33 to 1.11) (a)\n0.072 (u)\n0.105 (a)\na  Adjusted for age, gender, baseline House\u2013Brackmann (HB) grade, aciclovir (Yes\/No) and prednisolone (Yes\/No) and time \nto start of treatment.Results\n20\nconservatively..Unadjusted.odds.ratios.(column.\n4).were.respectively.2.79.and.3.81.(prednisolone.\nat.3.months.and.9.months);.and.0.79.and.0.60.\n(aciclovir.at.3.months.and.9.months).\nThere.were.significant.differences.in.complete.\nrecovery.at.3.months.between.the.prednisolone.\ncomparison.groups.(83.0%.for.prednisolone,.63.6%.\nfor.no.prednisolone,.a.difference.of.+.19.4%;.95%.\nconfidence.interval.(CI):.+.11.7%.to.+.27.1%,.p.\n<.0.001);.but.no.significant.difference.between.\nthe.aciclovir.comparison.groups.(71.2%.for.\naciclovir.and.75.7%.for.no.aciclovir,.a.difference.\nof.\u2013.4.5%.(95%.CI:.\u2013.12.4%.to.+.3.3%,.p.=.0.30,.\nadjusted.0.50)..Nine-month.assessments.of.\npatients.at.House\u2013Brackmann.grade.I.were:.94.4%.\nfor.prednisolone.compared.with.81.6%.for.no.\nprednisolone,.a.difference.of.+.12.8%.(95%.CI:.\n+.7.2%.to.+.18.4%,.p.<.0.001);.and.85.4%.for.\naciclovir.and.90.8%.for.no.aciclovir,.a.difference.\nof.\u2013.5.3%.(95%.CI:.\u2013.1.0%.to.+.0.3%,.p.=.0.07,.\nadjusted.0.10).\nAlthough.neither.the.results.at.3.months.nor.9.\nmonths.were.statistically.significant,.we.noted.that.\nrecovery.rates.were.higher.in.the.no-aciclovir.group.\nthan.in.the.aciclovir.group.\nNext.we.pursued.the.corresponding.four-arm.\nanalysis,.i.e..comparison.of.the.four.delivered.\ntreatments.(AP,.AO,.OP,.OO)..The.trial.was.not.\npowered.for.this,.but.primarily.it.provided.an.\nopportunity.to.assess.any.interaction.between.\nthe.active.therapies.(aciclovir.and.prednisolone).\nand.secondly.it.provided.a.very.convenient.and.\ninterpretable.comparison.for.clinicians.and.\nresearchers.(and.for.this.reason.was.also.adopted.in.\nthe.health.costs.analyses.in.Chapter.7).\nTable 17.and.Figure 7.demonstrate.the.proportion.\nof.patients.assessed.as.making.a.full.recovery,.i.e..\nhaving.normal.facial.function.(House\u2013Brackmann.\nI).at.baseline,.3.and.9.months.in.the.four.treatment.\nsubgroups.\nThere.was.no.significant.aciclovir\u2013prednisolone.\ninteraction.at.3.months.or.at.9.months.(p =.0.32,.\np =.0.72.respectively).\nWe.found.a.marginally.significant.aciclovir.effect.\nwhen.added.to.placebo.(AO.vs.OO,.p.=.0.078).and.\nwhen.added.to.prednisolone.(AP.vs.OP,.p.=.0.074);.\nhowever,.there.was.consistency.in.the.effect.\npreviously.noted:.aciclovir.added.to.prednisolone.\ntended.to.decrease.the.recovery.rate,.and.also.the.\nrecovery.rate.in.those.receiving.aciclovir.was.lower.\nthan.in.the.group.receiving.double-placebo..\nWe.noted.as.before.a.highly.significant.\nprednisolone.effect.(p.<.0.001).\nWe.repeated.the.foregoing.analysis.of.primary.\noutcome.for.patients.making.a.\u2018good\u2019.recovery,.i.e..\nHouse\u2013Brackmann.grade.I.or.II,.with.the.results.\nshown.in.Table 18.\nThe.proportions.making.a.good.recovery.(House\u2013\nBrackmann.I.or.II).at.3.months.and.9.months.in.\nthe.four.treatment.subgroups.shown.are.in.Figure 8.\nThere.was.no.significant.aciclovir\u2013prednisolone.\ninteraction.at.3.months.or.at.9.months.\n(p =.0.78,.p =.0.87.respectively)..There.were.\nsignificant.differences.in.complete.recovery.at.3.\nmonths.between.the.prednisolone.comparison.\ngroups.(93.9%.for.prednisolone,.77.8%.for.no.\nprednisolone,.a.difference.of.+.16.1%.(95%.CI.\n+.10.1%.to.+.22.2%,.p.<.0.001);.but.otherwise.there.\nwere.no.significant.differences.to.be.identified.\nbetween.the.treatment.comparison.groups.at.3.\nmonths.or.at.9.months.\nSecondary outcomes\nAll.the.analyses.in.this.section.were.pre-specified.\nReduction in neurological disability scores\nWe.explored.differences.in.House\u2013Brackmann.\nscore.at.baseline.and.9.months,.and.examined.\nwhich.treatment.combination.led.to.the.greatest.\nreduction.\nWe.first.looked.at.treatment.differences.A.versus.A\u2032.\nand.P.versus.P\u2032..The.mean.reduction.was.greater.\nfor.those.not.receiving.aciclovir.(2.54).than.for.\nthose.receiving.aciclovir.(2.44).but.the.difference.\nwas.not.significant.(p =.0.345)..Similarly,.and.\nsurprisingly.in.the.context.of.other.results,.the.\nmean.reduction.was.greater.for.those.not.receiving.\nprednisolone.(2.59).than.for.those.receiving.\nprednisolone.(2.39).but.the.difference.was.not.\nsignificant.(p.=.0.074).\nWe.then.looked.at.the.extent.of.reduction.for.the.\nfour.different.therapies:.the.mean.reduction.from.\ngreatest.to.least.was.2.64.(OO),.2.54.(AO),.2.45.\n(OP).and.2.33.(AP);.however,.there.is.no.evidence.\nthat.any.treatment.combination.achieved.a.greater.\nreduction.than.any.other.\nMeasurement of pain\nWe.first.distinguished.between.patients.who.\nreported.themselves.as.\u2018in.pain,.attributed.to.Bell\u2019s.\npalsy\u2019.and.those.reporting.no.pain.attributable.to.\ntheir.diagnosis..Figure 9.shows.the.proportion.of.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n21\nTABLE 17  Proportion of patients making a full recovery (House\u2013Brackmann I) at 3 and 9 months\nTreatment 0 months 3 months 9 months\nOP 10\/127 = 7.9% 107\/124 = 86.3% 122\/127 = 96.1%\nAP 10\/124 = 8.1% 98\/123 = 79.7% 115\/124 = 92.7%\nOO 6\/122 = 4.9% 77\/119 = 64.7% 104\/122 = 85.2%\nAO 8\/123 = 6.5% 75\/120 = 62.5% 96\/123 = 78.0%\nAO, aciclovir\u2013placebo group; AP , aciclovir\u2013prednisolone group; OO, placebo\u2013placebo group; OP , placebo\u2013prednisolone group.\nTABLE 18  Proportion of patients making a good recovery (House\u2013Brackmann I or II) at 3 and 9 months\nTreatment None\nUnadjusted % (n)a Unadjusted % (n)a OR (95% CI) p value\nPrednisolone\nHB I\/II at 3 months 93.9 (232\/247) 77.8 (186\/239) 4.41 (2.35 to 8.19) <0.001\nHB I\/II at 9 months 97.2 (244\/251) 94.7 (232\/245) 1.95 (0.74 to 5.41) 0.176\nAciclovir\nHB I\/II at 3 months 84.0 (204\/243) 88.0 (214\/243) 0.71 (0.41 to 1.19) 0.239\nHB I\/II at 9 months 95.1 (235\/247) 96.8 (241\/249) 0.65 (0.26 to 1.71) 0.372\na  Adjusted for age, gender, baseline House\u2013Brackmann (HB) grade, aciclovir (Yes\/No) and prednisolone (Yes\/No) and time to start \nof treatment.\nCactus Design and Illustration Ltd\nFigure Number: 7.ai   Title: 02-09-04 Proof Stage:  2\nOP: 7.9% (0 months) 86.3% (3 months) 96.1 % (9 months)\nAP: 8.1% (0 months) 79.7% (3 months) 92.7 % (9 months)\nOO: 4.9% (0 months) 64.7% (3 months) 85.2 % (9 months)\nAO: 6.5% (0 months) 62.5% (3 months) 78.0 % (9 months)\n0 3 9\nMonths\nP\nr\no\np\no\nr\nt\ni\no\nn\n \no\nf\n \np\na\nt\ni\ne\nn\nt\ns\n6\n0.0\n0.1\n0.3\n0.4\n0.5\n0.6\n0.7\n0.8\n0.9\n1.0\n0.2\nFIGURE 7  Proportion of patients making a full recovery (House\u2013Brackmann I) at three and 9 months. AO, aciclovir\u2013placebo group; AP , \naciclovir\u2013prednisolone group; OO, placebo\u2013placebo group; OP , placebo\u2013prednisolone group.Results\n22\nCactus Design and Illustration Ltd\nFigure Number: 08.ai   Title: 02-09-04 Proof Stage:  1\nOP: 19.0% (0 months) 95.2% (3 months) 98.4 % (9 months)\nAP: 12.8% (0 months) 80.7% (3 months) 95.9 % (9 months)\nOO: 18.5% (0 months) 92.7% (3 months) 96.8 % (9 months)\nAO: 14.8% (0 months) 75.0% (3 months) 93.5 % (9 months)\n0 3 9\nMonths\nP\nr\no\np\no\nr\nt\ni\no\nn\n \no\nf\n \np\na\nt\ni\ne\nn\nt\ns\n6\n0.0\n0.1\n0.3\n0.4\n0.5\n0.6\n0.7\n0.8\n0.9\n1.0\n0.2\nFIGURE 8  Proportion of patients making a good recovery (House\u2013Brackmann I or II) at 3 and 9 months. AO, aciclovir\u2013placebo group; \nAP , aciclovir\u2013prednisolone group; OO, placebo\u2013placebo group; OP , placebo\u2013prednisolone group.\npatients.describing.themselves.as.in.pain.at.onset,.\nafter.3.months.and.after.9.months.\nIn.all.four.treatment.groups.there.was.significantly.\nreduced.incidence.of.pain.after.3.months,.with.no.\nsignificant.additional.reduction.therafter.\nWe.next.assessed.patients.according.to.their.score.\non.the.BPI..Table 19.gives.the.number.of.patients.\nassessed,.the.mean.score.and.standard.deviation.\n(SD).for.the.BPI.in.each.of.the.treatment.groups.\nat.onset,.after.3.months.and.after.9.months..The.\nlower.number.of.9-month.visits.in.groups.OP.and.\nAP.confirms.the.more.rapid.recovery.of.patients.\nrandomised.to.receive.prednisolone.\nIn.all.cases.the.high.coefficient.of.variation.is.\nexplained.by.the.high.proportion.of.patients.\nscoring.0.(\u2018no.pain\u2019).during.their.visit.assessment.\nThe.lower.BPI.scores.at.the.baseline.visit.in.\npatients.who.had.started.oral.steroids.confirms.\ntheir.rapid.effectiveness.in.reducing.the.swelling.\nassociated.with.the.underlying.inflammatory.\npathophysiology.\nMeasurement of self-assessed appearance\nFirst.we.assessed.patients.according.to.whether.\nthey.reported.themselves.to.be.dissatisfied.or.\notherwise.concerned.with.their.appearance.(Part.\nI.of.the.DAS59)..Figure 10.gives.the.proportion.of.\npatients.expressing.themselves.as.\u2018dissatisfied.with.\nappearance\u2019.at.onset,.after.3.months.and.after.9.\nmonths..Patients.randomised.to.prednisolone.were.\nleast.bothered.by.their.appearance.at.3.months,.\nand.those.most.bothered.were.those.who.received.\naciclovir..Those.on.prednisolone.alone.(OP).are.\nsignificantly.less.bothered.by.their.appearance.at.9.\nmonths.\nThe.DAS.is.a.measuring.instrument.with.wide.\napplicability.and.(unlike.the.BPI).the.patients.\nwere.not.instructed.to.restrict.their.concerns.about.\nappearance.to.symptoms.and.consequences.of.\nBell\u2019s.palsy..Thus,.there.were.references.to.(e.g.).\nanxieties.about.weight.and.hairline.(men).and.\nweight,.size.and.the.signs.of.ageing.(women)..\nWe.attribute.the.apparent.increase.in.anxiety.at.\nthe.9-month.visits,.in.all.treatment.groups,.to.an.\nincreasing.willingness.to.engage.with.these.other.\nissues,.once.the.immediate.and.pressing.issues.of.\nBell\u2019s.palsy.became.diminished.with.the.passage.of.\ntime.\nWe.next.assessed.patients.according.to.their.score.\non.the.DAS59.(Part.II)..Table 20.gives.the.number.\nof.patients.assessed,.the.mean.score.and.standard.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n23\nCactus Design and Illustration Ltd\nFigure Number: 9.ai   Title: 02-09-04 Proof Stage:  1\nOP: 34.4% (0 months) 6.6% (3 months) 13.0% (9 months)\nAP: 37.9% (0 months) 8.9% (3 months) 3.7% (9 months)\nOO: 59.3% (0 months) 7.6% (3 months) 6.5% (9 months)\nAO: 52.5% (0 months) 13.3% (3 months) 12.5% (9 months)\n0 3 9\nMonths\nP\nr\no\np\no\nr\nt\ni\no\nn\n \no\nf\n \np\na\nt\ni\ne\nn\nt\ns\n6\n0.0\n0.1\n0.3\n0.4\n0.5\n0.6\n0.7\n0.8\n0.9\n1.0\n0.2\nFIGURE 9  Proportion of patients describing themselves as \u2018in pain\u2019 at onset, after 3 months and after 9 months. AO, aciclovir\u2013placebo \ngroup; AP , aciclovir\u2013prednisolone group; OO, placebo\u2013placebo group; OP , placebo\u2013prednisolone group.\ndeviation.for.the.DAS59.in.each.of.the.treatment.\ngroups.at.onset,.after.3.months.and.after.9.months.\nThe.reductions.noted.in.all.treatment.groups.after.\nthe.first.3.months.were.all.statistically.significant.\n(p.<.0.001.in.all.cases);.the.prednisolone-only.\ngroup.(OP).appears.unique.in.that.the.reduction.\ncontinues.to.the.9-month.assessment.whereas.in.\nthe.three.other.treatment.groups.the.mean.score.\nrises..However,.all.the.perceived.differences.are.\nnon-significant.(OP:.p.=.0.091;.AP:.p.=.0.387;.OO:.\np.=.0.074;.AO:.p.=.0.573).\nMeasurement of self-assessed health \nutility\nTable 21.gives.the.number.of.patients.assessed,.the.\nmean.score.and.standard.deviation.for.the.HUI3.\nin.each.of.the.treatment.groups.at.onset,.after.3.\nmonths.and.after.9.months.\nThe.quality.of.life.measured.using.HUI3.at.9.\nmonths.was.significantly.higher.for.patients.who.\ndid.not.receive.prednisolone.than.for.those.who.\ndid.(p.=.0.04)..Given.that.the.secondary.measures.\nwere.obtained.only.in.patients.who.had.not.\nrecovered.at.3.months.and.given.the.problem.of.\nmultiple.testing,.this.result.should.be.interpreted.\nwith.caution.\nTABLE 19  Number of patients, mean BPI score and SD for the BPI score\nTreatment \ngroup\n0 months  3 months 9 months\nn Mean SD n Mean  SD n Mean  SD\nOP 125 10.9 19.6 122 1.2 5.4 23 1.6 4.1\nAP 124 9.9 16.7 123 1.8 7.2 27 1.2 6.0\nOO 118 17.6 22.8 118 2.2 9.3 46 1.8 6.9\nAO 122 13.8 1.4 120 1.8 6.8 48 1.9 5.7\nAO, aciclovir\u2013placebo group; AP , aciclovir\u2013prednisolone group; OO, placebo\u2013placebo group; OP , placebo\u2013prednisolone group.Results\n24\nCactus Design and Illustration Ltd\nFigure Number: 10.ai   Title: 02-09-04 Proof Stage:  1\nOP: 66.4% (0 months) 14.8% (3 months) 17.4% (9 months)\nAP: 65.6% (0 months) 13.1% (3 months) 29.6% (9 months)\nOO: 73.5% (0 months) 20.2% (3 months) 25.0% (9 months)\nAO: 71.1% (0 months) 23.3% (3 months) 41.7% (9 months)\n0 3 9\nMonths\nP\nr\no\np\no\nr\nt\ni\no\nn\n \no\nf\n \np\na\nt\ni\ne\nn\nt\ns\n6\n0.0\n0.1\n0.3\n0.4\n0.5\n0.6\n0.7\n0.8\n0.9\n1.0\n0.2\nFIGURE 10  Proportion of patients dissatisfied with appearance. AO, aciclovir\u2013placebo group; AP , aciclovir\u2013prednisolone group; OO, \nplacebo\u2013placebo group; OP , placebo\u2013prednisolone group.\nTABLE 20  Number of patients, mean DAS59 score and SD for the DAS59 score\nTreatment \ngroup\n0 months  3 months 9 months\nn Mean  SD n Mean  SD n Mean SD\nOP 125 72.0 36.5 121 42.8 32.1 24 30.8 28.8\nAP 121 69.8 36.8 122 42.0 32.3 27 48.2 39.1\nOO 116 75.7 39.7 117 39.9 28.2 46 49.7 38.1\nAO 121 74.6 41.5 120 46.5 37.3 47 50.0 32.3\nAO, aciclovir\u2013placebo group; AP , aciclovir\u2013prednisolone group; OO, placebo\u2013placebo group; OP , placebo\u2013prednisolone group.\nTABLE 21  Number of patients, mean HUI3 score and SD for the HUI3 score\nTreatment \ngroup\n0 months  3 months 9 months\nn Mean  SD n Mean  SD n Mean SD\nOP 125 0.80 0.24 121 0.92 0.16 22 0.83 0.25\nAP 124 0.80 0.21 121 0.90 0.18 27 0.85 0.26\nOO 114 0.76 0.20 117 0.91 0.12 46 0.90 0.15\nAO 120 0.79 0.21 119 0.90 0.13 47 0.86 0.17\nAO, aciclovir\u2013placebo group; AP , aciclovir\u2013prednisolone group; OO, placebo\u2013placebo group; OP , placebo\u2013prednisolone group.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n25\nTABLE 22  Estimates of key outcome measures for the non-parametric Kaplan\u2013Meier fit\nTreatment\nLower quartile time \nto full recovery (days)\nMedian time to full \nrecovery (days)\nUpper quartile time \nto full recovery (days)\nMean time to full \nrecovery (days)\nOP 20 45 77 67\nAP 24 54 87 85\nOO 34 71 174 126\nAO 40 79 240 150\nAO, aciclovir\u2013placebo group; AP , aciclovir\u2013prednisolone group; OO, placebo\u2013placebo group; OP , placebo\u2013prednisolone group.\nTABLE 23  Number of adverse events by treatment group\nOP AP OO AO Total\nDizziness 5 4 4 5 18\nDyspepsia 2 4 3 1 10\nNausea 1 2 3 3 9\nConstipation 3 2 1 0 6\nHunger 1 1 0 2 4\nVomiting 0 2 1 0 3\nInsomnia 1 1 1 0 3\nNight sweats 2 1 0 0 3\nRash 0 1 0 2 3\nHot flushes 1 1 0 0 2\nDepression 0 0 0 1 1\nThirst 0 0 1 0 1\nAnorexia 0 1 0 0 1\nDiarrhoea 0 0 0 1 1\nDrowsiness 0 0 1 0 1\nPruritus 0 1 0 0 1\nCombinations of minor \nsymptomsa\n8 4 3 3 18\nSubtotal 24 25 18 18 85\nDeath 0 0 2 1 3\nTotal 24 25 20 19 88\nAO, aciclovir\u2013placebo group; AP , aciclovir\u2013prednisolone group; OO, placebo\u2013placebo group; OP , placebo\u2013prednisolone group.\na  Combinations of minor symptoms: Patients exhibiting two or more symptoms (e.g. dizziness and vomiting) are shown in this \nrow only and not duplicated in rows corresponding to a separate entry (i.e. dizziness, vomiting).\nThere was no evidence whatsoever of a treatment effect on the incidence of adverse events (P vs P\u2032: p = 0.464; A vs A\u2032: \np = 0.953).\nAncillary analyses\nWe.performed.one.additional.analysis.of.time.to.\nrecovery.against.treatment.group,.fitting.a.non-\nparametric.Kaplan\u2013Meier.survival.model.for.the.\ntime.to.recovery..We.found.a.highly.significant.\nbeneficial.prednisolone.effect.(p.<.0.001.for.OP.\nvs.OO,.p.<.0.001.for.AP.vs.AO).and.a.marginally.\nsignificant.aciclovir.effect.(p.=.0.079.for.AO.vs.\nOO,.p.=.0.081.for.AP.vs.OP).with.the.suggestion.\nthat.its.addition.to.treatment.may.slow.or.impede.\nrecovery;.and.there.was.negligible.aciclovir\u2013\nprednisolone.interaction.(p.=.0.536).\nKey.outcome.measures.for.each.treatment.group.\nare.shown.in.Table 22.Results\n26\nAdverse events and side \neffects\nAdverse events (deaths)\nThree.patient.deaths.were.reported.to.study.\npersonnel.during.follow-up..Such.are.our.processes.\nfor.patient.contact.and.the.maintenance.of.links.\nwith.general.practices.that.we.are.satisfied.this.is.\na.complete.accounting..All.deaths.were.explored.\nas.rapidly.as.possible.with.relevant.hospitals.and.\npractices..All.were.deemed.non-treatment-related.\nand.there.were.no.requests.for.or.discussions.about.\nindividual.decoding.of.study.treatment.allocations..\nThe.patient-specific.de-identified.data.are.provided.\nin.Appendix.21.\nAdverse events (other)\nInitially.the.study.team.advised.DMEC.of.all.\nreports.from.patients.of.side.effects,.albeit.\nstandard.and.well-known..After.four.reports.the.\nCommittee.chairman.indicated.that.these.reports.\nwere.not.necessary..Thereafter.symptoms.were.\nnoted.in.patient.study.notes..Any.patient.reporting.\nanxiety.with.troubling.or.persistent.symptoms.was.\nimmediately.directed.to.their.general.practitioner.\nSide effects\nA.log.was.maintained.of.any.reports.from.patients.\nof.side.effects.experienced.during.the.treatment.\nperiod,.these.reports.being.solicited.at.mid-\ntreatment.and.end-of-treatment.telephone.calls,.\nand.again.discussed.at.the.3-month.assessment.\nvisit..The.results.are.provided.in.Table 23.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n27\nIntroduction\nH\nealth-care.resources.are.always.scarce..The.\ncost.of.a.particular.treatment.can.be.seen.not.\nas.its.monetary.value.but.as.the.foregone.benefits.\n[i.e..years.of.life,.better.quality.of.life.(QoL)].of.\nan.alternative.treatment.that.we.cannot.provide.\nwhen.we.decide.to.use.these.scarce.resources.in.a.\nparticular.way..This.is.the.notion.of.opportunity.\ncost.\u2013.the.central.concept.of.economics.\u2013.that.is.\nused.to.help.identify.how.we.can.get.the.maximum.\nbenefit.from.the.limited.resources.available.\n(i.e..obtain.an.efficient.allocation.of.resources)..\nEconomic.evaluation.provides.guidance.on.how.\nbest.to.use.resources.as.it.is.a.systematic.analysis.\ncomparing.the.resources.used.(costs).and.benefits.\nof.alternative.courses.of.action.32.An.economic.\nevaluation,.in.this.context,.would.involve.assessing.\nthe.relative.costs.and.benefits.associated.with.the.\nalternative.treatments,.included.in.this.clinical.trial.\nfor.the.treatment.of.Bell\u2019s.palsy.33\nHow.an.economic.evaluation.brings.together.\ninformation.on.costs.and.effects.is.illustrated.\nin.Figure 11..The.vertical.axis.represents.the.\ndifference.in.costs.between.an.experimental.\n(e.g..an.\u2018active.treatment\u2019.for.Bell\u2019s.palsy).and.a.\ncontrol.treatment.(e.g..a.\u2018placebo\u2019)..The.difference.\nin.cost.will.reflect.the.difference.in.the.value.of.\nthe.resources.used.to.provide.treatment.(e.g..\nmedications).as.well.as.the.resource.consequences.\nof.treatment.(e.g..the.costs.of.the.use.of.\nhealth.services.during.the.follow-up.period)..\nThe.horizontal.axis.represents.differences.in.\neffectiveness.between.the.two.approaches,.which.\nmight.be.measured.in.clinical.terms,.e.g..the.\nreduction.in.House\u2013Brackmann.grading.score,.or.\nother.measures.such.as.quality-adjusted.life-years.\n(QALYs)..The.latter.combines.estimates.of.both.\nQoL.with.estimates.of.length.of.life..The.wider.the.\ndefinition.of.effectiveness.used,.usually,.the.more.\nlikely.it.is.to.measure.outcomes.of.importance.to.\nindividuals.\nIn.the.north-west.(NW).and.south-east.(SE).\nquadrants.of.Figure 11.a.clear.decision.about.which.\ntreatment.should.be.preferred.is.provided.because.\none.or.the..other.treatment.\u2018dominates\u2019..In.the.\nNW.quadrant.the.experimental.treatment.is.more.\ncostly.and.provides.less.benefit.and.therefore.the.\ncontrol.treatment.is.more.efficient.(is.dominant)..\nIn.the.SE.quadrant.the.opposite.situation.occurs.\nand.the.experimental.treatment.is.more.efficient.\n(is.dominant).as.it.is.less.costly.and.provides.more.\nbenefit..The.circle.in.the.centre.of.the.figure.\nrepresents.the.possibility.that.no.meaningful.\ndifferences.in.costs.or.benefits.exist.between.the.\ntreatments.and.for.practical.purposes.the.two.\ninterventions.are.equally.efficient..In.the.two.\nremaining.areas.of.the.figure,.the.north-east.(NE).\nand.south-west.(SW).quadrants,.a.judgement.is.\nrequired.as.to.whether.the.more.effective.treatment.\nis.worth.the.extra.cost..To.aid.these.judgements,.\ninformation.can.be.provided.in.terms.of.an.\nincremental.cost-effectiveness.ratio.(ICER)..This.\nis.the.difference.in.mean.costs.between.treatment.\nand.the.control.groups.divided.by.the.difference.in.\nmean.effectiveness.between.treatment.and.control.\ngroups..The.higher.the.ICER.for.the.comparison.\nof.one.intervention.with.another,.then.the.less.\nlikely.it.is.that.this.intervention.will.be.considered.\nefficient.\nAim\nThe.purpose.of.this.section.is.to.assess.the.\ncost-effectiveness.of.early.administration.of.\nprednisolone.and.or.aciclovir.compared.with.\nplacebo.for.treatment.of.Bell\u2019s.palsy.in.an.adult.\npopulation.in.the.UK.\nThree.separate.analyses.are.presented,.which.\ncorrespond.to.the.factorial.design.of.the.trial:\n\u2022. prednisolone.versus.no.prednisolone.(P.vs.P\u2032)\n\u2022. aciclovir.versus.no.aciclovir.(A.vs.A\u2032)\n\u2022. AP.versus.OP.versus.AO.versus.OO.\nAs.described.below.the.methods.used.to.make.\nthese.three.comparisons.are.similar..The.study.was.\ndesigned.as.a.2.\u00d7.2.factorial.design..The.first.two.\nanalyses.can.be.conducted.as.there.is.no.evidence.\nof.any.interaction.between.prednisolone.and.\naciclovir..Arguably,.for.an.economic.evaluation.\nthe.more.useful.comparison.is.the.four-arm.\ncomparison..However,.as.the.study.was.not.\npowered.to.compare.the.four.treatments.the.results.\nof.any.economic.evaluation.are.subject.to.a.further.\nlack.of.precision.\nChapter 5  \nEconomic evaluation of treatmentsEconomic evaluation of treatments\n28\nFIGURE 11  Relationship between the difference in costs and effects between a new (experimental) intervention and a standard \n(control) intervention.\nMethods\nThe.trial,.as.is.commonly.the.case,.was.not.powered.\nto.detect.difference.in.the.cost-effectiveness.of.the.\ndifferent.treatments..Thus,.a.modelling.approach.\nwas.adopted.as.a.way.of.gaining.precision.in.the.\ncost-effectiveness.estimates..\nModel structure of the two-arm models \nDecision.tree.models.were.constructed.to.compare.\nthe.cost-effectiveness.of.prednisolone.against.no.\nprednisolone.and.aciclovir.against.no.aciclovir..\nFigure 12.shows.the.structure.of.the.model.for.\nprednisolone,.and.a.tree.with.a.similar.structure.\nwas.used.for.the.aciclovir.cost-effectiveness.analysis..\nWithin.these.models.it.is.assumed.that.the.different.\ntrial.interventions.affect.the.probability.of.being.\ncured.or.not.cured..The.consequences.of.being.\ncured.or.not.cured.are.assumed.to.be.independent.\nof.the.initial.therapy.to.which.an.individual.\nwas.allocated..The.definition.of.\u2018cured\u2019.follows.\nthat.already.used.in.the.analysis.of.treatment.\ndifferences:.namely,.an.individual.is.classified.as.\nbeing.cured.if.he.or.she.has.a.value.for.the.House\u2013\nBrackmann.grading.system.equal.to.1.\nModel structure of the four-arm model \nA.further.decision.tree.model.was.developed.for.\nthe.third.comparison.performed.(see.Figure 13)..\nThis.decision.tree.has.four.decision.branches,.\nwhich.reflect.the.four.groups.provided.by.the.2.\u00d7.2.\nfactorial.trial.design..Again.it.has.been.assumed.\nthat.the.costs.of.the.consequences.of.being.cured.or.\nnot.cured.are.independent.of.the.initial.treatment.\na.person.was.allocated.to.\nParameter estimates used in the \nmodel\nParameter.estimates.on.probabilities,.costs.and.\neffectiveness,.required.to.populate.the.model,.\nwere.developed.mainly.from.trial.data..These.data.\nrelated.to.the.risk.of.being.cured.or.not.cured.at.\ndifferent.time.points,.health.services.resource.use,.\nand.costs.and.health.state.utilities.\nProbability of cure and not cure\nTwo-arm model\nTables 24 and 25.show.the.proportion.of.subjects.\ncured.and.not.cured.at.3.and.9.months..These.\nproportions.were.used.as.the.probability.of.being.\ncured.and.not.cured.at.3.and.9.months.within.the.\nmodels..Normal.probability.distributions.were.\nattached.to.the.difference.of.mean.values.between.\ngroups.to.allow.for.parameter.uncertainty..\nFour-arm model\nTable 26.shows.the.same.data.but.reported.to.the.\nfour.groups.of.the.2.\u00d7.2.factorial.trial.\nHealth-care resource use and \ncosts\nThe.costs.estimates.used.in.the.model.were.based.\non.the.cost.of.the.initial.treatments,.and.follow-up.\ncosts..Follow-up.costs.included.the.use.of.resources.\nin.primary.and.secondary.care,.the.unit.costs.of.\nthese.resources,.and.the.subsequent.use.of.other.\nmedications.\nCactus Design and Illustration Ltd\nFigure Number: 11ai   Title: 02-09-04 Proof Stage:  1\nExperimental intervention \nmore costly\nExperimental intervention \nmore effective\nControl intervention \nmore effective\nNW NE\nSE SW\nControl intervention \nmore costlyDOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n29\nFIGURE 12  Bell\u2019s palsy decision tree model: prednisolone vs no prednisolone.\nCactus Design and Illustration Ltd\nFigure Number: 12.ai   Title: 02-09-04 Proof Stage:  1\nCured at 3 months\nCured at 9 months\nNot cured at 9 months\nNot cured at 9 months\nNot cured at 3 months\nNot cured at 3 months\nCured at 9 months\nCured at 9 months\nCured at 3 months\nCured at 3 months\nNo prednisolone\nPrednisolone\nCured at 3 months\nCured at 9 months\nNot cured\nNot cured\nEstimated costs\nand effects for\nFIGURE 13  Decision tree model for early treatment for Bell\u2019s palsy: prednisolone alone vs aciclovir alone vs prednisolone + aciclovir vs \nno treatment (placebo).\nCactus Design and Illustration Ltd\nFigure Number: 13.ai   Title: 02-09-04 Proof Stage:  2\nNo treatment\nPrednisolone\nPrednisolone + aciclovir\nAciclovir\nCured at 3 months\nIdentical subtree structures\nfor all decision branches\nCured at 3 months\nCured at 9 months\nNot cured\nNot cured at 3 months\nEstimated costs\nand effects forEconomic evaluation of treatments\n30\nTABLE 25  Probability parameters: aciclovir vs no aciclovir model\nAciclovir No aciclovir\nDifference  \n(95% CIs)\nPD assumed for \ndifference\nProbability of being cured at 3 months 0.71 0.76 \u2013 0.05 (\u2013 0.12 to \n0.03)\nNormal\nProbability of being cured at 9 months \ngiven not cured at 3 months\n0.49 0.61\nPD, probability distribution.\nTABLE 24  Probability parameters: prednisolone vs no prednisolone model\nPrednisolone No prednisolone\nDifference  \n(95% CIs)\nPD assumed \nfor difference\nProbability of being cured at \n3 months\n0.83 0.64 0.19 (0.12 to 0.27) Normal\nProbability of being cured at \n9 months given not cured at \n3 months\n0.49 0.61\nPD, probability distribution.\nTABLE 26  Probability parameters: four-arm model\nPrednisolone \nalone Aciclovir alone\nAciclovir + \nprednisolone Placebo alone\nProbability of being cured at 3 \nmonths (SE)\n0.84 (0.03) 0.60 (0.04) 0.78 (0.04) 0.65 (0.04)\nProbability of being cured at \n9 months given not cured at 3 \nmonths (SE)\n0.71 (0.11) 0.44 (0.07) 0.68 (0.09) 0.57 (0.08)\nProbability distributions  Normal Normal Normal Normal\nSE, standard error.\nTreatment costs\nThe.doses.and.length.of.treatment.for.trial.\nmedications.were.defined.by.the.trial.protocol..The.\nunit.costs.were.obtained.from.the.British National \nFormulary (BNF)34.(see.Table 27)..These.data.were.\napplicable.to.both.the.two-arm.and.four-arm.\nmodels.\nFollow-up costs\nPrimary and secondary care resource use\nHealth-care.resources.used.were.collected.from.\nprimary.care.case.notes.on.any.contacts.made.\nwith.health.services.or.resources.used.by.trial.\nparticipants..This.analysis.was.based.on.a.15%.\nsample.of.study.participants.who.completed.the.\ntrial.(n =.74)..In.order.to.maximise.efficiency.of.\nresearcher.time.in.visiting.practices.to.collect.\ndata,.only.practices.who.had.referred.two.or.more.\nsubjects.into.the.study.were.visited..Data.collected.\non.primary.care.resource.use.included.visits.or.\nphone.calls.to:.a.general.practitioner,.practice.\nnurse,.district.nurse,.community.therapy.services,.\nand.health.visitor..Data.collection.on.the.use.of.\nsecondary.care.services.included:.hospital.inpatient.\nand.day-case.admissions.to.general.medicine.\nand.general.surgery..Finally,.hospital.outpatient.\nresource.use.included.contacts.with.A&E,.acute.\nservices,.dermatology,.ENT,.gastroenterology,.\nmental.health,.neurology,.occupational.therapist,.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n31\nTABLE 27  Treatment resource use and costs\nDrug Dose Cost Note BNF web pagea\nPrednisolone 50 mg\/day \n\u00d7 10 days\n4.32 Prednisolone\nTablets, 25 mg, 56-tab pack = \u00a312.09\nhttp:\/\/www.bnf.org\nAciclovir 2000 mg\/day \n\u00d7 10days\n6.57 Aciclovir\nTablets, 400 mg, 56-tab pack = \u00a37.31; \n800 mg, 35-tab pack = \u00a39.22\nhttp:\/\/www.bnf.org\na  Accessed 21 May 2007.\nophthalmology,.orthopaedics,.physiotherapy,.\nradiology,.speech.therapist,.urology.and.general.\nhealth-care.assistants..All.data.collection.was.\nmasked.as.to.the.allocation.group.\nTables 28\u201332.present.selected.summary.statistics.\nfor.the.main.resource.use.categories,.by.trial.arm.\nand.also.whether.someone.was.cured.or.not.cured..\nIt.is.these.latter.estimates.of.resource.use.for.those.\ncured.or.not.cured.that.were.used.within.all.three.\nmodels.\nPrimary and secondary care resource use \nfor the two-arm comparisons drawn in the \ntrial\nThis.is.shown.in.Tables 28.and.29.\nPrimary and secondary care resource use \nfor the four arms of the trial\nThis.is.shown.in.Tables 30\u201332.\nTABLE 28  Health-care resource use by main cost categories: prednisolone vs no prednisolone\nNo prednisolone Prednisolone\nConcept\nPrimary care \n(contacts)\nHospital \n(inpatient \ndays and day \ncases)\nHospital \noutpatient \n(visits)\nPrimary care \n(contacts)\nHospital \n(inpatient \ndays and day \ncases)\nHospital \noutpatient \n(visits)\nn 42 42 40 32 33 31\nMean (SD) 3.07 (4.47) 0.07 (0.34) 0.88 (1.84) 1.78 (2.25) 0.12 (0.33) 0.65 (1.05)\nMedian [IQR] 2 [0\u20134] 0 [0\u20130] 0 [0\u20131] 1 [0\u20132.5] 0 [0\u20130] 0 [0\u20131]\nIQR, interquartile range.\nTABLE 29  Health-care resource use by main cost categories: aciclovir vs no aciclovir\nNo aciclovir Aciclovir\nConcept\nPrimary care \n(contacts)\nHospital \n(inpatient \ndays and day \ncases)\nHospital \noutpatient \n(visits)\nPrimary care \n(contacts)\nHospital \n(inpatient \ndays and day \ncases)\nHospital \noutpatient \n(visits)\nn 48 48 46 26 27 25\nMean (SD) 2.25 (2.67) 0.08 (0.28) 0.74 (1.36) 3 (5.15) 0.11 (0.42) 0.84 (1.86)\nMedian [IQR] 2 [0\u20133] 0 [0\u20130] 0 [0\u20131] 1 [0\u20133] 0 [0\u20130] 0 [0\u20130]\nIQR, interquartile range.Economic evaluation of treatments\n32\nTABLE 30  Health-care resource use by main cost categories: four arms of the trial\nPrednisolone only Aciclovir only\nConcept\nPrimary care \n(contacts)\nHospital \n(inpatient \ndays and day \ncases)\nHospital \noutpatient \n(visits)\nPrimary care \n(contacts)\nHospital \n(inpatient \ndays and day \ncases)\nHospital \noutpatient \n(visits)\nn 22 22 21 16 16 15\nMean (SD) 1.77 (1.88) 0.14 (0.35) 0.62 (0.8) 3.75 (6.09) 0.13 (0.5) 0.93 (2.12)\nMedian [IQR] 1 [0\u20133] 0 [0\u20130] 0 [0\u20131] 2 [0.5\u20134.5] 0 [0\u20130] 0 [0\u20131]\nIQR, interquartile range.\nTABLE 31  Health-care resource use by main cost categories. Four arms of the trial\nPrednisolone and aciclovir Placebo only\nConcept\nPrimary care \n(contacts)\nHospital \n(inpatient \ndays and day \ncases)\nHospital \noutpatient \n(visits)\nPrimary care \n(contacts)\nHospital \n(inpatient \ndays and day \ncases)\nHospital \noutpatient \n(visits)\nn 10 11 10 25 25 25\nMean (SD) 1.8 (3.05) 0.09 (0.3) 0.7 (1.49) 2.76 (3.19) 0.04 (0.2) 0.84 (1.7)\nMedian [IQR] 1 [0\u20132] 0 [0\u20130] 0 [0\u20130] 2 [1\u20134] 0 [0\u20130] 0 [0\u20131]\nIQR, interquartile range.\nUnit costs of primary and secondary care \nservices\nUnit.costs.for.hospital-based.services.(inpatient.\ndays,.day.cases.and.outpatient.visits).were.obtained.\nfrom.Information.Services.Department.(ISD).for.\nScotland.35.Day.cases.and.inpatient.unit.costs.were.\ncalculated.using.total.gross.cost.and.deducting.\nthe.overheads.allocated.to.the.particular.cost.\ncategory.(e.g..total.allocated.cost.per.case.within.\nthe.ISD.tables)..Furthermore,.total.direct.costs.per.\nattendance.were.used.for.outpatient.visits.35.Unit.\ncosts.for.primary.care-based.services.were.obtained.\nfrom.Unit costs of health and social care36.(see.Table \n33)..These.unit.costs.were.applicable.to.both.the.\ntwo-arm.and.four-arm.models.\nUnit costs of health and social \ncare\nUse and cost of medications\nThis.category.relates.to.the.use.of.any.subsequent.\ntherapy.to.manage.symptoms..The.use.of.other.\nmedications.was.identified.from.patient.primary.\ncare.case.notes..Unit.costs.were.again.obtained.\nfrom.the.BNF.website.in.May.2007.(see.Table 34)..\nDue.to.the.wide.variety.of.medications.identified.\nonly.summary.cost.details.have.been.reported.in.\nterms.of.the.mean.costs.for.those.cured.and.not.\ncured..These.data.were.used.to.inform.both.the.\ntwo-.and.four-arm.models..\nDetermination of mean cost estimates\nUsing.data.described.in.this.section.(Health-care.\nresource.use.and.costs),.estimates.of.the.total.\nmean.costs.for.those.cured.and.not.cured.were.\ndetermined.(see.Table 35)..To.obtain.these.cost.\nestimates.a.simple.ordinary.least.squared.(OLS).\nregression.was.fitted.to.the.data.obtained.from.the.\n74.people.for.whom.data.collection.was.possible..\nThe.total.mean.values.used.within.the.three.models.\nwere.\u00a3210.and.\u00a3315,.for.cured.and.not.cured.at.\n3.months,.respectively..To.these.costs.the.cost.of.\ninitial.medication.was.added.(see.Table 27).\nNormal.distributions.were.added.to.the.total.cost.\nof.being.cured.and.not.cured..The.total.cost.of.not.\ncured.was.bounded.at.zero.within.the.probabilistic.\nsensitivity.analysis.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n33\nT\nA\nB\nL\nE\n \n3\n2\n \nH\ne\na\nl\nt\nh\n-\nc\na\nr\ne\n \nr\ne\ns\no\nu\nr\nc\ne\n \nu\ns\ne\n \nb\ny\n \nm\na\ni\nn\n \nc\no\ns\nt\n \nc\na\nt\ne\ng\no\nr\ni\ne\ns\n.\n \nC\nu\nr\ne\nd\n \no\nr\n \nn\no\nt\n \nc\nu\nr\ne\nd\nC\nu\nr\ne\nd\n \na\nt\n \n3\n \nm\no\nn\nt\nh\ns\nC\nu\nr\ne\nd\n \na\nt\n \n9\n \nm\no\nn\nt\nh\ns\nN\no\nt\n \nc\nu\nr\ne\nd\nC\no\nn\nc\ne\np\nt\nP\nr\ni\nm\na\nr\ny\n \nc\na\nr\ne\n(\nc\no\nn\nt\na\nc\nt\ns\n)\nH\no\ns\np\ni\nt\na\nl\n \n(\ni\nn\np\na\nt\ni\ne\nn\nt\n \nd\na\ny\ns\n \na\nn\nd\n \nd\na\ny\n \nc\na\ns\ne\ns\n)\nH\no\ns\np\ni\nt\na\nl\n \no\nu\nt\np\na\nt\ni\ne\nn\nt\n(\nv\ni\ns\ni\nt\ns\n)\nP\nr\ni\nm\na\nr\ny\n \nc\na\nr\ne\n \n(\nc\no\nn\nt\na\nc\nt\ns\n)\nH\no\ns\np\ni\nt\na\nl\n \n(\ni\nn\np\na\nt\ni\ne\nn\nt\n \nd\na\ny\ns\n \na\nn\nd\n \nd\na\ny\n \nc\na\ns\ne\ns\n)\nH\no\ns\np\ni\nt\na\nl\n \no\nu\nt\np\na\nt\ni\ne\nn\nt\n \n(\nv\ni\ns\ni\nt\ns\n)\nP\nr\ni\nm\na\nr\ny\n \nc\na\nr\ne\n \n(\nc\no\nn\nt\na\nc\nt\ns\n)\nH\no\ns\np\ni\nt\na\nl\n \n(\ni\nn\np\na\nt\ni\ne\nn\nt\n \nd\na\ny\ns\n \na\nn\nd\n \nd\na\ny\n \nc\na\ns\ne\ns\n)\nH\no\ns\np\ni\nt\na\nl\n \no\nu\nt\np\na\nt\ni\ne\nn\nt\n(\nv\ni\ns\ni\nt\ns\n)\nn\n5\n2\n5\n3\n5\n1\n1\n1\n1\n1\n1\n0\n9\n9\n9\nM\ne\na\nn\n \n(\nS\nD\n)\n2\n.\n1\n5\n \n(\n3\n.\n9\n)\n0\n.\n1\n1\n \n(\n0\n.\n3\n8\n)\n0\n.\n4\n9\n \n(\n1\n.\n1\n7\n)\n3\n.\n8\n2\n \n(\n3\n.\n6\n8\n)\n0\n.\n0\n9\n \n(\n0\n.\n3\n)\n1\n.\n8\n \n(\n2\n.\n6\n2\n)\n3\n.\n2\n2\n \n(\n2\n.\n7\n3\n)\n0\n \n(\n0\n)\n1\n.\n2\n2\n \n(\n1\n.\n5\n6\n)\nM\ne\nd\ni\na\nn\n \n[\nI\nQ\nR\n]\n1\n \n[\n0\n\u2013\n2\n]\n0\n \n[\n0\n\u2013\n0\n]\n0\n \n[\n0\n\u2013\n1\n]\n3\n \n[\n1\n\u2013\n5\n]\n0\n \n[\n0\n\u2013\n0\n]\n0\n.\n5\n \n[\n0\n\u2013\n3\n]\n3\n \n[\n2\n\u2013\n3\n]\n0\n \n[\n0\n\u2013\n0\n]\n1\n \n[\n0\n\u2013\n1\n]\nI\nQ\nR\n,\n \ni\nn\nt\ne\nr\nq\nu\na\nr\nt\ni\nl\ne\n \nr\na\nn\ng\ne\n.Economic evaluation of treatments\n34\nTABLE 34  Medication total cost per cured and not cured patient groups\nn\nMean\n(\u00a3)\nSD\n(\u00a3)\nRange (\u00a3) Interquartile range (\u00a3)\nMin. Max. p25 p75\nCured (at 3 months) 53 29.13 59.56 0 365.91 0 34.32\nNot cured (at 3months) 20 113.17 274.66 0 1205.02 0 48.06\nTABLE 33  Unit costs for hospital-based services and primary care services\nService\/ward Unit Cost per unit \u00a32005\/06 Note\nHospital costs\nGeneral Medicine Day case 309 ISD35 Table R042 \nGeneral Medicine Day 1061 ISD35 Table R040 \nGeneral Surgery  Day case 506 ISD35 Table R042 \nGeneral Surgery  Day 1671 ISD35 Table R040 \nGeneral Practice Day case 243 ISD35 Table R042 \nHospital outpatient costs\nA&E Visit 64 ISD35 Table R044 \nAcute Services Visit 238 ISD35 Table R044 \nDermatology Visit 66 ISD35 Table R044 \nENT Visit 74 ISD35 Table R044 \nGastroenterology Visit 142 ISD35 Table R044 \nMental Health Visit 98 ISD35 Table R044 \nNeurology Visit 131 ISD35 Table R044 \nOccupational Therapist Visit 34 ISD35 Table R046 \nOphthalmology Visit 52 ISD35 Table R044 \nOrthopaedics Visit 79 ISD35 Table R044 \nPhysiotherapy Visit 19 ISD35 Table R046 \nRadiology Visit 32 ISD35 Table R046 \nSpeech Therapist Visit 49 ISD35 Table R046\nUrology Visit 65 ISD35 Table R044\nHealth-Care Assistant Visit 24 ISD35 Table R045\nPrimary care costs\nGeneral Practice Visit 23 PSSRU36 Table 9.8b General practitioner, p. 143 \nGeneral Practice Telephone \nconsultation\n25 PSSRU36 Table 9.8b General practitioner, p. 143 \nPractice Nurse Visit 8 PSSRU36 Table 9.6 Nurse (GP practice), p. 140\nPractice Nurse Telephone \nconsultation\n8 PSSRU36 Table 9.6 Nurse (GP practice), p. 140\nDistrict Nurse Visit 18 PSSRU36 Table 9.1 Community nurse (includes \ndistrict nursing sister, district nurse), p. 135\nCommunity Therapy Services Visit 14 Assumed same as above Therapists Services36\nHealth Visitor Visit 31 PSSRU36 Table 9.3 Health visitor, p.137\nA&E, accident and emergency; ENT, ear, nose and throat; ISD, information services department; PSSRU, Personal Social \nServices Research Unit.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n35\nTABLE 35  Regression analysis results for total follow-up costs\nDependent variable total costa\nCoefficient SE 95% CI\nConstant 210 58.39 93.28 to 326.32\nNot cured at 3 months 105 112.08 \u2013 118.59 to 328.73\na  n = 70.\nTABLE 36  HUI3 regression analysis for 3 and 9 months cured and not cured utility weights\nDependent variable: HUI3 at 3 months\nNumber of obs = 487\nCoefficient SE 95% CI\nConstant 0.6146 0.0235 0.5684 to 0.6609\nCured 0.0574 0.0132 0.0314 to 0.0834\nDependent variable: HUI3 at 9 months\nNumber of obs = 137\nCoefficient SE 95% CI\nConstant 0.5265 0.0495 0.4287 to 0.6243\nCured \u2013 0.0019 0.0293 \u2013 0.0599 to 0.0561\nUtility weights (mean values)\nCured at 3 months Cured at 9 months Not cured\n0.9947 0.9900 0.9919\nBaseline characteristics: HUI3 data all participants\nMean = 0.786 SD = 0.216\nHU13, Health Utilities Index 3.\nTotal costs\nTotal.costs.estimates.used.within.the.model.were.\nthe.summation.of.treatment.cost.and.follow-up.\ncosts.(see.Tables 27 and 35).\nEstimation of utilities\nData.were.collected.on.HUI3.at.baseline,.3.\nmonths.and,.if.trial.participants.were.not.cured.\nat.3.months,.they.were.assessed.also.at.9.months..\nTwo.analyses.of.covariance.adjusting.for.baseline.\nHUI3.scores.were.used.to.obtain.utility.weights.\nfor.participants.who.were.cured.and.not.cured.at.\n3.and.9.months..Table 36.shows.the.results.of.these.\nanalyses..These.data.were.used.to.estimate.the.\nutility.scores.for.those.cured.at.3.months,.those.\ncured.at.9.months.and.those.not.cured..In.order.\nto.reflect.the.statistical.imprecision.surrounding.\nthese.estimates.when.used.in.the.model,.normal.\ndistributions.were.attached.to.the.mean.values.\nbased.upon.the.results.of.a.regression.analysis..\nThese.data.were.used.in.both.the.two-arm.and.the.\nfour-arm.models..Table 36.also.reports.data.for.\nHUI3.at.baseline.for.all.participants.from.the.trial.\nanalyses.\nWith.the.information.in.Table 36.utility.weights.\nwere.calculated.using.the.area.under.the.curve.\nmethod..For.instance,.for.a.participant.cured.at.3.\nmonths.the.QALY.weight.used.in.the.model.would.\nbe:\nQALY HUI HUI HUI\ncured base cured base 3 3\n3\n12\n= \u00d7 + \u2212 \u00d7 ( )\n3 3\n12\n1\n2\n6\n12\n3 \u00d7 + \u00d7 HUI\ncuredEconomic evaluation of treatments\n36\nSubstituting.values.into.this.expression.gives:\nQALYcured3 =.0.786.\u00d7.0.25.+.(0.995.\u2013.0.786).\u00d7.0.25.\u00d7.\n0.5.+.0.995.\u00d7.0.5.=.0.720.QALYs\nA.similar.approach.was.used.to.estimate.QALYs.for.\nthose.cured.at.9.months.and.QALYs.for.those.not.\ncured.\nBase case analysis\nBase.case.analyses.were.conducted.for.the.two.\nrandomised.controlled.comparisons.included.in.\nthe.trial:.prednisolone.versus.no.prednisolone.\nand.aciclovir.versus.no.aciclovir..A.further.analysis.\ncomparing.all.four.randomised.arms.was.also.\nconducted.although,.as.noted.above,.the.trial.\nwas.not.adequately.powered.even.for.its.primary.\noutcome.for.this.comparison..For.all.analyses.\ncumulative.mean.costs.were.estimated.for.the.\n9-month.follow-up.period.of.the.trial..All.costs.\nwere.expressed.in.2006\/07.pounds.Sterling..\nEffectiveness.was.measured.in.terms.of.number.of.\ncases.cured.(e.g..House\u2013Brackmann.score.=.1),.\nand.mean.QALYs.for.the.9-month.time.horizon..\nAs.the.time.horizon.for.the.analyses.was.less.than.a.\nyear,.neither.cost.nor.effectiveness.outcomes.were.\ndiscounted..ICERs.were.calculated;.these.measure.\nthe.extra.cost.needed.for.gaining.a.further.unit.of.\neffectiveness.\nDeterministic.and.probabilistic.sensitivity.analyses.\nwere.conducted..The.latter.involved.attaching.\nprobability.distributions.to.the.model.parameters.\nand.conducting.Monte.Carlo.simulations..One.\nthousand.iterations.were.obtained.for.each.Monte.\nCarlo.simulation.conducted..Therefore,.for.both.\nbase.case.analyses,.the.analysis.comparing.the.four.\narms.of.the.trial.and.for.each.of.the.sensitivity.\nanalyses,.one.thousand.mean.cost.and.mean.effects.\npairs.were.obtained..From.these,.incremental.cost.\nand.incremental.effectiveness.could.be.obtained.\nand\/or.cost-effectiveness.acceptability.curves.\n(CEAC).developed.using.the.net.benefit.approach..\nThe.net.benefit.approach.is.entirely.equivalent.to.\nthe.standard.rule.in.terms.of.ICER;.however,.when.\napplying.this.approach.to.Monte.Carlo.simulation.\ndata,.it.has.the.advantage.of.unambiguously.sorting.\nout.the.acceptability.of.an.individual.simulation.\ntrial.on.the.cost-effectiveness.plane..This.is.not.the.\ncase.with.the.ICER.approach,.where.simulations.of.\nthe.same.sign.but.within.opposite.quadrants.could.\nbe.mixed.up.37\nPoint.estimates.are.shown.for.deterministic.\nresults,.whereas.scatter.plots.and.cost-effectiveness.\nacceptability.curves.are.used.for.the.main.\nprobabilistic.analyses..These.curves.plot.the.\nprobability.of.each.strategy.being.the.optimal.\ndecision.against.a.range.of.values.for.society\u2019s.\nwillingness.to.pay.for.an.extra.unit.of.effectiveness..\nFor.the.probabilistic.analysis.results.are.also.\nreported.on.the.likelihood.of.an.intervention.being.\nconsidered.cost-effective.for.society\u2019s.willingness.\nto.pay.at.threshold.values.of.\u00a310,000,.\u00a320,000,.\n\u00a330,000.and.\u00a350,000.\nCentral.to.the.assessment.of.cost-effectiveness.\nis.the.value.that.society.would.put.on.gaining.\nan.additional.QALY..For.instance,.the.National.\nInstitute.for.Health.and.Clinical.Excellence.(NICE).\nstates.that.\u2018Below.a.most.plausible.ICER.of.\u00a320,000.\nper.QALY,.judgements.about.the.acceptability.of.\na.technology.as.an.effective.use.of.NHS.resources.\nare.based.primarily.on.the.cost-effectiveness.\nestimate..Above.a.most.plausible.ICER.of.\u00a320,000.\nper.QALY,.judgements.about.the.acceptability.of.\nthe.technology.as.an.effective.use.of.NHS.resources.\nare.more.likely.to.make.more.explicit.reference.to.\nfactors.including:\n\u2022. the.degree.of.uncertainty.surrounding.the.\ncalculation.of.ICERs;\n\u2022. the.innovative.nature.of.the.technology;\n\u2022. the.particular.features.of.the.condition.and.\npopulation.receiving.the.technology;.and\n\u2022. where.appropriate,.the.wider.societal.costs.and.\nbenefits.\nAbove.an.ICER.of.\u00a330,000.per.QALY,.the.case.for.\nsupporting.the.technology.on.these.factors.has.to.\nbe.increasingly.strong.\u201938.(p..33)..In.the.absence.of.\na.more.definitive.statement.this.report.focuses.on.a.\nwillingness-to-pay.of.\u00a330,000.for.a.QALY.\nSensitivity analysis\nAlthough.probabilistic.analyses.were.performed.\nthat.reflect.the.statistical.imprecision.in.model.\nparameters,.there.are.other.forms.of.imprecision.\nthat.need.to.be.explored.using.sensitivity.analysis..\nThese.sensitivity.analyses.related.to.changes.in.key.\nparameters.used.in.the.model,.for.example.unit.\ncost.values,.or.to.changes.in.model.assumptions.\nrelating.to.the.derivation.of.cost.and.the.definition.\nof.cure..With.respect.to.cost,.it.is.well.known.that.\noften.cost.data.are.skewed.to.the.right..In.other.\nwords,.there.are.usually.a.few.trial.participants.\nfor.whom.costs.are.extremely.high..A.sensitivity.\nanalysis.was.conducted.taking.these.potential.\noutliers.out.of.the.analysis.\nPotential.drivers.in.these.models.are.the.probability.\nof.being.cured.or.not.cured.at.3.months;.therefore,.\nthreshold.analysis.was.also.used.to.explore.the.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n37\neffect.of.the.probability.of.being.cured.or.not.\ncured.on.the.model.results..In.addition,.subgroup.\nanalyses.by.age.and.gender.were.also.performed..\nFinally,.structural.uncertainty.was.explored.by.\nassuming.an.exponential.regression.analysis.for.\ntotal.costs.instead.of.the.original.ordinary.least-\nsquared.regression.\nResults\nTwo-arm models\nPrednisolone vs no prednisolone model\nCost-effectiveness analysis\nWhen.the.proportion.of.cases.cured.is.used.as.\nthe.measure.of.effectiveness,.prednisolone.has.a.\nlower.mean.cost.and.is.more.effective.than.the.no.\nprednisolone.alternative,.i.e..it.is.the.SE.quadrant.\nof.Figure 11.(see.Table 37)..Thus,.prednisolone.\ndominates.the.\u2018no.prednisolone.intervention.\nCost\u2013utility analysis\nTable 38.shows.cost-effectiveness.deterministic.and.\nprobabilistic.results.when.QALYs.are.used.as.the.\neffectiveness..This.table.shows.the.likelihood.of.a.\nparticular.treatment.to.be.considered.cost-effective.\nfor.alternative.values.of.willingness.to.pay.for.an.\nextra.QALY..As.Table 38 shows,.the.results.of.the.\ncost\u2013utility.analysis.are.similar.to.those.from.the.\ncost-effectiveness.analysis.\nThe.results.of.the.probabilistic.analysis.indicate.\nthat.prednisolone.is.likely.to.be.considered.a.\nTABLE 37  Deterministic cost-effectiveness results. Prednisolone vs No prednisolone model\nTreatment Cost (\u00a3) Cured casesa at 9 months (%) ICERb\nPrednisolone 231.98 94.4%\nNo prednisolone 248.05 81.6% Dominated\na  Cured cases defined as HB score = 1.\nb  incremental cost-effectiveness ratio.\nTABLE 38  Cost-effectiveness results. Prednisolone vs No prednisolone model\nTreatment  Cost (\u00a3)  QALYs  ICER \nProbability that intervention is cost-effective for different \nthreshold values for society\u2019s willingness to pay for a QALY \n10,000 20,000 30,000 50,000\nPrednisolone 231.98 0.718 79.3% 77.5% 77.0% 76.0%\nNo prednisolone 248.05 0.717 Dominated 20.7% 22.5% 23.0% 24.0%\ncost-effective.treatment.at.all.values.for.society\u2019s.\nwillingness.to.pay.for.a.QALY..A.further.illustration.\nof.these.results.is.provided.by.the.scatterplot.(Figure \n14).and.the.cost-effectiveness.acceptability.curves.\n(Figure 15).\nFigure 14 shows.the.scatterplot.of.the.difference.\nin.cost.and.effects.pairs.for.the.comparison.of.\nprednisolone.with.no.prednisolone.from.the.Monte.\nCarlo.simulation.(represented.by.the.clear.squares.\non.the.figure)..A.high.proportion.of.the.dots.are.\nallocated.within.the.SE.quadrant..This.means.\nthat,.for.those.cases,.prednisolone.produced.more.\nQALYs.and.was.less.costly.than.no.prednisolone,.\nand.therefore.prednisolone.is.cost-effective.for.\nthese.iterations..The.opposite.argument.applies.\nto.those.cases.that.fall.within.the.NW.quadrant.\n(for.these.iterations.the.no.prednisolone.option.\nis.cost-effective)..Finally,.for.those.iterations.that.\nfall.within.the.NE.and.SW.quadrants.the.decision.\nfor.or.against.prednisolone.will.depend.on.the.\nthreshold.value.of.WTP.for.an.extra.QALY.\nFigure 15.shows.the.cost-effectiveness.acceptability.\ncurves.derived.using.the.cost-effectiveness.\ndata..These.curves.show.how.likely.a.particular.\noption.would.be.considered.cost-effective.for.\nalternative.values.for.society\u2019s.willingness.to.pay.\nfor.an.extra.QALY..As.this.figure.shows.there.is.\napproximately.an.80%.chance.that.prednisolone.\nwill.be.considered.cost-effective.compared.with.no.\nprednisolone.for.values.for.a.cost.per.QALY.that.\nsociety.might.consider.worthwhile.Economic evaluation of treatments\n38\nCactus Design and Illustration Ltd\nFigure Number: 14.ai   Title: 02-09-04 Proof Stage:  1\n\u20130.015 \u20130.010 \u20130.005 \u20130.000 0.005 0.010\nIncremental QALYs\nPrednisolone vs no prednisolone\nAverage\n0.015 0.020 0.025 0.030\n\u2013120\n\u2013100\n\u201380\n\u201360\n\u201340\n\u201320\n0\n20\n40\n60\n80\nI\nm\nc\nr\ne\nm\ne\nn\nt\na\nl\n \nc\no\ns\nt\n \n(\n\u00a3\n)\nFIGURE 14  Incremental cost-effectiveness scatterplot. Prednisolone vs no prednisolone model.\nCactus Design and Illustration Ltd\nFigure Number: 15.ai   Title: 02-09-04 Proof Stage:  2\nPrednisolone\nNo prednisolone\n0 5 10 15 20 30 40 35 45 50\nWillingness to pay for a QALY (\u00a3000)\nP\nr\no\nb\na\nb\ni\nl\ni\nt\ny\n \nt\nr\ne\na\nt\nm\ne\nn\nt\n \nc\no\ns\nt\n-\ne\nf\nf\ne\nc\nt\ni\nv\ne\n25\n0.0\n0.1\n0.3\n0.4\n0.5\n0.6\n0.7\n0.8\n0.9\n1.0\n0.2\nFIGURE 15  Cost-effectiveness acceptability curves. Prednisolone vs no prednisolone model.\nAciclovir vs no aciclovir model\nCost-effectiveness analysis\nTable 39.shows.the.incremental.cost.per.case.cured.\nfor.the.comparison.of.aciclovir.with.no.aciclovir..\nThe.no.aciclovir.alternative.has.on.average.lower.\ncosts.and.a.higher.proportion.of.individuals.\nrecovered..Therefore,.on.average.no.aciclovir.\ndominates.aciclovir.treatment.\nCost\u2013utility analysis\nIn.terms.of.incremental.cost.per.QALY,.the.\nresults.suggest.that.no.aciclovir.is.on.average.\nmore.effective.and.less.costly.that.aciclovir,.and.\nprobabilistic.analysis.reinforces.this.finding.(see.\nTable 40).\nThe.scatterplot.(Figure 16).of.the.incremental.cost.\nand.QALY.pairs.from.the.Monte.Carlo.simulation.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n39\nTABLE 39  Deterministic cost-effectiveness results: Aciclovir vs No aciclovir model\nTreatment Cost (\u00a3) Cured casesa at 9 months (%) ICER\nNo aciclovir 235.33 90.8%\nAciclovir 246.63 85.4% Dominated\na  Cured cases defined as HB score = 1.\nICER, incremental cost-effectiveness ratio.\nTABLE 40  Cost-effectiveness results: Aciclovir vs No aciclovir model\nTreatment\nProbability that intervention is cost-effective for different \nthreshold values for society\u2019s willingness to pay for a QALY\nCost (\u00a3) QALYs ICER 10,000 20,000 30,000 50,000\nNo aciclovir 235.33 0.718 91.1% 85.1% 82.2% 79.0%\nAciclovir 246.63 0.717 Dominated 8.9% 14.9% 17.8% 21.0%\nICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.\nshows.that.the.majority.of.the.iterations.lie.within.\nthe.NW.quadrant.(e.g..aciclovir.more.costly.\nand.less.effective.than.no.aciclovir)..The.cost-\neffectiveness.acceptability.curves.(Figure 17).show.\nthat.aciclovir.was.unlikely.to.be.considered.cost-\neffective.at.values.compared.with.no.aciclovir.\nComparison of all four \nrandomised groups in the four-\narm model\nCost-effectiveness analysis\nTable 41.shows.the.deterministic.cost-effectiveness.\nanalysis.results..On.average.prednisolone.only.\nCactus Design and Illustration Ltd\nFigure Number: 16.ai   Title: 02-09-04 Proof Stage:  1\n\u20130.010 \u20130.008 \u20130.006 \u20130.004 \u20130.002 0.000\nAverage\nAciclovir vs no aciclovir\n0.002\nIncremental QALYs\n0.006 0.004 0.008 0.010\n\u201320\n\u201310\n0\n10\n20\n30\n40\n50\n60\nI\nn\nc\nr\ne\nm\ne\nn\nt\na\nl\n \nc\no\ns\nt\n \n(\n\u00a3\n)\nFIGURE 16  Incremental cost-effectiveness scatterplot. Aciclovir vs no aciclovir model.Economic evaluation of treatments\n40\nFIGURE 17  Cost-effectiveness acceptability curves. Aciclovir vs no aciclovir model.\nCactus Design and Illustration Ltd\nFigure Number: 17.ai   Title: 02-09-04 Proof Stage:  2\nAciclovir\nNo aciclovir\n0 5 10 15 20 30 40 35 45 50\nWillingness to pay for a QALY (\u00a3000)\nP\nr\no\nb\na\nb\ni\nl\ni\nt\ny\n \nt\nr\ne\na\nt\nm\ne\nn\nt\n \nc\no\ns\nt\n-\ne\nf\nf\ne\nc\nt\ni\nv\ne\n25\n0.0\n0.1\n0.3\n0.4\n0.5\n0.6\n0.7\n0.8\n0.9\n1.0\n0.2\nis.the.least.costly.and.most.effective.of.the.four.\nalternative.interventions.out.of.the.prednisolone-\nonly,.aciclovir-only,.aciclovir.and.prednisolone,.\nand.placebo-only.arms.model,.i.e..it.dominates.the.\nother.interventions.\nCost\u2013utility analysis\nPrednisolone.only.is.on.average.less.costly.and.\nproduces.more.QALYs.than.any.of.the.other.\ntreatments.(see.Table 42)..Furthermore,.it.has.\napproximately.an.80%.chance.of.being.considered.\ncost-effective.compared.with.the.other.treatments..\nThis.is.illustrated.by.the.cost-effectiveness.\nacceptability.curves.(Figure 18),.which.indicate.that.\ncollectively.the.other.interventions.have.only.a.20%.\nchance.of.being.considered.cost-effective.\nSensitivity analysis\nSensitivity analyses on costs\nSensitivity.analysis.was.conducted.by.taking.out.of.\nthe.analysis.the.five.highest.total.costs.participants.\nas.outliers..Average.total.strategy.costs.were.\nreduced.by.around.\u00a3100..However,.none.of.the.\ncost-effectiveness.or.cost\u2013utility.analyses.results.\nchanged.\nFurther.scenario.sensitivity.analyses.were.\nconducted..Unit.costs.for.hospital-based.resource.\nuse,.outpatient.visits,.primary.care.visits,.or.\nmedications.were.cut.by.50%.or.doubled..Results.\nwere.not.sensitive.to.any.of.these.changes.\nAs.is.well.known,.cost.data.might.not.follow.\na.normal.distribution..In.this.case,.cost.data.\npresented.a.few.zero.observations.and.were.\nskewed.to.the.right.as.there.were.a.minority.of.\ntrial.participants.for.whom.costs.were.extremely.\nhigh..Therefore,.an.exponential.regression.was.\nfitted.to.obtain.total.cost.for.cured.and.not.cured.\nparticipants..Deterministic.and.probabilistic.results.\nwere.not.sensitive.to.this.change.in.the.way.average.\ntotal.costs.for.cured.and.not.cured.participants.\nwere.calculated.\nProbability of being cured at 3 months\nOne-way.sensitivity.analyses.were.conducted.on.the.\ndifference.in.the.probability.of.being.cured.at.3.\nmonths..The.95%.CI.upper.and.lower.limits.were.\nused.for.this.(Tables.24.and.25)..Cost-effectiveness.\nor.cost\u2013utility.analysis.results.were.not.sensitive.\nto.these.changes.for.the.prednisolone.versus.\nno.prednisolone.model..If.the.difference.in.the.\nprobability.of.being.cured.at.3.months.between.\nprednisolone.and.no.prednisolone.arms.was.\naround.2%,.well.below.the.lower.95%.CI.limit,.the.\nICER.would.be.of.about.\u00a321,000.per.additional.\nQALY.\nHowever,.results.were.sensitive.to.this.sensitivity.\nanalysis.within.the.aciclovir.versus.no.aciclovir.\nmodel..Specifically,.when.the.difference.in.the.\nprobability.of.being.cured.at.3.months.between.the.\naciclovir.arm.and.no.aciclovir.arm.was.0.033.(the.\nupper.limit.of.the.95%.CI),.the.ICER.was.\u00a39576..DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n41\nTABLE 41  Deterministic cost-effectiveness results. Four-arms model\nTreatment Cost (\u00a3) Cured casesa at 9 months (%) ICERb\nPrednisolone  230.61 96.1%\nAciclovir and prednisolone 244.02 92.7% Dominated\nNo treatment (placebo) 246.47 85.6% Dominated\nAciclovir  258.93 78.0% Dominated\na  Cured cases defined as HB score = 1.\nb  incremental cost-effectiveness ratio.\nTABLE 42  Results of cost\u2013utility analysis\nTreatment Cost (\u00a3) QALYs ICER\nProbability that intervention is cost-effective for different \nthreshold values for society\u2019s willingness to pay for a QALY\n10,000 20,000 30,000 50,000\nPrednisolone  230.62 0.719 79.1% 77.4% 76.9% 75.9%\nAciclovir and \nprednisolone\n244.02 0.718 Dominated 0.0% 0.0% 0.0% 0.1%\nNo treatment 246.47 0.717 Dominated 12.5% 9.5% 7.2% 5.2%\nAciclovir  258.93 0.716 Dominated 8.4% 13.1% 15.9% 18.8%\nICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.\nCactus Design and Illustration Ltd\nFigure Number: 18.ai   Title: 02-09-04 Proof Stage:  1\nAciclovir only\nAciclovir + prednisolone\nPrednisolone only\nPlacebo only\n0 20 40 60 80 100\nWillingness to pay for a QALY (\u00a3000)\nP\nr\no\nb\na\nb\ni\nl\ni\nt\ny\n \nt\nr\ne\na\nt\nm\ne\nn\nt\n \nc\no\ns\nt\n-\ne\nf\nf\ne\nc\nt\ni\nv\ne\n0.0\n0.1\n0.3\n0.4\n0.5\n0.6\n0.7\n0.8\n0.9\n1.0\n0.2\nFIGURE 18  Cost-effectiveness acceptability curves. Four-arms model.Economic evaluation of treatments\n42\nFurther.threshold.analyses.were.conducted.and.at.\nICERs.of.about.\u00a320,000.and.\u00a330,000.were.obtained.\nfor.2%.and.1.5%.differences.in.the.absolute.\nprobability.of.cure,.respectively..Nonetheless,.when.\nthis.difference.was.around.\u2013.0.32%.the.no.aciclovir.\narm.would.dominate.the.aciclovir.arm..All.of.these.\ndifference.values.are.within.the.95%.CI.results.\nreported.in.this.chapter.(see.Table 25).\nAge group and gender\nRegression.analyses.for.total.cost.and.for.utility.\nweights.show.age.group.variables.as.well.as.gender.\nas.statistically.non-significant..In.other.words,.there.\nwas.no.evidence.that.total.costs.would.differ.by.age.\ngroup.or.between.males.and.females..Similarly,.\nthere.was.no.evidence.of.a.difference.in.utility.\nweights.between.male.or.female.participants.cured.\nat.3.months,.males.and.females.cured.at.9.months,.\nor.males.and.females.not.cured..Given.these.data.\nno.estimates.of.incremental.cost.per.QALY.were.\nestimated.for.different.age.groups.or.by.gender.\nAfter.completion.of.our.analyses.we.were.made.\naware.of.a.late.reference.to.a.Japanese.study.\nfinding.in.favour.of.treatment.with.aciclovir.39.In.\nthe.language.of.the.BELLS.Study,.researchers.\nfound.the.overall.rate.of.patient.recovery.among.\nthose.treated.with.AP.(96.5%).was.significantly.\nbetter.(p.<.0.05).than.the.rate.among.those.treated.\nwith.OP.(89.7%)..We.examined.these.findings.in.\ndetail..This.study.was.smaller.than.ours,.treated.\npatients.in.tertiary.referral.centres,.and.the.\noutcome.assessors.were.not.masked.to.treatment.\nallocation..We.concluded.that.their.results.should.\nbe.treated.with.caution.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n43\nOutcome dependent on the \ntime delay to commencement \nof treatment\nWhere.the.time.delay.was.known,.we.compared.\nthe.recovery.rate.at.3.months.and.at.9.months,.\nonly.for.those.patients.treated.with.prednisolone.\nwith.the.recovery.rate.for.those.not.treated.with.\nprednisolone,.according.to.whether.the.time.\ndelay.between.onset.and.the.commencement.of.\ntreatment.was.less.than.24.hours,.less.than.48.\nhours.or.less.than.72.hours..The.recovery.rates.are.\nshown.in.Table 43.\nIn.all.cases.there.is.the.suggestion.that.treatment.\ncommenced.within.24.hours.leads.to.lower.\nrecovery.rates.than.treatment.commenced.within.\n24\u201372.hours..Collapsing.both.tables.to.a.2.\u00d7.2.\nfactorial.format.permits.a.comparison.of.treatment.\n(prednisolone.with.non-prednisolone).and.time.to.\ncommencement.of.treatment.(a.delay.of.less.than.\n24.hours.compared.with.a.delay.of.24\u201372.hours).\nAt.3.months.treatment.with.prednisolone.is.more.\neffective.than.treatment.without.prednisolone.\n(82.7%.recovery.vs.64.0%;.OR.=.2.69;.95%.\nCI:.1.71.to.4.20;.p.<.0.001);.comparison.of.the.\nrecovery.rates.at.3.months.suggests.that.treatment.\ndelayed.by.at.least.24.hours.is.useful.(67.7%.\nrecovery.for.those.treated.within.24.hours.vs.73.5%.\nfor.those.treated.later;.OR.=.0.49;.95%.CI:.0.31.\nto.0.78;.p.=.0.002)..At.9.months,.the.recovery.rate.\nafter.treatment.with.prednisolone.is.significantly.\nhigher.than.the.recovery.rate.without.prednisolone.\ntreatment.(95.7%.vs.83.2%;.OR.=.4.53;.95%.\nCI:.2.14.to.9.17;.p.<.0.001);.the.effect.of.a.24-\nhour.delay.before.commencing.treatment.is.still.\napparent.(87.1%.if.treatment.commences.early,.\n89.6%.otherwise;.OR.=.0.52;.95%.CI:.0.26.to.0.99;.\np.=.0.046).\nWe.can.currently.neither.identify.nor.suggest.\na.convincing.rationale.for.delaying.treatment.\nfor.24.hours,.in.the.face.of.all.the.evidence.(or.\nconventional.wisdom).that.early.commencement.\nof.treatment.is.an.important.adjunct.to.successful.\nresolution.of.Bell\u2019s.palsy.\nNeither.at.3.months.nor.at.9.months.is.any.\ninteraction.between.treatment.and.commencement.\nof.administration.evident.(p.=.0.73.and.p.=.0.97).\nChapter 6  \nSubgroup analyses\nTABLE 43  Recovery rates at 3 months vs delay to commencement of treatment\nDelay 0\u201324 hours 24\u201348 hours 48\u201372 hours\nP 90\/115 (0.78) 81\/93 (0.87) 20\/23 (0.87) 191\/231 (0.83)\nP\u2032 84\/142 (0.59) 45\/63 (0.71) 13\/17 (0.76) 142\/222 (0.64)\n174\/257 (0.68) 126\/156 (0.81) 33\/40 (0.83) 333\/453 (0.74)\nP , prednisolone group; P\u2032, no-prednisolone group.\nTABLE 44  Recovery rates at 9 months vs delay to commencement of treatment\nDelay 0\u201324 hours 24\u201348 hours 48\u201372 hours\nP 111\/117 (0.9487) 90\/94 (0.9574) 23\/23 (1) 224\/234 (0.9573)\nP\u2032 118\/146 (0.8082) 55\/63 (0.8730) 15\/17 (0.8824) 188\/226 (0.8319)\n229\/263 (0.8707) 145\/157 (0.9236) 38\/40 (0.9500) 412\/460 (0.8957)\nP , prednisolone group; P\u2032, no-prednisolone group.Subgroup analyses\n44\nTABLE 45  Recovery rates at 9 months\nSeverity at onset P P\u2032\nModerate (HB II\u2013IV) 169\/176 (0.9602) 122\/145 (0.8414) 291\/321 (0.9065)\nSevere (HB V\u2013VI) 42\/49 (0.8571) 59\/80 (0.7375) 101\/129 (0.7829)\n211\/225 (0.9378) 181\/225 (0.8044) 392\/450 (0.8711)\nP , prednisolone group; P\u2032, no-prednisolone group.\nTABLE 47  Assessors\u2019 consistency (intra-rater reliability)\nAssessor Same grading Same grading \u00b1 1 Difference \u2265 2 Cohen\u2019s kappa\nJ1 80 12 0 0.83\nJ2 71 21 0 0.70\nJ3 71 21 0 0.71\nJ, Judge.\nTABLE 46  Assessors\u2019 concordance (inter-rater reliability)\nPairing Unanimous Agreement \u00b1 1 Reassessment Cohen\u2019s kappa\nJ1 with J2 750 388 34 0.53\nJ1 with J3 722 395 55 0.50\nJ2 with J3 769 355 48 0.54\nJ, Judge.\nOutcome dependent on \nseverity at onset\nWe.looked.at.9-month.recovery.rates.for.those.\npatients.treated.with.prednisolone.and.for.those.\nnot.treated.with.prednisolone,.and.explored.the.\nextent.to.which.the.severity.of.the.episode.of.Bell\u2019s.\npalsy.as.measured.at.onset.dictated.recovery..There.\nwere.34.patients.graded.I.at.onset.who.were.also.\ngraded.I.at.3.months.and.not.visited.at.9.months..\nWe.characterised.those.graded.II.to.IV.at.onset.as.\n\u2018moderate\u2019,.and.those.graded.V.to.VI.at.onset.as.\n\u2018severe\u2019..The.recovery.rates.are.shown.in.Table 45.\nThe.9-month.recovery.rate.is.substantially.higher.\nin.both.treatment.groups.when.the.severity.at.onset.\nis.only.moderate;.also.the.9-month.recovery.rate.is.\nhigher.in.the.prednisolone.subgroups,.irrespective.\nof.severity..The.9-month.recovery.rate.in.the.\nprednisolone.group.is.93.8%.compared.with.80.4%.\nin.the.non-prednisolone.group.(OR.3.66;.95%.\nCI:.1.92.to.7.28;.p.<.0.001);.the.9-month.recovery.\nrate.in.the.moderately.affected.group.is.90.7%.\ncompared.with.78.3%.in.the.severely.affected.\ngroup.(OR.2.69;.95%.CI:.1.49.to.4.82;.p.<.0.001)..\nThe.interaction.is.non-significant.(p.=.0.182).\nAssessors\u2019 concordance\nThe.three.assessors.considered.altogether.1172.\npatient.photo.sets.in.order.to.provide.our.primary.\noutcome.measure..When.all.three.assessors.agreed.\nto.within.one.grade,.the.median.or.majority.\ngrade.(the.decision.is.equivalent).was.the.one.\nawarded.for.that.patient.visit..Otherwise,.all.three.\nassessors.were.invited.to.provide.a.new.assessment,.\nwhen.the.median.grade.was.the.one.awarded..\nThroughout,.all.the.assessors.were.masked.to.the.\ntreatment.and.the.time.of.the.visit.(i.e..whether.\nthe.portrait.records.derived.from.the.onset.visit,.\nor.the.3-month.or.9-month.visit)..The.extent.of.\nagreement.is.summarised.in.Table 46.\nSo.Judge.1.was.in.agreement.with.Judge.2.in.97%.\nof.cases,.with.Judge.3.in.95%.of.cases,.and.Judge.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n45\n2.with.Judge.3.in.96%.of.cases..The.kappa.values.\nawarded.are.all.\u2018moderate\u2019.40\nWe.also.tested.the.assessors.for.consistency.by.\nsending.them.92.repeat.photo.sets.for.assessment.\nwithout.additional.explanation..The.agreements.\nwere.as.shown.in.Table 47.\nAll.repeat.gradings.were.within.one.grade.of.the.\noriginal.decision..In.the.terminology.of.Landis.and.\nKoch,.the.consistency.of.Judge.1\u2019s.assessments.is.\n\u2018almost.perfect\u2019.and.that.of.both.Judge.2.and.Judge.\n3.is.\u2018substantial\u2019.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n47\nT\nhis.is.the.largest.randomised.controlled.trial.of.\nthe.effectiveness.of.treatment.for.Bell\u2019s.palsy.\nin.the.world.literature..We.have.confirmed.the.\ngenerally.favourable.outcome.for.untreated.Bell\u2019s.\npalsy,.with.63%.of.patients.recovered.at.3.months,.\nincreasing.to.85%.after.9.months..Early.treatment.\n(within.72.hours.of.onset.of.weakness).with.\nprednisolone.increased.these.rates.to.81%.and.94%.\nrespectively..Aciclovir.produced.no.benefit.over.\nplacebo.and.there.was.no.benefit.from.its.addition.\nto.prednisolone.\nThe.trial.was.not.powered.to.detect.a.difference.\nin.cost-effectiveness..However,.the.results.of.\nthe.economic.evaluation.suggest.that.the.use.\nof.prednisolone.is.likely.to.be.considered.cost-\neffective..Aciclovir,.in.contrast,.appears.to.be.on.\naverage.no.more.effective.but.more.costly.than.no.\ntreatment.or.treatment.with.prednisolone..Thus,.\nit.is.unlikely.to.be.considered.to.be.cost-effective..\nThe.time.horizon.of.the.model.was.only.9.months..\nTherefore,.an.implicit.assumption.of.the.model.is.\nthat.there.are.no.further.benefits.and.cost.savings.\nfrom.the.use.of.prednisolone.after.the.end.of.the.\ntime.horizon..Given.the.difference.in.cure.rates.\nthat.existed.at.9.months.it.is.possible.that.should.\nthe.time.horizon.be.extended.treatment.of.Bell\u2019s.\npalsy.with.prednisolone.would.be.associated.with.\nfurther.gains.in.QoL..Furthermore,.it.is.likely.\nthat.those.who.did.not.receive.prednisolone.\nwould.make.more.use.of.health.services,.thus.\nincreasing.their.cost.relative.to.those.who.received.\nprednisolone.\nStrengths and limitations of \nthe study\nThis.study,.which.was.independently.funded.\nby.the.HTA,.has.several.advantages.compared.\nto.earlier.trials,.which.have.lacked.power.\nand.produced.inconsistent.results..We.have.\nrecruited.double.the.number.of.patients.that.\nwere.included.in.the.Cochrane.systematic.\nreviews..We.recruited.the.majority.of.patients.\nfrom.primary.care,.thus.reducing.the.selection.\nbias.inherent.in.hospital-based.studies..The.\nhigh.acceptance.of.randomisation.and.low.\ndrop-out.rate.during.the.study.suggest.that.\nthese.results.are.likely.to.be.generalisable.to.\nother.settings.with.similar.populations..We.\nused.drugs.that.are.relatively.inexpensive.and.\nreadily.available.worldwide..The.diagnosis.and.\nabsence.of.exclusion.factors.was.confirmed.by.\nexperienced,.trained.otorhinolaryngologists..\nThe.randomisation.procedure.and.allocation.\nto.treatment.was.managed.by.an.experienced,.\ndedicated,.independent.trials.unit..The.assessment.\nof.outcomes.using.validated.study.tools.was.\nundertaken.by.observers.who.were.masked.to.\ntreatment.allocation..The.factorial.design.has.\npermitted.separate.assessment.of.the.effectiveness.\nof.both.treatments.as.well.as.serving.to.exclude.\nthe.possibility.of.a.beneficial.or.antagonistic.\ninteraction.\nWe.used.the.House\u2013Brackmann.scale.to.grade.\nlower.motor.neurone.facial.nerve.function.because.\nit.reliably.assigns.patients.to.a.recovered.status..The.\nscale.has.been.criticised.for.not.being.sufficiently.\nsensitive.to.change,.and.for.having.grades.that.are.\nsometimes.difficult.to.assign.because.patients.may.\nhave.contrasting.degrees.of.function.in.different.\nparts.of.their.face..Alternative.scales.such.as.\nSydney.or.Sunnybrook.are.available,.but.are.more.\ndemanding.to.use.for.frontline.clinicians..We.used.\nposed,.static.images.rather.than.moving.video.clips.\nas.we.believe.these.were.adequate.for.our.purpose..\nHowever,.researchers.noticed.both.asymmetry.and.\nslowness.in.blinking.in.patients,.and.that.this.was.\none.of.the.last.symptoms.to.disappear..Patients\u2019.\nenunciation.was.occasionally.compromised.and.in.\na.few.cases.the.disability.was.very.severe..Neither.of.\nthese.is.evident.from.static.poses,.and.both.would.\nbe.readily.identifiable.even.in.short.video.clips..\nThe.cameras.issued.to.researchers.were.inexpensive.\nand.(even.in.2004).possessed.the.capability.to.\nrecord.and.save.many.minutes.of.moderately.high.\nquality.video.material..This.capability.was.not.used..\nWe.visited.patients.three.times.over.9.months,.but.\nwould.have.preferred.to.visit.more.frequently.in.the.\nearly.course.of.the.illness.to.capture.more.detail.\nabout.the.recovery.process.and.to.obtain.serology..\nWe.did.not.collect.9-month.data.on.the.subgroup.\nwhose.facial.nerve.function.had.fully.recovered.\nat.3.months.because.patients.with.Bell\u2019s.palsy.\nwho.improve.do.not.subsequently.deteriorate..We.\nconsidered.that.we.were.likely.to.be.underpowered.\nto.detect.significant.differences.in.the.secondary.\nend.points.with.this.design.\nChapter 7  \nDiscussionDiscussion\n48\nThe.economic.analysis.used.a.modelling.framework.\nto.estimate.relative.efficiency..This.approach.has.\nthe.advantage.of.making.the.best.use.of.the.limited.\ndata.available.but.it.made.the.assumption.that.the.\nmain.determinant.of.relative.efficiency.is.whether.\nor.not.the.Bell\u2019s.palsy.was.cured.or.not..If.a.\nstandard.trial-based.cost-effectiveness.analysis.had.\nbeen.conducted.with.the.available.data.it.is.likely.\nthat.on.average.broadly.similar.results.would.have.\nbeen.achieved.but.the.results.would.have.lacked.\nprecision..Furthermore,.the.lack.of.data.on.costs.\nand.the.decision.not.to.follow.up.those.deemed.\ncured.at.3.months.would.have.necessitated.similar.\nassumptions.being.made.in.order.to.handle.the.\nmissing.cost.and.utilities.data.\nThe.data.on.costs.used.within.the.model.came.from.\na.sample.of.only.74.of.the.trial.participants.\u2013.only.\na.small.proportion.(15%).of.the.total.trial.sample..\nThis.led.to.a.reduction.in.the.precision.of.the.\nestimates..Despite.this.limitation.these.data.appear.\nrepresentative.of.the.whole.sample.and.the.reasons.\nfor.non-response.were.unconnected.to.the.therapy.\nthe.participant.received.or.their.outcomes..With.\nrespect.to.the.estimation.of.QALYs.measurements.\nof.health.state.utilities.were.censored.for.those.\ntrial.participants.who.were.judged.to.be.cured.at.\nthe.3-month.follow-up..Therefore,.an.assumption.\nwas.made.within.the.modelling.exercise.that.was.\ntantamount.to.imputing.utility.data.using.the.\u2018last.\nvalue.carried.forward\u2019.method..Ordinarily.this.\napproach,.while.simple,.is.normally.considered.to.\nbe.a.poor.method.of.imputation.41,42.However,.in.\nthis.situation.it.may.not.be.wholly.unrealistic.as.\nthese.trial.participants.were.judged.to.be.cured.at.\nthe.time.of.censoring..Nevertheless,.it.assumes.that.\nthere.is.no.possible.further.improvement.in.health.\nstatus.for.these.people.nor.is.there.any.possibility.\nof.relapse..This.latter.situation.is.clinically.\nimplausible.unless.there.is.a.new.episode.of.Bell\u2019s.\npalsy..The.results.of.the.economic.evaluation.would.\nhave.been.strengthened.by.further.data.on.both.\ncosts.and.health.state.utilities.\nWithin.the.model.the.results.are.driven.by.the.\nprobability.of.being.cured.at.3.months.and.to.a.\nlesser.extent,.the.probability.of.being.cured.at.\n9.months..Both.probabilistic.and.deterministic.\nsensitivity.analyses.were.conducted..The.\nprobabilistic.sensitivity.analysis.focused.on.the.\nstatistical.imprecision.surrounding.the.model.\nparameters.using.parameter.distributions.that.\nwere.plausible.and.based.upon.the.available.data..\nFurther.deterministic.sensitivity.analysis.was.\nconducted.to.address.uncertainty.in.the.model.\nstructure.or.uncertainty.surrounding.model.\nparameters.that.were.obtained.from.outwith.the.\nrandomised.controlled.trial.(RCT)..The.results.of.\nthese.sensitivity.analyses.indicate.that.conclusions.\nare.only.sensitive.to.assumptions.on.the.probability.\nof.being.cured.for.the.aciclovir.versus.no.aciclovir.\nmodel.\nOverall,.based.on.the.data.available.it.appears.that.\ntreatment.of.Bell\u2019s.palsy.with.prednisolone.is.likely.\nto.be.considered.cost-effective.while.treatment.\nwith.aciclovir.is.highly.unlikely.to.be.considered.\ncost-effective..Given.the.limited.data.available.on.\ncosts.and.utilities,.further.data.would.be.useful.to.\nconfirm.findings..Similarly,.although.it.is.unlikely.\nto.change.the.conclusion,.further.data.on.costs.and.\noutcomes.in.the.longer.term.(i.e..for.a.follow-up.\ngreater.than.9.months).would.also.serve.to.confirm.\nthe.findings.of.the.study.\nImplications for practice\nOf.the.two.most.common.treatments.for.Bell\u2019s.\npalsy.the.results.of.this.study.indicate.that.\nprednisolone.may.improve.outcomes.and.\npotentially.lower.net.NHS.costs.than.other.\ntreatments.(including.doing.nothing)..Should.\nthe.NHS.subsequently.recommend.the.adoption.\nof.prednisolone.for.the.firstline.treatment.of.\npeople.presenting.with.the.symptoms.of.Bell\u2019s.\npalsy.the.following.factors.should.be.considered:.\ncontraindications.to.prednisolone,.severity.at.onset.\nand.time.of.commencement.of.treatment.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n49\nI\nn.conclusion,.we.have.provided.robust.evidence.\nthat.the.early.use.of.oral.prednisolone.in.Bell\u2019s.\npalsy.is.an.effective.treatment..The.mechanism.of.\naction.is.uncertain.but.may.be.due.to.modulation.\nof.the.immune.response.to.the.causative.agent.or.\nby.direct.reduction.of.oedema.around.the.facial.\nnerve.within.the.facial.canal..Treatment.with.\nunesterified.aciclovir.at.these.doses.as.used.in.other.\ntrials,.either.alone.or.with.steroids,.had.no.effect.\non.outcome,.and.this.drug.should.not.be.used.in.\nBell\u2019s.palsy.unless.evidence.becomes.available.that.\nbetter.absorbed.formulations.are.effective..We.still.\ndo.not.know.how.best.to.treat.patients.who.present.\nChapter 8  \nConclusion\nlater.than.72.hours,.and.this.should.stimulate.early.\nand.rapid.assessment.of.all.patients.with.suspected.\nBell\u2019s.palsy..Most.patients.with.Bell\u2019s.palsy.recover.\nfully.without.any.treatment.but.this.study.has.\ndemonstrated.that.the.number.needed.to.treat.for.\nprednisolone.to.achieve.one.additional.complete.\nrecovery.is.six.at.3.months.and.eight.at.9.months.\nInevitably,.therefore,.for.some.clinicians.and.\ntheir.patients,.offering.no.treatment.will.remain.\nan.appropriate.strategy,.but.we.can.now.have.an.\ninformed.discussion.with.our.patients.regarding.\nthe.use.of.steroids,.based.on.data.that.were.lacking.\nhitherto.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n51\nT\nhe.opportunities.for.further.research.identified.\nduring.the.course.of.this.study.are.described.\nbriefly.below.\nPrimary research\nImportant.questions.unanswered.by.our.study.\ndesign.include:\n1.. the.extent.of.recovery.within.the.first.four.\nweeks.on.steroid.therapy\n2.. any.benefit.in.using.steroids.if.started.after.72.\nhours\n3.. the.optimally.effective.dose.of.prednisolone.\nin.the.25\u2013100-mg.range.that.has.been.used.in.\nother.studies\n4.. the.hazards,.if.any,.pertaining.to.short.courses.\nof.high-dose.steroid\n5.. the.contribution.of.serological.studies.to.the.\nunderlying.cause.of.Bell\u2019s.palsy\n6.. confirmation.whether.higher.tissue.\nconcentrations.of.antiviral.agents.\u2013.e.g..higher.\ndoses.or.esterified.forms.\u2013.may.have.benefits.\nwe.were.unable.to.detect\n7.. whether.static.poses.accurately.reflect.the.\nextent.of.functional.disability.compared.to.\nmoving.images.or.direct.observation.by.an.\nexperienced.clinician.\nEvidence synthesis\nWe.have.agreed.to.undertake.an.update.of.the.\nAntivirals.in.Bell\u2019s.Palsy.(Cochrane.review).and.this.\nwas.submitted.in.February.2009.\nChapter 9  \nOpportunities for further researchDOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n53\nAcknowledgements\nW\ne.would.like.to.take.this.opportunity.to.\nthank.all.the.patients.who.have.helped.us.by.\nagreeing.to.participate.in.this.national.clinical.trial;.\nour.patient.David.Bell.for.permission.to.use.his.\nphotographs.on.our.website.and.in.presentations.\nand.publications;.all.the.general.practitioners,.\nA&E.staff,.NHS24.nurses.and.others.who.helped.\nby.referring.patients.to.the.hospital.sites;.all.the.\nENT.consultants.and.senior.house.officers.in.the.\nhospital.wards.and.clinics.who.took.the.time.to.\nexplain.the.study.to.patients,.randomise.them.\nto.treatment.and.issue.the.treatment.capsules;.\nto.the.researchers.who.visited.the.patients;.to.\nthe.expert.panel.who.provided.the.House\u2013\nBrackmann.grading.assessments.and.hence.our.\nprimary.outcome.measure;.to.the.Scottish.School.\nof.Primary.Care.for.their.role.in.assisting.the.\nprocesses.of.referral.of.patients.to.the.trial.sites;.\nto.Tayside.Pharmaceuticals.at.Dundee.for.their.\ndedicated.attention.to.detail.in.manufacturing.the.\ncapsules,.bottling,.labelling.and.distributing.them;.\nto.the.randomisation.unit.at.HSRU.Aberdeen.\nfor.the.efficiency.of.their.systems.in.allocating.\nthe.treatments.to.patients;.and.to.Health.Boards,.\nR&D.Departments.and.Medical.Research.Ethics.\nCommittees.throughout.Scotland.who.provided.\nfacilities.and.the.ethical.foundation.for.the.delivery.\nof.this.study.\nThe.Health.Services.Research.Unit.and.the.\nHealth.Economics.Research.Unit.are.both.core.\nfunded.by.the.Chief.Scientist.Office.of.the.Scottish.\nGovernment.Health.Directorates..This.study.is.\nsponsored.by.the.University.of.Dundee.\nTrial Steering Committee\nProfessor.Chris.van.Weel,.University.of.Nijmegen.\n(Chair);.Dr.Ian.Williamson,.University.of.\nSouthampton;.Professor.Sally.Wyke,.University.\nof.Stirling;.Mrs.Caryl.Hamilton.(Patient.\nrepresentative).\nData Monitoring and Ethics \nCommittee\nProfessor.Marion.Campbell,.University.of.\nAberdeen.(Chair);.Dr.Carl.Counsell,.University.\nof.Aberdeen;.Mr.Rodney.Mountain,.University.\nof.Dundee;.co-opted.member:.Dr.Simon.Ogston,.\nUniversity.of.Dundee.(Statistician).\nLocal Principal Investigators\nMr.Kim.Ah-See,.Aberdeen.Royal.Infirmary;.Mr.\nNatarajan.Balaji,.Monklands.Hospital,.Airdrie;.\nMr.Hasan.Beg,.Victoria.Hospital,.Kirkcaldy;.Mr.\nQuentin.Gardiner,.Perth.Royal.Infirmary;.Mr.\nMusheer.Hussain,.Ninewells.Hospital,.Dundee;.\nMr.Alastair.Kerr,.Western.General.Hospital.and.\nRoyal.Infirmary,.Edinburgh;.Mr.John.Marshall,.\nSouthern.General.Hospital,.Glasgow;.Mr.William.\nMcKerrow,.Raigmore.Hospital,.Inverness;.Ms.Mary.\nShanks,.Crosshouse.Hospital,.Kilmarnock;.Mr.\nDavid.Simpson,.Stobhill.Hospital,.Glasgow;.Mr.\nGuy.Vernham,.St.John\u2019s.Hospital,.Livingston;.Miss.\nAileen.White,.Royal.Alexandra.Hospital,.Paisley.\nScottish School of Primary \nCare (SSPC)\nDr.Lucy.McCloughan.(SPPIRe);.Marie.Pitkethly,.\nKim.Stringer.(East.of.Scotland);.Susan.Campbell,.\nAmanda.Cardy.(North.of.Scotland);.Dr.Colette.\nFulton.(South.East.of.Scotland);.Colin.Cowan,.June.\nMcGill.(West.of.Scotland);.Dr.Karen.Bell.(NHS.\nAyrshire.and.Arran);.Dr.Brian.Rae.(NHS.North.\nGlasgow).\nContribution of authors\nAdditional.to.their.roles.on.the.BELLS.Trial.\nManagement.Committee.or.as.advisers.to.it.\n(R.Hern\u00e1ndez,.K.Stewart).and.to.their.specific.\ncontributions.to.the.production.of.this.report.and.\nthe.approval.of.this.version,.the.contributions.of.\nauthors.are.as.follows:.FM.Sullivan.(trial.design,.\nlinks.to.primary.care.in.Scotland,.overall.oversight.\nas.Chief.Investigator);.IRC.Swan.(trial.design,.\nlinks.to.ENT.in.Scotland,.assessment.of.primary.\noutcome);.PT.Donnan.(trial.design,.statistics);.JM.\nMorrison.(trial.design,.primary.care,.detection.\nand.assessment.of.psychological.distress);.BH.\nSmith.(trial.design,.primary.care,.assessment.of.\npain);.B.McKinstry.(primary.care,.recruitment.Acknowledgements\n54\nmethodology);.RJ.Davenport.(neurosciences,.\nassessment.of.primary.outcome);.LD.Vale,.R.\nHern\u00e1ndez.(health.economics);.JE.Clarkson.(trial.\ndesign,.links.to.dentistry.in.Scotland);.K.Stewart.\n(plastic.surgery,.assessment.of.primary.outcome);.\nV.Hammersley,.S.Hayavi,.A.McAteer,.D.Gray.\n(patient.contact,.data.collection);.F.Daly.(trial.\ncoordination,.statistics,.data.collection).\nPublications\nSullivan.F,.Daly.F..The.Scottish.Bell\u2019s.Palsy.Study..\nScottish Primary Care.2006;47:10.\nSullivan.FM,.Swan.IRC,.Donnan.PT,.Morrison.JM,.\nSmith.BH,.McKinstry.B,.et al..Early.treatment.with.\nprednisolone.or.aciclovir.in.Bell\u2019s.palsy..N Engl J \nMed 2007;357:16,1598\u20131607.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n55\n1.. Petruzelli.GJ,.Hirsch.BE..Bell\u2019s.Palsy..Postgrad Med.\n1991;90:115\u201327.\n2.. Sugita.T,.Murakami.S,.Yanagihara.N,.Fujiwara.Y,.\nHirata.Y,.Kurata.T..Facial.nerve.paralysis.induced.by.\nherpes.simplex.virus.in.mice:.an.animal.model.of.\nacute.and.transient.facial.paralysis..Ann Otol Rhinol \nLaryngol.1995;104:574\u201381.\n3.. Morgan.M,.Moffat.M,.Ritchie.L,.Collacott.I,.Brown.\nT..Is.Bell\u2019s.palsy.a.reactivation.of.varicella.Zoster.\nvirus?.J Infect.1995;30:29\u201336.\n4.. Bateman.DE..Facial.Palsy..Br J Hosp Med.\n1992;47:430\u20131.\n5.. Rowlands.S,.Hooper.R,.Hughes.R,.Burney.P..The.\nepidemiology.and.treatment.of.Bell\u2019s.palsy.in.the.\nUK..Eur J Neurol.2002;91:63\u20137.\n6.. Morgenlander.JC,.Massey.EW..Bell\u2019s.Palsy:.\nensuring.the.best.possible.outcome..Postgrad Med.\n1990;88:157\u201362.\n7.. Salinas.RA,.Alvarez.G,.Alvarez.MI,.Ferreira.J..\nCorticosteroids.for.Bell\u2019s.palsy.(idiopathic.facial.\nparalysis).(Cochrane.Review)..In:.The Cochrane \nLibrary,.Issue.2,.2002..Oxford:.Update.Software..\nDOI:.10.1002\/14651858.CD001942.pub3.\n8.. Sipe.J,.Dunn.L..Acyclovir.for.Bell\u2019s.palsy.(idiopathic.\nfacial.paralysis).(Cochrane.Review)..In:.The Cochrane \nLibrary,.Issue.2,.2002..Oxford:.Update.Software.\n9.. May.M,.Wette.R,.Hardin.WB..The.use.of.steroids.\nin.Bell\u2019s.palsy:.a.prospective.controlled.study..\nLaryngoscope.1976;86:1111\u20132.\n10.. Wolf.SM,.Wagner.JH,.Davidson.S,.Forsythe.\nA..Treatment.of.Bell\u2019s.palsy.with.prednisone:.\na.prospective.randomised.study..Neurology.\n1978;28:158\u201361.\n11.. Abiko.Y,.Ikeda.M,.Hondo.R..Secretion.and.\ndynamics.of.herpes.simplex.virus.in.tears.and.\nsaliva.of.patients.with.Bell\u2019s.Palsy..Otol Neurotol \n2002;23:779\u201383.\n12.. Rowlands.S,.Hooper.R,.Hughes.R,.Burney.P..The.\nepidemiology.and.treatment.of.Bell\u2019s.palsy.in.the.\nUK..Eur J Neurol.2002;91:63\u20137.\n13.. Foy.R,.Duggan.A,.Delaney.B,.Wilson.S,.Lewin-van.\nden.Broek.N,.lassen.A,.et al..How.evidence.based.\nare.recruitment.strategies.to.randomized.controlled.\ntrials.in.primary.care?.Experience.from.seven.\nstudies..Fam Pract.2003;20:83\u201392.\n14.. Scottish.Primary.Care.Network.Research.(SPCRN).\nURL:.http:\/\/www.sspc.ac.uk\/spcrn\/.\n15.. Prout.H,.Butler.C,.Kinnersley.P,.Robling.M,.Hood.\nK,.Tudor-Jones.R..A.qualitative.evaluation.of.\nimplementing.a.randomized.controlled.trial.in.\ngeneral.practice..Fam Pract.2003;20:675\u201381.\n16.. Deehan.A,.Templeton.L,.Taylor.C,.Drummond.\nC,.Strang.J..The.effect.of.cash.and.other.financial.\ninducements.on.the.response.rate.of.general.\npractitioners.in.a.national.postal.survey..Br J Gen \nPract 1997;47:87\u201390.\n17.. Soumerai.SB,.McLaughlin.TJ,.Gurwitz.JH,.\nGuadagndi.E,.Hauptman.PJ,.Borbas.C,.et al..Effect.\nof.local.medical.opinion.leaders.on.quality.of.care.\nfor.acute.myocardial.infarction..A.randomized.\ncontrolled.trial..JAMA.1998;279:1358\u201363.\n18.. Scottish.Bell\u2019s.Palsy.Study..URL:.http:\/\/www.dundee.\nac.uk\/bells\/.(accessed.22.August.2007).\n19.. Scottish.Bell\u2019s.Palsy.Study..Stop.Press..URL:.http:\/\/\nwww.dundee.ac.uk\/bells\/index_files\/stoppress.htm.\n(accessed.13.August.2009).\n20.. Sullivan.F,.Daly.F..The.Scottish.Bell\u2019s.Palsy.Study..\nScottish Primary Care.2006;47:10.\n21.. Puttick.H..Research.looks.to.ease.misery.for.Bell\u2019s.\npalsy.sufferers..The Herald,.July.20.2004.\n22.. Cunningham.J..I.had.never.heard.of.Bell\u2019s.palsy.\nbut.it.sounded.quite.scary..The Herald,.December.19.\n2005.\n23.. Wave.102:.Interview.with.Fergus.Daly,.July.2005.\n24.. Elliott.J..\u2018I had to eat my food through a straw\u2019..URL:.\nhttp:\/\/news.bbc.co.uk\/1\/hi\/health\/4703481.stm.\n(accessed.22.August.2007).\n25.. Holland.NJ,.Weiner.GM..Clinical.review,.Recent.\ndevelopments.in.Bell\u2019s.palsy..BMJ.2004;329:553\u20137..\nDOI:.10.1136\/bmj.329.7465.553.(accessed.22.\nAugust.2007).\nReferencesReferences\n56\n26.. Piercy.J..Primary.care:10-minute.consultation:.\nBell\u2019s.palsy..BMJ.2005;330:1374..DOI:.10.1136\/\nbmj.330.7504.1374.(accessed.22.August.2007).\n27.. Furlong.WJ,.Feeny.DH,.Torrance.GW,.Barr.RD..The.\nHealth.Utilities.Index.(HUI3).system.for.assessing.\nhealth-related.quality.of.life.in.clinical.studies..Ann \nMed.2001;33:375\u201384.\n28.. Furlong.W,.Feeny.D,.Torrance.GW,.Goldsmith.C,.\nDePauw.S,.Boyle.M,.et al..Multiplicative Multi-attribute \nUtility Finction for the Health Utilities Index Mark 3 \n(HUI3) System: a technical report. Working Paper No. \n98-11..Hamilton,.ON:.McMaster.University.Centre.\nfor.Health.Economics.and.Policy.Analysis..\n29.. Keller.S,.Bann.CM,.Dodd.SL,.Schein.J,.Mendoza.\nTR,.Cleeland.CS..Validity.of.the.brief.pain.\ninventory.for.use.in.documenting.the.outcomes.\nof.patients.with.noncancer.pain..Clin J Pain.\n2004;20:309\u201318.\n30.. Harris.DL,.Carr.AT..The.Derriford.Appearance.\nScale.(DAS59):.a.new.psychometric.scale.for.the.\nevaluation.of.patients.with.disfigurements.and.\naesthetic.problems.of.appearance..Br J Plast Surg.\n2001;54:216\u201322.\n31.. De.Diago-Sastre.JI,.Prim-Espada.MP,.Fernandez-\nGarcia.F..[The.epidemiology.of.Bell\u2019s.palsy.].Rev \nNeurol.2005;41:287\u201390.[in.Spanish].\n32.. Drummond.MF,.Sculpher.MJ,.Torrance.GW,.\nO\u2019Brien.BJ,.Stoddart.GL..Methods for the economic \nevaluation of health care programmes..3rd.edn..New.\nYork:.Oxford.University.Press;.2005.\n33.. Glick.H,.Polsky.D,.Schulman.K..Trial-based.\neconomic.evaluations:.An.overview.of.the.design.\nand.analysis..In.Drummond.M,.McGuire.A,.editors..\nEconomic evaluation in health care: merging theory with \npractice..1st.edn..Oxford:.Oxford.University.Press;.\n2001..pp..113\u201340.\n34.. British.Medical.Association\/Royal.Pharmaceutical.\nSociety.of.Great.Britain..British National Formulary..\nURL:.http:\/\/www.bnf.org\/bnf..\n35.. Information.Services.Department.for.Scotland;.\nNHS.National.Services.Scotland..URL:.www.\nisdscotland.org.\n36.. Personal.Social.Services.Research.Unit.(PSSRU)..\nUnit costs of health and social care 2006..Canterbury:.\nPSSRU;.University.of.Kent..URL:.http:\/\/www.pssru.\nac.uk\/pdf\/uc\/uc2006\/uc2006.pdf.(accessed.May.\n2007).\n37.. Briggs.A,.Sculpher.M,.Claxton.K..Decision modelling \nfor health economic evaluation..1st.edn..Oxford:.\nOxford.University.Press;.2006.\n38.. National.Institute.for.Clinical.Excellence..Guide to \nthe methods of technology appraisal..London:.National.\nInstitute.for.Clinical.Excellence;.2004;.ref..N0515.\n39.. Hato.N,.Yamada.H,.Kohno.H,.Matsumoto.S,.Honda.\nN,.Gyo.K,.et al..Valacyclovir.and.prednisolone.\ntreatment.for.Bell\u2019s.Palsy:.a.multicenter,.\nrandomized,.placebo-controlled.study..Otol Neurotol.\n2007;28:408\u201313.\n40.. Landis.JR,.Koch.GG..The.measurement.of.\nobserver.agreement.for.categorical.data..Biometrics.\n1977;33:159\u201374.\n41.. White.IR,.Wood.A,.Royston.P..Editorial:.Multiple.\nimputation.in.practice..Stat Methods Med Res.\n2007;16:195\u20137..\n42.. Kenward.MG,.Carpenter.J..Multiple.imputation:.\ncurrent.perspectives..Stat Methods Med Res.\n2007;16:199\u2013218.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n57\nProject title\nBell\u2019s.palsy:.Early.acicLovir.and\/or.prednisoLone.\nin.Scotland.\u2013.\u2018BELLS\u2019:.a.multicentre.factorial.\ntrial.of.the.early.administration.of.steroids.and\/or.\nantivirals.for.Bell\u2019s.palsy\n1  Principal Investigators\nProfessor.Frank.Sullivan,.NHS.Tayside.Professor.\nof.R&D.in.General.Practice.and.Primary.Care,.\nTayside.Centre.for.General.Practice,.University.of.\nDundee\nProfessor.Jillian.Morrison,.Professor.of.General.\nPractice,.Department.of.General.Practice,.\nUniversity.of.Glasgow\nMr.Iain.Swan,.Senior.Lecturer.in.Otolaryngology,.\nDepartment.of.Medicine,.University.of.Glasgow\nProfessor.John.Cairns,.Reader.in.Health.\nEconomics,.Health.Economics.Research.Unit,.\nUniversity.of.Aberdeen\nDr.Peter.Donnan,.Senior.Lecturer.in.Medical.\nStatistics,.Tayside.Centre.for.General.Practice,.\nUniversity.of.Dundee\nDr.Blair.H.Smith,.Senior.Lecturer.in.General.\nPractice,.Department.of.General.Practice.and.\nPrimary.Care,.University.of.Aberdeen\nDr.Brian.McKinstry,.Medical.Director,.Lothian.and.\nBorders.Primary.Care.Research.Network,.Ashgrove.\nHealth.Centre,.Blackburn,.West.Lothian\nDr.Richard.Davenport,.Consultant.Neurologist,.\nWestern.General.Hospital,.Edinburgh\nDr.Janet.Clarkson,.Senior.Lecturer.in.Dental.\nPrimary.Care,.Dental.Health.Services.Research.\nUnit,.University.of.Dundee\n2  Planned investigation\n(a)  Research objectives\n1.. To.describe.the.resolution.of.neurological.\ndeficit.and.cosmetic,.psychological.and.\nfunctional.recovery.in.each.of.four.groups.\nof.patients:.those.treated.with.prednisolone,.\naciclovir,.both.or.neither.\n2.. To.determine.which.group.of.patients.have.the.\ngreatest.reduction.in.neurological.disability.\nscores.on.the.House\u2013Brackmann.grading.\nsystem.at.3.and.9.months.after.randomisation.\n3.. To.compare.self-reported.health.status.\n(including.assessments.of.pain).at.3.and.9.\nmonths.after.randomisation.\n4.. To.compare.the.incremental.cost.per.\nneurological.deficit.resolved.and.incremental.\ncost.per.QALY.in.the.study.groups.\n(b)  Existing research\nBell\u2019s.palsy.is.an.acute.unilateral.paralysis.of.\nthe.facial.nerve.first.described.by.the.Scottish.\nsurgeon.Sir.Charles.Bell.(1774\u20131842).1.Its.cause.\nis.unknown.but.animal.studies.have.suggested.\nthe.possibility.that.reactivation.of.herpes.viruses.\nmay.be.responsible.for.demyelination.2,3.It.affects.\n25\u201335.people.per.100,000.in.the.population.per.\nannum,.most.commonly.in.the.age.group.30\u201345.4.\nThe.condition.presents.disproportionately.amongst.\npregnant.women.and.people.who.have.diabetes,.\ninfluenza,.a.cold,.or.some.other.upper.respiratory.\nailment..On.average.every.year.a.general.\npractitioner.will.see.one.or.two.patients.who.have.\ndeveloped.the.condition..A.recent.UK.study.using.\nthe.general.practice.research.database.(GPRD).\nshowed.that.36%.of.patients.were.treated.with.\noral.steroids.and.19%.were.referred.to.hospital.5.\nAlthough.most.recover.well,.30%.of.patients.have.a.\npoor.recovery.with.continuing.facial.disfigurement,.\npsychological.difficulties.and.sometimes.facial.\npain.(though.the.presence.and.course.of.pain.is.\nunclear.from.current.knowledge).6.In.the.absence.\nof.an.established.aetiology,.treatment.continues.to.\nbe.based.upon.the.established.pathophysiology:.\nswelling.and.entrapment.of.the.nerve.\nTwo.recent.Cochrane.reviews.concerning.the.\ntreatment.of.Bell\u2019s.palsy.have.examined.the.\neffectiveness.of.oral.prednisolone.and.aciclovir.7,8.\nThese.found.that.insufficient.data.exist.to.conclude.\nthat.either.or.both.therapies.are.effective..Many.of.\nthe.studies.included.in.the.reviews.either.failed.to.\nrandomise.patients.or,.when.correctly.randomised,.\nwere.erroneously.interpreted.in.a.favourable.\nlight.9,10.In.addition,.high-dose.steroid.therapy.\nAppendix 1  \nBELLS protocolAppendix 1\n58\nhas.numerous.potential.side.effects.including.\npeptic.ulceration,.hypertension.and.confusional.\nstates..Antiviral.therapy.is.expensive.and.should.be.\nreserved.for.circumstances.where.definite.benefits.\nare.likely.to.be.obtained..Current.recommendations.\nsuggest.that.aciclovir.needs.to.be.started.within.\n48.hours,.though.more.recent.studies.of.viral.\nreplication.in.patients.with.Bell\u2019s.palsy.suggest.that.\nthis.might.be.extended.11\n(c)  Research methods\nDesign\nA.randomised.2.\u00d7.2.factorial.design.to.assess.\nwhether.prednisolone.and\/or.aciclovir.commenced.\nwithin.the.first.72.hours.after.onset.of.Bell\u2019s.palsy.\nresults.in.the.same.level.of.disability.and.pain.after.\n9.months.as.treatment.with.placebo.12\nRecruitment\nIn.order.to.establish.whether.aciclovir.or.steroids.\nare.an.effective.therapy,.initial.treatment.needs.\nto.be.given.in.the.first.72.hours.after.the.onset.of.\nsymptoms.\nBecause.Bell\u2019s.palsy.is.a.comparatively.rare.\ncondition.only.a.co-ordinated.approach.across.a.\nlarge.population.will.provide.sufficient.numbers.\nto.allow.a.satisfactory.power.to.be.achieved.in.this.\nstudy..Our.pilot.work.with.the.Scottish.research.\nnetworks.led.to.almost.100%.participation.rates..\nWe.intend.to.approach.every.medical.and.dental.\npractice.in.Scotland.and.to.enhance.recruitment.\nthrough.existing.networks.of.influence,.which.will.\nencourage.referral.of.a.higher.proportion.of.cases.\nthan.would.be.expected.from.more.anonymised.\nexhortation..The.Scottish.School.of.Primary.Care.\nis.able.to.co-ordinate.recruitment.through.several.\nnetworks,.which.overlap.in.their.membership:\n\u2022. general.medical.practices.already.associated.\nwith.existing.primary.care.research.networks,.\nn.=.273\n\u2022. networks.of.practices.already.involved.in.\nundergraduate.and.postgraduate.teaching,.\nn.=.482\n\u2022. general.medical.practice.out.of.hours.co-\noperatives,.n.=.89\n\u2022. NHS24,.which.will.cover.most.of.Scotland.\nby.the.time.the.study.commences.(we.have.\narranged.to.amend.their.referral.scripts.and.\ntrain.their.nurses)\n\u2022. the.Medical.Research.Council.General.Practice.\nResearch.Framework.(MRC.GPRF),.n.=.90\n\u2022. Scottish.Dental.Practice.Based.Research.\nNetwork.dental.practices,.n.=.270\n\u2022. A&E.departments.across.Scotland.\nWe.will.also.advertise.the.study.with.articles.in.the.\nfree,.weekly.medical.press..Clinicians.throughout.\nScotland.will.be.reminded.on.a.quarterly.basis.to.\nrecruit.into.the.study.any.patients.who.present.\nwith.Bell\u2019s.palsy..As.soon.as.a.suitable.patient.\npresents.to.the.GMP,.GDP,.A&E.or.Out.of.Hours.\nCo-op.clinician.within.72.hours.of.onset,.they.\nwill.telephone.the.nearest.ENT.unit.and.arrange.\nwith.the.ENT.surgeon.on.call.for.the.patient.to.\nbe.seen.immediately..When.the.patient.is.seen.\nby.the.ENT.surgeon.the.criteria.for.study.entry.\nwill.be.confirmed,.consent.will.be.obtained.and.\nthe.randomisation.centre.will.be.contacted..\nAll.consultant.ENT.surgeons.in.Scotland.have.\nbeen.contacted.and.with.one.exception.have.\nagreed.to.take.part.in.the.study..We.will.ensure.\nthat.randomisation.is.secure.by.telephone.\nrandomisation,.which.will.be.centrally.controlled.\nby.the.Health.Services.Research.Unit.(HSRU).in.\nAberdeen.13.When.an.eligible.patient.has.given.\nconsent.to.participation,.the.doctor.will.telephone.\nthe.computerised.randomisation.service,.via.a.hot-\nkey,.and.receive.instructions.about.which.numbered.\npack.is.to.be.supplied..The.on-call.ENT.Registrar.\nwill.immediately.supply.the.medication.from.the.\nsupplies.available.in.the.unit.\nThe.HSRU.computer.will.notify.the.study.co-\nordinator.of.the.patient\u2019s.study.details.by.an.\nimmediate.email..This.mechanism.has.been.\nextensively.used.in.multicentre.trials.before..The.\nco-ordinator.will.arrange.for.the.nearest.research.\nassistant.to.visit.within.the.next.three.days.to.\ncomplete.the.baseline.assessments.and.arrange.\nfollow-up.\n(d)  Planned interventions\nPatients.will.be.randomised.to.receive.two.identical.\npreparations.for.10.days.simultaneously,.creating.\nfour.patient.groups:.(1).prednisolone.(50.mg.per.\nday).and.placebo;.(2).aciclovir.(2000.mg.per.day).\nand.placebo;.(3).prednisolone.and.aciclovir;.and.\n(4).placebo.and.placebo..Each.patient.will.be.\nsupplied.with.two.bottles.of.medication.(marked.by.\na.code).\n(e)  Planned inclusion and exclusion criteria\nInclusion criteria:\n\u2022. Adults.(16.or.older).with.unilateral.facial.nerve.\nweakness.of.no.identifiable.cause.seen.within.\n72.hours.of.the.onset.of.weakness.\nExclusion criteria:\n\u2022. Pregnancy\n\u2022. Uncontrolled.diabetes.(HbA1c.>.8%)\n\u2022. Peptic.ulcer.diseaseDOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n59\n\u2022. Suppurative.otitis.media\n\u2022. Herpes.zoster\n\u2022. Multiple.sclerosis\n\u2022. Sarcoidosis.and.other.rarer.conditions\n\u2022. Inability.to.give.informed.consent\nand.two.further.exclusions.identified.during.the.\nprocesses.of.MREC.application\n\u2022. Breast-feeding\n\u2022. Patients.with.systemic.infection.\n(f)  Ethical arrangements\nRisks and anticipated benefits\n\u2022. No.adverse.events.have.been.reported.for.the.\ninterventions.in.this.study.when.administered.\nin.similar.settings..There.is.a.theoretical.risk.of.\nadverse.events.from.the.prednisolone,.which.\nshould.be.greatly.reduced.by.adherence.to.the.\nexclusion.criteria.above.\n\u2022. The.potential.benefits.include.faster.and\/\nor.more.complete.resolution.of.neurological.\ndeficit.and.cosmetic,.psychological.and.\nfunctional.recovery.\nInformed consent\n\u2022. Will.be.obtained.before.entry.to.the.study.\nActions where informed consent is not \npossible\n\u2022. Unless.the.person.is.able.to.provide.informed.\nconsent.they.will.not.enter.the.study.\nProposed time period for retention of \ndocumentation\n\u2022. At.least.20.years.in.electronic.format.in.which.\nall.study.documentation.will.be.retained..\n(\u2018Personal.Information.in.Medical.Research\u2019,.\nMRC.2000,.2003;.also.\u2018MRC.Population.Data.\nArchiving.and.Access.Project,.Consultants\u2019.\nReport,.Draft.2\u2019,.MRC.2002.)\n(g)  Sample size\nThis.has.been.calculated.using.the.primary.\nendpoint.of.incomplete.recovery.of.facial.motor.\nfunction.(House\u2013Brackmann.grade.III.or.greater).\n9.months.after.randomisation.\nDesign\n2.\u00d7.2.factorial.randomised.controlled.trial.with.the.\nfollowing.treatments:\n1.. Aciclovir. (A)\n2.. Steroids. (B)\n3.. Aciclovir.+.Steroids. (AB)\n4.. Placebo. (O)\nMain.effect.of.aciclovir.=.\u00bd(A.+.AB).\u2013.\u00bd(B.+.O)\nNote.that.this.assumes.A.and.B.have.independent.\neffects.and.do.not.interact.\nThe.literature.is.sparse.about.likely.effect.sizes..\nOne.systematic.review.suggests.a.relative.risk.\n(RR).(of.incomplete.recovery).=.0.86.(95%.CI:.\n0.47.to.1.59).or.22%.on.steroids.compared.with.\n26%.in.the.control.group..Other.results.are.few.\nand.contradictory;.Adour.et al.14.suggest.24%.on.\nsteroids.compared.with.7.5%.on.aciclovir.plus.\nsteroids,.while.De.Diego.et al.15.suggest.6.4%.on.\nsteroids.and.22%.on.aciclovir.alone..Hence.the.\nliterature.gives.effect.sizes.from.4%.to.17%..We.\nregard.a.difference.in.incomplete.recovery.of.10%.\nor.more.to.be.clinically.meaningful.and.so,.in.Table \n1.below,.sample.sizes.are.given.for.differences.in.\npercentage.with.incomplete.recovery.from.10%.to.\n15%.\nIf.we.simultaneously.randomise.approximately.240.\npatients.per.treatment.(a.total.of.480).this.would.\nallow.detection.of.differences.of.the.order.of.12%..\nSince.the.study.design.is.factorial.the.power.is.the.\nsame.for.each.pair-wise.comparison.of.treatments.\nTABLE 1  Sample size required to show various differences in percent with incomplete recovery at 9 months with 80% power at the 5% \nsignificance level (two-sided)\nTrt 1 Trt 2\n% incomplete recovery % incomplete recovery Difference Relative risk n per group Total\n22% 32% 10% 0.69 328 656\n22% 34% 12% 0.65 235 470\n22% 37% 15% 0.59 157 314Appendix 1\n60\n(assuming.no.interaction)..Note.that.we.will.also.\ntreat.the.House\u2013Brackmann.scale.as.ordinal.as.well.\nas.binary,.which.serves.to.increase.power.\nThe.ability.to.detect.an.interaction.if.it.exists.is.an.\nattractive.feature.of.the.factorial.design..If.there.\nis.a.significant.interaction.the.overall.efficiency.of.\nthe.design.is.maintained.as.long.as.the.two.drugs.\ndo.not.act.antagonistically.to.cancel.each.other.\nout,.which.is.unlikely..With.an.interaction.it.is.still.\npossible.to.assess.each.drug.separately,.albeit.with.\nreduced.power.(72%.instead.of.80%).for.the.effect.\nsize.(12%).or.alternatively.to.detect.effect.sizes.\n>.15%.with.the.same.power.\nFor.clarity.of.numbers:.we.will.seek.to.recruit.\n720.patients.commencing.treatment.within.72.\nhours.after.onset,.of.whom.480.have.commenced.\ntreatment.within.48.hours.after.onset.\nThe.incidence.of.Bell\u2019s.palsy.in.Scottish.adults.\nis.33.per.100,000.per.year,.and.with.an.eligible.\npopulation.of.4.3.million.for.Scotland.the.expected.\nnumber.of.new.cases.per.year.in.Scotland.would.be.\n1419.after.one.year,.and.2129.over.18.months.16.We.\nhave.piloted.a.notification.process.for.early.cases.\nin.four.primary.care.research.networks.covering.\n1.4.million.patients.in.Scotland..During.one.month.\nof.observation.74.cases.of.Bell\u2019s.palsy.were.seen.\nand.35.of.these.within.48.hours..Based.on.this,.we.\nbelieve.we.are.able.to.recruit.approximately.one-\nthird.of.those.who.develop.Bell\u2019s.palsy.within.48.\nhours.(710).and.50%.by.72.hours,.and.that.70%.\n(a.conservative.estimate).will.attend.for.review.at.\n9.months.(see.Figure 19)..From.the.work.of.Adour.\nand.others.we.believe.that.at.least.50%.of.patients.\nwill.have.fully.recovered.by.3.months,.so.a.smaller.\nnumber.will.require.to.be.visited.at.9.months17.\n(see.Figure 20)..We.will.require.18.months.of.a.\nrecruitment.period.to.achieve.480.completed.\nexaminations.at.9.months..If.we.collaborate.with.\nanother.co-ordinating.centre.of.an.equivalent.size,.\nthis.could.be.reduced.to.9.months.\nFor.the.analyses,.results.will.be.stratified.and.\nanalysed.according.to.whether.treatment.started.\nwithin.48.hours.\nCactus Design and Illustration Ltd\nFigure Number: 19.ai   Title: 02-09-04 Proof Stage:  1\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 18 17 19 20 21 22 23 24 25\nMonth of study\nTotal recriuted within 48 hours Total assessed at 3 months Total assessed at 9 months\n100\n0\nN\nu\nm\nb\ne\nr\n \no\nf\n \np\na\nt\ni\ne\nn\nt\ns\n200\n300\n400\n500\n600\n700DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n61\nCactus Design and Illustration Ltd\nFigure Number: 20.ai   Title: 02-09-04 Proof Stage:  2\n2129 cases eligible\nover 18 months\nOne-third assessed\nrandomised and treatment\nstarted by ENT registrars\nwithin 48 hours\n720 randomised and baseline\nmeasures obtained\nAciclovir only\nn =180\nAciclovir + prednisolon\nn =180\nNeither\nn =180\nAssess at\n3 and 9 months  120 120 120 120\nPrednisolone only\nn =180\n(h)  Statistical analyses\nReporting.will.adhere.to.revised.CONSORT.\ncriteria.18\nThe.baseline.characteristics.in.each.treatment.\ngroup.will.be.described..The.following.will.be.used.\nto.adjust.the.results:.severity.at.initial.presentation,.\nage.and.gender..The.main.outcome.of.incomplete.\nrecovery.(House\u2013Brackmann.grade.III.or.higher).\nwill.be.compared.between.treatment.groups.using.\nchi-squared.tests.and.also.tests.for.linear.trends.\nas.the.nerve.function.scale.is.ordinal..We.will.use.\nlogistic.regression.to.adjust.for.the.prespecified.\nconfounding.factors.above..All.analyses.will.be.\nbased.on.an.intention-to-treat.principle..Similar.\nmethods.will.be.used.for.the.ordinal.scale.for.pain..\nThe.mean.or.median.HUI.score.will.be.compared.\nusing.t.tests.or.Mann\u2013Whitney.tests,.depending.\non.the.distributions.found..Two-sided.tests.will.\nbe.implemented.throughout,.using.spss.for.data.\nanalysis.\nGenerally,.subgroup.analyses.should.be.avoided.in.\nrandomised.controlled.trials,.or.at.least.specified.\nbefore.data.collection..It.is.intended.to.carry.out.\nformal.tests.of.interaction.between.treatment.\nand.severity.of.House\u2013Brackmann.scale.to.assess.\nwhether.treatment.effects.are.greater.in.those.\nmost.severely.affected..The.results.of.such.analyses.\nwill.be.treated.with.caution.and.as.hypothesis-\ngenerating.19\n(i)  Outcome measures\nFollowing.the.email.alert.from.HSRU.to.the.\nresearch.co-ordinator,.patients.will.then.be.seen.\nwithin.three.days.by.the.research.assistants,.at.\ntheir.GP.surgery.or.at.home,.for.more.detailed.\nassessment..At.this.first.post-randomisation.\nvisit.the.degree.of.facial.nerve.denervation.will.\nbe.recorded.by.a.digital.camera.and.the.other.\nstudy.instruments.administered..Patients.will.be.\nreassessed.by.questionnaire.and.digital.camera.at.3.\nand.9.months.post-randomisation..We.will.capture.\nfacial.appearances.in.digital.images.in.standard.\npositions.(at.rest,.forced.smile,.bared.teeth.and.\nburied.eyelashes)..These.will.be.assessed.blindly.\nby.a.panel.of.three.experts.in.otorhinolaryngology,.\nneurology.and.plastic.surgery.\nThe.key.outcome.measure.to.be.used.in.research.\nobjectives.1,.2.and.4.is.the.House\u2013Brackmann.\ngrading.system.for.facial.nerve.function.\nshown.below.20.It.has.been.validated.against.\nelectrophysiological.studies.Appendix 1\n62\nGrade Definition\nI Normal symmetrical function in all areas\nII Slight weakness noticeable only on close \ninspection. Complete eye closure with minimal \neffort. Slight asymmetry of smile with maximal \neffort. Synkinesis barely noticeable; contracture, \nor spasm absent\nIII Obvious weakness, but not disfiguring. May not \nbe able to lift eyebrow. Complete eye closure \nand strong but asymmetrical mouth movement \nwith maximal effort. Obvious, but not disfiguring \nsynkinesis, mass movement or spasm\nIV Obvious disfiguring weakness. Inability to lift brow. \nIncomplete eye closure and asymmetry of mouth \nwith maximal effort. Severe synkinesis, mass \nmovement, spasm\nV Motion barely perceptible. Incomplete eye \nclosure, slight movement corner mouth. \nSynkinesis, contracture, and spasm usually absent\nVI No movement, loss of tone, no synkinesis, \ncontracture, or spasm\nThe.Health.Utilities.Index.version.3.(HUI3).will.\nbe.used.to.assess.research.objectives.1.and.3..The.\nHUI3.represents.a.global.assessment.of.overall.\nhealth.status..It.has.eight.dimensions:.vision;.\nhearing;.speech;.ambulation;.dexterity;.emotion;.\ncognition.and.pain..For.details.see.www.fhs.\nmcmaster.ca\/hug\/..It.is.designed.for.use.in.clinical.\npractice.and.research,.health.policy.evaluations,.\nand.general.population.surveys..It.is.constructed.\nfor.self-administration.by.persons.14.years.of.age.\nand.older,.and.for.administration.by.a.trained.\ninterviewer.in.person.or.by.telephone..It.takes.\nabout.5.to.10.minutes.to.administer.\nPain.measures.will.be.used.to.achieve.research.\nobjective.3.\nThe.presence.and.duration.of.facial.pain.will.be.\ndetermined.by.a.simple.set.of.screening.questions,.\nbased.on.a.validated.chronic.pain.case.definition.\nquestionnaire.21.The.global.severity.of.any.pain.will.\nbe.assessed.using.a.visual.analogue.scale,.and.the.\nChronic.Pain.Grade,.a.simple.validated.measure.\nof.intensity.and.pain-related.disability,.providing.\nclassification.into.four.hierarchical.grades.of.\nseverity.(Grade.I.low.intensity\u2013low.disability;.Grade.\nIV.high.disability\u2013severely.limiting).22,23\nMeasure Baseline 3 months 9 months\nHouse\u2013\nBrackmann\n720   576   138  \nHealth Utilities \nIndex\n720   576   504  \nChronic Pain \nGrade\n720   576   504  \nCosts 720   576   504  \n(j)  Economic evaluation\nThe.cost-effectiveness.of.early.treatment.can.be.\nevaluated.by.calculating.the.incremental.cost.per.\nadditional.neurological.deficit.resolved..However,.\nit.is.not.clear.what.incremental.cost.per.additional.\ndeficit.resolved.decision-makers.should.consider.\ngood.or.poor.value.for.money..The.results.of.\nthe.trial.will.be.rendered.more.informative.by.\nalso.translating.the.resolution.of.a.neurological.\ndeficit.into.a.quality-adjusted.life-year.equivalent.\nby.estimating.the.duration.of.the.effect.and.the.\nimpact.on.the.patient\u2019s.quality.of.life..This.will.be.\nachieved.by.using.the.Health.Utilities.Index.to.\nmeasure.quality.of.life.at.baseline,.3.months.and.\n9.months.24.Unresolved.deficits.will.have.resource.\nimplications.for.the.NHS.and.thus.it.is.appropriate.\nto.subtract.any.savings.that.result.from.successful.\ntreatment.from.the.cost.of.that.treatment..These.\nsavings.will.be.estimated.by.comparing.the.use.of.\nhealth-care.resources.by.those.with.resolved.and.\nunresolved.deficits.\nWe.will.obtain.permission.from.participating.\npatients.to.review.their.primary.care.records.\nand.extract.data.on.treatments.in.practice.and.\nelsewhere..Other.variables.to.be.collected.are.\npatient.demographic.data,.blood.pressure,.current.\ndrug.therapy.and.concomitant.medical.conditions..\nThe.numbers.of.patients.undergoing.tarsorrhaphy.\nor.attending.outpatient.clinics.for.corneal.\nulceration.will.also.be.collected.from.patient.\nrecords..Scottish.Morbidity.Register.(SMR1).data.\non.outpatient.attendances.will.also.be.obtained.25\nNo.electrophysiological.studies.are.proposed.\nbecause.these.are.normally.unavailable.to.GPs.\nwithin.the.timeframe.of.therapy.initiation.\nand.because.of.uncertainty.as.to.what.useful.\ninformation.they.add.to.the.clinical.decision,.which.\nis.usually.based.on.clinical.examination.and.an.\nassessment.of.the.patient\u2019s.psychological.state.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n63\n(k)  Independent supervision\nIn.accordance.with.the.HTA\u2019s.research.governance.\nframework.we.will.form.an.independent.Trial.\nSteering.Committee.(TSC).under.the.chairmanship.\nof.Professor.Chris.van.Weel.(Catholic.University,.\nNijmegen).and.a.Data.Monitoring.and.Ethics.\nCommittee.(DMEC).under.the.chairmanship.of.Dr.\nMarion.Campbell.(HSRU,.University.of.Aberdeen)..\nWe.are.continuing.our.efforts.to.identify.a.suitable.\npatient.representative.through.health.councils.and.\nthe.Cochrane.collaboration.\n3  Project timetable and milestones\nMonth Activity\n\u2013 3   MREC Submission\nInform practices via local research, teaching and \ntraining networks, the MRC GP Research Framework, \ntwo direct mailshots to every medical and dental \npractice and out of hours co-operatives in Scotland. \nTrain NHS24 nurses and ENT registrars. General \nadvertisement via medical press\n1   Project-specific training of research team to use \nstudy instruments\nPilot study instruments and recruitment process\n2   Begin patient recruitment. Monthly reminders \nto health professionals. Data entry by research \nsecretary\n5   Begin 3-month assessments\n6   Provide first interim report and prepare \nconference submissions\n11   Begin 9-month assessments\n12   Provide second interim report\n18   Complete patient recruitment. Provide third \ninterim report\n21   Complete 3-month assessments\n24   Provide fourth interim report\n27   Complete 9-month assessments. Final analysis \nand writing up\n31   Provide final report and submit papers\n4  Expertise\nThe.research.team.comprises.multidisciplinary.\nexpertise.in.health.economics,.medical.statistics,.\nneurology,.otorhinolaryngology,.general.medical.\nand.dental.practice..Members.of.the.team.will.work.\nwithin.the.framework.of.the.Scottish.School.of.\nPrimary.Care.(SSPC),.which.co-ordinates.primary.\ncare.research.throughout.Scotland.\nProfessor.Sullivan,.the.lead.investigator,.has.\nexperience.of.participating.in.six.RCTs.and.of.\nleading.one.RCT..He.has.15.years.of.experience.\nof.other.types.of.research.in.primary.care..As.the.\nclinical.director.of.one.of.the.research.networks,.\nTayRen,.and.head.of.department.in.one.of.the.\nparticipating.universities,.he.will.be.able.positively.\nto.influence.recruitment.in.the.East.of.Scotland.\nProfessor.Morrison.contributes.expertise.in.the.\ndetection.and.assessment.of.psychological.distress.\nin.primary.care..She.also.has.experience.of.\nparticipating.in.and.leading.RCTs.in.primary.care..\nShe.will.be.able.to.influence.the.recruitment.of.\nstudy.subjects.by.general.practitioners.in.teaching.\nand.research.networks.in.the.West.of.Scotland.\nDr.Smith.is.a.primary.care.career.scientist.with.\nexpertise.in.the.epidemiology.of.pain.in.the.\ncommunity..As.a.respected.researcher.in.the.\nnorth-east.of.Scotland.he.will.be.able.to.influence.\nthe.recruitment.of.study.subjects.by.general.\npractitioners.in.teaching.and.research.networks.in.\nGrampian.and.Highland.\nDr.McKinstry.has.experience.of.leading.two.RCTs.\nin.telephone.triage.and.hypertension,.and.is.taking.\npart.in.another..He.has.15.years\u2019.experience.of.\nother.types.of.research.in.primary.care..He.is.a.\nworking.general.practitioner.and.Medical.Director.\nof.Lothian.and.Borders.Primary.Care.Research.\nNetwork.and.can.therefore.facilitate.recruitment.in.\nthis.area.\nMr.Swan.is.one.of.two.postgraduate.training.\ndirectors.in.ENT.in.Scotland..He.is.able.to.train.\nand.support.all.Scottish.ENT.registrars.likely.to.see.\npatients.eligible.for.study..He.has.already.secured.\nagreement.from.the.clinical.directors.of.12\/14.\nScottish.ENT.units.to.participate.\nDr.Donnan.is.a.senior.medical.statistician.who.has.\nadvised.on.the.study.methodology.and.will.remain.\nin.daily.contact.with.the.principal.investigator.and.\nresearch.fellow.as.the.study.proceeds.\nProfessor.Cairns.is.a.senior.health.economist.with.\nlongstanding.interests.in.community.interventions.\nDr.Davenport.is.a.neurologist.who.has.provided.\nadvice.on.the.study.methodology.and.will.be.a.\nmember.of.the.panel.of.photographic.reviewers.\nproviding.independent.assessment.of.the.key.\noutcome.variable.\nDr.Clarkson.is.the.director.of.the.Scottish.Dental.\nPractices.Research.Network..She.will.be.able.\nto.increase.the.recruitment.of.study.subjects.by.Appendix 1\n64\ngeneral.dental.practitioners.in.teaching.and.\nresearch.networks.throughout.Scotland.\n5  Trial process\nThe.trial.may.be.separated.into.eight.stages.as.\nfollows:.\n\u2013.1..Approvals,.advertisement,.awareness-raising\nThis.stage.covers.trial.administration.[MREC.\napprovals,.appropriate.LREC.approvals,.Doctors\u2019.\nand.Dentisits\u2019.Exemption.(DDX).certification,.\netc.].and.advice.of.the.existence.of.the.trial.to.all.\nrelevant.persons.with.a.potential.role,.including.\nGPs,.A&E.departments,.NHS24,.dentists.(stage.1).\nand.ENT.consultants,.registrars.and.nurses.(stage.\n2).\nStages.0.to.6.are.taken.from.the.patient\u2019s.point.of.\nview.and.are.as.follows:\n0.. Onset.(or.symptoms.noticed)\n1.. Seek.advice.(visit.GP,.dentist.or.A&E;.or.\ncontact.NHS24)\nThese.experts.need.to.be.sufficiently.aware.of.the.\ntrial.and.its.design.to.refer.the.patient.onward.to:\n2.. Visit.the.nearest.ENT.acute.receiving.clinic\nof.which.there.are.14.identified.so.far;.of.these,.\n13.have.agreed.to.collaborate..Here.diagnosis.\nis.confirmed.and,.if.appropriate,.consent,.\nrandomisation.and.the.commencement.of.\ntreatment.follow..It.is.here.that.the.first.written.\nrecord.is.taken.from.the.patient..The.Trial.Co-\nordinator.is.advised.of.the.new.recruitment,.\nand.the.appropriate.local.Research.Associate.is.\ninformed.\nIt is crucial to the design of the trial that the time delay \nfrom onset to first administration of treatment should not \nexceed 72 hours.\nOn.receipt.of.notification.from.the.Co-ordinator,.\nthe.local.RA.arranges\n3.. Baseline.visit.by.local.RA.to.the.patient\nto.take.place.at.the.patient\u2019s.home.or.GP.surgery.\n(if.preferred).within.3.days.(72.hours).of.the.ENT.\nvisit..At.this.point.photographs.of.the.patient\u2019s.\ncondition.are.taken.and.further.details.are.\nrecorded..This.is.followed.two.or.three.days.later.by\n4.. A.telephone.contact\nto.enquire.about.the.patient\u2019s.condition,.to.check.\nadherence.to.the.treatment.and.their.general.\nprogress.on.the.trial..The.two.final.stages.are\n5.. 3-month.visit\nat.which.follow-up.photographs.and.further.details.\nare.taken..The.final.stage.of.patient.involvement.is\n6.. 9-month.visit\nif.deemed.necessary.\nIt.is.anticipated.that.recruitment.will.commence.\non.1.February.2004.and.continue.for.18.months.\nup.to.31.July.2005..The.last.recruit\u2019s.9-month.visit.\nwill.therefore.take.place.on.or.about.30.April.2006.\nThat.27-month.period.is.also.the.approximate.\nperiod.of.employment.of.the.local.RAs..The.trial.\nis.scheduled.to.end.6.months.later.on.31.October.\n2006.\n6  Justification of support requested\nStudy Co-ordinator\nA.single,.full-time.postdoctoral.health.services.\nresearcher.is.required.to.co-ordinate.all.the.\ncomponents.of.the.study,.visit.each.of.the.centres.\nand.arrange.meetings.of.the.study.team..This.post.\nwill.be.full-time.for.the.duration.of.the.study.and.\nthe.postholder.will.be.experienced.in.multi-centre.\nhealth.services.research..They.will.be.supported.in.\nthis.role.by.the.Scottish.Clinical.Trials.co-ordinators.\ngroup.based.at.HSRU.in.Aberdeen.They.will.also.\nbe.responsible.for.visiting.the.study.subjects.in.\ntheir.own.region.of.Scotland,.i.e..Tayside,.Fife.and.\nForth.Valley.\nCentre Co-ordinators\nIn.the.three.other.centres,.Glasgow,.Edinburgh.\nand.Aberdeen,.the.baseline,.3-month.and.9-month.\nvisits.will.be.conducted.by.centre.co-ordinators.\nworking.respectively.full-time.(covering.all.West.\nof.Scotland.NHS.boards),.half-time.(covering.\nEdinburgh,.Lothian.and.Borders).and.half-time.\n(covering.Grampian.and.Highland).\nSecretary\nA.half-time.research.secretary.will.be.responsible.\nfor.correspondence.with.patients.and.practitioners,.\ndata.entry,.typing.reports.and.minutes.of.meetings,.\nand.general.office.administration.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n65\nStatistician\nFor.a.total.of.one.day.per.month.throughout.the.\nstudy.and.3.months.at.the.end.of.the.study.a.\npostdoctoral.statistician.will.be.required.to.assist.\nwith.analysis.of.the.data.and.assist.the.principal.\ninvestigators.in.completing.the.report.to.the.HTA.\nand.preparation.of.papers.for.publication.\nHealth economist\nFor.3.months.at.the.end.of.the.study.a.postdoctoral.\nhealth.economist.will.be.required.to.assist.with.\nthe.analysis.of.the.economic.data.and.assist.the.\nprincipal.investigators.in.completing.the.report.to.\nthe.HTA.and.preparation.of.papers.for.publication.\nRandomisation service\nThe.Health.Services.Research.Unit.in.Aberdeen.\nhas.experience.of.24-hour.factorial.randomisation.\nfor.clinical.trials..This.will.be.accessed.by.an.\n0800.number.from.the.ENT.department.where.\nthe.patient.is.first.seen,.and.data.on.entry.of.\nstudy.subjects.will.be.sent.every.day.to.the.study.\nco-ordinator.with.monthly.summary.statistics.\nprovided.\nOffice equipment\n\u2022. One.laptop.PC.for.the.study.co-ordinator.\nto.use.on.site.visits.and.conferences.as.well.\nas.daily.trial.management.(e.g..Dell.C640\u2013\n256Mb,.CD,.20.GB).\n\u2022. Printer:.e.g..HP.LaserJet.1200.\n\u2022. Other.equipment.will.be.supplied.by.the.study.\nsites.\nPostage + stationery\n\u2022. 3000.initial.requests.to.participate.to.all.\nmedical.and.dental.practices.as.well.as.\nA&E.units.and.out.of.hours.co-operatives..\nProduction.of.laminated.sheets.to.go.in.every.\nparticipating.site\u2019s.consulting.areas.\n\u2022. 1500.reminders.to.participants..Monthly.\nreminders.to.practices.and.hospitals.\nCameras\nFor.baseline.assessment.and.follow-up.of.patients.at.\n3.and.9.months.the.research.co-ordinators.in.each.\ncentre.will.need.a.camera.\n\u2022. Four.Canon.A40.8Mb.USB.cameras.for.onward.\ntransmission.of.digital.images.to.the.three.\nassessors.\nTravel to patients\u2019 homes and \nconference expenses\n\u2022. This.has.been.costed.on.the.assumption.of.a.\nreturn.car.journey.of.10.miles.either.of.the.\npatient.to.the.practice.or.the.co-ordinator.to.\nthe.patient\u2019s.home.\n7  References\n1.. Petruzelli.GJ,.Hirsch.BE..Bell\u2019s.Palsy..Postgrad Med.\n1991;90:115\u201327.\n2.. Sugita.T,.Murakami.S,.Yanagihara.N,.Fujiwara.Y,.\nHirata.Y,.Kurata.T..Facial.nerve.paralysis.induced.by.\nherpes.simplex.virus.in.mice:.an.animal.model.of.\nacute.and.transient.facial.paralysis..Ann Otol Rhinol \nLaryngol.1995;104:574\u201381.\n3.. Morgan.M,.Moffat.M,.Ritchie.L,.Collacott.I,.Brown.\nT..Is.Bell\u2019s.palsy.a.reactivation.of.varicella.Zoster.\nvirus?.J Infect.1995;30:29\u201336.\n4.. Bateman.DE..Facial.Palsy..Br J Hosp Med.\n1992;47:430\u20131.\n5.. Rowlands.S,.Hooper.R,.Hughes.R,.Burney.P..The.\nepidemiology.and.treatment.of.Bell\u2019s.palsy.in.the.\nUK..Eur J Neurol.2002;91:63\u20137.\n6.. Morgenlander.JC,.Massey.EW..Bell\u2019s.Palsy:.\nensuring.the.best.possible.outcome..Postgrad Med.\n1990;88:157\u201362.\n7.. Salinas.RA,.Alvarez.G,.Alvarez.MI,.Ferreira.J..\nCorticosteroids.for.Bell\u2019s.palsy.(idiopathic.facial.\nparalysis).(Cochrane.Review)..In:.The Cochrane \nLibrary,.Issue.2,.2002..Oxford:.Update.Software.\n8.. Sipe.J,.Dunn.L..Acyclovir.for.Bell\u2019s.palsy.(idiopathic.\nfacial.paralysis).(Cochrane.Review)..In:.The Cochrane \nLibrary,.Issue.2,.2002..Oxford:.Update.Software.\n9.. May.M,.Wette.R,.Hardin.WB..The.use.of.steroids.\nin.Bell\u2019s.palsy:.a.prospective.controlled.study..\nLaryngoscope.1976;86:1111\u20132.\n10.. Wolf.SM,.Wagner.JH,.Davidson.S,.Forsythe.\nA..Treatment.of.Bell\u2019s.palsy.with.prednisone:.\na.prospective.randomised.study..Neurology.\n1978;28:158\u201361.\n11.. Abiko.Y,.Ikeda.M,.Hondo.R..Secretion.and.\ndynamics.of.herpes.simplex.virus.in.tears.and.\nsaliva.of.patients.with.Bell\u2019s.Palsy..Otol Neurotol.\n2002;23:779\u201383.\n12.. Stampfer.MJ,.Buring.JE,.Willett.W,.Rosner.B,.\nEberlein.K,.Hennekens.CH..The.2x2.factorial.\ndesign:.its.application.to.a.randomised.trial.of.\naspirin.and.carotene.in.US.physicians..Stat Med.\n1985;4:111\u20136.\n13.. Moher.D,.Pham.B,.Jones.A,.Cook.DJ,.Jadad.\nAR,.Moher.M,.et al..Does.quality.of.reports.of.\nrandomised.trials.affect.estimates.of.intervention.Appendix 1\n66\nefficacy.reported.in.meta-analyses?.Lancet.\n1998;352:609\u201313.\n14.. Adour.KK,.Ruboyianes.JM,.Von.Doeersten.PG,.Byl.\nFM,.Trent.CS,.Queensberry.CP,.et al..Bell\u2019s.palsy.\ntreatment.with.acyclovir.and.prednisone.compared.\nwith.prednisone.alone:.a.double-blind,.randomised,.\ncontrolled.trial..Ann Otol Rhinol Laryngol.\n1996;105:371\u20138.\n15.. De.Diego.JI,.Prim.MP,.De.Sarria.MJ,.Madero.R,.\nGavilan.J..Idiopathic.facial.paralysis:.A.randomised,.\nprospective.and.controlled.study.using.single-\ndose.prednisone.versus.acyclovir.three.times.daily..\nLaryngoscope.1998;108:573\u20135.\n16.. Simpson.C..Personal.communication..Annual.\nincidence.of.Bell\u2019s.palsy.(Read.code.F130).in.\nScottish.Continuous.Morbidity.Recording.practices.\n17.. Ekstran.T..Bell\u2019s.palsy:.prognostic.accuracy.of.case.\nhistory,.sialometry.and.taste.impairment..Clin \nOtolaryngol.1979;4:183\u201396.\n18.. Altman.DG,.Schulz.KF,.Moher.D,.Egger.M,.\nDavidoff.F,.Elbourne.D,.et al..The.revised.\nCONSORT.statement.for.reporting.randomized.\ntrials:.explanation.and.elaboration..Ann Intern Med.\n2001;134:663\u201394.\n19.. Brookes.ST,.Whitley.E,.Peters.TJ,.Mulheran.PA,.\nEgger.M,.Davey-Smith.G..Subgroup.analyses.in.\nrandomized.controlled.trials:.quantifying.the.risks.\nof.false-positives.and.false-negatives..Health Technol \nAssess.2001;5:33.\n20.. House.JW,.Brackmann.DE..Facial.nerve.grading.\nsystem..Otolaryng Head Neck.1985;93:146\u20137.\n21.. Purves.AM,.Penny.KI,.Munro.C,.Smith.BH,.\nGrimshaw.J,.Wilson.B,.Smith.WC..Defining.chronic.\npain.for.epidemiological.research.\u2013.assessing.a.\nsubjective.definition..The Pain Clinic.1998;10:139\u2013\n47.\n22.. Von.Korff.M,.Ormel.J,.Keefe.FJ,.Dworkin.SF..\nGrading.the.severity.of.chronic.pain..Pain.\n1992;50:133\u201349.\n23.. Smith.BH,.Penny.KI,.Purves.AM,.Munro.C,.Smith.\nWC,.Grimshaw.J,.et al..The.Chronic.Pain.Grade.\nquestionnaire:.acceptability.and.validity.in.postal.\nresearch..Pain.1997;71:141\u20137.\n24.. Feeny.D,.Furlong.W,.Boyle.M,.Torrance.GW..Multi-\nattribute.health.status.classification.systems..Health.\nUtilities.Index..Pharmacoeconomics 1995;7:490\u2013502.\n25.. Information.and.Statistics.Division..ISD Scotland \nGuide: an A-Z of the work of the Information & Statistics \nDivision..Edinburgh:.Information.&.Statistics.\nDivision;.1996.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n67\nA.\nTrial.Steering.Committee.(TSC).should.be.set.\nup.with.the.following.terms.of.reference:\nTerms of reference\n1.. To.monitor.and.supervise.the.progress.of.the.\ntrial.towards.its.interim.and.overall.objectives.\n2.. To.review.at.regular.intervals.relevant.\ninformation.from.other.sources.(e.g..other.\nrelated.trials).\n3.. To.consider.the.recommendations.of.the.Data.\nMonitoring.and.Ethics.Committee.(DMEC).\n4.. To.advise.on.publicity.and.the.presentation.of.\nall.aspects.of.the.trial.\nMembership of TSC\nThe.membership.should.be.limited.and.include.\nan.independent.Chairman.(not.involved.directly.\nwith.the.trial.other.than.as.a.member.of.the.\nTSC),.two.or.more.other.independent.expert.\nmembers.and.the.Principal.Investigator..Where.\npossible.the.membership.should.include.a.lay\/\nconsumer.representative..The.trial.co-ordinator,.\ntrial.statistician,.etc.,.should.attend.meetings.as.\nappropriate..Observers.from.the.Host.Institution.\nmay.be.invited.to.all.meetings.\nGuidance notes\nMeetings\nBefore.the.trial.starts,.the.PI.should.organise.a.\nmeeting.of.the.TSC.to.finalise.the.protocol..The.\nTSC.should.then.meet.at.least.annually,.although.\nthere.may.be.periods.when.more.frequent.meetings.\nare.necessary..Meetings.should.be.organised.by.the.\nPI..Papers.for.the.meeting.should.be.circulated.in.\nadvance..An.accurate.minute.should.be.prepared.\nby.the.PI.and.agreed.by.all.the.members.\nTrial steering and management\nThe.role.of.the.TSC.is.to.provide.overall.\nsupervision.of.the.trial..In.particular,.the.TSC.\nshould.concentrate.on.the.progress.of.the.trial,.\nadherence.to.the.protocol,.patient.safety.and.\nconsideration.of.new.information..Day-to-day.\nmanagement.of.the.trial.is.the.responsibility.of.\nthe.PI..The.PI.may.wish.to.set.up.a.separate.Trial.\nManagement.Group.to.assist.with.this.function.\nGood clinical practice\nThe.TSC.should.endeavour.to.ensure.that.the.trial.\nis.conducted.at.all.times.to.the.standards.set.out.\nin.the.MRC.Guidelines.for.Good.Clinical.Practice.\n(GCP).\nPatient safety\nIn.all.the.deliberations.of.the.TSC.the.rights,.safety.\nand.well-being.of.the.trial.participants.are.the.most.\nimportant.considerations..The.TSC.should.ensure.\nthat.freely.given.informed.consent.is.obtained.from.\neach.trial.participant..The.TSC.should.advise.the.\ninvestigators.on.the.completeness.and.suitability.of.\nthe.patient.information.provided.\nProgress of the trial\nIt.is.the.role.of.the.TSC.to.monitor.the.progress.\nof.the.trial.and.to.maximise.the.chances.of.\ncompleting.the.trial.within.the.agreed.time.scale..\nAt.the.first.TSC.meeting,.targets.for.recruitment,.\ndata.collection,.compliance,.etc.,.should.be.agreed.\nwith.the.PI..Based.on.these.targets,.the.TSC.should.\nagree.a.set.of.data.that.should.be.presented.at.each.\nmeeting.(see.template).\nThe.PI.is.required.to.submit.an.annual.report.\nto.HTA..This.report.should.be.endorsed.by.the.\nTSC,.should.stand.alone,.and.contain.sufficient.\ninformation.to.enable.HTA.to.assess.the.progress.\nof.the.trial.without.the.need.to.refer.back.to.the.\noriginal.application..The.annual.report.should.\ninform.HTA.of.any.new.information.that.has.a.\nbearing.on.safety.or.ethical.acceptability.of.the.\ntrial.or.any.significant.complaints.arising,.with.a.\njustification.of.the.decisions.taken.\nThe.DMEC.should.be.asked.to.advise.the.TSC,.\nand.may.be.required.to.provide.information.on.\nthe.availability.of.data.collected.to.date.(from.this.\nand.other.studies).and.advice.on.the.likelihood.\nthat.continuation.of.the.trial.will.allow.detection.\nof.an.important.effect..This.should.be.done.using.\nmethods.that.do.not.unblind.the.trial.\nAdherence to protocol\nThe.full.protocol.should.be.presented.and.agreed.\nat.the.first.TSC.meeting..Any.subsequent.changes.\nto.the.protocol.must.be.approved.by.the.TSC,.\nLREC\/MREC.(and.by.HTA).\nAppendix 2  \nTrial Steering CommitteeAppendix 2 \n68\nData Monitoring and Ethics Committee\nAt.its.first.meeting,.the.TSC.should.establish.a.Data.\nMonitoring.and.Ethics.Committee.(DMEC).that.\nmeets.regularly.to.review.the.data.and.results.of.\nany.interim.analyses.\nMembers.of.the.DMEC.should.be.independent.of.\nboth.the.trial.and.TSC.\nConsideration of new information\nThe.TSC.should.consider.new.information.relevant.\nto.the.trial.including.reports.from.the.DMEC..It.\nis.the.responsibility.of.the.PI,.the.Chairman.and.\nother.independent.members.to.bring.results.from.\nother.studies.that.may.have.a.direct.bearing.on.\nfuture.conduct.of.the.trial.to.the.attention.of.the.\nTSC.\nOn.consideration.of.this.information.the.TSC.\nshould.recommend.appropriate.action,.such.\nas.changes.to.the.protocol,.additional.patient.\ninformation,.or.stopping.the.trial..The.rights,.\nsafety.and.well-being.of.the.trial.participants.\nshould.be.the.most.important.consideration.\nIt.is.the.responsibility.of.the.PI.to.notify.the.\nTSC,.DMEC.and.relevant.regulatory.authority.(if.\napplicable).immediately.of.any.unexpected.serious.\nadverse.events.occurring.during.the.course.of.the.\ntrial.\nTemplate for Trial Steering \nCommittee agendas and reports\nThe.TSC.should.meet.at.least.once.a.year.and.\ncompose.an.annual.report.\nThe.table.below.outlines.the.information.that.\nshould.be.provided.by.the.PI.at.each.meeting..This.\ntemplate.should.be.used.as.a.basis.for.the.agenda.\nof.TSC.meetings.and.a.template.for.the.annual.\nreport..These.headings.may.not.be.appropriate.at.\nevery.stage.of.an.individual.trial,.or.for.all.trials.\nTrial Steering Committee\nProfessor.Chris.van.Weel,.University.of.Nijmegen\nDr.Ian.Williamson,.University.of.Southampton\nProfessor.Sally.Wyke,.University.of.Stirling\nMrs.Caryl.Hamilton.(Patient.representative)\nProfessor.Frank.Sullivan,.University.of.Dundee\nDr.Peter.Donnan,.University.of.Dundee\nIn.attendance:\nDr.Fergus.Daly,.University.of.Dundee.\nTarget  \n(date set)\nAchieved \n(date)\nSample size sought\nDate recruitment started\nProposed date for end of \nrecruitment\nActual recruitment rate \nvs target rate (by month\/\nquarter)\nAcceptance rate, as a \nproportion (i) of those \ninvited to participate\n(ii) of all eligible \nparticipants, if known\nQuarterly\/monthly \nforecasts of recruitment \nfor the planned \nremainder of the trial\nLosses to follow-up (i) \nas a proportion of those \nentered\n(ii) per month\/quarter\nNumber still being \nfollowed up successfully \nand number who have \ncompleted follow-up\nCompleteness of data \ncollected\nAny available results \n(pooled)\nAny organisational \nproblems\nIssues specific to the trial \n(as specified by the TSC)\nPlease include a graph plotting the cumulative target and \nachieved recruitment numbers against time since start of \nrecruitmentDOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n69\nT\nhe.Data.Monitoring.and.Ethics.Committee.\n(DMEC).is.established.to.safeguard.the.\ninterests.of.patients.participating.in.randomised.\ncontrolled.trials.\nThe.terms.of.reference.and.membership.are.based.\non.the.Medical.Research.Council.Guidelines.for.\nGood.Clinical.Practice.In.Clinical.Trials.(1998).\nThe.DMEC.is.the.only.body.involved.in.the.trial.\nthat.has.access.to.the.unblinded.comparative.data..\nThe.role.of.committee.members.is.to.monitor.\nthese.data.and.make.recommendations.to.the.\nTrial.Steering.Committee.(TSC).if.there.are.any.\nethical.or.safety.reasons.why.the.trial.should.not.be.\ncontinued.\nThe.Chair.of.the.TSC.should.be.made.aware.of.all.\ncommunication.between.DMEC.and.the.Principal.\nInvestigator.(PI).\nThe.membership.of.the.DMEC.will.incorporate.a.\npool.of.statisticians.and.clinicians\/epidemiologists,.\nconsisting.of.at.least.three.members.to.represent.\nclinical,.statistical.and.clinical.trial.expertise.\nAll.members.of.the.group.should.be.independent.\nof.the.trial.they.are.monitoring..The.frequency.\nwith.which.the.DMEC.subgroup.meets.will.be.\ndependent.on.the.needs.of.the.individual.trial..The.\nPI.should.submit.a.detailed.plan.for.the.interim.\nanalysis.before.the.trial.commences..The.plan.must.\nsatisfy.members.of.the.DMEC.group.\nCommunication.between.the.PI.and.the.DMEC.\nChair.is.encouraged.but.should.not.bypass.the.TSC.\nChair..The.PI.and.the.Chair.of.the.TSC.will.agree.\nwith.their.DMEC.group.Chair.a.timely.mechanism.\nfor.reporting.to.the.DMEC.group..With.the.help.\nof.the.trial.statistician,.the.PI.must.provide.blinded.\ndata,.in.strict.confidence,.to.the.DMEC.group.as.\nfrequently.as.the.members.of.the.subgroup.request..\nSerious.adverse.events.must.be.reported.to.the.lead.\nclinician.of.the.DMEC.group.and.chairperson.of.\nthe.relevant.research.ethics.committee.immediately..\nIf.appropriate,.the.Medicines.Control.Agency.must.\nalso.be.informed.of.all.serious.adverse.events..The.\ntemplate.for.reporting.interim.data.should.be.used.\nby.all.the.PIs.\nThe.DMEC.group.will.discuss.the.data.on.adverse.\nevents.and,.if.appropriate,.efficacy.data,.either.\nin.a.meeting.or.by.teleconference..If.necessary,.\nthey.may.request.further.data.from.the.PI.and.\ntrial.statistician..In.the.light.of.interim.data,.and.\nother.evidence.from.relevant.studies.(including.\nupdated.overviews.of.the.relevant.randomised.\ncontrolled.trials),.the.DMEC.group.will.inform.the.\nTSC.if,.in.their.view,.the.trial.should.proceed.or.\nbe.terminated..They.may.also.advise.the.TSC.on.\nmodification.of.the.protocol.\nUnless.cessation.of.the.protocol.is.recommended.\nby.the.DMEC,.the.TSC.and.collaborators.and.\nadministrative.staff.will.remain.ignorant.of.the.\nresults.of.the.interim.analysis.of.efficacy.and.\ntoxicity..Collaborators.and.all.others.associated.\nwith.the.study.may.write.to.the.DMEC,.to.draw.\nattention.to.any.concerns.they.may.have.about.\nthe.possibility.of.harm.arising.from.the.treatment.\nunder.study,.or.about.any.other.matters.that.may.\nbe.relevant.\nTerms of reference\n1.. To.set.up.and.maintain.direct.communication.\nwith.the.PI.and.Chair.of.the.TSC..The.Chair.\nof.the.TSC.should.be.made.aware.of.all.\ncommunication.between.the.PI.and.DMEC.\ngroup.\n2.. To.receive.a.copy.of.the.trial.protocol.and.plans.\nfor.interim.analysis.prior.to.commencement.\nof.the.trial,.or,.in.the.case.of.the.first.wave.of.\ntrials,.as.early.as.possible.\n3.. To.receive.reports.(as.per.template).during.\nthe.trial.at.intervals.agreed.with.the.TSC.and.\nPI..It.would.be.expected.that.these.would.be.\n6-monthly.in.the.first.year,.and.no.less.frequent.\nthan.12-monthly.after.that.\n4.. If.interim.analysis.of.the.trial.data.is.not.\nplanned.in.the.protocol.the.subgroup.should.\ndetermine.whether.interim.analysis.should.be.\nundertaken.\nAppendix 3  \nData Monitoring and Ethics \nCommittee (DMEC)Appendix 3\n70\n5.. To.consider.data.from.interim.analyses,.\nunblinded.if.considered.appropriate,.plus.\nany.additional.safety.issues.for.the.trial.and.\nrelevant.information.from.the.template.and.\nother.sources.\n6.. In.the.light.of.points.3,.4.and.5,.and.\nensuring.that.ethical.considerations.are.of.\nprime.importance,.to.report.to.the.TSC.and.\nrecommend.on.the.continuation.of.the.trial..\nOutput and reporting by DMEC \ngroup\nFormat of first meeting\n1.. The.first.meeting.of.the.group.will.generally.\nbe.an.open.meeting.with.the.trial.investigators.\n(PI.and.trial.statistician)..The.output.of.that.\nmeeting.will.include.agreement.on.the.relevant.\nmaterial.for.that.particular.trial.that.needs.to.\nbe.reported.subsequently.within.the.template.\n2.. The.report.of.the.trial.statistician.to.the.DMEC.\ngroup.will.be.seen.only.by.the.group.members..\nEach.group.meeting.should.be.summarised.\nin.the.form.of.brief.minutes..These.minutes.\nand.the.report.of.the.trial.statistician.will.be.\ncirculated.only.to.the.DMEC.group.members.\n3.. A.very.brief.summary.of.the.recommendations.\nof.each.subgroup.meeting.should.be.sent.to.the.\nChairman.of.the.TSC.\nData Monitoring and Ethics \nCommittee\nProfessor.Marion.Campbell,.University.of.\nAberdeen\nDr.Carl.Counsell,.University.of.Aberdeen\nMr.Rodney.Mountain,.University.of.Dundee\nDr.Simon.Ogston.(Statistician),.University.of.\nDundeeDOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n71\nDATA MONITORING AND ETHICS COMMITTEE\nREPORT TEMPLATE 1\nTrial Summary and Analysis Plan for Pre-trial Submission\n1.. Title:\n2.. Grant.No.:\n3.. Principal.Investigator:\n4.. Introduction.to.the.trial\n4.1.Background.in.brief:\n5.. Methods.in.brief\n5.1.Design.of.the.trial\n5.2.Details.of.interventions\n5.3.Outcome.measures\nPrimary:\nSecondary:\n5.4.Eligibility.criteria\nInclusion.criteria:\nExclusion.criteria:\n5.5.Sample.size.and.analysis\n6.. Baseline.characteristics.that.will.be.analysed.for.internal.and.external.validity\nInternal.validity\n(Comparability.between.the.treatment.groups)\nExternal.validity\n(Comparability.between.trial.participants.and.non-participants)\n(Comparability.between.high.and.low.recruiting.centres)\nAll serious adverse events, as defined below, must be reported to the lead clinician of the DMEC monitoring subgroup \nand chairperson of the ethics committee as soon as possible.\nAny.untoward.medical.occurrence.that.at.any.dose:\n\u2022. Results.in.death\n\u2022. Is.life.threatening\n\u2022. Requires.inpatient.hospitalisation.or.prolongation.of.existing.hospitalisation\n\u2022. Results.in.persistent.or.significant.disability\/incapacity\n\u2022. Is.a.congenital.anomaly\/birth.defectAppendix 3\n72\nDATA MONITORING AND ETHICS COMMITTEE\nREPORT TEMPLATE 2\nDMEC.Report.Date:\nReport.Number:\n1.. Title:\n2.. Trial.progress\n2.1.Trial.recruitment\n2.1.1.. Plan.of.recruitment\nStart.date.of.recruitment.=\nEnd.date.of.recruitment.=\nRecruitment.period.=\nExpected.average.monthly.recruitment.=\nRecruiting.centres.=\n2.1.2.. Recruitment.to.date\nRecruitment.period.to.date.=\nTotal.recruitment.to.date.=\nObserved.average.monthly.recruitment.=\nRecruitment.stratified.by.centre.=\nExpected.recruitment.period.(based.on.current.recruitment.rate).=\nEnd.date.of.recruitment.(based.on.expected.recruitment.patterns).=\nPlease insert a graph showing the planned and observed recruitment rates \n2.1.3.. Recruitment.based.on.eligibility\nInclusion\/exclusion\nNumber.ineligible\nNon-consent\nProtocol.violation\n2.2.Internal.validity\nComparability.of.selected.baseline.characteristics.between.the.treatment.groups\n2.3.External.validity\nSelected.baseline.characteristics.of.trial.participants.and.non-participants\nSelected.baseline.characteristics.of.subjects.in.high.and.low.recruiting.centres\n2.4.Protocol.compliance\nNumber.of.patients.withdrawn.from.treatment.but.continued.being.followed.up\nNumber.of.patients.who.have.been.lost.to.follow-up\nNumber.of.patients.with.missing.follow-up.data\n2.5.Frequency.of.primary.events.(if.applicable)DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n73\n3.. Did.you.submit.any.data.for.interim.analysis.of.efficacy?\nYes\/No\n4.. Analysis.of.safety.data.\nThese.are.to.be.presented.overall.and.by.group:\n4.1.Serious.adverse.events\nThese are defined as any untoward medical occurrence that at any dose:\n\u2022. Results.in.death\n\u2022. Is.life.threatening\n\u2022. Requires.inpatient.hospitalisation.or.prolongation.of.existing.hospitalisation\n\u2022. Results.in.persistent.or.significant.disability\/incapacity\n\u2022. Is.a.congenital.anomaly\/birth.defect\nTo be summarised here but reported immediately to the Chairs of the DMEC subgroup and ethics committee and if \nappropriate to the Medicines Control Agency\n4.2.Other.adverse.events\n4.3.Abnormal.laboratory.tests.(if.applicable)\n5.. List.any.new.publications.on.the.safety.and.efficacy.of.the.trial.medications.and.provide.copies.\n6.. List.any.new.national.or.international.guidelines.on.the.treatment.of.the.disease.being.studied.and.\nprovide.copies.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n75\nFrank.M.Sullivan.PhD,.Scottish.School.of.Primary.\nCare,.University.of.Dundee\nIain.RC.Swan.MD,.Department.of.Otolaryngology,.\nUniversity.of.Glasgow\nPeter.T.Donnan.PhD,.Community.Health.Sciences,.\nUniversity.of.Dundee\nJillian.M.Morrison.PhD,.Division.of.Community.\nBased.Sciences,.University.of.Glasgow\nBlair.H.Smith.MD,.Department.of.General.Practice.\nand.Primary.Care,.University.of.Aberdeen\nBrian.McKinstry.MD,.Community.Health.Sciences,.\nUniversity.of.Edinburgh\nRichard.J.Davenport.DM,.Department.of.Clinical.\nNeurosciences,.University.of.Edinburgh\nLuke.D.Vale.PhD,.Health.Economics.Research.\nUnit,.University.of.Aberdeen\nJanet.E.Clarkson.PhD,.Dental.Health.Services.\nResearch.Unit,.University.of.Dundee\nVictoria.Hammersley.BSc,.Community.Health.\nSciences,.University.of.Edinburgh\nSima.Hayavi.PhD,.Division.of.Community.Based.\nSciences,.University.of.Glasgow\nAnne.McAteer.MSc,.Department.of.General.\nPractice.and.Primary.Care,.University.of.Aberdeen\nFergus.Daly.PhD,.Community.Health.Sciences,.\nUniversity.of.Dundee\nAppendix 4  \nBELLS Study Management CommitteeDOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n77\nS\ncottish.Bell\u2019s.Palsy.Study.The.\u2018BELLS\u2019.study\nHTA.02\/09\/04\nThe.application.to.HTA.was.naturally.preceded.by.\nan.interval.of.some.3.months.for.negotiation.and.\ndetailed.discussion,.the.identification.of.a.research.\nteam,.the.refinement.of.the.study.protocol,.and.\nfor.approaches.to.be.made.to,.and.provisional.\nagreements.reached.with,.local.investigators.at.18.\nhospital.sites.throughout.Scotland..This.relatively.\nshort.timescale.is.illustrative.of.the.enthusiasm.\nand.energy.that.the.project.was.generating.in.the.\nscientific.and.medical.community.\nNotwithstanding.substantial.changes.in.the.MREC.\napprovals.process.that.were.taking.place.during.\nthis.period,.there.was.altogether.an.interval.of.\nfive.months.between.the.date.of.the.successful.\napplication.to.HTA.and.the.date.of.final.MREC.\napproval..This.is.normal.and.acceptable,.taking.\naccount.of.the.6-week.period.for.advertisement.and.\nappointment.of.staff,.which.could.only.reasonably.\ncommence.after.provisional.MREC.approval.had.\nbeen.gained.\nThe.project.was.originally.planned.to.start.on.1.\nOctober.2003,.but.the.University.of.Dundee.and.\nHTA.agreed.a.revised.start.date.of.1.November.\n2003.\nApprovals from local committees\n1.  Legal, indemnity, sponsorship\nStudy.activity.in.Tayside.and.Fife.was.covered.by.\nthe.appointment.of.the.study.co-ordinator.at.the.\nUniversity.of.Dundee..Three.universities.were.\nrequired.to.sign.Letters.of.Agreement.before.\nstaff.could.be.appointed.to.progress.the.study.in.\nGrampian.and.Highlands.(University.of.Aberdeen),.\nLothian.and.Borders.(University.of.Edinburgh).and.\nGlasgow.and.the.West.of.Scotland.(University.of.\nGlasgow).\nEach.of.these.institutions.understandably.needed.\nto.scrutinise.the.terms.of.the.Agreement.and.also.\nto.explore.all.issues.of.indemnity.given.the.nature.\nof.the.project.and.particular.its.aspects.of.patient \ncare and contact..It.is.notable.that.notwithstanding.\nthe.award.of.the.DDX,.one.university.raised.\nquestions.about.the safety of steroid medication..\nThere.were.some.considerable.delays.induced.by.\nthe.lack.of.clarity.surrounding.the identity of the \nproject sponsor,.and.this.role.was.finally.accepted.\nby.the.University.of.Dundee.in.late.April.2004.\n(ref..2002PS27)..Only.then.could.the.process.of.\nstaff.appointments.commence..The.third.of.three.\nresearch.assistants.finally.commenced.employment.\non.5.July.2004.\n2.  NHS contracts\nThe.four.research.assistants.(study.co-ordinator.\nand.three.others).are.all.non-clinical.and.\nrequired.NHS.contracts.to.cover.their.dual.roles.\nwithin.hospitals.(issue,.handling.and.return.of.\ndrug.stocks,.secure.handling.of.patient.data.\nand.documentation).and.with.patients.(up.to.\nthree.home.visits,.incorporating.posed.portrait.\nphotographs.for.expert.clinical.assessment,.\ncompletion.of.questionnaires.and.gathering.of.\nadditional.data).\nEach.RA.required.a.contract.to.cover.activity.within.\ntheir.allocated.region.and.within.others\u2019,.in.order.\nto.achieve.a.proper.coverage.during.holiday.and.\nother.absences.(e.g..maternity.leave).\nAt.the.time.of.writing.not.all.these.contracts.\nhad.been.issued,.although.we.were.assured.\nthat.merely.having.applied.for.them.provides.a.\nsufficient.foundation.for.the.Research.Associates.to.\ncommence.their.work.\n3.  Local ethical approvals\nOur.applications.for.local.ethics.approvals.\ncommenced.on.18.December.2003.with.13.\napplications.despatched.to.regional.committees..\nLater.it.emerged.that.some.Glasgow.hospitals.have.\ntheir.own.committees.and.Greater.Glasgow.has.its.\nown.Primary.Care.ethics.committee,.and.another.\nfive.applications.were.despatched.up.to.March.\n2004.\nAppendix 5  \nTimetable of approvals\nCopy of report to Chief Scientist OfficeAppendix 5 \n78\nWe.had.been.led.to.believe,.and.it.was.the.\nintention.of.the.new.MREC.structure,.that.the.\nprocess.of.local.approvals.for.a.multi-centre.trial.\nwould.be.substantially.eased,.but.in.practice.this.\nwas.not.the.case..The.new.procedures.would.\nonly.come.into.place.in.May.2004,.and.the.study.\nteam.found.themselves.caught.between.the.new.\nMREC.application.form.and.old.procedures.in.the.\nregions.\nFor.instance,.one.ethics.committee.requested.their.\nown.version.of.the.previously.approved.Patient.\nInformation.Sheet.for.the.study..In.practice.this.is.\na.requirement.that.could.have.been.met.without.\ngreat.effort.(and.the.labour.of.its.construction.\nmight.have.been.less.than.that.expended.during.\na.discussion.of.the.principles.involved).but.the.\nformal.requirements.at.this.time.were.very.blurred.\nfor.all.concerned.\n4.  Local R&D approvals\nAt.the.same.time.(18.December.2003).we.made.\nsimultaneous.applications.to.19.primary.and.acute.\ncare.R&D.departments,.with.another.three.up.\nto.March.2004..The.first.approval.came.through.\nbefore.the.new.year,.but.three.difficulties.became.\napparent.in.February.\nFirst,.the.study.team.wish.to.reimburse.the.efforts.\nof.general.practitioners.in.referring.patients.into.\nthe.study..Early.discussion.with.the.HTA.had.\nconfirmed.the.principle,.but.HTA.insisted.that.\nthe.funding.for.this.should.come.from.Support.\nfor.Science..At.this.stage.neither.the.mechanisms.\nfor.making.and.paying.claims,.nor.the.amount.\nto.be.reimbursed.had.been.agreed..It.became.\napparent.that.not.all.R&D.departments.had.\napplied.for.Support.for.Science.and.therefore.not.\nall.had.funding.available.to.make.reimbursements,.\nwhich.had.been.agreed.at.\u00a351.per.referral..This.\nsituation.is.now.resolved,.though.not.without.some.\nadministrative.difficulties.and.some.feeling.on.both.\nsides.that.advantage.had.been.taken.\nSecond,.in.order.to.smooth.the.process.of.\nclaim,.it.was.required.to.identify.research-active.\nprofessionals.additional.to.the.team.of.nine.\nprincipal.investigators.and.17.local.principal.\ninvestigators,.and.two.additional.local.principal.\ninvestigators.were.added.to.the.list.of.team.\nmembers..Notwithstanding.the.professional.\nwisdom.and.experience.added.to.the.team.by.their.\nappointment,.this.is.essentially.a.device.invented.\nfor.no.better.reason.than.to.allow.an.administrative.\nprocess.to.take.place..\nThird,.as.a.consequence.of.the.requirement.for.\nuniformity.in.appearance.of.the.study.medications,.\nthe.study.budget.has.been.used.for.the.purchase.\nof.all.treatments,.active.and.placebo..In.fact.the.\nstudy.is.funded.only.for.the.costs.of.placebo,.\naccording.to.the.reasonable.principle.that.primary.\ncare.organisations.should.bear.the.cost.of.active.\ntreatment..These.costs.needed.to.be.recovered.\nfrom.the.primary.care.organisations.by.the.study,.\nbut.only.through.an.administrative.mechanism.that.\nhas.yet.to.be.invented.\n5.  Pharmacies\nBy.an.oversight,.the.new.local.approvals.form.\ndesigned.by.COREC.then.lacked.an.entry.allowing.\nfor.the.approval.of.pharmacies.to.contribute.\nexpertise.to.the.running.of.a.study,.and.the.team.\nfound.itself.in.the.position.of.having.to.approach.\nChief.Pharmacists.for.their.approval.after.R&D.\napproval.to.mount.the.study.locally.had.already.\nbeen.gained..In.many.cases.the.individuals.were.\naware.of.the.BELLS.Study.through.their.position.\non.local.ethics.committees.or.local.R&D.panels,.\nbut.in.all.cases.it.was.necessary.for.us.to.adopt.the.\nrole.of.supplicant.in.our.approach.to.pharmacies..\nAltogether.17.separate.applications.have.been.\nmade.\nIn.one.case.the.pharmacy.has.required.the.issue.of.\na.steroid.card.with.the.patient.pack,.but.also.kindly.\nagreed.to.the.printing.and.administration.of.the.\ncard.themselves.\nCommencement of recruitment\nRecruitment.to.the.study.finally.commenced.on.4.\nJune.2004,.with.two.of.four.researchers.in.post,.15.\nmonths.after.the.invitation.to.tender,.11.months.\nafter.our.successful.application.to.the.HTA,.10.\nmonths.after.the.first.application.to.MREC.and.\nallowing.altogether.5.months.for.the.processes.of.\nlocal.approvals.\nWe.would.state.again.the.need.for.the.project.as.\nclearly.articulated.in.successive.Cochrane.reviews.\nand.by.professionals;.we.would.draw.attention.\nto.the.prevailing.and.undiminished.enthusiasm.\nand.energy.for.the.project.from.the.scientists.and.\nresearchers.involved.in.the.project;.and.finally.\nand.crucially.we.would.reaffirm.the.fact.that.its.\ndesign,.its.approach.to.patient.care.and.its.ethical.\nframework.have.never.been.questioned.on.any.\nother.than.trivial.grounds.that.were.easily.and.\nimmediately.addressed.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n79\nTABLE 48  Approvals process from letter of award\nItem Number of applications Time taken\nMREC approval 1 + revision 15 weeks\nMHRA (DDX certificate) 1 4 weeks\nUniversity agreements 4 4 months\nUniversity sponsorship 2 months after identification of this item as an issue\nNHS contracts 4 \u00d7 4 Variable \u2013 some came back by return of post\nLocal ethics approvals 18 5 months. By the time the last two applications were \nmade the form and associated requirements had \naltered\nR&D approvals 22 5 months. Some took less than 3 weeks (including \nChristmas closure)\nPharmacies 17 Altogether about 6 weeks, with most taking 2 weeks \non average\nDDX, Doctors\u2019 and Dentists\u2019 Exemption; MHRA, Medicines and Healthcare Products Regulatory Agency; MREC, \nMulticentre Research Ethics Committee.\nThe.calendar.of.the.application.process.and.\napprovals.from.central.committees.was.as.follows:\nInvitation.to.tender.\n(HTA)\nMarch.2003\nApplication.from.\nUniversity.of.Dundee.to.\nHTA\nJune.2003\nDate.of.award.letter.from.\nHTA\n27.June.2003\nFirst.application.to.\nMREC\n14.August.2003*\nProvisional.approval.\nfrom.MREC\n26.August.2003\n*This.date,.14.August.2003,.may.be.regarded.as.\nthe.start.of.the.approvals.process.\nAppointment.of.Study.\nCo-ordinator\n16.October.2003\nApplication.to.MHRA.\nfor.DDX\n16.October.2003\nOfficial.start.date.for.\nBELLS\n1.November.2003\nDDX.received.\n(MF8000\/13139\u2013141)\n12.November.2003\nRevised.application.to.\nMREC\n19.November.2003\nMREC.approval.\nreceived.\n(MREC\/03\/0\/74)\n26.November.2003\nThe.delays.may.be.summarised.as.shown.in.Table \n48.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n81\nAppendix 6  \nHow cruel to call it Bell\u2019s palsy\nby Graeme Garden\nO\nn.December.1st.2002,.while.driving.south.\nalong.the.M6,.I.discovered.that.I.couldn\u2019t.\nwhistle..I.don\u2019t.know.why.I.wanted.to.whistle;.\nperhaps.it.was.because.I.was.on.the.way.home.after.\na.particularly.busy.week..The.previous.Sunday.\nevening.we.had.recorded.two.editions.of.\u2018I\u2019m.Sorry.\nI.Haven\u2019t.a.Clue\u2019.in.front.of.a.live.audience.at.\nBlackpool\u2019s.Grand.Theatre..Next.morning.I.drove.\nup.to.Edinburgh.for.a.lunchtime.meeting.with.\na.group.of.writers,.with.whom.I.spent.the.week.\noutlining.13.episodes.for.a.children\u2019s.drama.series.\ncalled.\u2018The.Shoebox.Zoo\u2019,.then.back.on.Saturday.\nto.visit.my.mother.in.Preston,.before.driving.home.\nagain.on.the.Sunday,.which.was.when.I.must.have.\nfelt.the.need.to.whistle,.and.discovered.it.was.\nimpossible.\nAt.home.that.evening.the.need.to.whistle.didn\u2019t.\narise,.but.I.did.notice.that.my.mouth.felt.odd.on.\nthe.left.hand.side;.not.numb.exactly,.or.puffy,.\nbut.sort.of.weak.and.loose.and\u2026.odd..I.began.to.\nsuspect.what.was.going.on,.and.so.it.didn\u2019t.come.\nas.an.enormous.surprise.the.next.morning.when.\nI.woke.to.find.the.left.side.of.my.face.completely.\nparalysed..I.revealed.the.condition.to.my.wife,.\nEmma,.as.gently.as.I.could;.having.caught.sight.\nof.myself.in.the.mirror.it.appeared.that.my.face.in.\nrepose.took.on.an.expression.of.shock.or.despair,.\nand.if.I.tried.to.smile,.what.came.across.was.a.most.\nunsettling.(and.uncharacteristic).leer..She.coped.\nwith.this.apparition.pretty.well,.but.was.concerned.\nabout.the.cause..As.a.non-practising.qualified.\ndoctor.I.knew.a.little.about.Bell\u2019s.palsy,.at.least.\nenough.to.diagnose.myself.and.rule.out.the.more.\nfrightening.possibilities.such.as.a.stroke..A.visit.to.\nmy.GP.confirmed.the.diagnosis,.and.I.was.duly.\nprescribed.a.short,.sharp.course.of.prednisolone.\nand.aciclovir.(no.famciclovir.being.immediately.\navailable)..After.that,.all.being.well,.I.could.look.\nforward.to.a.lop-sided.month.or.two,.followed.by.a.\ncomplete.recovery..Meanwhile,.I.had.to.phone.my.\nagent.\nThe.call.to.my.agent,.also.named.Emma,.was.a.\nmatter.of.some.urgency,.as.the.following.morning,.\nTuesday,.I.was.due.to.report.to.the.set.of.\u2018Holby.\nCity\u2019.to.record.two.episodes.playing.the.role.of.a.\ncardio-thoracic.surgeon..It.was.only.fair.to.let.the.\nproducer.know.that,.although.I.was.fit.enough.to.\nwork,.50%.of.my.face.was.simply.not.up.to.the.job..\nIt.was.too.late.to.recast.the.part,.so.I.said.I.was.\nprepared.to.give.it.a.go,.and.with.luck.we\u2019d.get.\naway.with.it,.but.if.the.results.were.unacceptable.\nthen.a.rethink.would.be.required..There.then.\nfollowed.a.series.of.phone.calls.between.my.agent.\nEmma,.my.wife.Emma,.and.the.producer.\u2013.yet.\nanother.Emma.\u2013.about.the.state.of.my.face,.how.\nbad.it.really.looked,.and.whether.viewers.might.\nthink.I.was.ill.or.had.suffered.a.stroke,.or.was.\ndrunk,.or.just.playing.the.fool..We.decided.to.\ngo.for.it,.so.it.was.off.to.Elstree.for.three.days\u2019.\nrecording.Appendix 6 \n82\nThe.production.staff.and.the.cast.were.very.\nunderstanding.and.supportive..My.performance.\nas.Mr.Loftwood.was.perhaps.a.little.more.muted.\nthan.normal,.but.I.think.we.got.away.with.it..It.was.\nhelped.in.the.Operating.Theatre.scenes.by.the.\nfact.that.I.wore.a.surgical.mask,.and.in.the.other.\nscenes.they.managed.to.favour.my.good.side.to.the.\ncamera,.although.there.were.moments.when.Mr.\nHyde.was.rather.more.in.evidence.than.Dr.Jekyll.\nOn.the.Saturday.at.the.end.of.the.first.week.of.\naffliction.we.had.a.family.dinner.party.to.celebrate.\nour.son.Tom\u2019s.18th.birthday..I.sat.at.the.head.of.\nthe.table,.and.towards.the.end.of.the.meal.noticed.\nthat.everybody.on.one.side.of.the.table.was.in.great.\nhigh.spirits,.while.those.on.the.other.side.seemed.\nrather.dour.and.gloomy..My.wife.pointed.out.that.\nthose.sitting.on.my.right.could.see.me.smiling.\nand.animated,.while.those.on.the.left.saw.only.the.\nparalysed,.grim.and.unresponsive.side.of.my.face,.\nwhich.put.a.bit.of.a.damper.on.their.mood..Even.\nwhen.people.understand.the.problem,.they.still.\ncan\u2019t.help.reacting.to.the.message.they.perceive.\nthe.Bell\u2019s-palsied.face.to.be.sending.out,.however.\nunintentionally,.and.it.is.also.very.tedious.having.\nto.keep.explaining.to.people.why.you.look.the.way.\nyou.do..The.other.peculiar.sensation.was.of.the.\naffected.side.of.the.head.having.its.own.personality,.\nbeing.cold.and.unresponsive,.unlike.the.\u2018normal\u2019.\nside,.which.at.times.felt.somehow.out.of.control..\nIf.I.smiled.or.laughed,.it.was.as.if.the.left.side.was.\nunamused,.and.saying.\u2018get.a.grip.of.yourself!\u2019.while.\nthe.right.side.contorted.itself.uncontrollably.into.\nhalf.a.grin.or.giggle:.a.strange.and.disconcerting.\nexperience..Eating.and.drinking.could.also.be.\ntroublesome,.with.a.spurt.of.tea.or.gravy.suddenly.\nscooting.out.of.the.affected.corner.of.the.mouth..\nI.could.understand.why.people.suffering.from.\nthis.embarrassing.condition.often.like.to.hide.\nthemselves.away.and.avoid.social.contact.wherever.\npossible..Unfortunately.my.diary.was.not.prepared.\nto.allow.me.this.luxury..Next.Monday,.December.\n9th,.I.was.to.record.another.two.editions.of.\u2018I\u2019m.\nSorry.I.Haven\u2019t.a.Clue\u2019,.this.time.at.Sadlers.Wells.in.\nLondon.\nThe.audience.of.a.thousand.or.so.responded.to.\nmy.opening.contributions.rather.coolly..Perhaps.\nthey.were.overcome.with.sympathy,.or.concern,.\nor.confusion,.or.fear,.or.perhaps.were.simply.not.\nminded.to.mock.the.afflicted..It.therefore.seemed.\na.good.idea.to.explain.to.them.about.Bell\u2019s.palsy,.\nand.how.it.affected.the.facial.expression,.and.\nindeed.speech..The.loose.lips.find.it.difficult.to.\npronounce.Bs.and.Ps.\u2013.which.makes.it.especially.\ncruel.of.the.medical.profession.to.call.it.Bell\u2019s.palsy..\nWhen.someone.asks.you.what\u2019s.wrong,.you.tend.to.\nreply.\u2018It\u2019s Whbhell\u2019s Whphalsy!\u2019\nThat.Thursday.saw.me.at.a.school.prize-giving,.and.\nonce.again.I.had.to.explain.the.condition.to.the.\nassembled.sixth-formers..It.also.seemed.prudent.\nto.let.them.know.that,.in.view.of.my.lopsided.leer.\nand.one.winking.eye,.Social.Services.had.been.\ninformed!.In.the.days.that.followed.there.was.a.\nradio.pilot.in.which.I.played.a.character.who.was.\nsupposed.to.be.pretty.leery.anyway,.so.that.was.\nall.right,.and.then.a.signing.session.for.Dr.Who.\nfans.to.promote.an.audio.episode.I\u2019d.been.in..The.\n\u2018Whovians\u2019.who.flocked.to.get.the.signatures.and.\nbuy.the.merchandise.may.just.have.thought.I.was.\nin.some.clever.prosthetic.make-up,.and.on.that.\noccasion.I.didn\u2019t.feel.the.need.to.do.any.explaining.\nat.all..After.that,.a.few.meetings,.brief.visits.to.the.\nodd.party,.and.Christmas..By.the.end.of.January.I.\nwas.counting.wrinkles.again,.and.by.February.my.\nface.was.back.to.as.near.normal.as.it.ever.was.\nI.am.very.well.aware.that.I.got.off.lightly..The.\ncondition.ran.its.course.according.to.the.textbook,.\nand.the.prompt.medication.may.well.have.helped..\nHowever,.I.am.also.aware.that.some.people.recover.\nwithout.treatment,.while.others.are.treated.but.\nhave.problems.lasting.many.months.or.years..\nOne.doctor.wrote.to.me.saying.that.she.had.\nsuffered.for.12.months,.then.fell.head.first.down.a.\nflight.of.stairs.in.New.Zealand,.and.on.regaining.\nconsciousness.found.she.was.cured..She.does.not.\nrecommend.this.course.of.treatment..What.causes.\nthe.condition.is.also.currently.unclear,.although.\nit.does.seem.to.be.associated.with.the.herpes.\nsimplex.virus..Then.again,.we.can\u2019t.rule.out.the.\nold.tale.that.sitting.in.a.draught.brings.it.on;.my.\nown.week.of.driving.long.distances.and.sitting.in.\na.draughty.Edinburgh.hotel.bedroom.working.on.\na.laptop.might.be.seen.to.point.in.that.direction..\nOne.thing.I.did.learn.from.my.own,.comparatively.\nbrief,.experience.of.the.palsy.was.that,.once.they.\nunderstand.what.the.problem.is,.people.are.much.\nmore.supportive.and.sympathetic.than.you.might.\nsuppose.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n83\nAppendix 7  \nLocal Principal Investigators\nMr.William.McKerrow,.Raigmore.Hospital,.\nInverness\nMs.Mary.Shanks,.Crosshouse.Hospital,.Kilmarnock\nMr.David.Simpson,.Stobhill.Hospital,.Glasgow\nMr.Guy.Vernham,.St.John\u2019s.Hospital,.Livingston\nMiss.Aileen.White,.Royal.Alexandra.Hospital,.\nPaisley\nMr.Kim.Ah-See,.Aberdeen.Royal.Infirmary\nMr.Natarajan.Balaji,.Monklands.Hospital,.Airdrie\nMr.Hasan.Beg,.Victoria.Hospital,.Kirkcaldy\nMr.Quentin.Gardiner,.Perth.Royal.Infirmar\nMr.Musheer.Hussain,.Ninewells.Hospital,.Dundee\nMr.Alastair.Kerr,.Western.General.Hospital.and.\nRoyal.Infirmary,.Edinburgh\nMr.John.Marshall,.Southern.General.Hospital,.\nGlasgowDOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n85\nWhat is Bell\u2019s palsy and how is it treated?\nA.doctor.has.told.you.that.you.may.have.a.condition.known.as.Bell\u2019s.palsy..The.most.common.symptoms.\nare.weakness.or.paralysis.on.one.side.of.your.face,.with.others.that.may.include.dizziness,.difficulty.with.\nblinking,.problems.tasting.and.increased.sensitivity.to.sound..The.cause.of.Bell\u2019s.palsy.is.not.known,.but.it.\nmay.be.due.to.local.swelling.or.a.viral.infection.of.the.facial.nerve.on.one.side.of.your.face..There.is.good.\nrecovery.in.the.majority.of.cases..Unfortunately.there.is.no.medical.treatment.that.is.known.for.certain.to.\nimprove.how.quickly.people.recover,.and.most.patients.with.Bell\u2019s.palsy.in.the.UK.are.currently.given.no.\nmedication.\nIt.has.been.suggested.that.some.medicines.might.improve.patients\u2019.recovery,.and.the.two.most.commonly.\nused.by.doctors.are.prednisolone.(a.steroid).and.aciclovir.(a.medicine.for.treating.viral.infections)..These.\nmedicines.are.in.common.use.and.licensed.for.other.conditions,.but.not.for.use.in.treating.Bell\u2019s.palsy,.\nbecause.it.is.not.known.which,.if.either,.is.better.at.aiding.recovery,.or.if.giving.no.medication.at.all.is.just.\nas.good.\nThe NHS has asked us to find out whether either of these medicines, separately or together, is most helpful in \nachieving a good recovery from Bell\u2019s palsy.\nTo.do.this,.we.need.your.help..The.Scottish.Bell\u2019s.Palsy.Study.(\u2018BELLS\u2019).is.being.conducted.throughout.\nScotland.and.has.been.approved.as.an.ethical.study.by.the.Scottish.Multicentre.Research.Ethics.\nCommittee.and.by.all.the.regional.Research.Ethics.Committees.\nWe.would.like.to.invite.you.to.join.the.Study..Please.take.time.to.read.the.following.information.carefully.\nand.discuss.it.with.others.if.you.wish..Ask.if.there.is.anything.that.is.not.clear,.or.if.you.would.like.more.\ninformation.\n\u2022. The.purpose.of.the.study.is.to.try.to.find.out.which.of.two.treatments,.a.steroid.(prednisolone).and.an.\nantiviral.medicine.(aciclovir),.or.neither,.or.both,.is.most.effective.in.achieving.a.good.recovery.from.\nBell\u2019s.palsy.\n\u2022. You.have.been.invited.to.join.the.study.because.you.have.recently.been.diagnosed.with.Bell\u2019s.palsy..\nIt.is.fairly.common.(about.1.person.in.60.during.their.lifetime).and.there.will.be.up.to.500.fellow.\nsufferers.included.in.the.study.\n\u2022. It.is.up.to.you.to.decide.whether.to.join..If.you.decide.not.to.(or.if.after.joining.the.study.you.change.\nyour.mind).your.decision.will.not.affect.your.future.care..You.don\u2019t.have.to.say.why,.and.the.doctor.will.\njust.treat.you.as.they.normally.would.if.the.study.was.not.taking.place.\nWhat will happen if I decide I am interested in taking part in the study?\nIf.you.decide.you.do.want.to.take.part.in.the.study.(and.if.you.are.suitable:.not.everybody.will.be).then.this.\nis.what.will.happen.to.you.\n\u2022. You.will.be.given.two.bottles.of.tablets.by.a.doctor.to.take.away.with.you,.providing.a.10-day.course.of.\ntreatment,.starting.immediately..One.bottle.will.contain.prednisolone.(the.steroid).or.a.\u2018placebo\u2019.(a.\nharmless.substance.that.looks.exactly.the.same.as.the.medicine,.but.has.no.effect)..The.second.bottle.\nwill.contain.aciclovir.(the.medicine.for.treating.viral.infections).or.another.placebo.\nAppendix 8  \nScottish Bell\u2019s Palsy Study: \u2018BELLS\u2019\nPatient Information Sheet\nwww.dundee.ac.uk\/bells\/Appendix 8 \n86\nSo.the.four.possible.combinations.of.tablets.are:\nSteroid.and.\nAntiviral\nSteroid.and.\nPlacebo\nPlacebo.and.\nAntiviral\nPlacebo.and.\nPlacebo\nThere.is.an.equal.chance.that.you.will.be.given.any.of.these.combinations..Since.nobody.knows.which.\nof.these.possibilities.is.better.than.any.other,.you.are.not.advantaged.or.disadvantaged.by.the.choice.of.\ntreatment.allocated.to.you.\n\u2022. The doctor has checked that there is no reason why you cannot take either of these medicines.\nThe.choice.of.treatment.is.made.by.a.computer,.and.neither.you.nor.the.doctor.will.know.which.tablets.\nyou.have.been.given..We.will.only.find.this.out.after.all.the.results.of.the.study.are.collected..If.for.medical.\nreasons.we.need.to.find.out.before.the.end.of.the.study.what.medication.you.are.taking,.we.can.do.this..\nYou.can.carry.on.your.life.completely.as.normal.during.the.treatment.and.thereafter..There.will.be.no.\nadded.difficulty.or.complications.from.taking.part.in.the.study.other.than.remembering.to.take.your.\nmedicine,.and.some.assessments.that.would.comprise.part.of.normal.care.anyway..You.can.continue.to.take.\nexercise,.drive,.and.eat.and.drink.as.you.normally.do.\nYou.may.take.any.additional.medicines.you.may.require.such.as.pain.relief,.headache.remedies,.\nindigestion.pills.and.so.on:.however,.you.should.avoid.any.other.steroid.or.antiviral.preparations.\nHow will recovery be measured?\nThe.severity.of.your.condition,.and.how.fast.and.how.well.you.recover,.will.be.assessed.three.times:.once.\nas.soon.as.possible.during.the.10-day.treatment.period,.again.after.3.months,.and.finally.after.9.months..\nA.researcher.will.visit.you.at.home.or.you.can.meet.them.at.your.GP\u2019s.surgery,.if.you.prefer..If.you.have.to.\ntravel.from.home.for.the.assessments,.then.your.travelling.expenses.will.be.reimbursed.\nThe.assessment.will.consist.of.questionnaires.to.record.your.symptoms,.and.a.series.of.photographs,.\ntaken.to.provide.a.record.of.how.the.condition.has.affected.the.appearance.and.control.of.your.face..The.\nphotographs.and.all.other.information.collected.that.is.personal.to.you.will.be.stored.securely.and.will.\nonly.be.made.available.to.those.connected.with.the.study.in.an.official.capacity..If.at.any.time.you.decide.\nto.withdraw.from.the.study,.it.will.be.necessary.to.retain.your.data.for.safety.and.monitoring.purposes,.\nbut.it.will.be.maintained.as.carefully.and.with.the.same.security.as.that.of.other.patients.who.complete.the.\nstudy..You.will.not.be.identified.in.any.report.\nWhen do I need to decide?\n\u2022. We.think.that.if.these.medicines.are.effective,.then.they.have.to.be.taken.early,.preferably.within.48.\nhours.of.you.first.noticing.your.condition.and.definitely.within.72.hours.\n\u2022. So, please let us know very soon if you are happy to join the study so that treatment can commence. Preferably, tell \nthe doctor that gave you this information sheet now.\nWill there be side effects?\nAlmost.all.medicines.lead.to.occasional.side.effects,.as.well.as.helping.the.condition.for.which.they.were.\ngiven..These.\u2018side.effects\u2019.are.usually.unwanted,.but.they.are.well-known.\nFor.the.medicines.used.in.this.study.the.side.effects.may.include.sickness,.headache,.dizziness,.sleepiness.\nor.rash.\nSo, what are we saying?\nWe.cannot.guarantee.you.a.benefit.by.taking.part.in.the.study,.but.given.current.medical.knowledge,.\nyou.are.not.being.disadvantaged.by.joining.the.study,.whichever.choice.of.treatment.is.allocated.to.you..\nOther.people.in.the.future.will.be.helped.when.we.know.which.treatment.is.best..Thank.you.very.much.for.\nhelping.us.to.learn.more.about.an.effective.and.appropriate.treatment.for.patients.with.Bell\u2019s.palsy.\nFinally\u2026\nIf.at.any.time.you.would.like.additional.advice.or.consultation.whilst.you.are.on.the.study,.then.this.can.be.\nobtained.from.<.contact name and details.>..The.results.of.this.study.will.be.published.in.medical.journals..\nAn.internal.report.will.be.written.on.completion.of.the.study.in.2006.and.will.be.distributed.to.all.taking.\npart.in.it..Individuals.will.not.be.identified.in.any.report.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n87\nAppendix 9  \nForm AAppendix 9 \n88\nScottish Bell\u2019s Palsy Study \n\u2018BELLS\u2019 \n \nPatient \ncase record form \nForm A \nv.8 dated 19th April 2004 \nPatient number \n(allocated by HSRU) \n2 6 0 4  __  __  __ \n \n \nTo be completed by the consultant\/ registrar\/ SHO on arrival of any patient presenting at the \nAcute Receiving Clinic with a possible Bell\u2019s Palsy. \nSection 1    This section is to be completed for all patients. \nPatient name \ntitle  forename  surname \nAddress \n \n     \npostcode \nTelephone \nday  evening  mobile \n \nDate of birth \nday \/ month \/ year  Sex \nm\/f \nWho sent the patient here? \ne.g. GP \/ A&E \/ NHS24 \/ dentist \/ patient\u2019s own decision \/ other \nName (consultant\/registrar\/SHO) \ntitle  initial(s)  surname \n \nIn your opinion does this patient have Bell\u2019s palsy? \nyes  no \n \nIf your answer is NO, complete the next box, sign and date the form and STOP. File the form. \nOtherwise, leave the next box entirely BLANK and proceed directly to Section 2. \nDiagnosis   \nSignature and date \nsignature  date \n \nSection 2    To be completed for all patients presenting with a confirmed diagnosis of Bell\u2019s Palsy \nIs the patient already on a trial?  no  yes \nIs the patient aged 16 or more today?  no  yes \nDid the patient become aware of symptoms less than 72 hours ago?  no  yes \nCould the patient be pregnant?  no  yes \nIs the patient breast-feeding?  no  yes \nIs the patient diabetic?  no  yes \nDoes the patient have any of the following conditions? \nA systemic infection  no  yes  An active peptic ulcer  no  yes \nSuppurative otitis media  no  yes  Herpes zoster  no   yes \nMultiple sclerosis  no  yes  Sarcoidosis or a similar condition  no  yes \n DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n89\nIf any shaded box in the preceding table has been ticked, complete the next box, sign and date the form, and \nSTOP. File the form. Otherwise, leave the next box entirely BLANK and proceed directly to Section 3. \nThis patient does not fulfil the criteria for entry into the BELLS study and is excluded. \nThe treatment I have prescribed for the diagnosed condition of Bell\u2019s palsy is given here. \ntreatment prescribed \nSignature and date \nsignature  date \n \nSection 3    To be completed for all patients eligible for entry into the BELLS study \nPlease ensure the patient has read the Patient Information Sheet for the BELLS study, and has had the \nopportunity to discuss its contents with an informed person (e.g. their GP, yourself, the clinic nurse). \nIf the patient declines to enter the study, despite being eligible, complete the next box, and STOP. File the \nform. Otherwise, leave the next box entirely BLANK and proceed directly to complete the rest of the form. \nThis patient is eligible for entry to the BELLS study, but has declined. \nI have indicated the treatment I have prescribed for this patient. \nIt is not necessary for the patient to provide a reason for their decision not to enter the study, but if a \nreason was given, please record it here. \ntreatment prescribed \nreason for decision \nSignature and date \nsignature  date \n \nFor any patient agreeing to enter the study, the Consent Form provided for the BELLS study MUST be \ninitialled, signed and dated appropriately by the patient and by the consenting clinician. Then attach the \ncompleted Consent Form to this sheet of paper. Please now call the randomisation centre at HSRU on \n0800 000000 \ngiving your centre number \n2604 (Perth Royal Infirmary) \nfor the allocation of patient number and treatment. Please complete, sign and date the final box following. \nThen file both forms. \nI have telephoned HSRU at Aberdeen and given the name, address and telephone number of this \npatient and advised them that the patient is a new entry to the Scottish Bell\u2019s Palsy Study. The patient \nnumber and the treatment given to the patient is that allocated by HSRU during the call, and I have \nrecorded the patient number and allocated treatment below. \nI have supplied the patient with two bottles containing the allocated treatment. I have recorded the \npatient number on both bottles. \nPatient number (allocated by HSRU) \n \n2 6 0 4  __  __  __ \n1 or 2 or 3 or 4 \nSignature and date \nsignature  date \n DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n91\nAppendix 10  \nConsent formAppendix 10 \n92\nScottish Bell\u2019s Palsy Study  Consent Form  v.6 dated 18th November 2003 \n \n \nScottish Bell\u2019s Palsy Study \n\u2018BELLS\u2019 \nConsent Form \n  Initials \nI confirm that I have read and understand the BELLS Patient Information \nSheet, and that I have had the opportunity to ask questions. \n \n \nI understand that my participation is voluntary, and that I am free to \nwithdraw from the study at any time, without giving any reason, and \nwithout my medical care or legal rights being affected. \n \nI understand that sections of my medical notes may be looked at by \nresponsible persons associated with the study, or by regulatory authorities \nwhere it is relevant to my taking part in the research. I give permission for \nthese persons to have access to my records. \n \nI understand that I may be approached for follow-up information, after my \nfinal assessment visit, by responsible persons associated with the study, \nand I give permission for such an approach to be made. \n \nI agree to take part in the BELLS Study. \n \n \n \nName of patient (print) \n \n \nDate  Signature \nName of person taking consent (who \nshould witness the patient\u2019s signature) \n \nDate  Signature \n DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n93\nAppendix 11  \nRandomisation Service User GuideAppendix 11 \n94\nScottish Bell\u2019s Palsy Study \n\u2018BELLS\u2019 \n24-hour Randomisation Service User Guide \nThe purpose of the Bell\u2019s Palsy Study Randomisation Service run by HSRU Aberdeen is \n(i) to allocate a patient ID and (ii) to allocate a treatment \nfor patients participating in the Scottish Bell\u2019s Palsy Study. \nThe number of the Randomisation Service is 0800 000000*. Before you begin you will need your \ncentre number which is 2 6 0 3 and should have immediately available your patient\u2019s name, \naddress and telephone number. \nAfter dialling the number, the call should proceed as follows. \nPrompt  Your response \nWelcome to the Aberdeen Trials Service. Please \nenter your Centre Number or Trial ID Code.   \n2603 \nThis is the Bell\u2019s Palsy Study. Your trial centre \nis < speaks hospital name >. \nPress 1 to continue or 2 to modify.   \nExample 1 \nPlease speak the patient\u2019s name, address and \ncontact telephone number after the tone, then \npress the star key.   \nExample Mr Charles Bell, \n47 Kirsty Semple Way, \nDundee DD4 8HZ, \ntelephone 01382 420049 \n \n \nPress * \nYou said < repeats spoken patient details >. \nPress 1 to continue or 2 to modify.   \nExample 1 \nThe allocated patient number is \n< utters seven digits such as 2603011 >. \nPlease confirm the patient number by dialling it \non the telephone keypad after the tone. \n \nExample 2603011 \nThe allocated treatment is treatment number \n< utters a single digit 1 2 3 or 4 >. \nPlease confirm the treatment number by dialling \nit on the telephone keypad after the tone. \n \nExample 3 \nThank you for calling the \nBell\u2019s Palsy Study Randomisation Service. \nPlease hang up now. \nHang up \nComplete Form A \n \n \n DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n95\nWhat to do if the call fails \nIf the call fails, then during office hours you should call \n01224 000000 \/ 000000 \nfor human assistance. If this call also fails, or if the allocation is required outside office hours, then \nyou should proceed as follows. \n(i)  Do not worry about allocating the patient ID: this number will be determined later by \nthe study researcher. \n(ii)  Determine the allocated treatment by choosing at random a single digit from the list \nbelow. \n4  1  3  4  2  4  2  3  1  1  2  4  4  3  1  3  2  1  2  2  4  1  3  1  4 \n1  3  1  3  1  4  2  2  3  3  1  4  3  1  1  4  1  4  1  1  3  3  1  1  2 \n1  2  2  3  1  3  3  2  2  3  4  4  1  3  4  2  1  2  3  2  2  3  1  3  2 \n4  4  2  3  4  4  2  3  3  2  1  2  3  2  1  3  2  3  2  1  3  3  3  2  3 \n4  3  3  1  2  4  3  4  3  3  3  3  1  4  3  2  1  2  4  1  3  3  2  3  1 \n2  1  1  2  4  2  3  2  2  2  3  4  1  3  2  3  1  4  3  2  2  1  3  3  4 \n4  4  1  2  4  3  1  2  1  3  2  2  2  3  2  4  1  4  3  4  2  1  3  3  3 \n1  2  1  3  2  1  4  3  1  4  2  3  1  4  2  1  1  4  2  1  2  1  1  3  2 \n3  2  3  3  3  4  3  4  4  4  1  2  1  2  1  3  1  2  2  1  4  3  2  1  2 \n2  1  3  2  1  4  4  1  3  2  3  2  2  4  3  4  1  4  3  3  4  4  1  1  3 \n1  3  2  4  1  2  2  3  3  1  4  2  3  2  1  4  4  1  4  4  4  4  4  2  1 \n1  1  2  4  3  1  1  1  1  1  1  3  4  4  2  4  2  4  2  1  1  2  3  4  1 \n2  2  2  4  4  4  3  1  1  3  4  2  3  4  3  1  3  1  4  2  3  2  1  1  2 \n3  1  1  3  1  1  1  1  4  1  3  2  2  3  2  1  2  3  3  1  2  3  1  3  3 \n3  1  2  1  4  4  2  4  1  2  1  2  2  4  1  4  3  2  4  2  1  3  2  4  4 \n1  4  3  3  1  1  3  1  2  4  3  2  2  2  2  2  4  1  3  3  2  4  3  1  4 \n4  1  1  1  3  4  1  2  4  4  3  2  2  3  4  1  2  2  4  4  1  1  3  1  4 \n2  2  4  3  4  3  4  1  2  3  4  1  1  1  3  3  4  3  2  2  2  1  4  4  2 \n2  1  2  1  2  3  4  3  3  3  3  1  4  4  2  2  4  4  2  4  1  4  4  1  4 \n3  2  2  1  4  2  1  3  3  1  4  2  2  3  4  2  4  2  2  3  2  4  1  3  3 \n \n(iii)  Please advise the BELLS Coordinator IMMEDIATELY that a new patient has been \nrecruited, and provide the patient\u2019s name, address and telephone number: \nf.daly@tcgp.dundee.ac.uk \n01382 000000 (W) \/ 01738 000000 (H) \/ 0771 000 0000 (M) DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n97\nAppendix 12  \nRecruiters\u2019 notesAppendix 12 \n98\nYou.probably.already.know.that.your.hospital.is.one.of.17.sites.in.Scotland.that.is.contributing.to.a.\nNHS-funded.national.study,.aimed.at.establishing.once.and.for.all.the.effectiveness.or.otherwise.of.\nprednisolone\/aciclovir.separately.or.in.combination.as.treatments.for.Bell\u2019s.palsy.\nThe.stationery.for.the.study\n\u2022. patient.information.sheet.(for.issue)\n\u2022. patient.case.record.form.(\u2018Form.A\u2019,.for.completion.and.filing)\n\u2022. consent.form.(for.signature.and.filing)\nis.already.provided.at.your.site,.as.are.the.medications,.labelled\n\u2022. Treatment.1.or.2.or.3.or.4\nThere.is.also.a\n\u2022. laminated.telephone.dialling.instruction.sheet\nexplaining.the.procedures.for.registration.and.randomisation.to.treatment..If.a.patient.with.suspected.\nBell\u2019s.palsy.presents.at.your.clinic.(usually.though.not.necessarily.as.a.referral.from.their.GP).then.please.\nexplain.that.this.important.national.study.is.in.progress,.and\n\u2022. complete.Form.A.(confirmation.of.diagnosis,.inclusions\/exclusions)\n\u2022. if.patient.is.eligible.and.interested,.issue.Patient.Information.Sheet\n\u2022. if.appropriate,.get.signatures.on.Consent.Form\nthen\n\u2022. complete.registration.and.randomisation.to.treatment\nby\n\u2022. dialling.HSRU.at.0800.000000.and.following.instructions\nTwo things might go wrong:\n\u2022. If for some reason the allocated treatment pack is not available to you, please do not make a 2nd call to HSRU; \nsimply allocate at random from the treatments available to you and note your decision on Form A.\n\u2022. If the call fails altogether, then again please simply allocate at random from the treatments available to you and \nnote your decision on Form A.\nIn.either.case.and.as.soon.as.you.can,.please.telephone.the.study.co-ordinator.on\n01382 000000 (W)  0771 000 000 (M)  01738 000000 (H)\nand.say.what.has.happened.\nFinally,.please\nissue.designated.treatment.and commence dose immediatelyDOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n99\nAppendix 13  \nWeekly recruitment update (example)Appendix 13 \n100\nDear.PIs,.RAs:\nBELLS: weekly recruitment update\nWeek number 81 (16.12.2005 \u2013 23.12.2005)\nof.108.recruitment.weeks..The.current.figures.for.the.BELLS.study.are.always.to.be.found.at.http:\/\/www.\ndundee.ac.uk\/bells\/index_files\/stoppress.htm.\nPart 1 Recruitment \nThe.cumulative.regional.figures.showing.last.week\u2019s.recruits.are\nGrampian and Highland  + 2 76\nTayside and Fife  + 0 67\nLothian and Borders  + 1 73\nGlasgow and the West  + 3 198\nTotal  + 6 414\nof.which.M.:.F.=.209.:.205.\nFIGURE 1  Weekly recruitment figures showing underlying recruitment rate.\nCactus Design and Illustration Ltd\nFigure Number: 22.ai   Title: 02-09-04 Proof Stage:  2\nActual\nTrend\n0 20 40 60 80\nWeeks\nN\nu\nm\nb\ne\nr\n \no\nf\n \np\na\nt\ni\ne\nn\nt\ns\n0\n1\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n2\nPart 2 Retention and adherence to target\nThere.were.0.patients.lost.to.follow-up.this.week..Since.the.start.of.the.project.23.patients.have.been.LTF,.\nso.there.are.391.patients.\u2018live\u2019.on.the.study..The.study.is.currently\n1 patient below target\/1 day behind schedule.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n101\nSeasonal comparison:.average.recruitment.over.the.last.month.is.6.1 pts\/week;.cf..the.same.period.last.year:.\n8.0 pts\/week.\nThe.next.figure.shows.current.retention.and.our.final.target.\nFIGURE 2  Retention and target.\nCactus Design and Illustration Ltd\nFigure Number: 23.ai   Title: 02-09-04 Proof Stage:  2\nActual\nTrend\nTarget\nWeeks\nN\nu\nm\nb\ne\nr\n \no\nf\n \np\na\nt\ni\ne\nn\nt\ns\n500\n400\n300\n200\n100\n0\n0 20 40 60 80 100\nPart 3 Patients missed\nThere.were.2.missed.cases.advised.to.us.this.week.(one.herpes.zoster;.in.the.other.case.a.locum.GP.\nstarted.steroid.treatment.and.told.the.patient.to.go.home.and.phone.me..Which.she.did,.to.some.mutual.\nconfusion)..The.total.number.of.missed.patients.(incl..87.found.at.ENT.to.have.exclusions).is.155.\nPart 4 Snapshot\nActivity.this.week:.6.recruits,.6.V1s,.2.V2s,.0.V3s,.0.LTF.Appendix 13 \n102\nPart 5 Status of the study\nRecruited, awaiting V1  3\nV1 made, awaiting V2  70\nV2 made, awaiting V2HB  90\nV2HB known, V3 not necessary  150\nV2HB known, awaiting V3  0\nV3 made, awaiting V3HB  42\nV3HB known  27\nNot easily classified*  9\nSubtotal  391\nLTF 23\nTotal  414\n*.At.any.one.time.there.is.a.small.number.of.patients.whose.status.is.not.easily.classified,.mainly.through.a.\nfailure.to.agree.appointments.or.through.other.communication.difficulties.\nThe.number.of.completed patients.is.150.+.27.=.177.\nFergus\nDr.Fergus.Daly\nCoordinator,.Scottish.Bell\u2019s.Palsy.Study\nTayside.Centre.for.General.Practice\nUniversity.of.Dundee.Kirsty.Semple.Way\nDundee\nDD2.4BF,.Scotland\ntel.01382.000000.(direct).000000.(secretary).000000.(reception)\nfax.01382.000000\ntel.01738.000000.(home).07715.000000.(mobile)\nemail.f.daly@tcgp.dundee.ac.uk\nproject.email.bells@tcgp.dundee.ac.uk\nproject.web.http:\/\/www.dundee.ac.uk\/bells\/DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n103\nAppendix 14  \nBriefing notes for researchersAppendix 14 \n104\nWhat happens after a new randomisation\nWhen.the.doctor.telephoned.the.HSRU.computer.in.Aberdeen.at.the.time.of.a.patient\u2019s.hospital.visit.in.\norder.to.register.the.patient.and.to.be.told.what.treatment.to.offer,.a.number.of.other.events.were.set.in.\ntrain.behind.the.scenes..The.Aberdeen.computer.immediately.sent.an.automatic.email.to.the.study.co-\nordinator.in.Dundee,.copied.to.all.the.other.three.RAs..This.email.includes.an.electronic.recording.of.the.\npatient\u2019s.personal.details.(name,.address.and.contact.telephone.number).as.reported.by.the.doctor.during.\nthe.telephone.call.\nIf.the.arrival.took.place.at.one.of.\u2018your\u2019.hospitals,.then,.you.will.be.alerted.to.this.fact.either.by.reading.the.\nemail.or,.if.the.co-ordinator.sees.the.message.before.you.do,.he.will.contact.you.by.phone.to.alert.you.to.\nthe.new.arrival..Once.you.know.that.a.new.arrival.is.\u2018yours\u2019.please\nadvise the other RAs by email that you have picked up responsibility for the call\ncontact the patient and arrange your first visit\nAt.this.first.visit.you.will.need.to\ncomplete Form B\nget the patient to complete three questionnaires\ntake 4 posed photographs\ntogether.with.other.minor.tasks.listed.at.Form.C,.which.is.your.checklist.\nTaking the photographs\nPlease.use.the.green.background.supplied..It.is.convenient.and.aids.uniformity.in.the.poses.if.the.patient.\nis.seated.in.front.of.it..(One.idea.that.seems.to.work.is.sticking.the.background.to.the.back.of.a.door.and.\nplacing.a.chair.appropriately.).The.tripod.will.aid.steadiness.and.clarity.of.the.images..Please.set.the.\ncamera.as.follows..Settings.1.to.5.can.be.set.beforehand.and.will.remain.set.thereafter..Unfortunately.\nsetting.6.needs.to.be.attended.to.at.each.use.\nResolution:.1280.\u00d7.960\nMacro.(the.\u2018flower\u2019.setting):.No\nRedeye.reduction:.Yes\nFlash:.Automatic.(camera.decides)\nDate\/time:.No\nand\nZoom:.suggest.3.0,.but.local.conditions.may.varyDOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n105\nIf.there.is.a.source.of.daylight.(e.g..a.window).try.to.place.the.patient.so.that.they.are.facing.the.source.\nand.you.have.your.back.to.it..Then.the.photograph.should.be.taken.as.though.for.a.passport.(portrait.not.\nlandscape,.some.clearance.around.the.face)..You.will.find.that.you.are.quite.close.to.the.subject.but.they.\nshould.not.find.this.too.oppressive.\nThe.required.poses.are\n1.. at.rest.(eyes.open,.no.expression)\n2.. smiling\n3.. eyes.tight.shut,.clenched\n4.. raised.eyebrows\nNote:.all.of.poses.2\u20134.are.highly exaggerated,.\u2018forced\u2019..(Quite.tiring.if.you.try.it.yourself.)\nLater,.please.download.the.images.to.your.computer.for.onward.communication.to.TCGP..Please.label.the.\n.jpg.files.as.shown.in.the.following.example,.showing.the.study.title,.patient.ID,.date,.visit.number.and.\npose:\nBELLS. ID2708033. 20040518. V2. Pose3.jpg\nIf.you.are.uncertain\/unhappy.with.any.of.the.poses.then.it.is.OK.to.send.more.than.one,.but.we.should.try.\nnot.to.send.more.than.two..In.such.a.case.please.call.the.pose.numbers.Pose3a.and.Pose3b.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n107\nAppendix 15  \nForm CAppendix 15\n108\nScottish Bell\u2019s Palsy Study \n\u2018BELLS\u2019 \nResearcher\u2019s \ncheck list \nForm C \nPatient number \n(allocated by HSRU) \n2  6  __  __  __  __  __   \n \nTo be completed by the researcher at (or soon after) all assessment visits including the first \nThe following should occur as soon as possible after notification of recruitment \nCopy Form A and Consent Form at site; extract originals and leave copy \nVisit number and date and approx duration \nThe following should occur during your visit \nHUI3 completed (all visits)  DAS59 completed (all visits) \nBPI completed (all visits)  4 poses photographed (all visits) \nProvide own contact details (V1)  Issue stamped Jiffy bag (V1) \nCheck labelling on bottle (V1)  Arrange next appointment (V1 and V2) \nThe following should occur as soon as possible after your visit is completed \nLetter to GP \nLetter to patient (acknowledgement of recruitment\/ cooperation; reminder of next appt) \nHUI3 copied and stored locally, original despatched to TCGP \nBPI copied and stored locally, original despatched to TCGP \nDAS59 copied and stored locally, original despatched to TCGP \nPhotographs emailed to TCGP \nj.sutherland@dundee.ac.uk \nThe following should occur after Visit 1 \nPhone call to patient (day 4\u20136 as convenient: compliance; well-being) \nPhone call to patient (day 10, to confirm end of treatment; \u2018Jiffy bag\u2019 reminder; well-being) \n \n \nSummary of paper management \nAfter Visit 1  despatch originals of Form A, Consent Form and Form B to TCGP, keep copies \n \nAfter all visits  send letters to GP and patient, keep copies \n    despatch original completed questionnaires to TCGP, keep copies \n    email photographs to TCGP DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n109\nAppendix 16  \nForm BAppendix 16 \n110\nScottish Bell\u2019s Palsy Study \n\u2018BELLS\u2019 \nPatient \nvisit record \nForm B \nPatient number \n(allocated by HSRU) \n2  6  __  __  __  __  __   \n \nTo be completed by the researcher at the patient\u2019s first assessment visit \ntitle  used name  surname \nName \nall forenames \nPersonal details \nsex  date of birth \nmarital status \nmother\u2019s maiden name \nOther details required for \nGeneral Register Office \nfor Scotland \nany previous surnames \naddress \n \n \n \n \npostcode \nContact details \nprevious address and postcode if present < 3 years \n \n \n \n \nTelephone numbers  work \n \nhome \n \nmobile \n \nEmail address   \nConsent details \ndate of consent  age at consent \nDetails of onset \ndate \/ time (approx)  symptoms \nGP\u2019s name and address \n \n \n \n \n \nTreatment interval \nstart date  end date \nArrangements for 3-\nmonth visit \ndate \/ time  place \nResearcher \nname  today\u2019s date DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n111\nMr.Iain.Swan,.Glasgow.Royal.Infirmary\nDr.Richard.Davenport,.Western.General.Hospital,.Edinburgh\nMr.Ken.Stewart,.St.John\u2019s.Hospital,.Livingston\nAppendix 17  \nHouse\u2013Brackmann AssessorsDOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n113\nAppendix 18  \nHealth Utilities Index Mark 3Appendix 18 \n114\n \nScottish Bell\u2019s Palsy Study \n \nHEALTH  UTILITIES  INDEX: \n \nMulti-Attribute Health Status Classification System \nHealth Utilities Index Mark 3 (HUI3) \n \n \n \n \nPatient name     \n \nPatient ID    _ _ _ _ _ _ _  \n \nDate     \n \nAssessment visit no.     \n \nResearcher     \n \n \nFor the given attribute, circle the most appropriate level. \nProvide only one answer for each attribute \n \nVISION \n \n1  Able to see well enough to read ordinary newsprint and recognize a friend on \nthe other side of the street, without glasses or contact lenses. \n2  Able to see well enough to read ordinary newsprint and recognize a friend on \nthe other side of the street, but with glasses. \n3  Able to read ordinary newsprint with or without glasses but unable to recognize \na friend on the other side of the street, even with glasses. \n4  Able to recognize a friend on the other side of the street with or without glasses \nbut unable to read ordinary newsprint, even with glasses. \n5  Unable to read ordinary newsprint and unable to recognize a friend on the other \nside of the street, even with glasses. \n6  Unable to see at all. \n DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n115\n \nHEARING \n \n1  Able to hear what is said in a group conversation with at least three other \npeople, without a hearing aid. \n2  Able to hear what is said in a conversation with one other person in a quiet \nroom without a hearing aid, but require a hearing aid to hear what is said in a \ngroup conversation with at least three other people. \n3  Able to hear what is said in a conversation with one other person in a quiet \nroom with a hearing aid, and able to hear what is said in a group conversation \nwith at least three other people, with a hearing aid. \n4  Able to hear what is said in a conversation with one other person in a quiet \nroom, without a hearing aid, but unable to hear what is said in a group \nconversation with at least three other people even with a hearing aid.  \n5  Able to hear what is said in a conversation with one other person in a quiet \nroom with a hearing aid, but unable to hear what is said in a group conversation \nwith at least three other people even with a hearing aid. \n6  Unable to hear at all. \n \n \nSPEECH \n \n1  Able to be understood completely when speaking with strangers or friends. \n2  Able to be understood partially when speaking with strangers but able to be \nunderstood completely when speaking with people who know me well. \n3  Able to be understood partially when speaking with strangers or people who \nknow me well. \n4  Unable to be understood when speaking with strangers but able to be \nunderstood partially by people who know me well. \n5  Unable to be understood when speaking to other people (or unable to speak at \nall). \n Appendix 18 \n116\n \nAMBULATION \n \n1  Able to walk around the neighbourhood without difficulty, and without walking \nequipment. \n2  Able to walk around the neighbourhood with difficulty; but do not require \nwalking equipment or the help of another person. \n3  Able to walk around the neighbourhood with walking equipment, but without \nthe help of another person. \n4  Able to walk only short distances with walking equipment, and require a \nwheelchair to get around the neighbourhood. \n5  Unable to walk alone, even with walking equipment. Able to walk short \ndistances with the help of another person, and require a wheelchair to get \naround the neighbourhood. \n6  Cannot walk at all. \n \n \nDEXTERITY \n \n1  Full use of two hands and ten fingers. \n2  Limitations in the use of hands or fingers, but do not require special tools or \nhelp of another person. \n3  Limitations in the use of hands or fingers, independent with use of special tools \n(do not require the help of another person). \n4  Limitations in the use of hands or fingers, require the help of another person for \nsome tasks (not independent even with use of special tools). \n5  Limitations in use of hands or fingers, require the help of another person for \nmost tasks (not independent even with use of special tools). \n6  Limitations in use of hands or fingers, require the help of another person for all \ntasks (not independent even with use of special tools). \n DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n117\n \nEMOTION \n \n1  Happy and interested in life. \n2  Somewhat happy. \n3  Somewhat unhappy. \n4  Very unhappy. \n5  So unhappy that life is not worthwhile. \n \n \nCOGNITION \n \n1  Able to remember most things, think clearly and solve day to day problems. \n2  Able to remember most things, but have a little difficulty when trying to think \nand solve day to day problems. \n3  Somewhat forgetful, but able to think clearly and solve day to day problems. \n4  Somewhat forgetful, and have a little difficulty when trying to think or solve \nday to day problems. \n5  Very forgetful, and have great difficulty when trying to think or solve day to \nday problems. \n6  Unable to remember anything at all, and unable to think or solve day to day \nproblems. \n \n \nPAIN \n \n1  Free of pain and discomfort. \n2  Mild to moderate pain that prevents no activities. \n3  Moderate pain that prevents a few activities. \n4  Moderate to severe pain that prevents some activities. \n5  Severe pain that prevents most activities. \n DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n119\nAppendix 19  \nBrief Pain InventoryAppendix 19 \n120\n \n \n \nS\nc\no\nt\nt\ni\ns\nh\n \nB\ne\nl\nl\n\u2019\ns\n \nP\na\nl\ns\ny\n \nS\nt\nu\nd\ny\n \n \nB\nr\ni\ne\nf\n \nP\na\ni\nn\n \nI\nn\nv\ne\nn\nt\no\nr\ny\n \n(\nS\nh\no\nr\nt\n \nF\no\nr\nm\n)\n \n \nP\na\nt\ni\ne\nn\nt\n \nn\na\nm\ne\n \n \n \n \nP\na\nt\ni\ne\nn\nt\n \nI\nD\n \n \n \n_\n_\n \n \n_\n_\n \n \n_\n_\n \n \n_\n_\n \n \n_\n_\n \n \n_\n_\n \n \n_\n_\n \nD\na\nt\ne\n \n \n \n\/\n \n \n \n \n \n \n \n \n\/\n \n \n \n \n \n \n \n \n \nA\ns\ns\ne\ns\ns\nm\ne\nn\nt\n \nv\ni\ns\ni\nt\n \n(\n1\n \n\/\n \n2\n \n\/\n \n3\n)\n \n \n \n_\n_\n_\n_\n \nR\ne\ns\ne\na\nr\nc\nh\ne\nr\n \nn\na\nm\ne\n \n \n \n \n \nT\nh\ne\n \nf\no\nl\nl\no\nw\ni\nn\ng\n \nq\nu\ne\ns\nt\ni\no\nn\ns\n \na\ns\nk\n \na\nb\no\nu\nt\n \nh\no\nw\n \nm\nu\nc\nh\n \np\na\ni\nn\n \ny\no\nu\n \nh\na\nv\ne\n \nb\ne\ne\nn\n \ne\nx\np\ne\nr\ni\ne\nn\nc\ni\nn\ng\n.\n \nP\nl\ne\na\ns\ne\n \na\nn\ns\nw\ne\nr\n \ne\nv\ne\nr\ny\n \nq\nu\ne\ns\nt\ni\no\nn\n \nb\ny\n \nm\na\nr\nk\ni\nn\ng\n \ni\nt\n \na\ns\n \ni\nn\nd\ni\nc\na\nt\ne\nd\n.\n \n \nQ\nu\ne\ns\nt\ni\no\nn\n \n1\n \nT\nh\nr\no\nu\ng\nh\no\nu\nt\n \no\nu\nr\n \nl\ni\nv\ne\ns\n,\n \nm\no\ns\nt\n \no\nf\n \nu\ns\n \nh\na\nv\ne\n \nh\na\nd\n \np\na\ni\nn\n \nf\nr\no\nm\n \nt\ni\nm\ne\n \nt\no\n \nt\ni\nm\ne\n \n(\ns\nu\nc\nh\n \na\ns\n \nm\ni\nn\no\nr\n \nh\ne\na\nd\na\nc\nh\ne\ns\n,\n \ns\np\nr\na\ni\nn\ns\n \na\nn\nd\n \nt\no\no\nt\nh\na\nc\nh\ne\ns\n)\n.\n \nH\na\nv\ne\n \ny\no\nu\n \nh\na\nd\n \np\na\ni\nn\n \no\nt\nh\ne\nr\n \nt\nh\na\nn\n \nt\nh\ne\ns\ne\n \ne\nv\ne\nr\ny\nd\na\ny\n \nk\ni\nn\nd\ns\n \no\nf\n \np\na\ni\nn\n \nA\nN\nD\n \nT\nH\nA\nT\n \nY\nO\nU\n \nA\nT\nT\nR\nI\nB\nU\nT\nE\n \nT\nO\n \nY\nO\nU\nR\n \nB\nE\nL\nL\n\u2019\nS\n \nP\nA\nL\nS\nY\n \ni\nn\n \nt\nh\ne\n \np\na\ns\nt\n \n2\n4\n \nh\no\nu\nr\ns\n?\n \nP\nl\ne\na\ns\ne\n \nt\ni\nc\nk\n.\n \nY\ne\ns\n \n \n \n \nN\no\n \n \n \n \n \nO\nn\nl\ny\n \ni\nf\n \ny\no\nu\nr\n \na\nn\ns\nw\ne\nr\n \ni\ns\n \nY\ne\ns\n \np\nr\no\nc\ne\ne\nd\n \nt\no\n \nt\nh\ne\n \nr\ne\ns\nt\n \no\nf\n \nt\nh\ne\n \nq\nu\ne\ns\nt\ni\no\nn\nn\na\ni\nr\ne\n.\n \n \n \n \n \nF\no\nr\n \nQ\nu\ne\ns\nt\ni\no\nn\ns\n \n2\n \nt\no\n \n5\n \nc\ni\nr\nc\nl\ne\n \no\nn\ne\n \nn\nu\nm\nb\ne\nr\n \no\nn\nl\ny\n \nf\nr\no\nm\n \n0\n \n(\nN\nO\n \nP\nA\nI\nN\n)\n \nt\no\n \n1\n0\n \n(\nP\nA\nI\nN\n \nA\nS\n \nB\nA\nD\n \nA\nS\n \nY\nO\nU\n \nC\nA\nN\n \nI\nM\nA\nG\nI\nN\nE\n)\n \n \nQ\nu\ne\ns\nt\ni\no\nn\n \n2\n \nP\nl\ne\na\ns\ne\n \nr\na\nt\ne\n \ny\no\nu\nr\n \np\na\ni\nn\n \nb\ny\n \nc\ni\nr\nc\nl\ni\nn\ng\n \nt\nh\ne\n \no\nn\ne\n \nn\nu\nm\nb\ne\nr\n \nt\nh\na\nt\n \nb\ne\ns\nt\n \nd\ne\ns\nc\nr\ni\nb\ne\ns\n \ny\no\nu\nr\n \np\na\ni\nn\n \nA\nT\n \nI\nT\nS\n \nW\nO\nR\nS\nT\n \ni\nn\n \nt\nh\ne\n \nl\na\ns\nt\n \n2\n4\n \nh\no\nu\nr\ns\n.\n \n0\n \n \n \n \n \n \n \n \n1\n \n \n \n \n \n \n \n \n2\n \n \n \n \n \n \n \n \n3\n \n \n \n \n \n \n \n \n4\n \n \n \n \n \n \n \n \n5\n \n \n \n \n \n \n \n \n6\n \n \n \n \n \n \n \n \n7\n \n \n \n \n \n \n \n \n8\n \n \n \n \n \n \n \n \n9\n \n \n \n \n \n \n \n \n1\n0\n \n \nQ\nu\ne\ns\nt\ni\no\nn\n \n3\n \nP\nl\ne\na\ns\ne\n \nr\na\nt\ne\n \ny\no\nu\nr\n \np\na\ni\nn\n \nb\ny\n \nc\ni\nr\nc\nl\ni\nn\ng\n \nt\nh\ne\n \no\nn\ne\n \nn\nu\nm\nb\ne\nr\n \nt\nh\na\nt\n \nb\ne\ns\nt\n \nd\ne\ns\nc\nr\ni\nb\ne\ns\n \ny\no\nu\nr\n \np\na\ni\nn\n \nA\nT\n \nI\nT\nS\n \nL\nE\nA\nS\nT\n \ni\nn\n \nt\nh\ne\n \nl\na\ns\nt\n \n2\n4\n \nh\no\nu\nr\ns\n.\n \n0\n \n \n \n \n \n \n \n \n1\n \n \n \n \n \n \n \n \n2\n \n \n \n \n \n \n \n \n3\n \n \n \n \n \n \n \n \n4\n \n \n \n \n \n \n \n \n5\n \n \n \n \n \n \n \n \n6\n \n \n \n \n \n \n \n \n7\n \n \n \n \n \n \n \n \n8\n \n \n \n \n \n \n \n \n9\n \n \n \n \n \n \n \n \n1\n0\n \n \nQ\nu\ne\ns\nt\ni\no\nn\n \n4\n \nP\nl\ne\na\ns\ne\n \nr\na\nt\ne\n \ny\no\nu\nr\n \np\na\ni\nn\n \nb\ny\n \nc\ni\nr\nc\nl\ni\nn\ng\n \nt\nh\ne\n \no\nn\ne\n \nn\nu\nm\nb\ne\nr\n \nt\nh\na\nt\n \nb\ne\ns\nt\n \nd\ne\ns\nc\nr\ni\nb\ne\ns\n \ny\no\nu\nr\n \np\na\ni\nn\n \nO\nN\n \nA\nV\nE\nR\nA\nG\nE\n \nd\nu\nr\ni\nn\ng\n \nt\nh\ne\n \nl\na\ns\nt\n \n2\n4\n \nh\no\nu\nr\ns\n.\n \n0\n \n \n \n \n \n \n \n \n1\n \n \n \n \n \n \n \n \n2\n \n \n \n \n \n \n \n \n3\n \n \n \n \n \n \n \n \n4\n \n \n \n \n \n \n \n \n5\n \n \n \n \n \n \n \n \n6\n \n \n \n \n \n \n \n \n7\n \n \n \n \n \n \n \n \n8\n \n \n \n \n \n \n \n \n9\n \n \n \n \n \n \n \n \n1\n0\n \n \nQ\nu\ne\ns\nt\ni\no\nn\n \n5\n \nP\nl\ne\na\ns\ne\n \nr\na\nt\ne\n \ny\no\nu\nr\n \np\na\ni\nn\n \nb\ny\n \nc\ni\nr\nc\nl\ni\nn\ng\n \nt\nh\ne\n \no\nn\ne\n \nn\nu\nm\nb\ne\nr\n \nt\nh\na\nt\n \nt\ne\nl\nl\ns\n \nh\no\nw\n \nm\nu\nc\nh\n \np\na\ni\nn\n \ny\no\nu\n \nh\na\nv\ne\n \nR\nI\nG\nH\nT\n \nN\nO\nW\n.\n \n0\n \n \n \n \n \n \n \n \n1\n \n \n \n \n \n \n \n \n2\n \n \n \n \n \n \n \n \n3\n \n \n \n \n \n \n \n \n4\n \n \n \n \n \n \n \n \n5\n \n \n \n \n \n \n \n \n6\n \n \n \n \n \n \n \n \n7\n \n \n \n \n \n \n \n \n8\n \n \n \n \n \n \n \n \n9\n \n \n \n \n \n \n \n \n1\n0\n DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n121\n \n \n \nF\no\nr\n \nQ\nu\ne\ns\nt\ni\no\nn\ns\n \n6\n \nt\no\n \n1\n2\n \nc\ni\nr\nc\nl\ne\n \no\nn\ne\n \nn\nu\nm\nb\ne\nr\n \no\nn\nl\ny\n \nt\nh\na\nt\n \nd\ne\ns\nc\nr\ni\nb\ne\ns\n \nh\no\nw\n \nD\nU\nR\nI\nN\nG\n \nT\nH\nE\n \nL\nA\nS\nT\n \n2\n4\n \nH\nO\nU\nR\nS\n \ny\no\nu\nr\n \np\na\ni\nn\n \nh\na\ns\n \ni\nn\nt\ne\nr\nf\ne\nr\ne\nd\n \nw\ni\nt\nh\n \ny\no\nu\nr\n \nl\ni\nf\ne\n \nf\nr\no\nm\n \n0\n \n(\nD\nO\nE\nS\n \nN\nO\nT\n \nI\nN\nT\nE\nR\nF\nE\nR\nE\n)\n \nt\no\n \n1\n0\n \n(\nI\nN\nT\nE\nR\nF\nE\nR\nE\nS\n \nC\nO\nM\nP\nL\nE\nT\nE\nL\nY\n)\n \n \nQ\nu\ne\ns\nt\ni\no\nn\n \n6\n \n \n \n \nG\ne\nn\ne\nr\na\nl\n \na\nc\nt\ni\nv\ni\nt\ny\n \n \n0\n \n \n \n \n \n \n \n \n1\n \n \n \n \n \n \n \n \n2\n \n \n \n \n \n \n \n \n3\n \n \n \n \n \n \n \n \n4\n \n \n \n \n \n \n \n \n5\n \n \n \n \n \n \n \n \n6\n \n \n \n \n \n \n \n \n7\n \n \n \n \n \n \n \n \n8\n \n \n \n \n \n \n \n \n9\n \n \n \n \n \n \n \n \n1\n0\n \n \nQ\nu\ne\ns\nt\ni\no\nn\n \n7\n \n \n \n \nM\no\no\nd\n \n \n0\n \n \n \n \n \n \n \n \n1\n \n \n \n \n \n \n \n \n2\n \n \n \n \n \n \n \n \n3\n \n \n \n \n \n \n \n \n4\n \n \n \n \n \n \n \n \n5\n \n \n \n \n \n \n \n \n6\n \n \n \n \n \n \n \n \n7\n \n \n \n \n \n \n \n \n8\n \n \n \n \n \n \n \n \n9\n \n \n \n \n \n \n \n \n1\n0\n \n \nQ\nu\ne\ns\nt\ni\no\nn\n \n8\n \n \n \n \nW\na\nl\nk\ni\nn\ng\n \na\nb\ni\nl\ni\nt\ny\n \n \n0\n \n \n \n \n \n \n \n \n1\n \n \n \n \n \n \n \n \n2\n \n \n \n \n \n \n \n \n3\n \n \n \n \n \n \n \n \n4\n \n \n \n \n \n \n \n \n5\n \n \n \n \n \n \n \n \n6\n \n \n \n \n \n \n \n \n7\n \n \n \n \n \n \n \n \n8\n \n \n \n \n \n \n \n \n9\n \n \n \n \n \n \n \n \n1\n0\n \n \nQ\nu\ne\ns\nt\ni\no\nn\n \n9\n \n \n \n \nN\no\nr\nm\na\nl\n \nw\no\nr\nk\n \n(\ni\nn\nc\nl\nu\nd\ne\ns\n \nb\no\nt\nh\n \nw\no\nr\nk\n \no\nu\nt\ns\ni\nd\ne\n \nt\nh\ne\n \nh\no\nm\ne\n \na\nn\nd\n \nh\no\nu\ns\ne\nw\no\nr\nk\n)\n \n \n0\n \n \n \n \n \n \n \n \n1\n \n \n \n \n \n \n \n \n2\n \n \n \n \n \n \n \n \n3\n \n \n \n \n \n \n \n \n4\n \n \n \n \n \n \n \n \n5\n \n \n \n \n \n \n \n \n6\n \n \n \n \n \n \n \n \n7\n \n \n \n \n \n \n \n \n8\n \n \n \n \n \n \n \n \n9\n \n \n \n \n \n \n \n \n1\n0\n \n \n \n \n \nR\ne\nm\ne\nm\nb\ne\nr\n,\n \nf\no\nr\n \nt\nh\ne\ns\ne\n \nq\nu\ne\ns\nt\ni\no\nn\ns\n \nc\ni\nr\nc\nl\ne\n \no\nn\ne\n \nn\nu\nm\nb\ne\nr\n \no\nn\nl\ny\n \nt\nh\na\nt\n \nd\ne\ns\nc\nr\ni\nb\ne\ns\n \nh\no\nw\n \nD\nU\nR\nI\nN\nG\n \nT\nH\nE\n \nL\nA\nS\nT\n \n2\n4\n \nH\nO\nU\nR\nS\n \ny\no\nu\nr\n \np\na\ni\nn\n \nh\na\ns\n \ni\nn\nt\ne\nr\nf\ne\nr\ne\nd\n \nw\ni\nt\nh\n \ny\no\nu\nr\n \nl\ni\nf\ne\n \nf\nr\no\nm\n \n0\n \n(\nD\nO\nE\nS\n \nN\nO\nT\n \nI\nN\nT\nE\nR\nF\nE\nR\nE\n)\n \nt\no\n \n1\n0\n \n(\nI\nN\nT\nE\nR\nF\nE\nR\nE\nS\n \nC\nO\nM\nP\nL\nE\nT\nE\nL\nY\n)\n \n \nQ\nu\ne\ns\nt\ni\no\nn\n \n1\n0\n \n \n \n \nR\ne\nl\na\nt\ni\no\nn\ns\n \nw\ni\nt\nh\n \no\nt\nh\ne\nr\n \np\ne\no\np\nl\ne\n \n \n0\n \n \n \n \n \n \n \n \n1\n \n \n \n \n \n \n \n \n2\n \n \n \n \n \n \n \n \n3\n \n \n \n \n \n \n \n \n4\n \n \n \n \n \n \n \n \n5\n \n \n \n \n \n \n \n \n6\n \n \n \n \n \n \n \n \n7\n \n \n \n \n \n \n \n \n8\n \n \n \n \n \n \n \n \n9\n \n \n \n \n \n \n \n \n1\n0\n \n \nQ\nu\ne\ns\nt\ni\no\nn\n \n1\n1\n \n \n \n \nS\nl\ne\ne\np\n \n \n0\n \n \n \n \n \n \n \n \n1\n \n \n \n \n \n \n \n \n2\n \n \n \n \n \n \n \n \n3\n \n \n \n \n \n \n \n \n4\n \n \n \n \n \n \n \n \n5\n \n \n \n \n \n \n \n \n6\n \n \n \n \n \n \n \n \n7\n \n \n \n \n \n \n \n \n8\n \n \n \n \n \n \n \n \n9\n \n \n \n \n \n \n \n \n1\n0\n \n \nQ\nu\ne\ns\nt\ni\no\nn\n \n1\n2\n \n \n \n \nE\nn\nj\no\ny\nm\ne\nn\nt\n \no\nf\n \nl\ni\nf\ne\n \n \n0\n \n \n \n \n \n \n \n \n1\n \n \n \n \n \n \n \n \n2\n \n \n \n \n \n \n \n \n3\n \n \n \n \n \n \n \n \n4\n \n \n \n \n \n \n \n \n5\n \n \n \n \n \n \n \n \n6\n \n \n \n \n \n \n \n \n7\n \n \n \n \n \n \n \n \n8\n \n \n \n \n \n \n \n \n9\n \n \n \n \n \n \n \n \n1\n0\n \n \n \n \n \nT\nh\na\nn\nk\n \ny\no\nu\n \nv\ne\nr\ny\n \nm\nu\nc\nh\n \nf\no\nr\n \nh\ne\nl\np\ni\nn\ng\n \nu\ns\n \nb\ny\n \np\nr\no\nv\ni\nd\ni\nn\ng\n \ny\no\nu\nr\n \na\nn\ns\nw\ne\nr\ns\n \nt\no\n \nt\nh\ni\ns\n \nq\nu\ne\ns\nt\ni\no\nn\nn\na\ni\nr\ne\n \n DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n123\nAppendix 20  \nDerriford Appearance Scale (DAS59)Appendix 20 \n124\nTHE DERRIFORD APPEARANCE SCALE (DAS 59) \n \nYOUR NAME  DATE \n      \/    \/     \nYOUR DATE OF BIRTH  SEX: Male  \/  Female \n    \/    \/       \nOCCUPATION: Yours  Partner\u2019s \/ Spouse\u2019s \n   \n \nYOUR FAMILY STATUS (please tick the option closest to your situation) \nMarried\/Living with partner  Living alone  Living with relatives\/friends \n     \n \nYOUR NATIONALITY \n \n \nYOUR ETHNIC BACKGROUND (please tick) \nBangladeshi    Pakistani    Black \u2013 African   \nIndian    Chinese    Black \u2013 Caribbean   \nWhite     \nOther (please specify)  Black \u2013 other (please specify \n   \n \nThis questionnaire is concerned about how you feel about your appearance \nThe first part of the scale is designed to find out if you are sensitive or self-conscious about any aspect of your appearance (even if \nthis is not usually visible to others). \n(a) Is there any aspect of your appearance (however small) that concerns you at all? \nYes \/ No    \nIf no, please turn to the next page If yes, please continue: \n(b) The aspect of my appearance about which I am most sensitive or self-conscious is \n \nFrom now on, we will refer to this aspect of your appearance as your \u2018feature\u2019 \n(c) The thing I do not like about my \u2018feature\u2019 is \n \n(d) If you are sensitive or concerned about any other features of your body or your appearance, please say what they are \n \n \nFor each question \nPlease read each statement carefully and then circle the appropriate number on the right hand side. \nIf a statement does not apply to you, circle N\/A. \nPlease be sure to answer the whole scale: do not miss out any items. \n DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n125\n \nFor questions 1 to 33 use the scale \n1  2  3  4  N\/A \nAlmost never  Sometimes  Often  Almost always  Does not apply \n \n1  I am self-concious of my \u2018feature\u2019  1  2  3  4  N\/A \n2  I avoid children in the street   1  2  3  4  N\/A \n3  I find it difficult to make friends  1  2  3  4  N\/A \n4  I avoid undressing in front of my spouse \/ partner  1  2  3  4  N\/A \n5  At present I try to avoid going to my school \/ college \/ work   1  2  3  4  N\/A \n6  I avoid going to pubs \/ restaurants   1  2  3  4  N\/A \n7  I avoid going to parties \/ discos   1  2  3  4  N\/A \n8  I take a special interest in what other people\u2019s \u2018feature\u2019 looks like  1  2  3  4  N\/A \n9  I avoid communal changing rooms   1  2  3  4  N\/A \n10  I avoid having my photograph taken  1  2  3  4  N\/A \n11  1 avoid getting my hair wet   1  2  3  4  N\/A \n12  I have been hurt by other people saying things about my \u2018feature\u2019   1  2  3  4  N\/A \n13  I avoid shopping in department stores   1  2  3  4  N\/A \n14  I avoid going out of the house   1  2  3  4  N\/A \n15  I raise the subject of my \u2018feature\u2019 in conversation before other people do  1  2  3  4  N\/A \n16  I close into my shell   1  2  3  4  N\/A \n17  My self-consciousness makes me  irritable at home   1  2  3  4  N\/A \n18  Other people misjudge me because of my \u2018feature\u2019   1  2  3  4  N\/A \n19  In the past I have tried to avoid going to school \/ college \/ work   1  2  3  4  N\/A \n20  I feel an embarrassment to my friends   1  2  3  4  N\/A \n21  I feel a freak   1  2  3  4  N\/A \n22  I worry about my sanity   1  2  3  4  N\/A \n23  My self-consciousness has an adverse effect on my sex life   1  2  3  4  N\/A \n24  My self-consciousness has an adverse effect on my marriage   1  2  3  4  N\/A \n25  My \u2018feature\u2019 causes me pain or discomfort   1  2  3  4  N\/A \n26  My \u2018feature\u2019 physically limits my ability to do the things I want to do   1  2  3  4  N\/A \n27  My \u2018feature\u2019 makes me feel unattractive   1  2  3  4  N\/A \n28  My \u2018feature\u2019 makes me feel unlovable   1  2  3  4  N\/A \n29  My \u2018feature\u2019 makes me feel isolated   1  2  3  4  N\/A \n30  My \u2018feature\u2019 makes me feel embarrassed   1  2  3  4  N\/A \n21  My \u2018feature\u2019 makes me feel inferior   1  2  3  4  N\/A \n32  My \u2018feature\u2019 makes me feel rejected   1  2  3  4  N\/A \n33  My \u2018feature\u2019 makes me feel useless   1  2  3  4  N\/A \n \n Appendix 20 \n126\nFor questions 34 to 51 use the scale \n1  2  3  4  5  N\/A \nNot at all distressed    Moderately distressed    Extremely distressed  Does not apply \n \nHOW DISTRESSED DO YOU GET WHEN: \n34  Other people stare at your \u2018feature\u2019  1  2  3  4  5  N\/A \n35  Other people make remarks about your \u2018feature\u2019   1  2  3  4  5  N\/A \n36  Other people ask about your \u2018feature\u2019   1  2  3  4  5  N\/A \n37  You go to the beach   1  2  3  4  5  N\/A \n38  Others see you in a particular view (eg. front, side)   1  2  3  4  5  N\/A \n39  You go to your school \/ college \/ work   1  2  3  4  5  N\/A \n40  You travel on public transport   1  2  3  4  5  N\/A \n41  You see yourself in a mirror \/ window   1  2  3  4  5  N\/A \n42  You meet strangers   1  2  3  4  5  N\/A \n \nHOW DISTRESSED ARE YOU BY: \n43  Being unable to wear your favourite clothes   1  2  3  4  5  N\/A \n44  Being unable to change your hairstyle   1  2  3  4  5  N\/A \n45  Not being able to go swimming   1  2  3  4  5  N\/A \n46  Not being able to play games   1  2  3  4  5  N\/A \n47  Not being able to go to social events   1  2  3  4  5  N\/A \n48  Being unable to answer the front door at home   1  2  3  4  5  N\/A \n49  Being unable to look at yourself in the mirror   1  2  3  4  5  N\/A \n50  Being unable to go to pubs \/ restaurants   1  2  3  4  5  N\/A \n51  Not being able to go out in windy weather   1  2  3  4  5  N\/A \n \nFor questions 52 to 59 use the scale \n1  2  3  4  5 \nNot at all  Slightly  Moderately  Greatly  Extremely \n \nIN GENERAL \n52  How confident do you feel?   1  2  3  4  5 \n53  How irritable do you feel?   1  2  3  4  5 \n54  How secure do you feel?   1  2  3  4  5 \n55  How cheerful do you feel?   1  2  3  4  5 \n56  How normal do you feel?   1  2  3  4  5 \n57  How feminine \/ masculine do you feel?   1  2  3  4  5 \n58  How hurt do you feel?   1  2  3  4  5 \n59  How hostile do you feel?   1  2  3  4  5 \n DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n127\nAppendix 21  \nPatient deaths on the BELLS study\nPatient reference 2613014\nDate.of.Consent.to.BELLS.study. 27.03.2005.\nSite. Monklands.Hospital.Airdrie.\nAllocated.treatment. Trt.2.(not.decoded).\nPlanned.treatment.period. 27.03.2005.\u2013.5.04.2005.\nDate.of.Death. 04.2005.\nAge. 78.\nCause.of.Death. 1A.bronchial.pneumonia.\n. 1B.stroke.\n. 2.liver.metastases,.primary.unknown.\nCompliance. This.patient.never.commenced.BELLS.medications\nPatient reference 2617009\nDate.of.Consent.to.BELLS.study. 17.12.2004.\nSite. Glasgow.Royal.Infirmary.\nAllocated.treatment. Trt.4.(not.decoded).\nPlanned.treatment.period. 17.12.2004.\u2013.26.12.2004.\nDate.of.Death. 04.2005.\nAge. 53.\nCause.of.Death. Sudden.Death.(believed.MI).\nCompliance. 9\/10.days.prednisolone\/placebo,.9\/10.days.aciclovir\/placebo\nPatient reference 2613030\nDate.of.Consent.to.BELLS.study. 14\/01\/2006.\nSite. Monklands.Hospital.Airdrie.\nAllocated.treatment. Trt.2.(not.decoded).\nPlanned.treatment.interval. 14\/01\/2006.\u2013.24\/01\/2006.\nDate.of.Death. 04\/2006.\nCause.of.Death. Ischaemic.heart.disease.\n. Coronary.atheroma.\n. Hypertensive.heart.disease.\nCompliance. Not.known.(containers.not.returned).assumed.complete\nThe.treatments.were.decoded.following.the.end.of.patient.follow-up.in.March.2007.\nTrt.2.(two.of.the.three.events).is.double-placebo.and.Trt.4.is.aciclovir.with.placebo.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n129\nAppendix 22  \nCONSORT Checklist of items to include \nwhen reporting a randomised trialAppendix 22 \n130\nSECTION\/topic Item Description Page\nTITLE & ABSTRACT 1 How participants were allocated to interventions (e.g., \u2018random \nallocation\u2019, \u2018randomised\u2019, or \u2018randomly assigned\u2019)\ni,iii\nINTRODUCTION \nBackground\n2 Scientific background and explanation of rationale 1,2\nMETHODS \nParticipants\n3 Eligibility criteria for participants and the settings and locations where the \ndata were collected\n5,6\nInterventions 4 Precise details of the interventions intended for each group and how and \nwhen they were actually administered\n6, 7\nObjectives 5 Specific objectives and hypotheses 9\nOutcomes 6 Clearly defined primary and secondary outcome measures and, when \napplicable, any methods used to enhance the quality of measurements \n(e.g., multiple observations, training of assessors)\n9\u201311\nSample size 7 How sample size was determined and, when applicable, explanation of \nany interim analyses and stopping rules\n13\nRandomisation \u2013 Sequence \ngeneration\n8 Method used to generate the random allocation sequence, including \ndetails of any restrictions (e.g., blocking, stratification)\n13\nRandomisation \u2013 Allocation \nconcealment\n9 Method used to implement the random allocation sequence (e.g., \nnumbered containers or central telephone), clarifying whether the \nsequence was concealed until interventions were assigned\n13, 14\nRandomisation \u2013 \nImplementation\n10 Who generated the allocation sequence, who enrolled participants, and \nwho assigned participants to their groups\n13, 14\nBlinding (masking) 11 Whether or not participants, those administering the interventions, and \nthose assessing the outcomes were blinded to group assignment. When \nrelevant, how the success of blinding was evaluated\n14\nStatistical methods 12 Statistical methods used to compare groups for primary outcome(s); \nMethods for additional analyses, such as subgroup analyses and adjusted \nanalyses\n13, 14, \n43\u201345\nRESULTS\nParticipant flow\n13 Flow of participants through each stage (a diagram is strongly \nrecommended). Specifically, for each group report the numbers of \nparticipants randomly assigned, receiving intended treatment, completing \nthe study protocol, and analysed for the primary outcome. Describe \nprotocol deviations from study as planned, together with reasons\n16\nRecruitment 14 Dates defining the periods of recruitment and follow-up 15, 17, 18\nBaseline data 15 Baseline demographic and clinical characteristics of each group 18\nNumbers analysed 16 Number of participants (denominator) in each group included in each \nanalysis and whether the analysis was by \u2018intention-to-treat\u2019. State the \nresults in absolute numbers when feasible (e.g., 10\/20, not 50%)\n17\nOutcomes and estimation 17 For each primary and secondary outcome, a summary of results for \neach group, and the estimated effect size and its precision (e.g., 95% \nconfidence interval)\n18\u201321\nAncillary analyses 18 Address multiplicity by reporting any other analyses performed, including \nsubgroup analyses and adjusted analyses, indicating those prespecified \nand those exploratory\n25\nAdverse events 19 All important adverse events or side effects in each intervention group 25,26\nDISCUSSION \nInterpretation\n20 Interpretation of the results, taking into account study hypotheses, \nsources of potential bias or imprecision and the dangers associated with \nmultiplicity of analyses and outcomes\n47, 48\nGeneralisability 21 Generalisability (external validity) of the trial findings 47, 48\nOverall evidence 22 General interpretation of the results in the context of current evidence 48, 49DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n131\nHealth Technology Assessment reports \npublished to date\nVolume 1, 1997\nNo. 1\nHome.parenteral.nutrition:.a.systematic.\nreview.\nBy.Richards.DM,.Deeks.JJ,.Sheldon.\nTA,.Shaffer.JL.\nNo. 2\nDiagnosis,.management.and.screening.\nof.early.localised.prostate.cancer.\nA.review.by.Selley.S,.Donovan.J,.\nFaulkner.A,.Coast.J,.Gillatt.D.\nNo. 3\nThe.diagnosis,.management,.treatment.\nand.costs.of.prostate.cancer.in.England.\nand.Wales.\nA.review.by.Chamberlain.J,.Melia.J,.\nMoss.S,.Brown.J.\nNo. 4\nScreening.for.fragile.X.syndrome.\nA.review.by.Murray.J,.Cuckle.H,.\nTaylor.G,.Hewison.J.\nNo. 5\nA.review.of.near.patient.testing.in.\nprimary.care.\nBy.Hobbs.FDR,.Delaney.BC,.\nFitzmaurice.DA,.Wilson.S,.Hyde.CJ,.\nThorpe.GH,.et al.\nNo. 6\nSystematic.review.of.outpatient.services.\nfor.chronic.pain.control.\nBy.McQuay.HJ,.Moore.RA,.Eccleston.\nC,.Morley.S,.de.C.Williams.AC.\nNo. 7\nNeonatal.screening.for.inborn.errors.of.\nmetabolism:.cost,.yield.and.outcome.\nA.review.by.Pollitt.RJ,.Green.A,.\nMcCabe.CJ,.Booth.A,.Cooper.NJ,.\nLeonard.JV,.et al.\nNo. 8\nPreschool.vision.screening.\nA.review.by.Snowdon.SK,.\nStewart-Brown.SL.\nNo. 9\nImplications.of.socio-cultural.contexts.\nfor.the.ethics.of.clinical.trials.\nA.review.by.Ashcroft.RE,.Chadwick.\nDW,.Clark.SRL,.Edwards.RHT,.Frith.L,.\nHutton.JL.\nNo. 10\nA.critical.review.of.the.role.of.neonatal.\nhearing.screening.in.the.detection.of.\ncongenital.hearing.impairment.\nBy.Davis.A,.Bamford.J,.Wilson.I,.\nRamkalawan.T,.Forshaw.M,.Wright.S.\nNo. 11\nNewborn.screening.for.inborn.errors.of.\nmetabolism:.a.systematic.review.\nBy.Seymour.CA,.Thomason.MJ,.\nChalmers.RA,.Addison.GM,.Bain.MD,.\nCockburn.F,.et al.\nNo. 12\nRoutine.preoperative.testing:.a.\nsystematic.review.of.the.evidence.\nBy.Munro.J,.Booth.A,.Nicholl.J.\nNo. 13\nSystematic.review.of.the.effectiveness.of.\nlaxatives.in.the.elderly.\nBy.Petticrew.M,.Watt.I,.Sheldon.T.\nNo. 14\nWhen.and.how.to.assess.fast-changing.\ntechnologies:.a.comparative.study.of.\nmedical.applications.of.four.generic.\ntechnologies.\nA.review.by.Mowatt.G,.Bower.DJ,.\nBrebner.JA,.Cairns.JA,.Grant.AM,.\nMcKee.L.\nVolume 2, 1998\nNo. 1\nAntenatal.screening.for.Down\u2019s.\nsyndrome.\nA.review.by.Wald.NJ,.Kennard.A,.\nHackshaw.A,.McGuire.A.\nNo. 2\nScreening.for.ovarian.cancer:.a.\nsystematic.review.\nBy.Bell.R,.Petticrew.M,.Luengo.S,.\nSheldon.TA.\nNo. 3\nConsensus.development.methods,.\nand.their.use.in.clinical.guideline.\ndevelopment.\nA.review.by.Murphy.MK,.Black.NA,.\nLamping.DL,.McKee.CM,.Sanderson.\nCFB,.Askham.J,.et al.\nNo. 4\nA.cost\u2013utility.analysis.of.interferon.beta.\nfor.multiple.sclerosis.\nBy.Parkin.D,.McNamee.P,.Jacoby.A,.\nMiller.P,.Thomas.S,.Bates.D.\nNo. 5\nEffectiveness.and.efficiency.of.methods.\nof.dialysis.therapy.for.end-stage.renal.\ndisease:.systematic.reviews.\nBy.MacLeod.A,.Grant.A,.Donaldson.\nC,.Khan.I,.Campbell.M,.Daly.C,.et al.\nNo. 6\nEffectiveness.of.hip.prostheses.in.\nprimary.total.hip.replacement:.a.critical.\nreview.of.evidence.and.an.economic.\nmodel.\nBy.Faulkner.A,.Kennedy.LG,.Baxter.\nK,.Donovan.J,.Wilkinson.M,.Bevan.G.\nNo. 7\nAntimicrobial.prophylaxis.in.colorectal.\nsurgery:.a.systematic.review.of.\nrandomised.controlled.trials.\nBy.Song.F,.Glenny.AM.\nNo. 8\nBone.marrow.and.peripheral.\nblood.stem.cell.transplantation.for.\nmalignancy.\nA.review.by.Johnson.PWM,.\nSimnett.SJ,.Sweetenham.JW,.Morgan.GJ,.\nStewart.LA.\nNo. 9\nScreening.for.speech.and.language.\ndelay:.a.systematic.review.of.the.\nliterature.\nBy.Law.J,.Boyle.J,.Harris.F,.\nHarkness.A,.Nye.C.\nNo. 10\nResource.allocation.for.chronic.\nstable.angina:.a.systematic.\nreview.of.effectiveness,.costs.and.\ncost-effectiveness.of.alternative.\ninterventions.\nBy.Sculpher.MJ,.Petticrew.M,.\nKelland.JL,.Elliott.RA,.Holdright.DR,.\nBuxton.MJ.\nNo. 11\nDetection,.adherence.and.control.of.\nhypertension.for.the.prevention.of.\nstroke:.a.systematic.review.\nBy.Ebrahim.S.\nNo. 12\nPostoperative.analgesia.and.vomiting,.\nwith.special.reference.to.day-case.\nsurgery:.a.systematic.review.\nBy.McQuay.HJ,.Moore.RA.\nNo. 13\nChoosing.between.randomised.and.\nnonrandomised.studies:.a.systematic.\nreview.\nBy.Britton.A,.McKee.M,.Black.N,.\nMcPherson.K,.Sanderson.C,.Bain.C.\nNo. 14\nEvaluating.patient-based.outcome.\nmeasures.for.use.in.clinical.trials.\nA.review.by.Fitzpatrick.R,.Davey.C,.\nBuxton.MJ,.Jones.DR.Health Technology Assessment reports published to date\n132\nNo. 15\nEthical.issues.in.the.design.and.conduct.\nof.randomised.controlled.trials.\nA.review.by.Edwards.SJL,.Lilford.RJ,.\nBraunholtz.DA,.Jackson.JC,.Hewison.J,.\nThornton.J.\nNo. 16\nQualitative.research.methods.in.health.\ntechnology.assessment:.a.review.of.the.\nliterature.\nBy.Murphy.E,.Dingwall.R,.\nGreatbatch.D,.Parker.S,.Watson.P.\nNo. 17\nThe.costs.and.benefits.of.paramedic.\nskills.in.pre-hospital.trauma.care.\nBy.Nicholl.J,.Hughes.S,.Dixon.S,.\nTurner.J,.Yates.D.\nNo. 18\nSystematic.review.of.endoscopic.\nultrasound.in.gastro-oesophageal.\ncancer.\nBy.Harris.KM,.Kelly.S,.Berry.E,.\nHutton.J,.Roderick.P,.Cullingworth.J,.\net al.\nNo. 19\nSystematic.reviews.of.trials.and.other.\nstudies.\nBy.Sutton.AJ,.Abrams.KR,.Jones.DR,.\nSheldon.TA,.Song.F.\nNo. 20\nPrimary.total.hip.replacement.surgery:.\na.systematic.review.of.outcomes.\nand.modelling.of.cost-effectiveness.\nassociated.with.different.prostheses.\nA.review.by.Fitzpatrick.R,.Shortall.\nE,.Sculpher.M,.Murray.D,.Morris.R,.\nLodge.M,.et al.\nVolume 3, 1999\nNo. 1\nInformed.decision.making:.an.\nannotated.bibliography.and.systematic.\nreview.\nBy.Bekker.H,.Thornton.JG,.\nAirey.CM,.Connelly.JB,.Hewison.J,.\nRobinson.MB,.et al.\nNo. 2\nHandling.uncertainty.when.performing.\neconomic.evaluation.of.healthcare.\ninterventions.\nA.review.by.Briggs.AH,.Gray.AM.\nNo. 3\nThe.role.of.expectancies.in.the.placebo.\neffect.and.their.use.in.the.delivery.of.\nhealth.care:.a.systematic.review.\nBy.Crow.R,.Gage.H,.Hampson.S,.\nHart.J,.Kimber.A,.Thomas.H.\nNo. 4\nA.randomised.controlled.trial.of.\ndifferent.approaches.to.universal.\nantenatal.HIV.testing:.uptake.and.\nacceptability..Annex:.Antenatal.HIV.\ntesting.\u2013.assessment.of.a.routine.\nvoluntary.approach.\nBy.Simpson.WM,.Johnstone.FD,.\nBoyd.FM,.Goldberg.DJ,.Hart.GJ,.\nGormley.SM,.et al.\nNo. 5\nMethods.for.evaluating.area-wide.and.\norganisation-based.interventions.in.\nhealth.and.health.care:.a.systematic.\nreview.\nBy.Ukoumunne.OC,.Gulliford.MC,.\nChinn.S,.Sterne.JAC,.Burney.PGJ.\nNo. 6\nAssessing.the.costs.of.healthcare.\ntechnologies.in.clinical.trials.\nA.review.by.Johnston.K,.Buxton.MJ,.\nJones.DR,.Fitzpatrick.R.\nNo. 7\nCooperatives.and.their.primary.care.\nemergency.centres:.organisation.and.\nimpact.\nBy.Hallam.L,.Henthorne.K.\nNo. 8\nScreening.for.cystic.fibrosis.\nA.review.by.Murray.J,.Cuckle.H,.\nTaylor.G,.Littlewood.J,.Hewison.J.\nNo. 9\nA.review.of.the.use.of.health.status.\nmeasures.in.economic.evaluation.\nBy.Brazier.J,.Deverill.M,.Green.C,.\nHarper.R,.Booth.A.\nNo. 10\nMethods.for.the.analysis.of.quality-\nof-life.and.survival.data.in.health.\ntechnology.assessment.\nA.review.by.Billingham.LJ,.\nAbrams.KR,.Jones.DR.\nNo. 11\nAntenatal.and.neonatal.\nhaemoglobinopathy.screening.in.the.\nUK:.review.and.economic.analysis.\nBy.Zeuner.D,.Ades.AE,.Karnon.J,.\nBrown.J,.Dezateux.C,.Anionwu.EN.\nNo. 12\nAssessing.the.quality.of.reports.of.\nrandomised.trials:.implications.for.the.\nconduct.of.meta-analyses.\nA.review.by.Moher.D,.Cook.DJ,.\nJadad.AR,.Tugwell.P,.Moher.M,.\nJones.A,.et al.\nNo. 13\n\u2018Early.warning.systems\u2019.for.identifying.\nnew.healthcare.technologies.\nBy.Robert.G,.Stevens.A,.Gabbay.J.\nNo. 14\nA.systematic.review.of.the.role.of.\nhuman.papillomavirus.testing.within.a.\ncervical.screening.programme.\nBy.Cuzick.J,.Sasieni.P,.Davies.P,.\nAdams.J,.Normand.C,.Frater.A,.et al.\nNo. 15\nNear.patient.testing.in.diabetes.clinics:.\nappraising.the.costs.and.outcomes.\nBy.Grieve.R,.Beech.R,.Vincent.J,\nMazurkiewicz.J.\nNo. 16\nPositron.emission.tomography:.\nestablishing.priorities.for.health.\ntechnology.assessment.\nA.review.by.Robert.G,.Milne.R.\nNo. 17 (Pt 1)\nThe.debridement.of.chronic.wounds:.a.\nsystematic.review.\nBy.Bradley.M,.Cullum.N,.Sheldon.T.\nNo. 17 (Pt 2)\nSystematic.reviews.of.wound.care.\nmanagement:.(2).Dressings.and.topical.\nagents.used.in.the.healing.of.chronic.\nwounds.\nBy.Bradley.M,.Cullum.N,.Nelson.EA,.\nPetticrew.M,.Sheldon.T,.Torgerson.D.\nNo. 18\nA.systematic.literature.review.of.\nspiral.and.electron.beam.computed.\ntomography:.with.particular.reference.\nto.clinical.applications.in.hepatic.\nlesions,.pulmonary.embolus.and.\ncoronary.artery.disease.\nBy.Berry.E,.Kelly.S,.Hutton.J,.\nHarris.KM,.Roderick.P,.Boyce.JC,.et al.\nNo. 19\nWhat.role.for.statins?.A.review.and.\neconomic.model.\nBy.Ebrahim.S,.Davey.Smith.\nG,.McCabe.C,.Payne.N,.Pickin.M,.\nSheldon.TA,.et al.\nNo. 20\nFactors.that.limit.the.quality,.number.\nand.progress.of.randomised.controlled.\ntrials.\nA.review.by.Prescott.RJ,.Counsell.CE,.\nGillespie.WJ,.Grant.AM,.Russell.IT,.\nKiauka.S,.et al.\nNo. 21\nAntimicrobial.prophylaxis.in.total.hip.\nreplacement:.a.systematic.review.\nBy.Glenny.AM,.Song.F.\nNo. 22\nHealth.promoting.schools.and.health.\npromotion.in.schools:.two.systematic.\nreviews.\nBy.Lister-Sharp.D,.Chapman.S,.\nStewart-Brown.S,.Sowden.A.\nNo. 23\nEconomic.evaluation.of.a.primary.\ncare-based.education.programme.for.\npatients.with.osteoarthritis.of.the.knee.\nA.review.by.Lord.J,.Victor.C,.\nLittlejohns.P,.Ross.FM,.Axford.JS.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n133\nVolume 4, 2000\nNo. 1\nThe.estimation.of.marginal.time.\npreference.in.a.UK-wide.sample.\n(TEMPUS).project.\nA.review.by.Cairns.JA,.\nvan.der.Pol.MM.\nNo. 2\nGeriatric.rehabilitation.following.\nfractures.in.older.people:.a.systematic.\nreview.\nBy.Cameron.I,.Crotty.M,.Currie.C,.\nFinnegan.T,.Gillespie.L,.Gillespie.W,.\net al.\nNo. 3\nScreening.for.sickle.cell.disease.and.\nthalassaemia:.a.systematic.review.with.\nsupplementary.research.\nBy.Davies.SC,.Cronin.E,.Gill.M,.\nGreengross.P,.Hickman.M,.Normand.C.\nNo. 4\nCommunity.provision.of.hearing.aids.\nand.related.audiology.services.\nA.review.by.Reeves.DJ,.Alborz.A,.\nHickson.FS,.Bamford.JM.\nNo. 5\nFalse-negative.results.in.screening.\nprogrammes:.systematic.review.of.\nimpact.and.implications.\nBy.Petticrew.MP,.Sowden.AJ,.\nLister-Sharp.D,.Wright.K.\nNo. 6\nCosts.and.benefits.of.community.\npostnatal.support.workers:.a.\nrandomised.controlled.trial.\nBy.Morrell.CJ,.Spiby.H,.Stewart.P,.\nWalters.S,.Morgan.A.\nNo. 7\nImplantable.contraceptives.(subdermal.\nimplants.and.hormonally.impregnated.\nintrauterine.systems).versus.other.\nforms.of.reversible.contraceptives:.two.\nsystematic.reviews.to.assess.relative.\neffectiveness,.acceptability,.tolerability.\nand.cost-effectiveness.\nBy.French.RS,.Cowan.FM,.\nMansour.DJA,.Morris.S,.Procter.T,.\nHughes.D,.et al.\nNo. 8\nAn.introduction.to.statistical.methods.\nfor.health.technology.assessment.\nA.review.by.White.SJ,.Ashby.D,.\nBrown.PJ.\nNo. 9\nDisease-modifying.drugs.for.multiple.\nsclerosis:.a.rapid.and.systematic.review.\nBy.Clegg.A,.Bryant.J,.Milne.R.\nNo. 10\nPublication.and.related.biases.\nA.review.by.Song.F,.Eastwood.AJ,.\nGilbody.S,.Duley.L,.Sutton.AJ.\nNo. 11\nCost.and.outcome.implications.of.the.\norganisation.of.vascular.services.\nBy.Michaels.J,.Brazier.J,.\nPalfreyman.S,.Shackley.P,.Slack.R.\nNo. 12\nMonitoring.blood.glucose.control.in.\ndiabetes.mellitus:.a.systematic.review.\nBy.Coster.S,.Gulliford.MC,.Seed.PT,.\nPowrie.JK,.Swaminathan.R.\nNo. 13\nThe.effectiveness.of.domiciliary.\nhealth.visiting:.a.systematic.review.of.\ninternational.studies.and.a.selective.\nreview.of.the.British.literature.\nBy.Elkan.R,.Kendrick.D,.Hewitt.M,.\nRobinson.JJA,.Tolley.K,.Blair.M,.et al.\nNo. 14\nThe.determinants.of.screening.uptake.\nand.interventions.for.increasing.\nuptake:.a.systematic.review.\nBy.Jepson.R,.Clegg.A,.Forbes.C,.\nLewis.R,.Sowden.A,.Kleijnen.J.\nNo. 15\nThe.effectiveness.and.cost-effectiveness.\nof.prophylactic.removal.of.wisdom.\nteeth.\nA.rapid.review.by.Song.F,.O\u2019Meara.S,.\nWilson.P,.Golder.S,.Kleijnen.J.\nNo. 16\nUltrasound.screening.in.pregnancy:.\na.systematic.review.of.the.clinical.\neffectiveness,.cost-effectiveness.and.\nwomen\u2019s.views.\nBy.Bricker.L,.Garcia.J,.Henderson.J,.\nMugford.M,.Neilson.J,.Roberts.T,.et al.\nNo. 17\nA.rapid.and.systematic.review.of.the.\neffectiveness.and.cost-effectiveness.of.\nthe.taxanes.used.in.the.treatment.of.\nadvanced.breast.and.ovarian.cancer.\nBy.Lister-Sharp.D,.McDonagh.MS,.\nKhan.KS,.Kleijnen.J.\nNo. 18\nLiquid-based.cytology.in.cervical.\nscreening:.a.rapid.and.systematic.\nreview.\nBy.Payne.N,.Chilcott.J,.McGoogan.E.\nNo. 19\nRandomised.controlled.trial.of.non-\ndirective.counselling,.cognitive\u2013\nbehaviour.therapy.and.usual.general.\npractitioner.care.in.the.management.of.\ndepression.as.well.as.mixed.anxiety.and.\ndepression.in.primary.care.\nBy.King.M,.Sibbald.B,.Ward.E,.\nBower.P,.Lloyd.M,.Gabbay.M,.et al.\nNo. 20\nRoutine.referral.for.radiography.of.\npatients.presenting.with.low.back.pain:.\nis.patients\u2019.outcome.influenced.by.GPs\u2019.\nreferral.for.plain.radiography?\nBy.Kerry.S,.Hilton.S,.Patel.S,.\nDundas.D,.Rink.E,.Lord.J.\nNo. 21\nSystematic.reviews.of.wound.care.\nmanagement:.(3).antimicrobial.agents.\nfor.chronic.wounds;.(4).diabetic.foot.\nulceration.\nBy.O\u2019Meara.S,.Cullum.N,.Majid.M,.\nSheldon.T.\nNo. 22\nUsing.routine.data.to.complement.\nand.enhance.the.results.of.randomised.\ncontrolled.trials.\nBy.Lewsey.JD,.Leyland.AH,.Murray.\nGD,.Boddy.FA.\nNo. 23\nCoronary.artery.stents.in.the.treatment.\nof.ischaemic.heart.disease:.a.rapid.and.\nsystematic.review.\nBy.Meads.C,.Cummins.C,.Jolly.K,.\nStevens.A,.Burls.A,.Hyde.C.\nNo. 24\nOutcome.measures.for.adult.critical.\ncare:.a.systematic.review.\nBy.Hayes.JA,.Black.NA,.Jenkinson.C,.\nYoung.JD,.Rowan.KM,.Daly.K,.et al.\nNo. 25\nA.systematic.review.to.evaluate.the.\neffectiveness.of.interventions.to.\npromote.the.initiation.of.breastfeeding.\nBy.Fairbank.L,.O\u2019Meara.S,.\nRenfrew.MJ,.Woolridge.M,.Sowden.AJ,.\nLister-Sharp.D.\nNo. 26\nImplantable.cardioverter.defibrillators:.\narrhythmias..A.rapid.and.systematic.\nreview.\nBy.Parkes.J,.Bryant.J,.Milne.R.\nNo. 27\nTreatments.for.fatigue.in.multiple.\nsclerosis:.a.rapid.and.systematic.review.\nBy.Bra\u00f1as.P,.Jordan.R,.Fry-Smith.A,.\nBurls.A,.Hyde.C.\nNo. 28\nEarly.asthma.prophylaxis,.natural.\nhistory,.skeletal.development.and.\neconomy.(EASE):.a.pilot.randomised.\ncontrolled.trial.\nBy.Baxter-Jones.ADG,.Helms.PJ,.\nRussell.G,.Grant.A,.Ross.S,.Cairns.JA,.\net al.\nNo. 29\nScreening.for.hypercholesterolaemia.\nversus.case.finding.for.familial.\nhypercholesterolaemia:.a.systematic.\nreview.and.cost-effectiveness.analysis.\nBy.Marks.D,.Wonderling.\nD,.Thorogood.M,.Lambert.H,.\nHumphries.SE,.Neil.HAW.\nNo. 30\nA.rapid.and.systematic.review.of.\nthe.clinical.effectiveness.and.cost-\neffectiveness.of.glycoprotein.IIb\/IIIa.\nantagonists.in.the.medical.management.\nof.unstable.angina.\nBy.McDonagh.MS,.Bachmann.LM,.\nGolder.S,.Kleijnen.J,.ter.Riet.G.Health Technology Assessment reports published to date\n134\nNo. 31\nA.randomised.controlled.trial.\nof.prehospital.intravenous.fluid.\nreplacement.therapy.in.serious.trauma.\nBy.Turner.J,.Nicholl.J,.Webber.L,.\nCox.H,.Dixon.S,.Yates.D.\nNo. 32\nIntrathecal.pumps.for.giving.opioids.in.\nchronic.pain:.a.systematic.review.\nBy.Williams.JE,.Louw.G,.\nTowlerton.G.\nNo. 33\nCombination.therapy.(interferon.\nalfa.and.ribavirin).in.the.treatment.\nof.chronic.hepatitis.C:.a.rapid.and.\nsystematic.review.\nBy.Shepherd.J,.Waugh.N,.\nHewitson.P.\nNo. 34\nA.systematic.review.of.comparisons.of.\neffect.sizes.derived.from.randomised.\nand.non-randomised.studies.\nBy.MacLehose.RR,.Reeves.BC,.\nHarvey.IM,.Sheldon.TA,.Russell.IT,.\nBlack.AMS.\nNo. 35\nIntravascular.ultrasound-guided.\ninterventions.in.coronary.artery.\ndisease:.a.systematic.literature.review,.\nwith.decision-analytic.modelling,.of.\noutcomes.and.cost-effectiveness.\nBy.Berry.E,.Kelly.S,.Hutton.J,.\nLindsay.HSJ,.Blaxill.JM,.Evans.JA,.et al.\nNo. 36\nA.randomised.controlled.trial.to.\nevaluate.the.effectiveness.and.cost-\neffectiveness.of.counselling.patients.\nwith.chronic.depression.\nBy.Simpson.S,.Corney.R,.\nFitzgerald.P,.Beecham.J.\nNo. 37\nSystematic.review.of.treatments.for.\natopic.eczema.\nBy.Hoare.C,.Li.Wan.Po.A,.\nWilliams.H.\nNo. 38\nBayesian.methods.in.health.technology.\nassessment:.a.review.\nBy.Spiegelhalter.DJ,.Myles.JP,.\nJones.DR,.Abrams.KR.\nNo. 39\nThe.management.of.dyspepsia:.a.\nsystematic.review.\nBy.Delaney.B,.Moayyedi.P,.Deeks.J,.\nInnes.M,.Soo.S,.Barton.P,.et al.\nNo. 40\nA.systematic.review.of.treatments.for.\nsevere.psoriasis.\nBy.Griffiths.CEM,.Clark.CM,.\nChalmers.RJG,.Li.Wan.Po.A,.\nWilliams.HC.\nVolume 5, 2001\nNo. 1\nClinical.and.cost-effectiveness.\nof.donepezil,.rivastigmine.and.\ngalantamine.for.Alzheimer\u2019s.disease:.a.\nrapid.and.systematic.review.\nBy.Clegg.A,.Bryant.J,.Nicholson.T,.\nMcIntyre.L,.De.Broe.S,.Gerard.K,.et al.\nNo. 2\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.riluzole.for.motor.\nneurone.disease:.a.rapid.and.systematic.\nreview.\nBy.Stewart.A,.Sandercock.J,.Bryan.S,.\nHyde.C,.Barton.PM,.Fry-Smith.A,.et al.\nNo. 3\nEquity.and.the.economic.evaluation.of.\nhealthcare.\nBy.Sassi.F,.Archard.L,.Le.Grand.J.\nNo. 4\nQuality-of-life.measures.in.chronic.\ndiseases.of.childhood.\nBy.Eiser.C,.Morse.R.\nNo. 5\nEliciting.public.preferences.for.\nhealthcare:.a.systematic.review.of\ntechniques.\nBy.Ryan.M,.Scott.DA,.Reeves.C,.Bate.\nA,.van.Teijlingen.ER,.Russell.EM,.et al.\nNo. 6\nGeneral.health.status.measures.for.\npeople.with.cognitive.impairment:.\nlearning.disability.and.acquired.brain.\ninjury.\nBy.Riemsma.RP,.Forbes.CA,.\nGlanville.JM,.Eastwood.AJ,.Kleijnen.J.\nNo. 7\nAn.assessment.of.screening.strategies.\nfor.fragile.X.syndrome.in.the.UK.\nBy.Pembrey.ME,.Barnicoat.AJ,.\nCarmichael.B,.Bobrow.M,.Turner.G.\nNo. 8\nIssues.in.methodological.research:.\nperspectives.from.researchers.and.\ncommissioners.\nBy.Lilford.RJ,.Richardson.A,.Stevens.\nA,.Fitzpatrick.R,.Edwards.S,.Rock.F,.et al.\nNo. 9\nSystematic.reviews.of.wound.\ncare.management:.(5).beds;.\n(6).compression;.(7).laser.therapy,.\ntherapeutic.ultrasound,.electrotherapy.\nand.electromagnetic.therapy.\nBy.Cullum.N,.Nelson.EA,.\nFlemming.K,.Sheldon.T.\nNo. 10\nEffects.of.educational.and.psychosocial.\ninterventions.for.adolescents.with.\ndiabetes.mellitus:.a.systematic.review.\nBy.Hampson.SE,.Skinner.TC,.Hart.J,.\nStorey.L,.Gage.H,.Foxcroft.D,.et al.\nNo. 11\nEffectiveness.of.autologous.chondrocyte.\ntransplantation.for.hyaline.cartilage.\ndefects.in.knees:.a.rapid.and.systematic.\nreview.\nBy.Jobanputra.P,.Parry.D,.Fry-Smith.\nA,.Burls.A.\nNo. 12\nStatistical.assessment.of.the.learning.\ncurves.of.health.technologies.\nBy.Ramsay.CR,.Grant.AM,.Wallace.\nSA,.Garthwaite.PH,.Monk.AF,.Russell.IT.\nNo. 13\nThe.effectiveness.and.cost-effectiveness.\nof.temozolomide.for.the.treatment.of.\nrecurrent.malignant.glioma:.a.rapid.\nand.systematic.review.\nBy.Dinnes.J,.Cave.C,.Huang.S,.\nMajor.K,.Milne.R.\nNo. 14\nA.rapid.and.systematic.review.of.\nthe.clinical.effectiveness.and.cost-\neffectiveness.of.debriding.agents.in.\ntreating.surgical.wounds.healing.by.\nsecondary.intention.\nBy.Lewis.R,.Whiting.P,.ter.Riet.G,.\nO\u2019Meara.S,.Glanville.J.\nNo. 15\nHome.treatment.for.mental.health.\nproblems:.a.systematic.review.\nBy.Burns.T,.Knapp.M,.Catty.J,.\nHealey.A,.Henderson.J,.Watt.H,.et al.\nNo. 16\nHow.to.develop.cost-conscious.\nguidelines.\nBy.Eccles.M,.Mason.J.\nNo. 17\nThe.role.of.specialist.nurses.in.multiple.\nsclerosis:.a.rapid.and.systematic.review.\nBy.De.Broe.S,.Christopher.F,.\nWaugh.N.\nNo. 18\nA.rapid.and.systematic.review.\nof.the.clinical.effectiveness.and.\ncost-effectiveness.of.orlistat.in.the.\nmanagement.of.obesity.\nBy.O\u2019Meara.S,.Riemsma.R,.\nShirran.L,.Mather.L,.ter.Riet.G.\nNo. 19\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.pioglitazone.for.\ntype.2.diabetes.mellitus:.a.rapid.and.\nsystematic.review.\nBy.Chilcott.J,.Wight.J,.Lloyd.Jones.\nM,.Tappenden.P.\nNo. 20\nExtended.scope.of.nursing.practice:.\na.multicentre.randomised.controlled.\ntrial.of.appropriately.trained.nurses.\nand.preregistration.house.officers.in.\npreoperative.assessment.in.elective.\ngeneral.surgery.\nBy.Kinley.H,.Czoski-Murray.C,.\nGeorge.S,.McCabe.C,.Primrose.J,.\nReilly.C,.et al.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n135\nNo. 21\nSystematic.reviews.of.the.effectiveness.\nof.day.care.for.people.with.severe.\nmental.disorders:.(1).Acute.day.hospital.\nversus.admission;.(2).Vocational.\nrehabilitation;.(3).Day.hospital.versus.\noutpatient.care.\nBy.Marshall.M,.Crowther.R,.\nAlmaraz-.Serrano.A,.Creed.F,.Sledge.W,.\nKluiter.H,.et al.\nNo. 22\nThe.measurement.and.monitoring.of.\nsurgical.adverse.events.\nBy.Bruce.J,.Russell.EM,.Mollison.J,.\nKrukowski.ZH.\nNo. 23\nAction.research:.a.systematic.review.and.\nguidance.for.assessment.\nBy.Waterman.H,.Tillen.D,.Dickson.R,.\nde.Koning.K.\nNo. 24\nA.rapid.and.systematic.review.of.\nthe.clinical.effectiveness.and.cost-\neffectiveness.of.gemcitabine.for.the.\ntreatment.of.pancreatic.cancer.\nBy.Ward.S,.Morris.E,.Bansback.N,.\nCalvert.N,.Crellin.A,.Forman.D,.et al.\nNo. 25\nA.rapid.and.systematic.review.of.the.\nevidence.for.the.clinical.effectiveness.\nand.cost-effectiveness.of.irinotecan,.\noxaliplatin.and.raltitrexed.for.the.\ntreatment.of.advanced.colorectal.\ncancer.\nBy.Lloyd.Jones.M,.Hummel.S,.\nBansback.N,.Orr.B,.Seymour.M.\nNo. 26\nComparison.of.the.effectiveness.of.\ninhaler.devices.in.asthma.and.chronic.\nobstructive.airways.disease:.a.systematic.\nreview.of.the.literature.\nBy.Brocklebank.D,.Ram.F,.Wright.J,.\nBarry.P,.Cates.C,.Davies.L,.et al.\nNo. 27\nThe.cost-effectiveness.of.magnetic.\nresonance.imaging.for.investigation.of.\nthe.knee.joint.\nBy.Bryan.S,.Weatherburn.G,.Bungay.\nH,.Hatrick.C,.Salas.C,.Parry.D,.et al.\nNo. 28\nA.rapid.and.systematic.review.of.\nthe.clinical.effectiveness.and.cost-\neffectiveness.of.topotecan.for.ovarian.\ncancer.\nBy.Forbes.C,.Shirran.L,.Bagnall.A-M,.\nDuffy.S,.ter.Riet.G.\nNo. 29\nSuperseded.by.a.report.published.in.a.\nlater.volume.\nNo. 30\nThe.role.of.radiography.in.primary.\ncare.patients.with.low.back.pain.of.at.\nleast.6.weeks.duration:.a.randomised.\n(unblinded).controlled.trial.\nBy.Kendrick.D,.Fielding.K,.Bentley.\nE,.Miller.P,.Kerslake.R,.Pringle.M.\nNo. 31\nDesign.and.use.of.questionnaires:.a.\nreview.of.best.practice.applicable.to.\nsurveys.of.health.service.staff.and.\npatients.\nBy.McColl.E,.Jacoby.A,.Thomas.L,.\nSoutter.J,.Bamford.C,.Steen.N,.et al.\nNo. 32\nA.rapid.and.systematic.review.of.\nthe.clinical.effectiveness.and.cost-\neffectiveness.of.paclitaxel,.docetaxel,.\ngemcitabine.and.vinorelbine.in.non-\nsmall-cell.lung.cancer.\nBy.Clegg.A,.Scott.DA,.Sidhu.M,.\nHewitson.P,.Waugh.N.\nNo. 33\nSubgroup.analyses.in.randomised.\ncontrolled.trials:.quantifying.the.risks.\nof.false-positives.and.false-negatives.\nBy.Brookes.ST,.Whitley.E,.Peters.TJ,.\nMulheran.PA,.Egger.M,.Davey.Smith.G.\nNo. 34\nDepot.antipsychotic.medication.\nin.the.treatment.of.patients.with.\nschizophrenia:.(1).Meta-review;.(2).\nPatient.and.nurse.attitudes.\nBy.David.AS,.Adams.C.\nNo. 35\nA.systematic.review.of.controlled.\ntrials.of.the.effectiveness.and.cost-\neffectiveness.of.brief.psychological.\ntreatments.for.depression.\nBy.Churchill.R,.Hunot.V,.Corney.R,.\nKnapp.M,.McGuire.H,.Tylee.A,.et al.\nNo. 36\nCost.analysis.of.child.health.\nsurveillance.\nBy.Sanderson.D,.Wright.D,.Acton.C,.\nDuree.D.\nVolume 6, 2002\nNo. 1\nA.study.of.the.methods.used.to.select.\nreview.criteria.for.clinical.audit.\nBy.Hearnshaw.H,.Harker.R,.\nCheater.F,.Baker.R,.Grimshaw.G.\nNo. 2\nFludarabine.as.second-line.therapy.for.\nB.cell.chronic.lymphocytic.leukaemia:.a.\ntechnology.assessment.\nBy.Hyde.C,.Wake.B,.Bryan.S,.Barton.\nP,.Fry-Smith.A,.Davenport.C,.et al.\nNo. 3\nRituximab.as.third-line.treatment.for.\nrefractory.or.recurrent.Stage.III.or.IV.\nfollicular.non-Hodgkin\u2019s.lymphoma:.\na.systematic.review.and.economic.\nevaluation.\nBy.Wake.B,.Hyde.C,.Bryan.S,.Barton.\nP,.Song.F,.Fry-Smith.A,.et al.\nNo. 4\nA.systematic.review.of.discharge.\narrangements.for.older.people.\nBy.Parker.SG,.Peet.SM,.McPherson.\nA,.Cannaby.AM,.Baker.R,.Wilson.A,.et al.\nNo. 5\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.inhaler.devices.used.\nin.the.routine.management.of.chronic.\nasthma.in.older.children:.a.systematic.\nreview.and.economic.evaluation.\nBy.Peters.J,.Stevenson.M,.Beverley.C,.\nLim.J,.Smith.S.\nNo. 6\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.sibutramine.in.the.\nmanagement.of.obesity:.a.technology.\nassessment.\nBy.O\u2019Meara.S,.Riemsma.R,.Shirran.\nL,.Mather.L,.ter.Riet.G.\nNo. 7\nThe.cost-effectiveness.of.magnetic.\nresonance.angiography.for.carotid.\nartery.stenosis.and.peripheral.vascular.\ndisease:.a.systematic.review.\nBy.Berry.E,.Kelly.S,.Westwood.ME,.\nDavies.LM,.Gough.MJ,.Bamford.JM,.\net al.\nNo. 8\nPromoting.physical.activity.in.South.\nAsian.Muslim.women.through.\u2018exercise.\non.prescription\u2019.\nBy.Carroll.B,.Ali.N,.Azam.N.\nNo. 9\nZanamivir.for.the.treatment.of.\ninfluenza.in.adults:.a.systematic.review.\nand.economic.evaluation.\nBy.Burls.A,.Clark.W,.Stewart.T,.\nPreston.C,.Bryan.S,.Jefferson.T,.et al.\nNo. 10\nA.review.of.the.natural.history.and.\nepidemiology.of.multiple.sclerosis:.\nimplications.for.resource.allocation.and.\nhealth.economic.models.\nBy.Richards.RG,.Sampson.FC,.\nBeard.SM,.Tappenden.P.\nNo. 11\nScreening.for.gestational.diabetes:.\na.systematic.review.and.economic.\nevaluation.\nBy.Scott.DA,.Loveman.E,.McIntyre.\nL,.Waugh.N.\nNo. 12\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.surgery.for.people.with.\nmorbid.obesity:.a.systematic.review.and.\neconomic.evaluation.\nBy.Clegg.AJ,.Colquitt.J,.Sidhu.MK,.\nRoyle.P,.Loveman.E,.Walker.A.\nNo. 13\nThe.clinical.effectiveness.of.\ntrastuzumab.for.breast.cancer:.a.\nsystematic.review.\nBy.Lewis.R,.Bagnall.A-M,.Forbes.C,.\nShirran.E,.Duffy.S,.Kleijnen.J,.et al.\nNo. 14\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.vinorelbine.for.breast.\ncancer:.a.systematic.review.and.\neconomic.evaluation.\nBy.Lewis.R,.Bagnall.A-M,.King.S,.\nWoolacott.N,.Forbes.C,.Shirran.L,.et al.Health Technology Assessment reports published to date\n136\nNo. 15\nA.systematic.review.of.the.effectiveness.\nand.cost-effectiveness.of.metal-on-\nmetal.hip.resurfacing.arthroplasty.for.\ntreatment.of.hip.disease.\nBy.Vale.L,.Wyness.L,.McCormack.K,.\nMcKenzie.L,.Brazzelli.M,.Stearns.SC.\nNo. 16\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.bupropion.and.nicotine.\nreplacement.therapy.for.smoking.\ncessation:.a.systematic.review.and.\neconomic.evaluation.\nBy.Woolacott.NF,.Jones.L,.Forbes.CA,.\nMather.LC,.Sowden.AJ,.Song.FJ,.et al.\nNo. 17\nA.systematic.review.of.effectiveness.\nand.economic.evaluation.of.new.drug.\ntreatments.for.juvenile.idiopathic.\narthritis:.etanercept.\nBy.Cummins.C,.Connock.M,.\nFry-Smith.A,.Burls.A.\nNo. 18\nClinical.effectiveness.and.cost-\neffectiveness.of.growth.hormone.in.\nchildren:.a.systematic.review.and.\neconomic.evaluation.\nBy.Bryant.J,.Cave.C,.Mihaylova.B,.\nChase.D,.McIntyre.L,.Gerard.K,.et al.\nNo. 19\nClinical.effectiveness.and.cost-\neffectiveness.of.growth.hormone.\nin.adults.in.relation.to.impact.on.\nquality.of.life:.a.systematic.review.and.\neconomic.evaluation.\nBy.Bryant.J,.Loveman.E,.Chase.D,.\nMihaylova.B,.Cave.C,.Gerard.K,.et al.\nNo. 20\nClinical.medication.review.by.a.\npharmacist.of.patients.on.repeat.\nprescriptions.in.general.practice:.a.\nrandomised.controlled.trial.\nBy.Zermansky.AG,.Petty.DR,.Raynor.\nDK,.Lowe.CJ,.Freementle.N,.Vail.A.\nNo. 21\nThe.effectiveness.of.infliximab.and.\netanercept.for.the.treatment.of.\nrheumatoid.arthritis:.a.systematic.\nreview.and.economic.evaluation.\nBy.Jobanputra.P,.Barton.P,.Bryan.S,.\nBurls.A.\nNo. 22\nA.systematic.review.and.economic.\nevaluation.of.computerised.cognitive.\nbehaviour.therapy.for.depression.and.\nanxiety.\nBy.Kaltenthaler.E,.Shackley.P,.\nStevens.K,.Beverley.C,.Parry.G,.\nChilcott.J.\nNo. 23\nA.systematic.review.and.economic.\nevaluation.of.pegylated.liposomal.\ndoxorubicin.hydrochloride.for.ovarian.\ncancer.\nBy.Forbes.C,.Wilby.J,.Richardson.G,.\nSculpher.M,.Mather.L,.Reimsma.R.\nNo. 24\nA.systematic.review.of.the.effectiveness.\nof.interventions.based.on.a.stages-of-\nchange.approach.to.promote.individual.\nbehaviour.change.\nBy.Riemsma.RP,.Pattenden.J,.Bridle.\nC,.Sowden.AJ,.Mather.L,.Watt.IS,.et al.\nNo. 25\nA.systematic.review.update.of.the.\nclinical.effectiveness.and.cost-\neffectiveness.of.glycoprotein.IIb\/IIIa.\nantagonists.\nBy.Robinson.M,.Ginnelly.L,.Sculpher.\nM,.Jones.L,.Riemsma.R,.Palmer.S,.et al.\nNo. 26\nA.systematic.review.of.the.effectiveness,.\ncost-effectiveness.and.barriers.to.\nimplementation.of.thrombolytic.and.\nneuroprotective.therapy.for.acute.\nischaemic.stroke.in.the.NHS.\nBy.Sandercock.P,.Berge.E,.Dennis.M,.\nForbes.J,.Hand.P,.Kwan.J,.et al.\nNo. 27\nA.randomised.controlled.crossover.trial.\nof.nurse.practitioner.versus.doctor-\nled.outpatient.care.in.a.bronchiectasis.\nclinic.\nBy.Caine.N,.Sharples.LD,.\nHollingworth.W,.French.J,.Keogan.M,.\nExley.A,.et al.\nNo. 28\nClinical.effectiveness.and.cost.\u2013.\nconsequences.of.selective.serotonin.\nreuptake.inhibitors.in.the.treatment.of.\nsex.offenders.\nBy.Adi.Y,.Ashcroft.D,.Browne.K,.\nBeech.A,.Fry-Smith.A,.Hyde.C.\nNo. 29\nTreatment.of.established.osteoporosis:.\na.systematic.review.and.cost\u2013utility.\nanalysis.\nBy.Kanis.JA,.Brazier.JE,.Stevenson.\nM,.Calvert.NW,.Lloyd.Jones.M.\nNo. 30\nWhich.anaesthetic.agents.are.cost-\neffective.in.day.surgery?.Literature.\nreview,.national.survey.of.practice.and.\nrandomised.controlled.trial.\nBy.Elliott.RA.Payne.K,.Moore.JK,.\nDavies.LM,.Harper.NJN,.St.Leger.AS,.\net al.\nNo. 31\nScreening.for.hepatitis.C.among.\ninjecting.drug.users.and.in.\ngenitourinary.medicine.clinics:.\nsystematic.reviews.of.effectiveness,.\nmodelling.study.and.national.survey.of.\ncurrent.practice.\nBy.Stein.K,.Dalziel.K,.Walker.A,.\nMcIntyre.L,.Jenkins.B,.Horne.J, et al.\nNo. 32\nThe.measurement.of.satisfaction.with.\nhealthcare:.implications.for.practice.\nfrom.a.systematic.review.of.the.\nliterature.\nBy.Crow.R,.Gage.H,.Hampson.S,.\nHart.J,.Kimber.A,.Storey.L,.et al.\nNo. 33\nThe.effectiveness.and.cost-effectiveness.\nof.imatinib.in.chronic.myeloid.\nleukaemia:.a.systematic.review.\nBy.Garside.R,.Round.A,.Dalziel.K,.\nStein.K,.Royle.R.\nNo. 34\nA.comparative.study.of.hypertonic.\nsaline,.daily.and.alternate-day.rhDNase.\nin.children.with.cystic.fibrosis.\nBy.Suri.R,.Wallis.C,.Bush.A,.\nThompson.S,.Normand.C,.Flather.M,.\net al.\nNo. 35\nA.systematic.review.of.the.costs.and.\neffectiveness.of.different.models.of.\npaediatric.home.care.\nBy.Parker.G,.Bhakta.P,.Lovett.CA,.\nPaisley.S,.Olsen.R,.Turner.D,.et al.\nVolume 7, 2003\nNo. 1\nHow.important.are.comprehensive.\nliterature.searches.and.the.assessment.\nof.trial.quality.in.systematic.reviews?.\nEmpirical.study.\nBy.Egger.M,.Ju\u0308ni.P,.Bartlett.C,.\nHolenstein.F,.Sterne.J.\nNo. 2\nSystematic.review.of.the.effectiveness.\nand.cost-effectiveness,.and.economic.\nevaluation,.of.home.versus.hospital.or.\nsatellite.unit.haemodialysis.for.people.\nwith.end-stage.renal.failure.\nBy.Mowatt.G,.Vale.L,.Perez.J,.Wyness.\nL,.Fraser.C,.MacLeod.A,.et al.\nNo. 3\nSystematic.review.and.economic.\nevaluation.of.the.effectiveness.of.\ninfliximab.for.the.treatment.of.Crohn\u2019s.\ndisease.\nBy.Clark.W,.Raftery.J,.Barton.P,.\nSong.F,.Fry-Smith.A,.Burls.A.\nNo. 4\nA.review.of.the.clinical.effectiveness.\nand.cost-effectiveness.of.routine.anti-D.\nprophylaxis.for.pregnant.women.who.\nare.rhesus.negative.\nBy.Chilcott.J,.Lloyd.Jones.M,.Wight.\nJ,.Forman.K,.Wray.J,.Beverley.C,.et al.\nNo. 5\nSystematic.review.and.evaluation.of.the.\nuse.of.tumour.markers.in.paediatric.\noncology:.Ewing\u2019s.sarcoma.and.\nneuroblastoma.\nBy.Riley.RD,.Burchill.SA,.\nAbrams.KR,.Heney.D,.Lambert.PC,.\nJones.DR,.et al.\nNo. 6\nThe.cost-effectiveness.of.screening.for.\nHelicobacter pylori to.reduce.mortality.\nand.morbidity.from.gastric.cancer.and.\npeptic.ulcer.disease:.a.discrete-event.\nsimulation.model.\nBy.Roderick.P,.Davies.R,.Raftery.J,.\nCrabbe.D,.Pearce.R,.Bhandari.P,.et al.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n137\nNo. 7\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.routine.dental.checks:.\na.systematic.review.and.economic.\nevaluation.\nBy.Davenport.C,.Elley.K,.Salas.\nC,.Taylor-Weetman.CL,.Fry-Smith.A,.\nBryan.S,.et al.\nNo. 8\nA.multicentre.randomised.controlled.\ntrial.assessing.the.costs.and.benefits.\nof.using.structured.information.and.\nanalysis.of.women\u2019s.preferences.in.the.\nmanagement.of.menorrhagia.\nBy.Kennedy.ADM,.Sculpher.MJ,.\nCoulter.A,.Dwyer.N,.Rees.M,.Horsley.S,.\net al.\nNo. 9\nClinical.effectiveness.and.cost\u2013utility.\nof.photodynamic.therapy.for.wet.\nage-related.macular.degeneration:.\na.systematic.review.and.economic.\nevaluation.\nBy.Meads.C,.Salas.C,.Roberts.T,.\nMoore.D,.Fry-Smith.A,.Hyde.C.\nNo. 10\nEvaluation.of.molecular.tests.for.\nprenatal.diagnosis.of.chromosome.\nabnormalities.\nBy.Grimshaw.GM,.Szczepura.A,.\nHult\u00e9n.M,.MacDonald.F,.Nevin.NC,.\nSutton.F,.et al.\nNo. 11\nFirst.and.second.trimester.antenatal.\nscreening.for.Down\u2019s.syndrome:.\nthe.results.of.the.Serum,.Urine.and.\nUltrasound.Screening.Study.(SURUSS).\nBy.Wald.NJ,.Rodeck.C,.Hackshaw.\nAK,.Walters.J,.Chitty.L,.Mackinson.AM.\nNo. 12\nThe.effectiveness.and.cost-effectiveness.\nof.ultrasound.locating.devices.for.\ncentral.venous.access:.a.systematic.\nreview.and.economic.evaluation.\nBy.Calvert.N,.Hind.D,.McWilliams.\nRG,.Thomas.SM,.Beverley.C,.\nDavidson.A.\nNo. 13\nA.systematic.review.of.atypical.\nantipsychotics.in.schizophrenia.\nBy.Bagnall.A-M,.Jones.L,.Lewis.R,.\nGinnelly.L,.Glanville.J,.Torgerson.D,\net al.\nNo. 14\nProstate.Testing.for.Cancer.and.\nTreatment.(ProtecT).feasibility.study.\nBy.Donovan.J,.Hamdy.F,.Neal.D,.\nPeters.T,.Oliver.S,.Brindle.L,.et al.\nNo. 15\nEarly.thrombolysis.for.the.treatment.\nof.acute.myocardial.infarction:.a.\nsystematic.review.and.economic.\nevaluation.\nBy.Boland.A,.Dundar.Y,.Bagust.A,.\nHaycox.A,.Hill.R,.Mujica.Mota.R,.et al.\nNo. 16\nScreening.for.fragile.X.syndrome:.a.\nliterature.review.and.modelling.\nBy.Song.FJ,.Barton.P,.Sleightholme.\nV,.Yao.GL,.Fry-Smith.A.\nNo. 17\nSystematic.review.of.endoscopic.sinus.\nsurgery.for.nasal.polyps.\nBy.Dalziel.K,.Stein.K,.Round.A,.\nGarside.R,.Royle.P.\nNo. 18\nTowards.efficient.guidelines:.how.to.\nmonitor.guideline.use.in.primary.care.\nBy.Hutchinson.A,.McIntosh.A,.\nCox.S,.Gilbert.C.\nNo. 19\nEffectiveness.and.cost-effectiveness.\nof.acute.hospital-based.spinal.cord.\ninjuries.services:.systematic.review.\nBy.Bagnall.A-M,.Jones.L,.Richardson.\nG,.Duffy.S,.Riemsma.R.\nNo. 20\nPrioritisation.of.health.technology.\nassessment..The.PATHS.model:.\nmethods.and.case.studies.\nBy.Townsend.J,.Buxton.M,.\nHarper.G.\nNo. 21\nSystematic.review.of.the.clinical.\neffectiveness.and.cost-effectiveness.of.\ntension-free.vaginal.tape.for.treatment.\nof.urinary.stress.incontinence.\nBy.Cody.J,.Wyness.L,.Wallace.S,.\nGlazener.C,.Kilonzo.M,.Stearns.S,.et al.\nNo. 22\nThe.clinical.and.cost-effectiveness.of.\npatient.education.models.for.diabetes:.\na.systematic.review.and.economic.\nevaluation.\nBy.Loveman.E,.Cave.C,.Green.C,.\nRoyle.P,.Dunn.N,.Waugh.N.\nNo. 23\nThe.role.of.modelling.in.prioritising.\nand.planning.clinical.trials.\nBy.Chilcott.J,.Brennan.A,.Booth.A,.\nKarnon.J,.Tappenden.P.\nNo. 24\nCost\u2013benefit.evaluation.of.routine.\ninfluenza.immunisation.in.people.\n65\u201374.years.of.age.\nBy.Allsup.S,.Gosney.M,.Haycox.A,.\nRegan.M.\nNo. 25\nThe.clinical.and.cost-effectiveness.of.\npulsatile.machine.perfusion.versus.cold.\nstorage.of.kidneys.for.transplantation.\nretrieved.from.heart-beating.and.non-\nheart-beating.donors.\nBy.Wight.J,.Chilcott.J,.Holmes.M,.\nBrewer.N.\nNo. 26\nCan.randomised.trials.rely.on.existing.\nelectronic.data?.A.feasibility.study.to.\nexplore.the.value.of.routine.data.in.\nhealth.technology.assessment.\nBy.Williams.JG,.Cheung.WY,.\nCohen.DR,.Hutchings.HA,.Longo.MF,.\nRussell.IT.\nNo. 27\nEvaluating.non-randomised.\nintervention.studies.\nBy.Deeks.JJ,.Dinnes.J,.D\u2019Amico.R,.\nSowden.AJ,.Sakarovitch.C,.Song.F,.et al.\nNo. 28\nA.randomised.controlled.trial.to.assess.\nthe.impact.of.a.package.comprising.a.\npatient-orientated,.evidence-based.self-.\nhelp.guidebook.and.patient-centred.\nconsultations.on.disease.management.\nand.satisfaction.in.inflammatory.bowel.\ndisease.\nBy.Kennedy.A,.Nelson.E,.Reeves.D,.\nRichardson.G,.Roberts.C,.Robinson.A,.\net al.\nNo. 29\nThe.effectiveness.of.diagnostic.tests.for.\nthe.assessment.of.shoulder.pain.due.\nto.soft.tissue.disorders:.a.systematic.\nreview.\nBy.Dinnes.J,.Loveman.E,.McIntyre.L,.\nWaugh.N.\nNo. 30\nThe.value.of.digital.imaging.in.diabetic.\nretinopathy.\nBy.Sharp.PF,.Olson.J,.Strachan.F,.\nHipwell.J,.Ludbrook.A,.O\u2019Donnell.M,.\net al.\nNo. 31\nLowering.blood.pressure.to.prevent.\nmyocardial.infarction.and.stroke:.a.new.\npreventive.strategy.\nBy.Law.M,.Wald.N,.Morris.J.\nNo. 32\nClinical.and.cost-effectiveness.of.\ncapecitabine.and.tegafur.with.uracil.for.\nthe.treatment.of.metastatic.colorectal.\ncancer:.systematic.review.and.economic.\nevaluation.\nBy.Ward.S,.Kaltenthaler.E,.Cowan.J,.\nBrewer.N.\nNo. 33\nClinical.and.cost-effectiveness.of.new.\nand.emerging.technologies.for.early.\nlocalised.prostate.cancer:.a.systematic.\nreview.\nBy.Hummel.S,.Paisley.S,.Morgan.A,.\nCurrie.E,.Brewer.N.\nNo. 34\nLiterature.searching.for.clinical.and.\ncost-effectiveness.studies.used.in.health.\ntechnology.assessment.reports.carried.\nout.for.the.National.Institute.for.\nClinical.Excellence.appraisal.system.\nBy.Royle.P,.Waugh.N.Health Technology Assessment reports published to date\n138\nNo. 35\nSystematic.review.and.economic.\ndecision.modelling.for.the.prevention.\nand.treatment.of.influenza.A.and.B.\nBy.Turner.D,.Wailoo.A,.Nicholson.K,.\nCooper.N,.Sutton.A,.Abrams.K.\nNo. 36\nA.randomised.controlled.trial.\nto.evaluate.the.clinical.and.cost-\neffectiveness.of.Hickman.line.insertions.\nin.adult.cancer.patients.by.nurses.\nBy.Boland.A,.Haycox.A,.Bagust.A,.\nFitzsimmons.L.\nNo. 37\nRedesigning.postnatal.care:.a.\nrandomised.controlled.trial.of.protocol-\nbased.midwifery-led.care.focused.\non.individual.women\u2019s.physical.and.\npsychological.health.needs.\nBy.MacArthur.C,.Winter.HR,.\nBick.DE,.Lilford.RJ,.Lancashire.RJ,.\nKnowles.H,.et al.\nNo. 38\nEstimating.implied.rates.of.discount.in.\nhealthcare.decision-making.\nBy.West.RR,.McNabb.R,.Thompson.\nAGH,.Sheldon.TA,.Grimley.Evans.J.\nNo. 39\nSystematic.review.of.isolation.policies.\nin.the.hospital.management.of.\nmethicillin-resistant.Staphylococcus \naureus:.a.review.of.the.literature.\nwith.epidemiological.and.economic.\nmodelling.\nBy.Cooper.BS,.Stone.SP,.Kibbler.CC,.\nCookson.BD,.Roberts.JA,.Medley.GF,.\net al.\nNo. 40\nTreatments.for.spasticity.and.pain.in.\nmultiple.sclerosis:.a.systematic.review.\nBy.Beard.S,.Hunn.A,.Wight.J.\nNo. 41\nThe.inclusion.of.reports.of.randomised.\ntrials.published.in.languages.other.than.\nEnglish.in.systematic.reviews.\nBy.Moher.D,.Pham.B,.Lawson.ML,.\nKlassen.TP.\nNo. 42\nThe.impact.of.screening.on.future.\nhealth-promoting.behaviours.and.\nhealth.beliefs:.a.systematic.review.\nBy.Bankhead.CR,.Brett.J,.Bukach.C,.\nWebster.P,.Stewart-Brown.S,.Munafo.M,.\net al.\nVolume 8, 2004\nNo. 1\nWhat.is.the.best.imaging.strategy.for.\nacute.stroke?\nBy.Wardlaw.JM,.Keir.SL,.Seymour.J,.\nLewis.S,.Sandercock.PAG,.Dennis.MS,.\net al.\nNo. 2\nSystematic.review.and.modelling.of.the.\ninvestigation.of.acute.and.chronic.chest.\npain.presenting.in.primary.care.\nBy.Mant.J,.McManus.RJ,.Oakes.RAL,.\nDelaney.BC,.Barton.PM,.Deeks.JJ,.et al.\nNo. 3\nThe.effectiveness.and.cost-effectiveness.\nof.microwave.and.thermal.balloon.\nendometrial.ablation.for.heavy.\nmenstrual.bleeding:.a.systematic.review.\nand.economic.modelling.\nBy.Garside.R,.Stein.K,.Wyatt.K,.\nRound.A,.Price.A.\nNo. 4\nA.systematic.review.of.the.role.of.\nbisphosphonates.in.metastatic.disease.\nBy.Ross.JR,.Saunders.Y,.\nEdmonds.PM,.Patel.S,.Wonderling.D,.\nNormand.C,.et al.\nNo. 5\nSystematic.review.of.the.clinical.\neffectiveness.and.cost-effectiveness.\nof.capecitabine.(Xeloda\u00ae).for.locally.\nadvanced.and\/or.metastatic.breast.\ncancer.\nBy.Jones.L,.Hawkins.N,.Westwood.M,.\nWright.K,.Richardson.G,.Riemsma.R.\nNo. 6\nEffectiveness.and.efficiency.of.guideline.\ndissemination.and.implementation.\nstrategies.\nBy.Grimshaw.JM,.Thomas.RE,.\nMacLennan.G,.Fraser.C,.Ramsay.CR,.\nVale.L,.et al.\nNo. 7\nClinical.effectiveness.and.costs.of.the.\nSugarbaker.procedure.for.the.treatment.\nof.pseudomyxoma.peritonei.\nBy.Bryant.J,.Clegg.AJ,.Sidhu.MK,.\nBrodin.H,.Royle.P,.Davidson.P.\nNo. 8\nPsychological.treatment.for.insomnia.\nin.the.regulation.of.long-term.hypnotic.\ndrug.use.\nBy.Morgan.K,.Dixon.S,.Mathers.N,.\nThompson.J,.Tomeny.M.\nNo. 9\nImproving.the.evaluation.of.\ntherapeutic.interventions.in.multiple.\nsclerosis:.development.of.a.patient-\nbased.measure.of.outcome.\nBy.Hobart.JC,.Riazi.A,.Lamping.DL,.\nFitzpatrick.R,.Thompson.AJ.\nNo. 10\nA.systematic.review.and.economic.\nevaluation.of.magnetic.resonance.\ncholangiopancreatography.compared.\nwith.diagnostic.endoscopic.retrograde.\ncholangiopancreatography.\nBy.Kaltenthaler.E,.Bravo.Vergel.Y,.\nChilcott.J,.Thomas.S,.Blakeborough.T,.\nWalters.SJ,.et al.\nNo. 11\nThe.use.of.modelling.to.evaluate.\nnew.drugs.for.patients.with.a.chronic.\ncondition:.the.case.of.antibodies.\nagainst.tumour.necrosis.factor.in.\nrheumatoid.arthritis.\nBy.Barton.P,.Jobanputra.P,.Wilson.J,.\nBryan.S,.Burls.A.\nNo. 12\nClinical.effectiveness.and.cost-\neffectiveness.of.neonatal.screening.\nfor.inborn.errors.of.metabolism.using.\ntandem.mass.spectrometry:.a.systematic.\nreview.\nBy.Pandor.A,.Eastham.J,.Beverley.C,.\nChilcott.J,.Paisley.S.\nNo. 13\nClinical.effectiveness.and.cost-\neffectiveness.of.pioglitazone.and.\nrosiglitazone.in.the.treatment.of.type.\n2.diabetes:.a.systematic.review.and.\neconomic.evaluation.\nBy.Czoski-Murray.C,.Warren.E,.\nChilcott.J,.Beverley.C,.Psyllaki.MA,.\nCowan.J.\nNo. 14\nRoutine.examination.of.the.newborn:.\nthe.EMREN.study..Evaluation.of.an.\nextension.of.the.midwife.role.including.\na.randomised.controlled.trial.of.\nappropriately.trained.midwives.and.\npaediatric.senior.house.officers.\nBy.Townsend.J,.Wolke.D,.Hayes.J,.\nDav\u00e9.S,.Rogers.C,.Bloomfield.L,.et al.\nNo. 15\nInvolving.consumers.in.research.and.\ndevelopment.agenda.setting.for.the.\nNHS:.developing.an.evidence-based.\napproach.\nBy.Oliver.S,.Clarke-Jones.L,.Rees.R,.\nMilne.R,.Buchanan.P,.Gabbay.J,.et al.\nNo. 16\nA.multi-centre.randomised.controlled.\ntrial.of.minimally.invasive.direct.\ncoronary.bypass.grafting.versus.\npercutaneous.transluminal.coronary.\nangioplasty.with.stenting.for.proximal.\nstenosis.of.the.left.anterior.descending.\ncoronary.artery.\nBy.Reeves.BC,.Angelini.GD,.Bryan.\nAJ,.Taylor.FC,.Cripps.T,.Spyt.TJ,.et al.\nNo. 17\nDoes.early.magnetic.resonance.imaging.\ninfluence.management.or.improve.\noutcome.in.patients.referred.to.\nsecondary.care.with.low.back.pain?.A.\npragmatic.randomised.controlled.trial.\nBy.Gilbert.FJ,.Grant.AM,.Gillan.\nMGC,.Vale.L,.Scott.NW,.Campbell.MK,.\net al.\nNo. 18\nThe.clinical.and.cost-effectiveness.\nof.anakinra.for.the.treatment.of.\nrheumatoid.arthritis.in.adults:.a.\nsystematic.review.and.economic.\nanalysis.\nBy.Clark.W,.Jobanputra.P,.Barton.P,.\nBurls.A.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n139\nNo. 19\nA.rapid.and.systematic.review.and.\neconomic.evaluation.of.the.clinical.\nand.cost-effectiveness.of.newer.drugs.\nfor.treatment.of.mania.associated.with.\nbipolar.affective.disorder.\nBy.Bridle.C,.Palmer.S,.Bagnall.A-M,.\nDarba.J,.Duffy.S,.Sculpher.M,.et al.\nNo. 20\nLiquid-based.cytology.in.cervical.\nscreening:.an.updated.rapid.and.\nsystematic.review.and.economic.\nanalysis.\nBy.Karnon.J,.Peters.J,.Platt.J,.\nChilcott.J,.McGoogan.E,.Brewer.N.\nNo. 21\nSystematic.review.of.the.long-term.\neffects.and.economic.consequences.of.\ntreatments.for.obesity.and.implications.\nfor.health.improvement.\nBy.Avenell.A,.Broom.J,.Brown.TJ,.\nPoobalan.A,.Aucott.L,.Stearns.SC,.et al.\nNo. 22\nAutoantibody.testing.in.children.\nwith.newly.diagnosed.type.1.diabetes.\nmellitus.\nBy.Dretzke.J,.Cummins.C,.\nSandercock.J,.Fry-Smith.A,.Barrett.T,.\nBurls.A.\nNo. 23\nClinical.effectiveness.and.cost-\neffectiveness.of.prehospital.intravenous.\nfluids.in.trauma.patients.\nBy.Dretzke.J,.Sandercock.J,.Bayliss.\nS,.Burls.A.\nNo. 24\nNewer.hypnotic.drugs.for.the.short-\nterm.management.of.insomnia:.a.\nsystematic.review.and.economic.\nevaluation.\nBy.Du\u0308ndar.Y,.Boland.A,.Strobl.J,.\nDodd.S,.Haycox.A,.Bagust.A,.et al.\nNo. 25\nDevelopment.and.validation.of.\nmethods.for.assessing.the.quality.of.\ndiagnostic.accuracy.studies.\nBy.Whiting.P,.Rutjes.AWS,.Dinnes.J,.\nReitsma.JB,.Bossuyt.PMM,.Kleijnen.J.\nNo. 26\nEVALUATE.hysterectomy.trial:.\na.multicentre.randomised.trial.\ncomparing.abdominal,.vaginal.and.\nlaparoscopic.methods.of.hysterectomy.\nBy.Garry.R,.Fountain.J,.Brown.J,.\nManca.A,.Mason.S,.Sculpher.M,.et al.\nNo. 27\nMethods.for.expected.value.of.\ninformation.analysis.in.complex.health.\neconomic.models:.developments.on.\nthe.health.economics.of.interferon-\u03b2.\nand.glatiramer.acetate.for.multiple.\nsclerosis.\nBy.Tappenden.P,.Chilcott.JB,.\nEggington.S,.Oakley.J,.McCabe.C.\nNo. 28\nEffectiveness.and.cost-effectiveness.\nof.imatinib.for.first-line.treatment.\nof.chronic.myeloid.leukaemia.in.\nchronic.phase:.a.systematic.review.and.\neconomic.analysis.\nBy.Dalziel.K,.Round.A,.Stein.K,.\nGarside.R,.Price.A.\nNo. 29\nVenUS.I:.a.randomised.controlled.trial.\nof.two.types.of.bandage.for.treating.\nvenous.leg.ulcers.\nBy.Iglesias.C,.Nelson.EA,.Cullum.\nNA,.Torgerson.DJ,.on.behalf.of.the.\nVenUS.Team.\nNo. 30\nSystematic.review.of.the.effectiveness.\nand.cost-effectiveness,.and.economic.\nevaluation,.of.myocardial.perfusion.\nscintigraphy.for.the.diagnosis.and.\nmanagement.of.angina.and.myocardial.\ninfarction.\nBy.Mowatt.G,.Vale.L,.Brazzelli.M,.\nHernandez.R,.Murray.A,.Scott.N,.et al.\nNo. 31\nA.pilot.study.on.the.use.of.decision.\ntheory.and.value.of.information.\nanalysis.as.part.of.the.NHS.Health.\nTechnology.Assessment.programme.\nBy.Claxton.K,.Ginnelly.L,.Sculpher.\nM,.Philips.Z,.Palmer.S.\nNo. 32\nThe.Social.Support.and.Family.Health.\nStudy:.a.randomised.controlled.trial.\nand.economic.evaluation.of.two.\nalternative.forms.of.postnatal.support.\nfor.mothers.living.in.disadvantaged.\ninner-city.areas.\nBy.Wiggins.M,.Oakley.A,.Roberts.I,.\nTurner.H,.Rajan.L,.Austerberry.H,.et al.\nNo. 33\nPsychosocial.aspects.of.genetic.\nscreening.of.pregnant.women.and.\nnewborns:.a.systematic.review.\nBy.Green.JM,.Hewison.J,.Bekker.HL,.\nBryant,.Cuckle.HS.\nNo. 34\nEvaluation.of.abnormal.uterine.\nbleeding:.comparison.of.three.\noutpatient.procedures.within.cohorts.\ndefined.by.age.and.menopausal.status.\nBy.Critchley.HOD,.Warner.P,.Lee.AJ,.\nBrechin.S,.Guise.J,.Graham.B.\nNo. 35\nCoronary.artery.stents:.a.rapid.\nsystematic.review.and.economic.\nevaluation.\nBy.Hill.R,.Bagust.A,.Bakhai.A,.\nDickson.R,.Du\u0308ndar.Y,.Haycox.A,.et al.\nNo. 36\nReview.of.guidelines.for.good.practice.\nin.decision-analytic.modelling.in.health.\ntechnology.assessment.\nBy.Philips.Z,.Ginnelly.L,.Sculpher.M,.\nClaxton.K,.Golder.S,.Riemsma.R,.et al.\nNo. 37\nRituximab.(MabThera\u00ae).for.\naggressive.non-Hodgkin\u2019s.lymphoma:.\nsystematic.review.and.economic.\nevaluation.\nBy.Knight.C,.Hind.D,.Brewer.N,.\nAbbott.V.\nNo. 38\nClinical.effectiveness.and.cost-\neffectiveness.of.clopidogrel.and.\nmodified-release.dipyridamole.in.the.\nsecondary.prevention.of.occlusive.\nvascular.events:.a.systematic.review.and.\neconomic.evaluation.\nBy.Jones.L,.Griffin.S,.Palmer.S,.Main.\nC,.Orton.V,.Sculpher.M,.et al.\nNo. 39\nPegylated.interferon.\u03b1-2a.and.-2b.\nin.combination.with.ribavirin.in.the.\ntreatment.of.chronic.hepatitis.C:.\na.systematic.review.and.economic.\nevaluation.\nBy.Shepherd.J,.Brodin.H,.Cave.C,.\nWaugh.N,.Price.A,.Gabbay.J.\nNo. 40\nClopidogrel.used.in.combination.with.\naspirin.compared.with.aspirin.alone.\nin.the.treatment.of.non-ST-segment-.\nelevation.acute.coronary.syndromes:.\na.systematic.review.and.economic.\nevaluation.\nBy.Main.C,.Palmer.S,.Griffin.S,.Jones.\nL,.Orton.V,.Sculpher.M,.et al.\nNo. 41\nProvision,.uptake.and.cost.of.cardiac.\nrehabilitation.programmes:.improving.\nservices.to.under-represented.groups.\nBy.Beswick.AD,.Rees.K,.Griebsch.I,.\nTaylor.FC,.Burke.M,.West.RR,.et al.\nNo. 42\nInvolving.South.Asian.patients.in.\nclinical.trials.\nBy.Hussain-Gambles.M,.Leese.B,.\nAtkin.K,.Brown.J,.Mason.S,.Tovey.P.\nNo. 43\nClinical.and.cost-effectiveness.of.\ncontinuous.subcutaneous.insulin.\ninfusion.for.diabetes.\nBy.Colquitt.JL,.Green.C,.Sidhu.MK,.\nHartwell.D,.Waugh.N.\nNo. 44\nIdentification.and.assessment.of.\nongoing.trials.in.health.technology.\nassessment.reviews.\nBy.Song.FJ,.Fry-Smith.A,.Davenport.\nC,.Bayliss.S,.Adi.Y,.Wilson.JS,.et al.\nNo. 45\nSystematic.review.and.economic.\nevaluation.of.a.long-acting.insulin.\nanalogue,.insulin.glargine\nBy.Warren.E,.Weatherley-Jones.E,.\nChilcott.J,.Beverley.C.Health Technology Assessment reports published to date\n140\nNo. 46\nSupplementation.of.a.home-based.\nexercise.programme.with.a.class-\nbased.programme.for.people.\nwith.osteoarthritis.of.the.knees:.a.\nrandomised.controlled.trial.and.health.\neconomic.analysis.\nBy.McCarthy.CJ,.Mills.PM,.Pullen.R,.\nRichardson.G,.Hawkins.N,.Roberts.CR,.\net al.\nNo. 47\nClinical.and.cost-effectiveness.of.once-\ndaily.versus.more.frequent.use.of.same.\npotency.topical.corticosteroids.for.\natopic.eczema:.a.systematic.review.and.\neconomic.evaluation.\nBy.Green.C,.Colquitt.JL,.Kirby.J,.\nDavidson.P,.Payne.E.\nNo. 48\nAcupuncture.of.chronic.headache.\ndisorders.in.primary.care:.randomised.\ncontrolled.trial.and.economic.analysis.\nBy.Vickers.AJ,.Rees.RW,.Zollman.CE,.\nMcCarney.R,.Smith.CM,.Ellis.N,.et al.\nNo. 49\nGeneralisability.in.economic.evaluation.\nstudies.in.healthcare:.a.review.and.case.\nstudies.\nBy.Sculpher.MJ,.Pang.FS,.Manca.A,.\nDrummond.MF,.Golder.S,.Urdahl.H,.\net al.\nNo. 50\nVirtual.outreach:.a.randomised.\ncontrolled.trial.and.economic.\nevaluation.of.joint.teleconferenced.\nmedical.consultations.\nBy.Wallace.P,.Barber.J,.Clayton.W,.\nCurrell.R,.Fleming.K,.Garner.P,.et al.\nVolume 9, 2005\nNo. 1\nRandomised.controlled.multiple.\ntreatment.comparison.to.provide.a.cost-\neffectiveness.rationale.for.the.selection.\nof.antimicrobial.therapy.in.acne.\nBy.Ozolins.M,.Eady.EA,.Avery.A,.\nCunliffe.WJ,.O\u2019Neill.C,.Simpson.NB,.\net al.\nNo. 2\nDo.the.findings.of.case.series.studies.\nvary.significantly.according.to.\nmethodological.characteristics?\nBy.Dalziel.K,.Round.A,.Stein.K,.\nGarside.R,.Castelnuovo.E,.Payne.L.\nNo. 3\nImproving.the.referral.process.\nfor.familial.breast.cancer.genetic.\ncounselling:.findings.of.three.\nrandomised.controlled.trials.of.two.\ninterventions.\nBy.Wilson.BJ,.Torrance.N,.\nMollison.J,.Wordsworth.S,.Gray.JR,.\nHaites.NE,.et al.\nNo. 4\nRandomised.evaluation.of.alternative.\nelectrosurgical.modalities.to.treat.\nbladder.outflow.obstruction.in.men.\nwith.benign.prostatic.hyperplasia.\nBy.Fowler.C,.McAllister.W,.Plail.R,.\nKarim.O,.Yang.Q.\nNo. 5\nA.pragmatic.randomised.controlled.\ntrial.of.the.cost-effectiveness.of.\npalliative.therapies.for.patients.with.\ninoperable.oesophageal.cancer.\nBy.Shenfine.J,.McNamee.P,.Steen.N,.\nBond.J,.Griffin.SM.\nNo. 6\nImpact.of.computer-aided.detection.\nprompts.on.the.sensitivity.and.\nspecificity.of.screening.mammography.\nBy.Taylor.P,.Champness.J,.Given-.\nWilson.R,.Johnston.K,.Potts.H.\nNo. 7\nIssues.in.data.monitoring.and.interim.\nanalysis.of.trials.\nBy.Grant.AM,.Altman.DG,.Babiker.\nAB,.Campbell.MK,.Clemens.FJ,.\nDarbyshire.JH,.et al.\nNo. 8\nLay.public\u2019s.understanding.of.equipoise.\nand.randomisation.in.randomised.\ncontrolled.trials.\nBy.Robinson.EJ,.Kerr.CEP,.\nStevens.AJ,.Lilford.RJ,.Braunholtz.DA,.\nEdwards.SJ,.et al.\nNo. 9\nClinical.and.cost-effectiveness.of.\nelectroconvulsive.therapy.for.depressive.\nillness,.schizophrenia,.catatonia.\nand.mania:.systematic.reviews.and.\neconomic.modelling.studies.\nBy.Greenhalgh.J,.Knight.C,.Hind.D,.\nBeverley.C,.Walters.S.\nNo. 10\nMeasurement.of.health-related.quality.\nof.life.for.people.with.dementia:.\ndevelopment.of.a.new.instrument.\n(DEMQOL).and.an.evaluation.of.\ncurrent.methodology.\nBy.Smith.SC,.Lamping.DL,.Banerjee.\nS,.Harwood.R,.Foley.B,.Smith.P,.et al.\nNo. 11\nClinical.effectiveness.and.cost-\neffectiveness.of.drotrecogin.alfa.\n(activated).(Xigris\u00ae).for.the.treatment.\nof.severe.sepsis.in.adults:.a.systematic.\nreview.and.economic.evaluation.\nBy.Green.C,.Dinnes.J,.Takeda.A,.\nShepherd.J,.Hartwell.D,.Cave.C,.et al.\nNo. 12\nA.methodological.review.of.how.\nheterogeneity.has.been.examined.in.\nsystematic.reviews.of.diagnostic.test.\naccuracy.\nBy.Dinnes.J,.Deeks.J,.Kirby.J,.\nRoderick.P.\nNo. 13\nCervical.screening.programmes:.can.\nautomation.help?.Evidence.from.\nsystematic.reviews,.an.economic.\nanalysis.and.a.simulation.modelling.\nexercise.applied.to.the.UK.\nBy.Willis.BH,.Barton.P,.Pearmain.P,.\nBryan.S,.Hyde.C.\nNo. 14\nLaparoscopic.surgery.for.inguinal.\nhernia.repair:.systematic.review.of.\neffectiveness.and.economic.evaluation.\nBy.McCormack.K,.Wake.B,.Perez.J,.\nFraser.C,.Cook.J,.McIntosh.E,.et al.\nNo. 15\nClinical.effectiveness,.tolerability.and.\ncost-effectiveness.of.newer.drugs.for.\nepilepsy.in.adults:.a.systematic.review.\nand.economic.evaluation.\nBy.Wilby.J,.Kainth.A,.Hawkins.N,.\nEpstein.D,.McIntosh.H,.McDaid.C,.et al.\nNo. 16\nA.randomised.controlled.trial.to.\ncompare.the.cost-effectiveness.of.\ntricyclic.antidepressants,.selective.\nserotonin.reuptake.inhibitors.and.\nlofepramine.\nBy.Peveler.R,.Kendrick.T,.Buxton.M,.\nLongworth.L,.Baldwin.D,.Moore.M,.et al.\nNo. 17\nClinical.effectiveness.and.cost-\neffectiveness.of.immediate.angioplasty.\nfor.acute.myocardial.infarction:.\nsystematic.review.and.economic.\nevaluation.\nBy.Hartwell.D,.Colquitt.J,.Loveman.\nE,.Clegg.AJ,.Brodin.H,.Waugh.N,.et al.\nNo. 18\nA.randomised.controlled.comparison.of.\nalternative.strategies.in.stroke.care.\nBy.Kalra.L,.Evans.A,.Perez.I,.\nKnapp.M,.Swift.C,.Donaldson.N.\nNo. 19\nThe.investigation.and.analysis.of.\ncritical.incidents.and.adverse.events.in.\nhealthcare.\nBy.Woloshynowych.M,.Rogers.S,.\nTaylor-Adams.S,.Vincent.C.\nNo. 20\nPotential.use.of.routine.databases.in.\nhealth.technology.assessment.\nBy.Raftery.J,.Roderick.P,.Stevens.A.\nNo. 21\nClinical.and.cost-effectiveness.of.newer.\nimmunosuppressive.regimens.in.renal.\ntransplantation:.a.systematic.review.and.\nmodelling.study.\nBy.Woodroffe.R,.Yao.GL,.Meads.C,.\nBayliss.S,.Ready.A,.Raftery.J,.et al.\nNo. 22\nA.systematic.review.and.economic.\nevaluation.of.alendronate,.etidronate,.\nrisedronate,.raloxifene.and.teriparatide.\nfor.the.prevention.and.treatment.of.\npostmenopausal.osteoporosis.\nBy.Stevenson.M,.Lloyd.Jones.M,.De.\nNigris.E,.Brewer.N,.Davis.S,.Oakley.J.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n141\nNo. 23\nA.systematic.review.to.examine.\nthe.impact.of.psycho-educational.\ninterventions.on.health.outcomes.\nand.costs.in.adults.and.children.with.\ndifficult.asthma.\nBy.Smith.JR,.Mugford.M,.Holland.\nR,.Candy.B,.Noble.MJ,.Harrison.BDW,.\net al.\nNo. 24\nAn.evaluation.of.the.costs,.effectiveness.\nand.quality.of.renal.replacement.\ntherapy.provision.in.renal.satellite.units.\nin.England.and.Wales.\nBy.Roderick.P,.Nicholson.T,.Armitage.\nA,.Mehta.R,.Mullee.M,.Gerard.K,.et al.\nNo. 25\nImatinib.for.the.treatment.of.patients.\nwith.unresectable.and\/or.metastatic.\ngastrointestinal.stromal.tumours:.\nsystematic.review.and.economic.\nevaluation.\nBy.Wilson.J,.Connock.M,.Song.F,.\nYao.G,.Fry-Smith.A,.Raftery.J,.et al.\nNo. 26\nIndirect.comparisons.of.competing.\ninterventions.\nBy.Glenny.AM,.Altman.DG,.Song.F,.\nSakarovitch.C,.Deeks.JJ,.D\u2019Amico.R,.\net al.\nNo. 27\nCost-effectiveness.of.alternative.\nstrategies.for.the.initial.medical.\nmanagement.of.non-ST.elevation.acute.\ncoronary.syndrome:.systematic.review.\nand.decision-analytical.modelling.\nBy.Robinson.M,.Palmer.S,.Sculpher.\nM,.Philips.Z,.Ginnelly.L,.Bowens.A,.et al.\nNo. 28\nOutcomes.of.electrically.stimulated.\ngracilis.neosphincter.surgery.\nBy.Tillin.T,.Chambers.M,.Feldman.R.\nNo. 29\nThe.effectiveness.and.cost-effectiveness.\nof.pimecrolimus.and.tacrolimus.for.\natopic.eczema:.a.systematic.review.and.\neconomic.evaluation.\nBy.Garside.R,.Stein.K,.Castelnuovo.\nE,.Pitt.M,.Ashcroft.D,.Dimmock.P,.et al.\nNo. 30\nSystematic.review.on.urine.albumin.\ntesting.for.early.detection.of.diabetic.\ncomplications.\nBy.Newman.DJ,.Mattock.MB,.\nDawnay.ABS,.Kerry.S,.McGuire.A,.\nYaqoob.M,.et al.\nNo. 31\nRandomised.controlled.trial.of.the.cost-\neffectiveness.of.water-based.therapy.for.\nlower.limb.osteoarthritis.\nBy.Cochrane.T,.Davey.RC,.\nMatthes.Edwards.SM.\nNo. 32\nLonger.term.clinical.and.economic.\nbenefits.of.offering.acupuncture.care.to.\npatients.with.chronic.low.back.pain.\nBy.Thomas.KJ,.MacPherson.\nH,.Ratcliffe.J,.Thorpe.L,.Brazier.J,.\nCampbell.M,.et al.\nNo. 33\nCost-effectiveness.and.safety.of.\nepidural.steroids.in.the.management.\nof.sciatica.\nBy.Price.C,.Arden.N,.Coglan.L,.\nRogers.P.\nNo. 34\nThe.British.Rheumatoid.Outcome.\nStudy.Group.(BROSG).randomised.\ncontrolled.trial.to.compare.the.\neffectiveness.and.cost-effectiveness.of.\naggressive.versus.symptomatic.therapy.\nin.established.rheumatoid.arthritis.\nBy.Symmons.D,.Tricker.K,.Roberts.\nC,.Davies.L,.Dawes.P,.Scott.DL.\nNo. 35\nConceptual.framework.and.systematic.\nreview.of.the.effects.of.participants\u2019.\nand.professionals\u2019.preferences.in.\nrandomised.controlled.trials.\nBy.King.M,.Nazareth.I,.Lampe.F,.\nBower.P,.Chandler.M,.Morou.M,.et al.\nNo. 36\nThe.clinical.and.cost-effectiveness.of.\nimplantable.cardioverter.defibrillators:.\na.systematic.review.\nBy.Bryant.J,.Brodin.H,.Loveman.E,.\nPayne.E,.Clegg.A.\nNo. 37\nA.trial.of.problem-solving.by.\ncommunity.mental.health.nurses.for.\nanxiety,.depression.and.life.difficulties.\namong.general.practice.patients..The.\nCPN-GP.study.\nBy.Kendrick.T,.Simons.L,.\nMynors-Wallis.L,.Gray.A,.Lathlean.J,.\nPickering.R,.et al.\nNo. 38\nThe.causes.and.effects.of.socio-\ndemographic.exclusions.from.clinical.\ntrials.\nBy.Bartlett.C,.Doyal.L,.Ebrahim.S,.\nDavey.P,.Bachmann.M,.Egger.M,.et al.\nNo. 39\nIs.hydrotherapy.cost-effective?.\nA randomised.controlled.trial.of.\ncombined hydrotherapy.programmes.\ncompared with.physiotherapy.land.\ntechniques.in children.with.juvenile.\nidiopathic arthritis.\nBy.Epps.H,.Ginnelly.L,.Utley.M,.\nSouthwood.T,.Gallivan.S,.Sculpher.M,.\net al.\nNo. 40\nA.randomised.controlled.trial.and.\ncost-effectiveness.study.of.systematic.\nscreening.(targeted.and.total.\npopulation.screening).versus.routine.\npractice.for.the.detection.of.atrial.\nfibrillation.in.people.aged.65.and.over..\nThe.SAFE.study.\nBy.Hobbs.FDR,.Fitzmaurice.DA,.\nMant.J,.Murray.E,.Jowett.S,.Bryan.S,.\net al.\nNo. 41\nDisplaced.intracapsular.hip.fractures.\nin.fit,.older.people:.a.randomised.\ncomparison.of.reduction.and.fixation,.\nbipolar.hemiarthroplasty.and.total.hip.\narthroplasty.\nBy.Keating.JF,.Grant.A,.Masson.M,.\nScott.NW,.Forbes.JF.\nNo. 42\nLong-term.outcome.of.cognitive.\nbehaviour.therapy.clinical.trials.in.\ncentral.Scotland.\nBy.Durham.RC,.Chambers.JA,.\nPower.KG,.Sharp.DM,.Macdonald.RR,.\nMajor.KA,.et al.\nNo. 43\nThe.effectiveness.and.cost-effectiveness.\nof.dual-chamber.pacemakers.compared.\nwith.single-chamber.pacemakers.for.\nbradycardia.due.to.atrioventricular.\nblock.or.sick.sinus.syndrome:.systematic.\nreview.and.economic.evaluation.\nBy.Castelnuovo.E,.Stein.K,.Pitt.M,.\nGarside.R,.Payne.E.\nNo. 44\nNewborn.screening.for.congenital.heart.\ndefects:.a.systematic.review.and.cost-\neffectiveness.analysis.\nBy.Knowles.R,.Griebsch.I,.\nDezateux.C,.Brown.J,.Bull.C,.Wren.C.\nNo. 45\nThe.clinical.and.cost-effectiveness.of.\nleft.ventricular.assist.devices.for.end-\nstage.heart.failure:.a.systematic.review.\nand.economic.evaluation.\nBy.Clegg.AJ,.Scott.DA,.Loveman.E,.\nColquitt.J,.Hutchinson.J,.Royle.P,.et al.\nNo. 46\nThe.effectiveness.of.the.Heidelberg.\nRetina.Tomograph.and.laser.diagnostic.\nglaucoma.scanning.system.(GDx).in.\ndetecting.and.monitoring.glaucoma.\nBy.Kwartz.AJ,.Henson.DB,.Harper.\nRA,.Spencer.AF,.McLeod.D.\nNo. 47\nClinical.and.cost-effectiveness.of.\nautologous.chondrocyte.implantation.\nfor.cartilage.defects.in.knee.joints:.\nsystematic.review.and.economic.\nevaluation.\nBy.Clar.C,.Cummins.E,.McIntyre.L,.\nThomas.S,.Lamb.J,.Bain.L,.et al.Health Technology Assessment reports published to date\n142\nNo. 48\nSystematic.review.of.effectiveness.of.\ndifferent.treatments.for.childhood.\nretinoblastoma.\nBy.McDaid.C,.Hartley.S,.Bagnall.\nA-M,.Ritchie.G,.Light.K,.Riemsma.R.\nNo. 49\nTowards.evidence-based.guidelines.\nfor.the.prevention.of.venous.\nthromboembolism:.systematic.\nreviews.of.mechanical.methods,.oral.\nanticoagulation,.dextran.and.regional.\nanaesthesia.as.thromboprophylaxis.\nBy.Roderick.P,.Ferris.G,.Wilson.K,.\nHalls.H,.Jackson.D,.Collins.R,.et al.\nNo. 50\nThe.effectiveness.and.cost-effectiveness.\nof.parent.training\/education.\nprogrammes.for.the.treatment.\nof.conduct.disorder,.including.\noppositional.defiant.disorder,.in.\nchildren.\nBy.Dretzke.J,.Frew.E,.Davenport.C,.\nBarlow.J,.Stewart-Brown.S,.Sandercock.J,.\net al.\nVolume 10, 2006\nNo. 1\nThe.clinical.and.cost-effectiveness.of.\ndonepezil,.rivastigmine,.galantamine.\nand.memantine.for.Alzheimer\u2019s.\ndisease.\nBy.Loveman.E,.Green.C,.Kirby.J,.\nTakeda.A,.Picot.J,.Payne.E,.et al.\nNo. 2\nFOOD:.a.multicentre.randomised.trial.\nevaluating.feeding.policies.in.patients.\nadmitted.to.hospital.with.a.recent.\nstroke.\nBy.Dennis.M,.Lewis.S,.Cranswick.G,.\nForbes.J.\nNo. 3\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.computed.tomography.\nscreening.for.lung.cancer:.systematic.\nreviews.\nBy.Black.C,.Bagust.A,.Boland.A,.\nWalker.S,.McLeod.C,.De.Verteuil.R,.et al.\nNo. 4\nA.systematic.review.of.the.effectiveness.\nand.cost-effectiveness.of.neuroimaging.\nassessments.used.to.visualise.the.seizure.\nfocus.in.people.with.refractory.epilepsy.\nbeing.considered.for.surgery.\nBy.Whiting.P,.Gupta.R,.Burch.J,.\nMujica.Mota.RE,.Wright.K,.Marson.A,.\net al.\nNo. 5\nComparison.of.conference.abstracts.\nand.presentations.with.full-text.articles.\nin.the.health.technology.assessments.of.\nrapidly.evolving.technologies.\nBy.Dundar.Y,.Dodd.S,.Dickson.R,.\nWalley.T,.Haycox.A,.Williamson.PR.\nNo. 6\nSystematic.review.and.evaluation.\nof.methods.of.assessing.urinary.\nincontinence.\nBy.Martin.JL,.Williams.KS,.Abrams.\nKR,.Turner.DA,.Sutton.AJ,.Chapple.C,.\net al.\nNo. 7\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.newer.drugs.for.\nchildren.with.epilepsy..A.systematic.\nreview.\nBy.Connock.M,.Frew.E,.Evans.B-W,.\nBryan.S,.Cummins.C,.Fry-Smith.A,.et al.\nNo. 8\nSurveillance.of.Barrett\u2019s.oesophagus:.\nexploring.the.uncertainty.through.\nsystematic.review,.expert.workshop.and.\neconomic.modelling.\nBy.Garside.R,.Pitt.M,.Somerville.M,.\nStein.K,.Price.A,.Gilbert.N.\nNo. 9\nTopotecan,.pegylated.liposomal.\ndoxorubicin.hydrochloride.and.\npaclitaxel.for.second-line.or.subsequent.\ntreatment.of.advanced.ovarian.cancer:.\na.systematic.review.and.economic.\nevaluation.\nBy.Main.C,.Bojke.L,.Griffin.S,.\nNorman.G,.Barbieri.M,.Mather.L,.et al.\nNo. 10\nEvaluation.of.molecular.techniques.\nin.prediction.and.diagnosis.\nof.cytomegalovirus.disease.in.\nimmunocompromised.patients.\nBy.Szczepura.A,.Westmoreland.D,.\nVinogradova.Y,.Fox.J,.Clark.M.\nNo. 11\nScreening.for.thrombophilia.in.high-\nrisk.situations:.systematic.review.\nand.cost-effectiveness.analysis..The.\nThrombosis:.Risk.and.Economic.\nAssessment.of.Thrombophilia.\nScreening.(TREATS).study.\nBy.Wu.O,.Robertson.L,.Twaddle.S,.\nLowe.GDO,.Clark.P,.Greaves.M,.et al.\nNo. 12\nA.series.of.systematic.reviews.to.inform.\na.decision.analysis.for.sampling.and.\ntreating.infected.diabetic.foot.ulcers.\nBy.Nelson.EA,.O\u2019Meara.S,.Craig.D,.\nIglesias.C,.Golder.S,.Dalton.J,.et al.\nNo. 13\nRandomised.clinical.trial,.observational.\nstudy.and.assessment.of.cost-\neffectiveness.of.the.treatment.of.\nvaricose.veins.(REACTIV.trial).\nBy.Michaels.JA,.Campbell.WB,.\nBrazier.JE,.MacIntyre.JB,.Palfreyman.SJ,.\nRatcliffe.J,.et al.\nNo. 14\nThe.cost-effectiveness.of.screening.for.\noral.cancer.in.primary.care.\nBy.Speight.PM,.Palmer.S,.Moles.DR,.\nDowner.MC,.Smith.DH,.Henriksson.M,.\net al.\nNo. 15\nMeasurement.of.the.clinical.and.cost-\neffectiveness.of.non-invasive.diagnostic.\ntesting.strategies.for.deep.vein.\nthrombosis.\nBy.Goodacre.S,.Sampson.F,.\nStevenson.M,.Wailoo.A,.Sutton.A,.\nThomas.S,.et al.\nNo. 16\nSystematic.review.of.the.effectiveness.\nand.cost-effectiveness.of.HealOzone\u00ae.\nfor.the.treatment.of.occlusal.pit\/fissure.\ncaries.and.root.caries.\nBy.Brazzelli.M,.McKenzie.L,.Fielding.\nS,.Fraser.C,.Clarkson.J,.Kilonzo.M,.et al.\nNo. 17\nRandomised.controlled.trials.of.\nconventional.antipsychotic.versus.\nnew.atypical.drugs,.and.new.atypical.\ndrugs.versus.clozapine,.in.people.with.\nschizophrenia.responding.poorly.to,.or.\nintolerant.of,.current.drug.treatment.\nBy.Lewis.SW,.Davies.L,.Jones.PB,.\nBarnes.TRE,.Murray.RM,.Kerwin.R,.\net al.\nNo. 18\nDiagnostic.tests.and.algorithms.used.\nin.the.investigation.of.haematuria:.\nsystematic.reviews.and.economic.\nevaluation.\nBy.Rodgers.M,.Nixon.J,.Hempel.S,.\nAho.T,.Kelly.J,.Neal.D,.et al.\nNo. 19\nCognitive.behavioural.therapy.in.\naddition.to.antispasmodic.therapy.for.\nirritable.bowel.syndrome.in.primary.\ncare:.randomised.controlled.trial.\nBy.Kennedy.TM,.Chalder.T,.\nMcCrone.P,.Darnley.S,.Knapp.M,.\nJones.RH,.et al.\nNo. 20\nA.systematic.review.of.the.\nclinical.effectiveness.and.cost-\neffectiveness.of.enzyme.replacement.\ntherapies.for.Fabry\u2019s.disease.and.\nmucopolysaccharidosis.type.1.\nBy.Connock.M,.Juarez-Garcia.A,.\nFrew.E,.Mans.A,.Dretzke.J,.Fry-Smith.A,.\net al.\nNo. 21\nHealth.benefits.of.antiviral.therapy.for.\nmild.chronic.hepatitis.C:.randomised.\ncontrolled.trial.and.economic.\nevaluation.\nBy.Wright.M,.Grieve.R,.Roberts.J,.\nMain.J,.Thomas.HC,.on.behalf.of.the.\nUK.Mild.Hepatitis.C.Trial.Investigators.\nNo. 22\nPressure.relieving.support.surfaces:.a.\nrandomised.evaluation.\nBy.Nixon.J,.Nelson.EA,.Cranny.G,.\nIglesias.CP,.Hawkins.K,.Cullum.NA,.et al.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n143\nNo. 23\nA.systematic.review.and.economic.\nmodel.of.the.effectiveness.and.cost-\neffectiveness.of.methylphenidate,.\ndexamfetamine.and.atomoxetine.\nfor.the.treatment.of.attention.deficit.\nhyperactivity.disorder.in.children.and.\nadolescents.\nBy.King.S,.Griffin.S,.Hodges.Z,.\nWeatherly.H,.Asseburg.C,.Richardson.G,.\net al.\nNo. 24\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.enzyme.replacement.\ntherapy.for.Gaucher\u2019s.disease:.a.\nsystematic.review.\nBy.Connock.M,.Burls.A,.Frew.E,.\nFry-Smith.A,.Juarez-Garcia.A,.McCabe.C,.\net al.\nNo. 25\nEffectiveness.and.cost-effectiveness.\nof.salicylic.acid.and.cryotherapy.for.\ncutaneous.warts..An.economic.decision.\nmodel.\nBy.Thomas.KS,.Keogh-Brown.MR,.\nChalmers.JR,.Fordham.RJ,.Holland.RC,.\nArmstrong.SJ,.et al.\nNo. 26\nA.systematic.literature.review.of.the.\neffectiveness.of.non-pharmacological.\ninterventions.to.prevent.wandering.in.\ndementia.and.evaluation.of.the.ethical.\nimplications.and.acceptability.of.their.\nuse.\nBy.Robinson.L,.Hutchings.D,.Corner.\nL,.Beyer.F,.Dickinson.H,.Vanoli.A,.et al.\nNo. 27\nA.review.of.the.evidence.on.the.effects.\nand.costs.of.implantable.cardioverter.\ndefibrillator.therapy.in.different.\npatient.groups,.and.modelling.of.cost-\neffectiveness.and.cost\u2013utility.for.these.\ngroups.in.a.UK.context.\nBy.Buxton.M,.Caine.N,.Chase.D,.\nConnelly.D,.Grace.A,.Jackson.C,.et al.\nNo. 28\nAdefovir.dipivoxil.and.pegylated.\ninterferon.alfa-2a.for.the.treatment.of.\nchronic.hepatitis.B:.a.systematic.review.\nand.economic.evaluation.\nBy.Shepherd.J,.Jones.J,.Takeda.A,.\nDavidson.P,.Price.A.\nNo. 29\nAn.evaluation.of.the.clinical.and.cost-\neffectiveness.of.pulmonary.artery.\ncatheters.in.patient.management.in.\nintensive.care:.a.systematic.review.and.a.\nrandomised.controlled.trial.\nBy.Harvey.S,.Stevens.K,.Harrison.D,.\nYoung.D,.Brampton.W,.McCabe.C,.et al.\nNo. 30\nAccurate,.practical.and.cost-effective.\nassessment.of.carotid.stenosis.in.the.\nUK.\nBy.Wardlaw.JM,.Chappell.FM,.\nStevenson.M,.De.Nigris.E,.Thomas.S,.\nGillard.J,.et al.\nNo. 31\nEtanercept.and.infliximab.for.the.\ntreatment.of.psoriatic.arthritis:.a.\nsystematic.review.and.economic.\nevaluation.\nBy.Woolacott.N,.Bravo.Vergel.Y,.\nHawkins.N,.Kainth.A,.Khadjesari.Z,.\nMisso.K,.et al.\nNo. 32\nThe.cost-effectiveness.of.testing.for.\nhepatitis.C.in.former.injecting.drug.\nusers.\nBy.Castelnuovo.E,.Thompson-Coon.\nJ,.Pitt.M,.Cramp.M,.Siebert.U,.Price.A,.\net al.\nNo. 33\nComputerised.cognitive.behaviour.\ntherapy.for.depression.and.anxiety.\nupdate:.a.systematic.review.and.\neconomic.evaluation.\nBy.Kaltenthaler.E,.Brazier.J,.\nDe.Nigris.E,.Tumur.I,.Ferriter.M,.\nBeverley.C,.et al.\nNo. 34\nCost-effectiveness.of.using.prognostic.\ninformation.to.select.women.with.breast.\ncancer.for.adjuvant.systemic.therapy.\nBy.Williams.C,.Brunskill.S,.Altman.D,.\nBriggs.A,.Campbell.H,.Clarke.M,.et al.\nNo. 35\nPsychological.therapies.including.\ndialectical.behaviour.therapy.for.\nborderline.personality.disorder:.a.\nsystematic.review.and.preliminary.\neconomic.evaluation.\nBy.Brazier.J,.Tumur.I,.Holmes.M,.\nFerriter.M,.Parry.G,.Dent-Brown.K,.et al.\nNo. 36\nClinical.effectiveness.and.cost-\neffectiveness.of.tests.for.the.diagnosis.\nand.investigation.of.urinary.tract.\ninfection.in.children:.a.systematic.\nreview.and.economic.model.\nBy.Whiting.P,.Westwood.M,.Bojke.L,.\nPalmer.S,.Richardson.G,.Cooper.J,.et al.\nNo. 37\nCognitive.behavioural.therapy.\nin.chronic.fatigue.syndrome:.a.\nrandomised.controlled.trial.of.an.\noutpatient.group.programme.\nBy.O\u2019Dowd.H,.Gladwell.P,.Rogers.\nCA,.Hollinghurst.S,.Gregory.A.\nNo. 38\nA.comparison.of.the.cost-effectiveness.\nof.five.strategies.for.the.prevention.\nof.nonsteroidal.anti-inflammatory.\ndrug-induced.gastrointestinal.toxicity:.\na.systematic.review.with.economic.\nmodelling.\nBy.Brown.TJ,.Hooper.L,.Elliott.RA,.\nPayne.K,.Webb.R,.Roberts.C,.et.al.\nNo. 39\nThe.effectiveness.and.cost-effectiveness.\nof.computed.tomography.screening.\nfor.coronary.artery.disease:.systematic.\nreview.\nBy.Waugh.N,.Black.C,.Walker.S,.\nMcIntyre.L,.Cummins.E,.Hillis.G.\nNo. 40\nWhat.are.the.clinical.outcome.and.cost-\neffectiveness.of.endoscopy.undertaken.\nby.nurses.when.compared.with.doctors?.\nA.Multi-Institution.Nurse.Endoscopy.\nTrial.(MINuET).\nBy.Williams.J,.Russell.I,.Durai.D,.\nCheung.W-Y,.Farrin.A,.Bloor.K,.et al.\nNo. 41\nThe.clinical.and.cost-effectiveness.of.\noxaliplatin.and.capecitabine.for.the.\nadjuvant.treatment.of.colon.cancer:.\nsystematic.review.and.economic.\nevaluation.\nBy.Pandor.A,.Eggington.S,.Paisley.S,.\nTappenden.P,.Sutcliffe.P.\nNo. 42\nA.systematic.review.of.the.effectiveness.\nof.adalimumab,.etanercept.and.\ninfliximab.for.the.treatment.of.\nrheumatoid.arthritis.in.adults.and.\nan.economic.evaluation.of.their.cost-\neffectiveness.\nBy.Chen.Y-F,.Jobanputra.P,.Barton.P,.\nJowett.S,.Bryan.S,.Clark.W,.et al.\nNo. 43\nTelemedicine.in.dermatology:.a.\nrandomised.controlled.trial.\nBy.Bowns.IR,.Collins.K,.Walters.SJ,.\nMcDonagh.AJG.\nNo. 44\nCost-effectiveness.of.cell.salvage.and.\nalternative.methods.of.minimising.\nperioperative.allogeneic.blood.\ntransfusion:.a.systematic.review.and.\neconomic.model.\nBy.Davies.L,.Brown.TJ,.Haynes.S,.\nPayne.K,.Elliott.RA,.McCollum.C.\nNo. 45\nClinical.effectiveness.and.cost-\neffectiveness.of.laparoscopic.surgery.\nfor.colorectal.cancer:.systematic.reviews.\nand.economic.evaluation.\nBy.Murray.A,.Lourenco.T,.de.Verteuil.\nR,.Hernandez.R,.Fraser.C,.McKinley.A,.\net al.\nNo. 46\nEtanercept.and.efalizumab.for.the.\ntreatment.of.psoriasis:.a.systematic.\nreview.\nBy.Woolacott.N,.Hawkins.N,.\nMason.A,.Kainth.A,.Khadjesari.Z,.Bravo.\nVergel.Y,.et al.\nNo. 47\nSystematic.reviews.of.clinical.decision.\ntools.for.acute.abdominal.pain.\nBy.Liu.JLY,.Wyatt.JC,.Deeks.JJ,.\nClamp.S,.Keen.J,.Verde.P,.et al.\nNo. 48\nEvaluation.of.the.ventricular.assist.\ndevice.programme.in.the.UK.\nBy.Sharples.L,.Buxton.M,.Caine.N,.\nCafferty.F,.Demiris.N,.Dyer.M,.et al.Health Technology Assessment reports published to date\n144\nNo. 49\nA.systematic.review.and.economic.\nmodel.of.the.clinical.and.cost-\neffectiveness.of.immunosuppressive.\ntherapy.for.renal.transplantation.in.\nchildren.\nBy.Yao.G,.Albon.E,.Adi.Y,.Milford.D,.\nBayliss.S,.Ready.A,.et al.\nNo. 50\nAmniocentesis.results:.investigation.of.\nanxiety..The.ARIA.trial.\nBy.Hewison.J,.Nixon.J,.Fountain.J,.\nCocks.K,.Jones.C,.Mason.G,.et al.\nVolume 11, 2007\nNo. 1\nPemetrexed.disodium.for.the.treatment.\nof.malignant.pleural.mesothelioma:.\na.systematic.review.and.economic.\nevaluation.\nBy.Dundar.Y,.Bagust.A,.Dickson.R,.\nDodd.S,.Green.J,.Haycox.A,.et al.\nNo. 2\nA.systematic.review.and.economic.\nmodel.of.the.clinical.effectiveness.\nand.cost-effectiveness.of.docetaxel.\nin.combination.with.prednisone.or.\nprednisolone.for.the.treatment.of.\nhormone-refractory.metastatic.prostate.\ncancer.\nBy.Collins.R,.Fenwick.E,.Trowman.R,.\nPerard.R,.Norman.G,.Light.K,.et al.\nNo. 3\nA.systematic.review.of.rapid.diagnostic.\ntests.for.the.detection.of.tuberculosis.\ninfection.\nBy.Dinnes.J,.Deeks.J,.Kunst.H,.\nGibson.A,.Cummins.E,.Waugh.N,.et al.\nNo. 4\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.strontium.ranelate.for.\nthe.prevention.of.osteoporotic.fragility.\nfractures.in.postmenopausal.women.\nBy.Stevenson.M,.Davis.S,.Lloyd-Jones.\nM,.Beverley.C.\nNo. 5\nA.systematic.review.of.quantitative.and.\nqualitative.research.on.the.role.and.\neffectiveness.of.written.information.\navailable.to.patients.about.individual.\nmedicines.\nBy.Raynor.DK,.Blenkinsopp.\nA,.Knapp.P,.Grime.J,.Nicolson.DJ,.\nPollock.K,.et al.\nNo. 6\nOral.naltrexone.as.a.treatment.for.\nrelapse.prevention.in.formerly.opioid-\ndependent.drug.users:.a.systematic.\nreview.and.economic.evaluation.\nBy.Adi.Y,.Juarez-Garcia.A,.Wang.D,.\nJowett.S,.Frew.E,.Day.E,.et al.\nNo. 7\nGlucocorticoid-induced.osteoporosis:.\na.systematic.review.and.cost\u2013utility.\nanalysis.\nBy.Kanis.JA,.Stevenson.M,.\nMcCloskey.EV,.Davis.S,.Lloyd-Jones.M.\nNo. 8\nEpidemiological,.social,.diagnostic.and.\neconomic.evaluation.of.population.\nscreening.for.genital.chlamydial.\ninfection.\nBy.Low.N,.McCarthy.A,.Macleod.J,.\nSalisbury.C,.Campbell.R,.Roberts.TE,.\net al.\nNo. 9\nMethadone.and.buprenorphine.for.the.\nmanagement.of.opioid.dependence:.\na.systematic.review.and.economic.\nevaluation.\nBy.Connock.M,.Juarez-Garcia.A,.\nJowett.S,.Frew.E,.Liu.Z,.Taylor.RJ,.et al.\nNo. 10\nExercise.Evaluation.Randomised.\nTrial.(EXERT):.a.randomised.trial.\ncomparing.GP.referral.for.leisure.\ncentre-based.exercise,.community-based.\nwalking.and.advice.only.\nBy.Isaacs.AJ,.Critchley.JA,.See.Tai.\nS,.Buckingham.K,.Westley.D,.Harridge.\nSDR,.et al.\nNo. 11\nInterferon.alfa.(pegylated.and.non-\npegylated).and.ribavirin.for.the.\ntreatment.of.mild.chronic.hepatitis.\nC:.a.systematic.review.and.economic.\nevaluation.\nBy.Shepherd.J,.Jones.J,.Hartwell.D,.\nDavidson.P,.Price.A,.Waugh.N.\nNo. 12\nSystematic.review.and.economic.\nevaluation.of.bevacizumab.and.\ncetuximab.for.the.treatment.of.\nmetastatic.colorectal.cancer.\nBy.Tappenden.P,.Jones.R,.Paisley.S,.\nCarroll.C.\nNo. 13\nA.systematic.review.and.economic.\nevaluation.of.epoetin.alfa,.epoetin.\nbeta.and.darbepoetin.alfa.in.anaemia.\nassociated.with.cancer,.especially.that.\nattributable.to.cancer.treatment.\nBy.Wilson.J,.Yao.GL,.Raftery.J,.\nBohlius.J,.Brunskill.S,.Sandercock.J,.\net al.\nNo. 14\nA.systematic.review.and.economic.\nevaluation.of.statins.for.the.prevention.\nof.coronary.events.\nBy.Ward.S,.Lloyd.Jones.M,.Pandor.A,.\nHolmes.M,.Ara.R,.Ryan.A,.et al.\nNo. 15\nA.systematic.review.of.the.effectiveness.\nand.cost-effectiveness.of.different.\nmodels.of.community-based.respite.\ncare.for.frail.older.people.and.their.\ncarers.\nBy.Mason.A,.Weatherly.H,.Spilsbury.\nK,.Arksey.H,.Golder.S,.Adamson.J,.et al.\nNo. 16\nAdditional.therapy.for.young.\nchildren.with.spastic.cerebral.palsy:.a.\nrandomised.controlled.trial.\nBy.Weindling.AM,.Cunningham.CC,.\nGlenn.SM,.Edwards.RT,.Reeves.DJ.\nNo. 17\nScreening.for.type.2.diabetes:.literature.\nreview.and.economic.modelling.\nBy.Waugh.N,.Scotland.G,.McNamee.\nP,.Gillett.M,.Brennan.A,.Goyder.E,.et al.\nNo. 18\nThe.effectiveness.and.cost-effectiveness.\nof.cinacalcet.for.secondary.\nhyperparathyroidism.in.end-stage.renal.\ndisease.patients.on.dialysis:.a.systematic.\nreview.and.economic.evaluation.\nBy.Garside.R,.Pitt.M,.Anderson.R,.\nMealing.S,.Roome.C,.Snaith.A,.et al.\nNo. 19\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.gemcitabine.for.\nmetastatic.breast.cancer:.a.systematic.\nreview.and.economic.evaluation.\nBy.Takeda.AL,.Jones.J,.Loveman.E,.\nTan.SC,.Clegg.AJ.\nNo. 20\nA.systematic.review.of.duplex.\nultrasound,.magnetic.resonance.\nangiography.and.computed.\ntomography.angiography.for.\nthe.diagnosis.and.assessment.of.\nsymptomatic,.lower.limb.peripheral.\narterial.disease.\nBy.Collins.R,.Cranny.G,.Burch.J,.\nAguiar-Ib\u00e1\u00f1ez.R,.Craig.D,.Wright.K,.\net al.\nNo. 21\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.treatments.for.children.\nwith.idiopathic.steroid-resistant.\nnephrotic.syndrome:.a.systematic.\nreview.\nBy.Colquitt.JL,.Kirby.J,.Green.C,.\nCooper.K,.Trompeter.RS.\nNo. 22\nA.systematic.review.of.the.routine.\nmonitoring.of.growth.in.children.of.\nprimary.school.age.to.identify.growth-\nrelated.conditions.\nBy.Fayter.D,.Nixon.J,.Hartley.S,.\nRithalia.A,.Butler.G,.Rudolf.M,.et al.\nNo. 23\nSystematic.review.of.the.effectiveness.of.\npreventing.and.treating.Staphylococcus \naureus carriage.in.reducing.peritoneal.\ncatheter-related.infections.\nBy.McCormack.K,.Rabindranath.K,.\nKilonzo.M,.Vale.L,.Fraser.C,.McIntyre.L,.\net al.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n145\nNo. 24\nThe.clinical.effectiveness.and.cost.\nof.repetitive.transcranial.magnetic.\nstimulation.versus.electroconvulsive.\ntherapy.in.severe.depression:.a.\nmulticentre.pragmatic.randomised.\ncontrolled.trial.and.economic.analysis.\nBy.McLoughlin.DM,.Mogg.A,.Eranti.\nS,.Pluck.G,.Purvis.R,.Edwards.D,.et al.\nNo. 25\nA.randomised.controlled.trial.and.\neconomic.evaluation.of.direct.versus.\nindirect.and.individual.versus.group.\nmodes.of.speech.and.language.therapy.\nfor.children.with.primary.language.\nimpairment.\nBy.Boyle.J,.McCartney.E,.Forbes.J,.\nO\u2019Hare.A.\nNo. 26\nHormonal.therapies.for.early.breast.\ncancer:.systematic.review.and.economic.\nevaluation.\nBy.Hind.D,.Ward.S,.De.Nigris.E,.\nSimpson.E,.Carroll.C,.Wyld.L.\nNo. 27\nCardioprotection.against.the.toxic.\neffects.of.anthracyclines.given.to.\nchildren.with.cancer:.a.systematic.\nreview.\nBy.Bryant.J,.Picot.J,.Levitt.G,.\nSullivan.I,.Baxter.L,.Clegg.A.\nNo. 28\nAdalimumab,.etanercept.and.infliximab.\nfor.the.treatment.of.ankylosing.\nspondylitis:.a.systematic.review.and.\neconomic.evaluation.\nBy.McLeod.C,.Bagust.A,.Boland.A,.\nDagenais.P,.Dickson.R,.Dundar.Y,.et al.\nNo. 29\nPrenatal.screening.and.treatment.\nstrategies.to.prevent.group.B.\nstreptococcal.and.other.bacterial.\ninfections.in.early.infancy:.cost-\neffectiveness.and.expected.value.of.\ninformation.analyses.\nBy.Colbourn.T,.Asseburg.C,.Bojke.L,.\nPhilips.Z,.Claxton.K,.Ades.AE,.et al.\nNo. 30\nClinical.effectiveness.and.cost-\neffectiveness.of.bone.morphogenetic.\nproteins.in.the.non-healing.of.fractures.\nand.spinal.fusion:.a.systematic.review.\nBy.Garrison.KR,.Donell.S,.Ryder.J,.\nShemilt.I,.Mugford.M,.Harvey.I,.et al.\nNo. 31\nA.randomised.controlled.trial.of.\npostoperative.radiotherapy.following.\nbreast-conserving.surgery.in.a.\nminimum-risk.older.population..The.\nPRIME.trial.\nBy.Prescott.RJ,.Kunkler.IH,.Williams.\nLJ,.King.CC,.Jack.W,.van.der.Pol.M,.\net al.\nNo. 32\nCurrent.practice,.accuracy,.effectiveness.\nand.cost-effectiveness.of.the.school.\nentry.hearing.screen.\nBy.Bamford.J,.Fortnum.H,.Bristow.\nK,.Smith.J,.Vamvakas.G,.Davies.L,.et al.\nNo. 33\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.inhaled.insulin.in.\ndiabetes.mellitus:.a.systematic.review.\nand.economic.evaluation.\nBy.Black.C,.Cummins.E,.Royle.P,.\nPhilip.S,.Waugh.N.\nNo. 34\nSurveillance.of.cirrhosis.for.\nhepatocellular.carcinoma:.systematic.\nreview.and.economic.analysis.\nBy.Thompson.Coon.J,.Rogers.G,.\nHewson.P,.Wright.D,.Anderson.R,.\nCramp.M,.et al.\nNo. 35\nThe.Birmingham.Rehabilitation.\nUptake.Maximisation.Study.(BRUM)..\nHomebased.compared.with.hospital-\nbased.cardiac.rehabilitation.in.a.multi-\nethnic.population:.cost-effectiveness.\nand.patient.adherence.\nBy.Jolly.K,.Taylor.R,.Lip.GYH,.\nGreenfield.S,.Raftery.J,.Mant.J,.et al.\nNo. 36\nA.systematic.review.of.the.clinical,.\npublic.health.and.cost-effectiveness.of.\nrapid.diagnostic.tests.for.the.detection.\nand.identification.of.bacterial.intestinal.\npathogens.in.faeces.and.food.\nBy.Abubakar.I,.Irvine.L,.Aldus.CF,.\nWyatt.GM,.Fordham.R,.Schelenz.S,.et al.\nNo. 37\nA.randomised.controlled.trial.\nexamining.the.longer-term.outcomes.\nof.standard.versus.new.antiepileptic.\ndrugs..The.SANAD.trial.\nBy.Marson.AG,.Appleton.R,.Baker.\nGA,.Chadwick.DW,.Doughty.J,.Eaton.B,.\net al.\nNo. 38\nClinical.effectiveness.and.cost-\neffectiveness.of.different.models.\nof.managing.long-term.oral.anti-\ncoagulation.therapy:.a.systematic.\nreview.and.economic.modelling.\nBy.Connock.M,.Stevens.C,.Fry-Smith.\nA,.Jowett.S,.Fitzmaurice.D,.Moore.D,.\net al.\nNo. 39\nA.systematic.review.and.economic.\nmodel.of.the.clinical.effectiveness.\nand.cost-effectiveness.of.interventions.\nfor.preventing.relapse.in.people.with.\nbipolar.disorder.\nBy.Soares-Weiser.K,.Bravo.Vergel.Y,.\nBeynon.S,.Dunn.G,.Barbieri.M,.Duffy.S,.\net al.\nNo. 40\nTaxanes.for.the.adjuvant.treatment.of.\nearly.breast.cancer:.systematic.review.\nand.economic.evaluation.\nBy.Ward.S,.Simpson.E,.Davis.S,.Hind.\nD,.Rees.A,.Wilkinson.A.\nNo. 41\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.screening.for.open.\nangle.glaucoma:.a.systematic.review.\nand.economic.evaluation.\nBy.Burr.JM,.Mowatt.G,.Hern\u00e1ndez.\nR,.Siddiqui.MAR,.Cook.J,.Lourenco.T,.\net al.\nNo. 42\nAcceptability,.benefit.and.costs.of.early.\nscreening.for.hearing.disability:.a.study.\nof.potential.screening.tests.and.models.\nBy.Davis.A,.Smith.P,.Ferguson.M,.\nStephens.D,.Gianopoulos.I.\nNo. 43\nContamination.in.trials.of.educational.\ninterventions.\nBy.Keogh-Brown.MR,.Bachmann.\nMO,.Shepstone.L,.Hewitt.C,.Howe.A,.\nRamsay.CR,.et al.\nNo. 44\nOverview.of.the.clinical.effectiveness.of.\npositron.emission.tomography.imaging.\nin.selected.cancers.\nBy.Facey.K,.Bradbury.I,.Laking.G,.\nPayne.E.\nNo. 45\nThe.effectiveness.and.cost-effectiveness.\nof.carmustine.implants.and.\ntemozolomide.for.the.treatment.of.\nnewly.diagnosed.high-grade.glioma:.\na.systematic.review.and.economic.\nevaluation.\nBy.Garside.R,.Pitt.M,.Anderson.R,.\nRogers.G,.Dyer.M,.Mealing.S,.et al.\nNo. 46\nDrug-eluting.stents:.a.systematic.review.\nand.economic.evaluation.\nBy.Hill.RA,.Boland.A,.Dickson.R,.\nDu\u0308ndar.Y,.Haycox.A,.McLeod.C,.et al.\nNo. 47\nThe.clinical.effectiveness.and.\ncost-effectiveness.of.cardiac.\nresynchronisation.(biventricular.pacing).\nfor.heart.failure:.systematic.review.and.\neconomic.model.\nBy.Fox.M,.Mealing.S,.Anderson.R,.\nDean.J,.Stein.K,.Price.A,.et al.\nNo. 48\nRecruitment.to.randomised.trials:.\nstrategies.for.trial.enrolment.and.\nparticipation.study..The.STEPS.study.\nBy.Campbell.MK,.Snowdon.C,.\nFrancis.D,.Elbourne.D,.McDonald.AM,.\nKnight.R,.et al.Health Technology Assessment reports published to date\n146\nNo. 49\nCost-effectiveness.of.functional.\ncardiac.testing.in.the.diagnosis.and.\nmanagement.of.coronary.artery.\ndisease:.a.randomised.controlled.trial..\nThe.CECaT.trial.\nBy.Sharples.L,.Hughes.V,.Crean.A,.\nDyer.M,.Buxton.M,.Goldsmith.K,.et al.\nNo. 50\nEvaluation.of.diagnostic.tests.when.\nthere.is.no.gold.standard..A.review.of.\nmethods.\nBy.Rutjes.AWS,.Reitsma.\nJB,.Coomarasamy.A,.Khan.KS,.\nBossuyt.PMM.\nNo. 51\nSystematic.reviews.of.the.clinical.\neffectiveness.and.cost-effectiveness.of.\nproton.pump.inhibitors.in.acute.upper.\ngastrointestinal.bleeding.\nBy.Leontiadis.GI,.Sreedharan.\nA,.Dorward.S,.Barton.P,.Delaney.B,.\nHowden.CW,.et al.\nNo. 52\nA.review.and.critique.of.modelling.in.\nprioritising.and.designing.screening.\nprogrammes.\nBy.Karnon.J,.Goyder.E,.Tappenden.\nP,.McPhie.S,.Towers.I,.Brazier.J,.et al.\nNo. 53\nAn.assessment.of.the.impact.of.the.\nNHS.Health.Technology.Assessment.\nProgramme.\nBy.Hanney.S,.Buxton.M,.Green.C,.\nCoulson.D,.Raftery.J.\nVolume 12, 2008\nNo. 1\nA.systematic.review.and.economic.\nmodel.of.switching.from.\nnonglycopeptide.to.glycopeptide.\nantibiotic.prophylaxis.for.surgery.\nBy.Cranny.G,.Elliott.R,.Weatherly.H,.\nChambers.D,.Hawkins.N,.Myers.L,.et al.\nNo. 2\n\u2018Cut.down.to.quit\u2019.with.nicotine.\nreplacement.therapies.in.smoking.\ncessation:.a.systematic.review.of.\neffectiveness.and.economic.analysis.\nBy.Wang.D,.Connock.M,.Barton.P,.\nFry-Smith.A,.Aveyard.P,.Moore.D.\nNo. 3\nA.systematic.review.of.the.effectiveness.\nof.strategies.for.reducing.fracture.risk.\nin.children.with.juvenile.idiopathic.\narthritis.with.additional.data.on.long-\nterm.risk.of.fracture.and.cost.of.disease.\nmanagement.\nBy.Thornton.J,.Ashcroft.D,.O\u2019Neill.T,.\nElliott.R,.Adams.J,.Roberts.C,.et al.\nNo. 4\nDoes.befriending.by.trained.lay.workers.\nimprove.psychological.well-being.and.\nquality.of.life.for.carers.of.people.\nwith.dementia,.and.at.what.cost?.A.\nrandomised.controlled.trial.\nBy.Charlesworth.G,.Shepstone.L,.\nWilson.E,.Thalanany.M,.Mugford.M,.\nPoland.F.\nNo. 5\nA.multi-centre.retrospective.cohort.\nstudy.comparing.the.efficacy,.safety.\nand.cost-effectiveness.of.hysterectomy.\nand.uterine.artery.embolisation.for.\nthe.treatment.of.symptomatic.uterine.\nfibroids..The.HOPEFUL.study.\nBy.Hirst.A,.Dutton.S,.Wu.O,.Briggs.\nA,.Edwards.C,.Waldenmaier.L,.et al.\nNo. 6\nMethods.of.prediction.and.prevention.\nof.pre-eclampsia:.systematic.reviews.of.\naccuracy.and.effectiveness.literature.\nwith.economic.modelling.\nBy.Meads.CA,.Cnossen.JS,.Meher.S,.\nJuarez-Garcia.A,.ter.Riet.G,.Duley.L,.\net al.\nNo. 7\nThe.use.of.economic.evaluations.in.\nNHS.decision-making:.a.review.and.\nempirical.investigation.\nBy.Williams.I,.McIver.S,.Moore.D,.\nBryan.S.\nNo. 8\nStapled.haemorrhoidectomy.\n(haemorrhoidopexy).for.the.treatment.\nof.haemorrhoids:.a.systematic.review.\nand.economic.evaluation.\nBy.Burch.J,.Epstein.D,.Baba-Akbari.\nA,.Weatherly.H,.Fox.D,.Golder.S,.et al.\nNo. 9\nThe.clinical.effectiveness.of.diabetes.\neducation.models.for.Type.2.diabetes:.a.\nsystematic.review.\nBy.Loveman.E,.Frampton.GK,.\nClegg.AJ.\nNo. 10\nPayment.to.healthcare.professionals.for.\npatient.recruitment.to.trials:.systematic.\nreview.and.qualitative.study.\nBy.Raftery.J,.Bryant.J,.Powell.J,.\nKerr.C,.Hawker.S.\nNo. 11\nCyclooxygenase-2.selective.non-\nsteroidal.anti-inflammatory.drugs.\n(etodolac,.meloxicam,.celecoxib,.\nrofecoxib,.etoricoxib,.valdecoxib.and.\nlumiracoxib).for.osteoarthritis.and.\nrheumatoid.arthritis:.a.systematic.\nreview.and.economic.evaluation.\nBy.Chen.Y-F,.Jobanputra.P,.Barton.P,.\nBryan.S,.Fry-Smith.A,.Harris.G,.et al.\nNo. 12\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.central.venous.catheters.\ntreated.with.anti-infective.agents.in.\npreventing.bloodstream.infections:.\na.systematic.review.and.economic.\nevaluation.\nBy.Hockenhull.JC,.Dwan.K,.Boland.\nA,.Smith.G,.Bagust.A,.Dundar.Y,.et al.\nNo. 13\nStepped.treatment.of.older.adults.on.\nlaxatives..The.STOOL.trial.\nBy.Mihaylov.S,.Stark.C,.McColl.E,.\nSteen.N,.Vanoli.A,.Rubin.G,.et al.\nNo. 14\nA.randomised.controlled.trial.of.\ncognitive.behaviour.therapy.in.\nadolescents.with.major.depression.\ntreated.by.selective.serotonin.reuptake.\ninhibitors..The.ADAPT.trial.\nBy.Goodyer.IM,.Dubicka.B,.\nWilkinson.P,.Kelvin.R,.Roberts.C,.\nByford.S,.et al.\nNo. 15\nThe.use.of.irinotecan,.oxaliplatin.\nand.raltitrexed.for.the.treatment.of.\nadvanced.colorectal.cancer:.systematic.\nreview.and.economic.evaluation.\nBy.Hind.D,.Tappenden.P,.Tumur.I,.\nEggington.E,.Sutcliffe.P,.Ryan.A.\nNo. 16\nRanibizumab.and.pegaptanib.for.\nthe.treatment.of.age-related.macular.\ndegeneration:.a.systematic.review.and.\neconomic.evaluation.\nBy.Colquitt.JL,.Jones.J,.Tan.SC,.\nTakeda.A,.Clegg.AJ,.Price.A.\nNo. 17\nSystematic.review.of.the.clinical.\neffectiveness.and.cost-effectiveness.\nof.64-slice.or.higher.computed.\ntomography.angiography.as.an.\nalternative.to.invasive.coronary.\nangiography.in.the.investigation.of.\ncoronary.artery.disease.\nBy.Mowatt.G,.Cummins.E,.Waugh.N,.\nWalker.S,.Cook.J,.Jia.X,.et al.\nNo. 18\nStructural.neuroimaging.in.psychosis:.\na.systematic.review.and.economic.\nevaluation.\nBy.Albon.E,.Tsourapas.A,.Frew.E,.\nDavenport.C,.Oyebode.F,.Bayliss.S,.et al.\nNo. 19\nSystematic.review.and.economic.\nanalysis.of.the.comparative.\neffectiveness.of.different.inhaled.\ncorticosteroids.and.their.usage.with.\nlong-acting.beta2.agonists.for.the.\ntreatment.of.chronic.asthma.in.adults.\nand.children.aged.12.years.and.over.\nBy.Shepherd.J,.Rogers.G,.Anderson.\nR,.Main.C,.Thompson-Coon.J,.\nHartwell.D,.et al.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n147\nNo. 20\nSystematic.review.and.economic.\nanalysis.of.the.comparative.\neffectiveness.of.different.inhaled.\ncorticosteroids.and.their.usage.with.\nlong-acting.beta2.agonists.for.the.\ntreatment.of.chronic.asthma.in.children.\nunder.the.age.of.12.years.\nBy.Main.C,.Shepherd.J,.Anderson.R,.\nRogers.G,.Thompson-Coon.J,.Liu.Z,.\net al.\nNo. 21\nEzetimibe.for.the.treatment.of.\nhypercholesterolaemia:.a.systematic.\nreview.and.economic.evaluation.\nBy.Ara.R,.Tumur.I,.Pandor.A,.\nDuenas.A,.Williams.R,.Wilkinson.A,.et al.\nNo. 22\nTopical.or.oral.ibuprofen.for.chronic.\nknee.pain.in.older.people..The.TOIB.\nstudy.\nBy.Underwood.M,.Ashby.D,.Carnes.\nD,.Castelnuovo.E,.Cross.P,.Harding.G,.\net al.\nNo. 23\nA.prospective.randomised.comparison.\nof.minor.surgery.in.primary.and.\nsecondary.care..The.MiSTIC.trial.\nBy.George.S,.Pockney.P,.Primrose.J,.\nSmith.H,.Little.P,.Kinley.H,.et al.\nNo. 24\nA.review.and.critical.appraisal.\nof.measures.of.therapist\u2013patient.\ninteractions.in.mental.health.settings.\nBy.Cahill.J,.Barkham.M,.Hardy.G,.\nGilbody.S,.Richards.D,.Bower.P,.et al.\nNo. 25\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.screening.programmes.\nfor.amblyopia.and.strabismus.in.\nchildren.up.to.the.age.of.4\u20135.years:.\na.systematic.review.and.economic.\nevaluation.\nBy.Carlton.J,.Karnon.J,.Czoski-\nMurray.C,.Smith.KJ,.Marr.J.\nNo. 26\nA.systematic.review.of.the.clinical.\neffectiveness.and.cost-effectiveness.\nand.economic.modelling.of.minimal.\nincision.total.hip.replacement.\napproaches.in.the.management.of.\narthritic.disease.of.the.hip.\nBy.de.Verteuil.R,.Imamura.M,.Zhu.S,.\nGlazener.C,.Fraser.C,.Munro.N,.et al.\nNo. 27\nA.preliminary.model-based.assessment.\nof.the.cost\u2013utility.of.a.screening.\nprogramme.for.early.age-related.\nmacular.degeneration.\nBy.Karnon.J,.Czoski-Murray.C,.\nSmith.K,.Brand.C,.Chakravarthy.U,.\nDavis.S,.et al.\nNo. 28\nIntravenous.magnesium.sulphate.\nand.sotalol.for.prevention.of.atrial.\nfibrillation.after.coronary.artery.\nbypass.surgery:.a.systematic.review.and.\neconomic.evaluation.\nBy.Shepherd.J,.Jones.J,.Frampton.\nGK,.Tanajewski.L,.Turner.D,.Price.A.\nNo. 29\nAbsorbent.products.for.urinary\/faecal.\nincontinence:.a.comparative.evaluation.\nof.key.product.categories.\nBy.Fader.M,.Cottenden.A,.Getliffe.K,.\nGage.H,.Clarke-O\u2019Neill.S,.Jamieson.K,.\net al.\nNo. 30\nA.systematic.review.of.repetitive.\nfunctional.task.practice.with.modelling.\nof.resource.use,.costs.and.effectiveness.\nBy.French.B,.Leathley.M,.Sutton.C,.\nMcAdam.J,.Thomas.L,.Forster.A,.et al.\nNo. 31\nThe.effectiveness.and.cost-effectivness.\nof.minimal.access.surgery.amongst.\npeople.with.gastro-oesophageal.reflux.\ndisease.\u2013.a.UK.collaborative.study..The.\nreflux.trial.\nBy.Grant.A,.Wileman.S,.Ramsay.C,.\nBojke.L,.Epstein.D,.Sculpher.M,.et al.\nNo. 32\nTime.to.full.publication.of.studies.of.\nanti-cancer.medicines.for.breast.cancer.\nand.the.potential.for.publication.bias:.a.\nshort.systematic.review.\nBy.Takeda.A,.Loveman.E,.Harris.P,.\nHartwell.D,.Welch.K.\nNo. 33\nPerformance.of.screening.tests.for.\nchild.physical.abuse.in.accident.and.\nemergency.departments.\nBy.Woodman.J,.Pitt.M,.Wentz.R,.\nTaylor.B,.Hodes.D,.Gilbert.RE.\nNo. 34\nCurative.catheter.ablation.in.atrial.\nfibrillation.and.typical.atrial.flutter:.\nsystematic.review.and.economic.\nevaluation.\nBy.Rodgers.M,.McKenna.C,.Palmer.\nS,.Chambers.D,.Van.Hout.S,.Golder.S,.\net al.\nNo. 35\nSystematic.review.and.economic.\nmodelling.of.effectiveness.and.cost.\nutility.of.surgical.treatments.for.men.\nwith.benign.prostatic.enlargement.\nBy.Lourenco.T,.Armstrong.N,.N\u2019Dow.\nJ,.Nabi.G,.Deverill.M,.Pickard.R,.et al.\nNo. 36\nImmunoprophylaxis.against.respiratory.\nsyncytial.virus.(RSV).with.palivizumab.\nin.children:.a.systematic.review.and.\neconomic.evaluation.\nBy.Wang.D,.Cummins.C,.Bayliss.S,.\nSandercock.J,.Burls.A.\nVolume 13, 2009\nNo. 1\nDeferasirox.for.the.treatment.of.iron.\noverload.associated.with.regular.\nblood.transfusions.(transfusional.\nhaemosiderosis).in.patients.suffering.\nwith.chronic.anaemia:.a.systematic.\nreview.and.economic.evaluation.\nBy.McLeod.C,.Fleeman.N,.Kirkham.\nJ,.Bagust.A,.Boland.A,.Chu.P,.et al.\nNo. 2\nThrombophilia.testing.in.people.with.\nvenous.thromboembolism:.systematic.\nreview.and.cost-effectiveness.analysis.\nBy.Simpson.EL,.Stevenson.MD,.\nRawdin.A,.Papaioannou.D.\nNo. 3\nSurgical.procedures.and.non-surgical.\ndevices.for.the.management.of.non-\napnoeic.snoring:.a.systematic.review.of.\nclinical.effects.and.associated.treatment.\ncosts.\nBy.Main.C,.Liu.Z,.Welch.K,.Weiner.\nG,.Quentin.Jones.S,.Stein.K.\nNo. 4\nContinuous.positive.airway.pressure.\ndevices.for.the.treatment.of.obstructive.\nsleep.apnoea\u2013hypopnoea.syndrome:.a.\nsystematic.review.and.economic.analysis.\nBy.McDaid.C,.Griffin.S,.Weatherly.H,.\nDur\u00e9e.K,.van.der.Burgt.M,.van.Hout.S,.\nAkers.J,.et al.\nNo. 5\nUse.of.classical.and.novel.biomarkers.\nas.prognostic.risk.factors.for.localised.\nprostate.cancer:.a.systematic.review.\nBy.Sutcliffe.P,.Hummel.S,.Simpson.E,.\nYoung.T,.Rees.A,.Wilkinson.A,.et al.\nNo. 6\nThe.harmful.health.effects.of.\nrecreational.ecstasy:.a.systematic.review.\nof.observational.evidence.\nBy.Rogers.G,.Elston.J,.Garside.R,.\nRoome.C,.Taylor.R,.Younger.P,.et al.\nNo. 7\nSystematic.review.of.the.clinical.\neffectiveness.and.cost-effectiveness.\nof.oesophageal.Doppler.monitoring.\nin.critically.ill.and.high-risk.surgical.\npatients.\nBy.Mowatt.G,.Houston.G,.Hern\u00e1ndez.\nR,.de.Verteuil.R,.Fraser.C,.Cuthbertson.\nB,.et al.\nNo. 8\nThe.use.of.surrogate.outcomes.in.\nmodel-based.cost-effectiveness.analyses:.\na.survey.of.UK.Health.Technology.\nAssessment.reports.\nBy.Taylor.RS,.Elston.J.\nNo. 9\nControlling.Hypertension.and.\nHypotension.Immediately.Post.Stroke.\n(CHHIPS).\u2013.a.randomised.controlled.\ntrial.\nBy.Potter.J,.Mistri.A,.Brodie.F,.\nChernova.J,.Wilson.E,.Jagger.C,.et al.Health Technology Assessment reports published to date\n148\nNo. 10\nRoutine.antenatal.anti-D.prophylaxis.\nfor.RhD-negative.women:.a.systematic.\nreview.and.economic.evaluation.\nBy.Pilgrim.H,.Lloyd-Jones.M,.Rees.A.\nNo. 11\nAmantadine,.oseltamivir.and.zanamivir.\nfor.the.prophylaxis.of.influenza.\n(including.a.review.of.existing.guidance.\nno..67):.a.systematic.review.and.\neconomic.evaluation.\nBy.Tappenden.P,.Jackson.R,.Cooper.\nK,.Rees.A,.Simpson.E,.Read.R,.et al.\nNo. 12\nImproving.the.evaluation.of.\ntherapeutic.interventions.in.multiple.\nsclerosis:.the.role.of.new.psychometric.\nmethods.\nBy.Hobart.J,.Cano.S.\nNo. 13\nTreatment.of.severe.ankle.sprain:.a.\npragmatic.randomised.controlled.trial.\ncomparing.the.clinical.effectiveness.\nand.cost-effectiveness.of.three.types.of.\nmechanical.ankle.support.with.tubular.\nbandage..The.CAST.trial.\nBy.Cooke.MW,.Marsh.JL,.Clark.M,.\nNakash.R,.Jarvis.RM,.Hutton.JL,.et al.,.\non.behalf.of.the.CAST.trial.group.\nNo. 14\nNon-occupational.postexposure.\nprophylaxis.for.HIV:.a.systematic.\nreview.\nBy.Bryant.J,.Baxter.L,.Hird.S.\nNo. 15\nBlood.glucose.self-monitoring.in.type.2.\ndiabetes:.a.randomised.controlled.trial.\nBy.Farmer.AJ,.Wade.AN,.French.DP,.\nSimon.J,.Yudkin.P,.Gray.A,.et al.\nNo. 16\nHow.far.does.screening.women.for.\ndomestic.(partner).violence.in.different.\nhealth-care.settings.meet.criteria.for.\na.screening.programme?.Systematic.\nreviews.of.nine.UK.National.Screening.\nCommittee.criteria.\nBy.Feder.G,.Ramsay.J,.Dunne.D,.\nRose.M,.Arsene.C,.Norman.R,.et al.\nNo. 17\nSpinal.cord.stimulation.for.chronic.\npain.of.neuropathic.or.ischaemic.\norigin:.systematic.review.and.economic.\nevaluation.\nBy.Simpson,.EL,.Duenas.A,.Holmes.\nMW,.Papaioannou.D,.Chilcott.J.\nNo. 18\nThe.role.of.magnetic.resonance.\nimaging.in.the.identification.of.\nsuspected.acoustic.neuroma:.a.\nsystematic.review.of.clinical.and.cost-\neffectiveness.and.natural.history.\nBy.Fortnum.H,.O\u2019Neill.C,.Taylor.R,.\nLenthall.R,.Nikolopoulos.T,.Lightfoot.\nG,.et al.\nNo. 19\nDipsticks.and.diagnostic.algorithms.in.\nurinary.tract.infection:.development.\nand.validation,.randomised.trial,.\neconomic.analysis,.observational.cohort.\nand.qualitative.study.\nBy.Little.P,.Turner.S,.Rumsby.K,.\nWarner.G,.Moore.M,.Lowes.JA, et al.\nNo. 20\nSystematic.review.of.respite.care.in.the.\nfrail.elderly.\nBy.Shaw.C,.McNamara.R,.Abrams.\nK,.Cannings-John.R,.Hood.K,.Longo.\nM, et al.\nNo. 21\nNeuroleptics.in.the.treatment.of.\naggressive.challenging.behaviour.for.\npeople.with.intellectual.disabilities:.\na.randomised.controlled.trial.\n(NACHBID).\nBy.Tyrer.P,.Oliver-Africano.P,.Romeo.\nR,.Knapp.M,.Dickens.S,.Bouras.N, et al.\nNo. 22\nRandomised.controlled.trial.to.\ndetermine.the.clinical.effectiveness.\nand.cost-effectiveness.of.selective.\nserotonin.reuptake.inhibitors.plus.\nsupportive.care,.versus.supportive.care.\nalone,.for.mild.to.moderate.depression.\nwith.somatic.symptoms.in.primary.\ncare:.the.THREAD.(THREshold.for.\nAntiDepressant.response).study.\nBy.Kendrick.T,.Chatwin.J,.Dowrick.C,.\nTylee.A,.Morriss.R,.Peveler.R, et al.\nNo. 23\nDiagnostic.strategies.using.DNA.testing.\nfor.hereditary.haemochromatosis.in.\nat-risk.populations:.a.systematic.review.\nand.economic.evaluation.\nBy.Bryant.J,.Cooper.K,.Picot.J,.Clegg.\nA,.Roderick.P,.Rosenberg.W,.et al.\nNo. 24\nEnhanced.external.counterpulsation.\nfor.the.treatment.of.stable.angina.and.\nheart.failure:.a.systematic.review.and.\neconomic.analysis.\nBy.McKenna.C,.McDaid.C,.\nSuekarran.S,.Hawkins.N,.Claxton.K,.\nLight.K,.et al.\nNo. 25\nDevelopment.of.a.decision.support.\ntool.for.primary.care.management.of.\npatients.with.abnormal.liver.function.\ntests.without.clinically.apparent.liver.\ndisease:.a.record-linkage.population.\ncohort.study.and.decision.analysis.\n(ALFIE).\nBy.Donnan.PT,.McLernon.D,.Dillon.\nJF,.Ryder.S,.Roderick.P,.Sullivan.F,.et al.\nNo. 26\nA.systematic.review.of.presumed.\nconsent.systems.for.deceased.organ.\ndonation.\nBy.Rithalia.A,.McDaid.C,.Suekarran.\nS,.Norman.G,.Myers.L,.Sowden.A.\nNo. 27\nParacetamol.and.ibuprofen.for.the.\ntreatment.of.fever.in.children:.the.\nPITCH.randomised.controlled.trial.\nBy.Hay.AD,.Redmond.NM,.Costelloe.\nC,.Montgomery.AA,.Fletcher.M,.\nHollinghurst..S,.et al.\nNo. 28\nA.randomised.controlled.trial.to.\ncompare.minimally.invasive.glucose.\nmonitoring.devices.with.conventional.\nmonitoring.in.the.management.of.\ninsulin-treated.diabetes.mellitus.\n(MITRE).\nBy.Newman.SP,.Cooke.D,.Casbard.A,.\nWalker.S,.Meredith.S,.Nunn.A,.et al.\nNo. 29\nSensitivity.analysis.in.economic.\nevaluation:.an.audit.of.NICE.current.\npractice.and.a.review.of.its.use.and.\nvalue.in.decision-making.\nBy.Andronis.L,.Barton.P,.Bryan.S.\nSuppl. 1\nTrastuzumab.for.the.treatment.of.\nprimary.breast.cancer.in.HER2-positive.\nwomen:.a.single.technology.appraisal.\nBy.Ward.S,.Pilgrim.H,.Hind.D.\nDocetaxel.for.the.adjuvant.treatment.\nof.early.node-positive.breast.cancer:.a.\nsingle.technology.appraisal.\nBy.Chilcott.J,.Lloyd.Jones.M,.\nWilkinson.A.\nThe.use.of.paclitaxel.in.the.\nmanagement.of.early.stage.breast.\ncancer.\nBy.Griffin.S,.Dunn.G,.Palmer.S,.\nMacfarlane.K,.Brent.S,.Dyker.A,.et al.\nRituximab.for.the.first-line.treatment.\nof.stage.III\/IV.follicular.non-Hodgkin\u2019s.\nlymphoma.\nBy.Dundar.Y,.Bagust.A,.Hounsome.J,.\nMcLeod.C,.Boland.A,.Davis.H,.et al.\nBortezomib.for.the.treatment.of.\nmultiple.myeloma.patients.\nBy.Green.C,.Bryant.J,.Takeda.A,.\nCooper.K,.Clegg.A,.Smith.A,.et al.\nFludarabine.phosphate.for.the.first-\nline.treatment.of.chronic.lymphocytic.\nleukaemia.\nBy.Walker.S,.Palmer.S,.Erhorn.S,.\nBrent.S,.Dyker.A,.Ferrie.L,.et al.\nErlotinib.for.the.treatment.of.relapsed.\nnon-small.cell.lung.cancer.\nBy.McLeod.C,.Bagust.A,.Boland.A,.\nHockenhull.J,.Dundar.Y,.Proudlove.C,.\net al.\nCetuximab.plus.radiotherapy.for.the.\ntreatment.of.locally.advanced.squamous.\ncell.carcinoma.of.the.head.and.neck.\nBy.Griffin.S,.Walker.S,.Sculpher.M,.\nWhite.S,.Erhorn.S,.Brent.S,.et al.\nInfliximab.for.the.treatment.of.adults.\nwith.psoriasis.\nBy.Loveman.E,.Turner.D,.Hartwell.\nD,.Cooper.K,.Clegg.A.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n149\nNo. 30\nPsychological.interventions.for.\npostnatal.depression:.cluster.\nrandomised.trial.and.economic.\nevaluation..The.PoNDER.trial.\nBy.Morrell.CJ,.Warner.R,.Slade.P,.\nDixon.S,.Walters.S,.Paley.G,.et al.\nNo. 31\nThe.effect.of.different.treatment.\ndurations.of.clopidogrel.in.patients.\nwith.non-ST-segment.elevation.acute.\ncoronary.syndromes:.a.systematic.\nreview.and.value.of.information.\nanalysis.\nBy.Rogowski.R,.Burch.J,.Palmer.S,.\nCraigs.C,.Golder.S,.Woolacott.N.\nNo. 32\nSystematic.review.and.individual.\npatient.data.meta-analysis.of.diagnosis.\nof.heart.failure,.with.modelling.of.\nimplications.of.different.diagnostic.\nstrategies.in.primary.care.\nBy.Mant.J,.Doust.J,.Roalfe.A,.Barton.\nP,.Cowie.MR,.Glasziou.P,.et al.\nNo. 33\nA.multicentre.randomised.controlled.\ntrial.of.the.use.of.continuous.positive.\nairway.pressure.and.non-invasive.\npositive.pressure.ventilation.in.the.early.\ntreatment.of.patients.presenting.to.the.\nemergency.department.with.severe.\nacute.cardiogenic.pulmonary.oedema:.\nthe.3CPO.trial.\nBy.Gray.AJ,.Goodacre.S,.Newby.\nDE,.Masson.MA,.Sampson.F,.Dixon.\nS,.et al.,.on.behalf.of.the.3CPO.study.\ninvestigators.\nNo. 34\nEarly.high-dose.lipid-lowering.therapy.\nto.avoid.cardiac.events:.a.systematic.\nreview.and.economic.evaluation.\nBy.Ara.R,.Pandor.A,.Stevens.J,.Rees.\nA,.Rafia.R..\nNo. 35\nAdefovir.dipivoxil.and.pegylated.\ninterferon.alpha.for.the.treatment.\nof.chronic.hepatitis.B:.an.updated.\nsystematic.review.and.economic.\nevaluation.\nBy.Jones.J,.Shepherd.J,.Baxter.L,.\nGospodarevskaya.E,.Hartwell.D,.Harris.\nP,.et al.\nNo. 36\nMethods.to.identify.postnatal.\ndepression.in.primary.care:.an.\nintegrated.evidence.synthesis.and.value.\nof.information.analysis.\nBy.Hewitt.CE,.Gilbody.SM,.Brealey.\nS,.Paulden.M,.Palmer.S,.Mann.R,.et al..\nNo. 37\nA.double-blind.randomised.placebo-\ncontrolled.trial.of.topical.intranasal.\ncorticosteroids.in.4-.to.11-year-old.\nchildren.with.persistent.bilateral.otitis.\nmedia.with.effusion.in.primary.care.\nBy.Williamson.I,.Benge.S,.Barton.S,.\nPetrou.S,.Letley.L,.Fasey.N,.et al.\nNo. 38\nThe.effectiveness.and.cost-effectiveness.\nof.methods.of.storing.donated.kidneys.\nfrom.deceased.donors:.a.systematic.\nreview.and.economic.model.\nBy.Bond.M,.Pitt.M,.Akoh.J,.Moxham.\nT,.Hoyle.M,.Anderson.R.\nNo. 39\nRehabilitation.of.older.patients:.day.\nhospital.compared.with.rehabilitation.\nat.home..A.randomised.controlled.trial.\nBy.Parker.SG,.Oliver.P,.Pennington.\nM,.Bond.J,.Jagger.C,.Enderby.PM,.et al.\nNo. 40\nBreastfeeding.promotion.for.infants.in.\nneonatal.units:.a.systematic.review.and.\neconomic.analysis\nBy.Renfrew.MJ,.Craig.D,.Dyson.L,.\nMcCormick.F,.Rice.S,.King.SE,.et al.\nNo. 41\nThe.clinical.effectiveness.and.cost-\neffectiveness.of.bariatric.(weight.loss).\nsurgery.for.obesity:.a.systematic.review.and.\neconomic.evaluation.\nBy.Picot.J,.Jones.J,.Colquitt.JL,.\nGospodarevskaya.E,.Loveman.E,.Baxter.\nL,.et al.\nNo. 42\nRapid.testing.for.group.B.streptococcus.\nduring.labour:.a.test.accuracy.study.\nwith.evaluation.of.acceptability.and.\ncost-effectiveness.\nBy.Daniels.J,.Gray.J,.Pattison.H,.\nRoberts.T,.Edwards.E,.Milner.P,.et al.\nNo. 43\nScreening.to.prevent.spontaneous.\npreterm.birth:.systematic.reviews.of.\naccuracy.and.effectiveness.literature.\nwith.economic.modelling.\nBy.Honest.H,.Forbes.CA,.Dur\u00e9e.KH,.\nNorman.G,.Duffy.SB,.Tsourapas.A,.et al.\nNo. 44\nThe.effectiveness.and.cost-effectiveness.\nof.cochlear.implants.for.severe.to.\nprofound.deafness.in.children.and.\nadults:.a.systematic.review.and.\neconomic.model.\nBy.Bond.M,.Mealing.S,.Anderson.R,.\nElston.J,.Weiner.G,.Taylor.RS,.et al.\nSuppl. 2\nGemcitabine.for.the.treatment.of.\nmetastatic.breast.cancer.\nBy.Jones.J,.Takeda.A,.Tan.SC,.\nCooper.K,.Loveman.E,.Clegg.A.\nVarenicline.in.the.management.of.\nsmoking.cessation:.a.single.technology.\nappraisal.\nBy.Hind.D,.Tappenden.P,.Peters.J,.\nKenjegalieva.K.\nAlteplase.for.the.treatment.of.acute.\nischaemic.stroke:.a.single.technology.\nappraisal.\nBy.Lloyd.Jones.M,.Holmes.M.\nRituximab.for.the.treatment.of.\nrheumatoid.arthritis.\nBy.Bagust.A,.Boland.A,.Hockenhull.\nJ,.Fleeman.N,.Greenhalgh.J,.Dundar.Y,.\net al.\nOmalizumab.for.the.treatment.of.\nsevere.persistent.allergic.asthma.\nBy.Jones.J,.Shepherd.J,.Hartwell.D,.\nHarris.P,.Cooper.K,.Takeda.A,.et al.\nRituximab.for.the.treatment.of.relapsed.\nor.refractory.stage.III.or.IV.follicular.\nnon-Hodgkin\u2019s.lymphoma.\nBy.Boland.A,.Bagust.A,.Hockenhull.\nJ,.Davis.H,.Chu.P,.Dickson.R.\nAdalimumab.for.the.treatment.of.\npsoriasis.\nBy.Turner.D,.Picot.J,.Cooper.K,.\nLoveman.E.\nDabigatran.etexilate.for.the.prevention.\nof.venous.thromboembolism.in.patients.\nundergoing.elective.hip.and.knee.\nsurgery:.a.single.technology.appraisal.\nBy.Holmes.M,.C.Carroll.C,.\nPapaioannou.D.\nRomiplostim.for.the.treatment.\nof.chronic.immune.or.idiopathic.\nthrombocytopenic.purpura:.a.single.\ntechnology.appraisal.\nBy.Mowatt.G,.Boachie.C,.Crowther.\nM,.Fraser.C,.Hern\u00e1ndez.R,.Jia.X,.et al.\nSunitinib.for.the.treatment.of.\ngastrointestinal.stromal.tumours:.a.\ncritique.of.the.submission.from.Pfizer.\nBy.Bond.M,.Hoyle.M,.Moxham.T,.\nNapier.M,.Anderson.R.\nNo. 45\nVitamin.K.to.prevent.fractures.in.\nolder.women:.systematic.review.and.\neconomic.evaluation..\nBy.Stevenson.M,.Lloyd-Jones.M,.\nPapaioannou.D.\nNo. 46\nThe.effects.of.biofeedback.for.the.\ntreatment.of.essential.hypertension:.a.\nsystematic.review.\nBy.Greenhalgh.J,.Dickson.R,.\nDundar.Y.DOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n151\nHealth Technology Assessment  \nprogramme\nDirector,\nProfessor Tom Walley,\nDirector,.NIHR.HTA.\nprogramme,.Professor.of.\nClinical.Pharmacology,.\nUniversity.of.Liverpool\nDeputy Director,\nProfessor Jon Nicholl,\nDirector,.Medical.Care.Research.\nUnit,.University.of.Sheffield\nPrioritisation.Strategy.Group\nMembers\nChair,\nProfessor Tom Walley,\nDirector,.NIHR.HTA.\nprogramme,.Professor.of.\nClinical.Pharmacology,.\nUniversity.of.Liverpool\nDeputy Chair,\nProfessor Jon Nicholl,\nDirector,.Medical.Care.Research.\nUnit,.University.of.Sheffield\nDr.Bob.Coates,\nConsultant.Advisor,.NETSCC,.\nHTA\nDr.Andrew.Cook,\nConsultant.Advisor,.NETSCC,.\nHTA\nDr.Peter.Davidson,\nDirector.of.Science.Support,.\nNETSCC,.HTA\nProfessor.Robin.E.Ferner,.\nConsultant.Physician.and.\nDirector,.West.Midlands.Centre.\nfor.Adverse.Drug.Reactions,.\nCity.Hospital.NHS.Trust,.\nBirmingham\nProfessor.Paul.Glasziou,.\nProfessor.of.Evidence-Based.\nMedicine,.University.of.Oxford\nDr.Nick.Hicks,\nDirector.of.NHS.Support,.\nNETSCC,.HTA\nDr.Edmund.Jessop,\nMedical.Adviser,.National.\nSpecialist,.National.\nCommissioning.Group.(NCG),.\nDepartment.of.Health,.London\nMs.Lynn.Kerridge,\nChief.Executive.Officer,.\nNETSCC.and.NETSCC,.HTA\nDr.Ruairidh.Milne,\nDirector.of.Strategy.and.\nDevelopment,.NETSCC\nMs.Kay.Pattison,\nSection.Head,.NHS.R&D.\nProgramme,.Department.of.\nHealth\nMs.Pamela.Young,\nSpecialist.Programme.Manager,.\nNETSCC,.HTA\nHTA.Commissioning.Board\nMembers\nProgramme Director,\nProfessor Tom Walley,\nDirector,.NIHR.HTA.\nprogramme,.Professor.of.\nClinical.Pharmacology,.\nUniversity.of.Liverpool\nChair,\nProfessor Jon Nicholl,\nDirector,.Medical.Care.Research.\nUnit,.University.of.Sheffield\nDeputy Chair,\nDr Andrew Farmer,\nSenior.Lecturer.in.General.\nPractice,.Department.of.\nPrimary.Health.Care,.\nUniversity.of.Oxford\nProfessor.Ann.Ashburn,\nProfessor.of.Rehabilitation.\nand.Head.of.Research,.\nSouthampton.General.Hospital\nProfessor.Deborah.Ashby,\nProfessor.of.Medical.Statistics,.\nQueen.Mary,.University.of.\nLondon\nProfessor.John.Cairns,\nProfessor.of.Health.Economics,.\nLondon.School.of.Hygiene.and.\nTropical.Medicine\nProfessor.Peter.Croft,\nDirector.of.Primary.Care.\nSciences.Research.Centre,.Keele.\nUniversity\nProfessor.Nicky.Cullum,\nDirector.of.Centre.for.Evidence-\nBased.Nursing,.University.of.\nYork\nProfessor.Jenny.Donovan,\nProfessor.of.Social.Medicine,.\nUniversity.of.Bristol\nProfessor.Steve.Halligan,\nProfessor.of.Gastrointestinal.\nRadiology,.University.College.\nHospital,.London\nProfessor.Freddie.Hamdy,\nProfessor.of.Urology,\nUniversity.of.Sheffield\nProfessor.Allan.House,\nProfessor.of.Liaison.Psychiatry,.\nUniversity.of.Leeds\nDr.Martin.J.Landray,\nReader.in.Epidemiology,.\nHonorary.Consultant.Physician,.\nClinical.Trial.Service.Unit,.\nUniversity.of.Oxford.\nProfessor.Stuart.Logan,\nDirector.of.Health.&.Social.\nCare.Research,.The.Peninsula.\nMedical.School,.Universities.of.\nExeter.and.Plymouth\nDr.Rafael.Perera,\nLecturer.in.Medical.Statisitics,.\nDepartment.of.Primary.Health.\nCare,.Univeristy.of.Oxford\nProfessor.Ian.Roberts,.\nProfessor.of.Epidemiology.&.\nPublic.Health,.London.School.\nof.Hygiene.and.Tropical.\nMedicine\nProfessor.Mark.Sculpher,\nProfessor.of.Health.Economics,.\nUniversity.of.York\nProfessor.Helen.Smith,\nProfessor.of.Primary.Care,.\nUniversity.of.Brighton\nProfessor.Kate.Thomas,\nProfessor.of.Complementary.&.\nAlternative.Medicine.Research,.\nUniversity.of.Leeds\nProfessor.David.John.\nTorgerson,\nDirector.of.York.Trials.Unit,.\nUniversity.of.York\nProfessor.Hywel.Williams,\nProfessor.of.Dermato-\nEpidemiology,.University.of.\nNottingham\nObservers\nMs.Kay.Pattison,\nSection.Head,.NHS.R&D.\nProgramme,.Department.of.\nHealth\nDr.Morven.Roberts,\nClinical.Trials.Manager,.\nMedical.Research.CouncilHealth Technology Assessment programme \n152\nCurrent and past membership details of all HTA programme \u2018committees\u2019 are available from the HTA website (www.hta.ac.uk)\nDiagnostic.Technologies.&.Screening.Panel\nMembers\nChair,\nProfessor Paul Glasziou,\nProfessor.of.Evidence-Based.\nMedicine,.University.of.Oxford\nDeputy Chair,\nDr David Elliman,\nConsultant.Paediatrician.and.\nHonorary.Senior.Lecturer,.\nGreat.Ormond.Street.Hospital,.\nLondon\nProfessor.Judith.E.Adams,.\nConsultant.Radiologist,.\nManchester.Royal.Infirmary,.\nCentral.Manchester.&.\nManchester.Children\u2019s.\nUniversity.Hospitals.NHS.Trust,.\nand.Professor.of.Diagnostic.\nRadiology,.Imaging.Science.\nand.Biomedical.Engineering,.\nCancer.&.Imaging.Sciences,.\nUniversity.of.Manchester\nMs.Jane.Bates,\nConsultant.Ultrasound.\nPractitioner,.Ultrasound.\nDepartment,.Leeds.Teaching.\nHospital.NHS.Trust\nDr.Stephanie.Dancer,\nConsultant.Microbiologist,.\nHairmyres.Hospital,.East.\nKilbride\nProfessor.Glyn.Elwyn,\nPrimary.Medical.Care.Research.\nGroup,.Swansea.Clinical.School,.\nUniversity.of.Wales\nDr.Ron.Gray,\nConsultant.Clinical.\nEpidemiologist,.Department.\nof.Public.Health,.University.of.\nOxford\nProfessor.Paul.D.Griffiths,.\nProfessor.of.Radiology,.\nUniversity.of.Sheffield\nDr.Jennifer.J.Kurinczuk,\nConsultant.Clinical.\nEpidemiologist,.National.\nPerinatal.Epidemiology.Unit,.\nOxford\nDr.Susanne.M.Ludgate,\nMedical.Director,.Medicines.&.\nHealthcare.Products.Regulatory.\nAgency,.London\nDr.Anne.Mackie,\nDirector.of.Programmes,.UK.\nNational.Screening.Committee\nDr.Michael.Millar,.\nConsultant.Senior.Lecturer.in.\nMicrobiology,.Barts.and.The.\nLondon.NHS.Trust,.Royal.\nLondon.Hospital\nMr.Stephen.Pilling,\nDirector,.Centre.for.Outcomes,.\nResearch.&.Effectiveness,.\nJoint.Director,.National.\nCollaborating.Centre.for.\nMental.Health,.University.\nCollege.London\nMrs.Una.Rennard,\nService.User.Representative\nDr.Phil.Shackley,\nSenior.Lecturer.in.Health.\nEconomics,.School.of.\nPopulation.and.Health.\nSciences,.University.of.\nNewcastle.upon.Tyne\nObservers\nDr.Tim.Elliott,\nTeam.Leader,.Cancer.\nScreening,.Department.of.\nHealth\nDr.Catherine.Moody,\nProgramme.Manager,.\nNeuroscience.and.Mental.\nHealth.Board\nDr.Ursula.Wells,\nPrincipal.Research.Officer,.\nDepartment.of.Health\nDr.W.Stuart.A.Smellie,\nConsultant.in.Chemical.\nPathology,.Bishop.Auckland.\nGeneral.Hospital\nDr.Nicholas.Summerton,.\nConsultant.Clinical.and.Public.\nHealth.Advisor,.NICE\nMs.Dawn.Talbot,\nService.User.Representative\nDr.Graham.Taylor,\nScientific.Advisor,.Regional.\nDNA.Laboratory,.St.James\u2019s.\nUniversity.Hospital,.Leeds\nProfessor.Lindsay.Wilson.\nTurnbull,\nScientific.Director.of.the.\nCentre.for.Magnetic.Resonance.\nInvestigations.and.YCR.\nProfessor.of.Radiology,.Hull.\nRoyal.Infirmary\nPharmaceuticals.Panel\nMembers\nChair,\nProfessor Robin Ferner,\nConsultant.Physician.and.\nDirector,.West.Midlands.Centre.\nfor.Adverse.Drug.Reactions,.\nCity.Hospital.NHS.Trust,.\nBirmingham\nDeputy Chair,\nProfessor Imti Choonara,\nProfessor.in.Child.Health,.\nUniversity.of.Nottingham\nMrs.Nicola.Carey,\nSenior.Research.Fellow,..\nSchool.of.Health.and.Social.\nCare,.The.University.of.\nReading\nMr.John.Chapman,\nService.User.Representative\nDr.Peter.Elton,\nDirector.of.Public.Health,\nBury.Primary.Care.Trust\nDr.Ben.Goldacre,\nResearch.Fellow,.Division.of.\nPsychological.Medicine.and.\nPsychiatry,.King\u2019s.College.\nLondon\nMrs.Barbara.Greggains,\nService.User.Representative\nDr.Bill.Gutteridge,\nMedical.Adviser,.London.\nStrategic.Health.Authority\nDr.Dyfrig.Hughes,\nReader.in.Pharmacoeconomics.\nand.Deputy.Director,.Centre.\nfor.Economics.and.Policy.in.\nHealth,.IMSCaR,.Bangor.\nUniversity\nProfessor.Jonathan.Ledermann,\nProfessor.of.Medical.Oncology.\nand.Director.of.the.Cancer.\nResearch.UK.and.University.\nCollege.London.Cancer.Trials.\nCentre\nDr.Yoon.K.Loke,\nSenior.Lecturer.in.Clinical.\nPharmacology,.University.of.\nEast.Anglia\nProfessor.Femi.Oyebode,\nConsultant.Psychiatrist.\nand.Head.of.Department,.\nUniversity.of.Birmingham\nDr.Andrew.Prentice,\nSenior.Lecturer.and.Consultant.\nObstetrician.and.Gynaecologist,.\nThe.Rosie.Hospital,.University.\nof.Cambridge\nDr.Martin.Shelly,\nGeneral.Practitioner,.Leeds,.\nand.Associate.Director,.NHS.\nClinical.Governance.Support.\nTeam,.Leicester\nDr.Gillian.Shepherd,\nDirector,.Health.and.Clinical.\nExcellence,.Merck.Serono.Ltd\nMrs.Katrina.Simister,\nAssistant.Director.New.\nMedicines,.National.Prescribing.\nCentre,.Liverpool\nMr.David.Symes,\nService.User.Representative\nDr.Lesley.Wise,\nUnit.Manager,.\nPharmacoepidemiology.\nResearch.Unit,.VRMM,.\nMedicines.&.Healthcare.\nProducts.Regulatory.Agency\nObservers\nMs.Kay.Pattison,\nSection.Head,.NHS.R&D.\nProgramme,.Department.of.\nHealth\nMr.Simon.Reeve,\nHead.of.Clinical.and.Cost-\nEffectiveness,.Medicines,.\nPharmacy.and.Industry.Group,.\nDepartment.of.Health\nDr.Heike.Weber,\nProgramme.Manager,.\nMedical.Research.Council\nDr.Ursula.Wells,\nPrincipal.Research.Officer,.\nDepartment.of.HealthDOI: 10.3310\/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47\n\u00a9 2009 Queen\u2019s Printer and Controller of HMSO. All rights reserved.\n153\nTherapeutic.Procedures.Panel\nMembers\nChair,\nDr John C Pounsford,\nConsultant.Physician,.North.\nBristol.NHS.Trust\nDeputy Chair,\nProfessor Scott Weich,\nProfessor.of.Psychiatry,.Division.\nof.Health.in.the.Community,.\nUniversity.of.Warwick,.\nCoventry\nProfessor.Jane.Barlow,\nProfessor.of.Public.Health.in.\nthe.Early.Years,.Health.Sciences.\nResearch.Institute,.Warwick.\nMedical.School,.Coventry\nMs.Maree.Barnett,\nActing.Branch.Head.of.Vascular.\nProgramme,.Department.of.\nHealth\nMrs.Val.Carlill,\nService.User.Representative\nMrs.Anthea.De.Barton-Watson,\nService.User.Representative\nMr.Mark.Emberton,\nSenior.Lecturer.in.Oncological.\nUrology,.Institute.of.Urology,.\nUniversity.College.Hospital,.\nLondon\nProfessor.Steve.Goodacre,\nProfessor.of.Emergency.\nMedicine,.University.of.\nSheffield\nProfessor.Christopher.Griffiths,\nProfessor.of.Primary.Care,.Barts.\nand.The.London.School.of.\nMedicine.and.Dentistry\nMr.Paul.Hilton,\nConsultant.Gynaecologist.\nand.Urogynaecologist,.Royal.\nVictoria.Infirmary,.Newcastle.\nupon.Tyne\nProfessor.Nicholas.James,.\nProfessor.of.Clinical.Oncology,.\nUniversity.of.Birmingham,.\nand.Consultant.in.Clinical.\nOncology,.Queen.Elizabeth.\nHospital\nDr.Peter.Martin,\nConsultant.Neurologist,.\nAddenbrooke\u2019s.Hospital,.\nCambridge\nDr.Kate.Radford,\nSenior.Lecturer.(Research),.\nClinical.Practice.Research.\nUnit,.University.of.Central.\nLancashire,.Preston\nMr.Jim.Reece\nService.User.Representative\nDr.Karen.Roberts,\nNurse.Consultant,.Dunston.Hill.\nHospital.Cottages\nObservers\nDr.Phillip.Leech,\nPrincipal.Medical.Officer.for.\nPrimary.Care,.Department.of.\nHealth\nMs.Kay.Pattison,\nSection.Head,.NHS.R&D.\nProgramme,.Department.of.\nHealth\nDr.Morven.Roberts,\nClinical.Trials.Manager,.\nMedical.Research.Council\nProfessor.Tom.Walley,\nDirector,.NIHR.HTA.\nprogramme,.Professor.of.\nClinical.Pharmacology,.\nUniversity.of.Liverpool\nDisease.Prevention.Panel\nMembers\nChair,\nDr Edmund Jessop,\nMedical.Adviser,.National.\nSpecialist,.National.\nCommissioning.Group.(NCG),.\nLondon\nDeputy Chair,\nDr David Pencheon,\nDirector,.NHS.Sustainable.\nDevelopment.Unit,.Cambridge\nDr.Elizabeth.Fellow-Smith,\nMedical.Director,.West.London.\nMental.Health.Trust,.Middlesex\nDr.John.Jackson,\nGeneral.Practitioner,.Parkway.\nMedical.Centre,.Newcastle.\nupon.Tyne\nProfessor.Mike.Kelly,\nDirector,.Centre.for.Public.\nHealth.Excellence,.NICE,.\nLondon\nDr.Chris.McCall,\nGeneral.Practitioner,.The.\nHadleigh.Practice,.Corfe.\nMullen,.Dorset\nMs.Jeanett.Martin,\nDirector.of.Nursing,..BarnDoc.\nLimited,.Lewisham.Primary.\nCare.Trust\nDr.Julie.Mytton,\nLocum.Consultant.in.Public.\nHealth.Medicine,.Bristol.\nPrimary.Care.Trust\nMiss.Nicky.Mullany,\nService.User.Representative\nProfessor.Ian.Roberts,\nProfessor.of.Epidemiology.and.\nPublic.Health,.London.School.\nof.Hygiene.&.Tropical.Medicine\nProfessor.Ken.Stein,\nSenior.Clinical.Lecturer.in.\nPublic.Health,.University.of.\nExeter\nObservers\nMs.Christine.McGuire,\nResearch.&.Development,.\nDepartment.of.Health\nDr.Caroline.Stone,\nProgramme.Manager,.Medical.\nResearch.Council\nDr.Ursula.Wells,\nPrincipal.Research.Officer,.\nDepartment.of.Health\nDr.Kieran.Sweeney,\nHonorary.Clinical.Senior.\nLecturer,.Peninsula.College.\nof.Medicine.and.Dentistry,.\nUniversities.of.Exeter.and.\nPlymouth\nProfessor.Carol.Tannahill,\nGlasgow.Centre.for.Population.\nHealth\nProfessor.Margaret.Thorogood,\nProfessor.of.Epidemiology,.\nUniversity.of.Warwick.Medical.\nSchool,.CoventryHealth Technology Assessment programme \n154\nCurrent and past membership details of all HTA programme \u2018committees\u2019 are available from the HTA website (www.hta.ac.uk)\nExpert.Advisory.Network\nMembers\nProfessor.Douglas.Altman,\nProfessor.of.Statistics.in.\nMedicine,.Centre.for.Statistics.\nin.Medicine,.University.of.\nOxford\nProfessor.John.Bond,\nProfessor.of.Social.Gerontology.\n&.Health.Services.Research,.\nUniversity.of.Newcastle.upon.\nTyne\nProfessor.Andrew.Bradbury,\nProfessor.of.Vascular.Surgery,.\nSolihull.Hospital,.Birmingham\nMr.Shaun.Brogan,\nChief.Executive,.Ridgeway.\nPrimary.Care.Group,.Aylesbury\nMrs.Stella.Burnside.OBE,\nChief.Executive,.Regulation.\nand.Improvement.Authority,.\nBelfast\nMs.Tracy.Bury,\nProject.Manager,.World.\nConfederation.for.Physical.\nTherapy,.London\nProfessor.Iain.T.Cameron,\nProfessor.of.Obstetrics.and.\nGynaecology.and.Head.of.the.\nSchool.of.Medicine,.University.\nof.Southampton\nDr.Christine.Clark,\nMedical.Writer.and.Consultant.\nPharmacist,.Rossendale\nProfessor.Collette.Clifford,\nProfessor.of.Nursing.and.\nHead.of.Research,.The.\nMedical.School,.University.of.\nBirmingham\nProfessor.Barry.Cookson,\nDirector,.Laboratory.of.Hospital.\nInfection,.Public.Health.\nLaboratory.Service,.London\nDr.Carl.Counsell,\nClinical.Senior.Lecturer.in.\nNeurology,.University.of.\nAberdeen\nProfessor.Howard.Cuckle,\nProfessor.of.Reproductive.\nEpidemiology,.Department.\nof.Paediatrics,.Obstetrics.&.\nGynaecology,.University.of.\nLeeds\nDr.Katherine.Darton,\nInformation.Unit,.MIND.\u2013.The.\nMental.Health.Charity,.London\nProfessor.Carol.Dezateux,\nProfessor.of.Paediatric.\nEpidemiology,.Institute.of.Child.\nHealth,.London\nMr.John.Dunning,.\nConsultant.Cardiothoracic.\nSurgeon,.Papworth.Hospital.\nNHS.Trust,.Cambridge\nMr.Jonothan.Earnshaw,\nConsultant.Vascular.Surgeon,.\nGloucestershire.Royal.Hospital,.\nGloucester\nProfessor.Martin.Eccles,\nProfessor.of.Clinical.\nEffectiveness,.Centre.for.Health.\nServices.Research,.University.of.\nNewcastle.upon.Tyne\nProfessor.Pam.Enderby,\nDean.of.Faculty.of.Medicine,.\nInstitute.of.General.Practice.\nand.Primary.Care,.University.of.\nSheffield\nProfessor.Gene.Feder,\nProfessor.of.Primary.Care.\nResearch.&.Development,.\nCentre.for.Health.Sciences,.\nBarts.and.The.London.School.\nof.Medicine.and.Dentistry\nMr.Leonard.R.Fenwick,\nChief.Executive,.Freeman.\nHospital,.Newcastle.upon.Tyne\nMrs.Gillian.Fletcher,\nAntenatal.Teacher.and.Tutor.\nand.President,.National.\nChildbirth.Trust,.Henfield\nProfessor.Jayne.Franklyn,\nProfessor.of.Medicine,.\nUniversity.of.Birmingham\nMr.Tam.Fry,\nHonorary.Chairman,.Child.\nGrowth.Foundation,.London\nProfessor.Fiona.Gilbert,\nConsultant.Radiologist.and.\nNCRN.Member,.University.of.\nAberdeen\nProfessor.Paul.Gregg,\nProfessor.of.Orthopaedic.\nSurgical.Science,.South.Tees.\nHospital.NHS.Trust\nBec.Hanley,\nCo-director,.TwoCan.Associates,.\nWest.Sussex\nDr.Maryann.L.Hardy,\nSenior.Lecturer,.University.of.\nBradford\nMrs.Sharon.Hart,\nHealthcare.Management.\nConsultant,.Reading\nProfessor.Robert.E.Hawkins,\nCRC.Professor.and.Director.\nof.Medical.Oncology,.Christie.\nCRC.Research.Centre,.\nChristie.Hospital.NHS.Trust,.\nManchester\nProfessor.Richard.Hobbs,\nHead.of.Department.of.Primary.\nCare.&.General.Practice,.\nUniversity.of.Birmingham\nProfessor.Alan.Horwich,\nDean.and.Section.Chairman,.\nThe.Institute.of.Cancer.\nResearch,.London\nProfessor.Allen.Hutchinson,\nDirector.of.Public.Health.and.\nDeputy.Dean.of.ScHARR,.\nUniversity.of.Sheffield\nProfessor.Peter.Jones,\nProfessor.of.Psychiatry,.\nUniversity.of.Cambridge,.\nCambridge\nProfessor.Stan.Kaye,\nCancer.Research.UK.Professor.\nof.Medical.Oncology,.Royal.\nMarsden.Hospital.and.Institute.\nof.Cancer.Research,.Surrey\nDr.Duncan.Keeley,\nGeneral.Practitioner.(Dr.Burch.\n&.Ptnrs),.The.Health.Centre,.\nThame\nDr.Donna.Lamping,\nResearch.Degrees.Programme.\nDirector.and.Reader.in.\nPsychology,.Health.Services.\nResearch.Unit,.London.School.\nof.Hygiene.and.Tropical.\nMedicine,.London\nMr.George.Levvy,\nChief.Executive,.Motor.\nNeurone.Disease.Association,.\nNorthampton\nProfessor.James.Lindesay,\nProfessor.of.Psychiatry.for.the.\nElderly,.University.of.Leicester\nProfessor.Julian.Little,\nProfessor.of.Human.Genome.\nEpidemiology,.University.of.\nOttawa\nProfessor.Alistaire.McGuire,\nProfessor.of.Health.Economics,.\nLondon.School.of.Economics\nProfessor.Rajan.Madhok,\nMedical.Director.and.Director.\nof.Public.Health,.Directorate.\nof.Clinical.Strategy.&.Public.\nHealth,.North.&.East.Yorkshire.\n&.Northern.Lincolnshire.\nHealth.Authority,.York\nProfessor.Alexander.Markham,\nDirector,.Molecular.Medicine.\nUnit,.St.James\u2019s.University.\nHospital,.Leeds\nDr.Peter.Moore,\nFreelance.Science.Writer,.\nAshtead\nDr.Andrew.Mortimore,\nPublic.Health.Director,.\nSouthampton.City.Primary.\nCare.Trust\nDr.Sue.Moss,\nAssociate.Director,.Cancer.\nScreening.Evaluation.Unit,.\nInstitute.of.Cancer.Research,.\nSutton\nProfessor.Miranda.Mugford,\nProfessor.of.Health.Economics.\nand.Group.Co-ordinator,.\nUniversity.of.East.Anglia\nProfessor.Jim.Neilson,\nHead.of.School.of.Reproductive.\n&.Developmental.Medicine.\nand.Professor.of.Obstetrics.\nand.Gynaecology,.University.of.\nLiverpool\nMrs.Julietta.Patnick,\nNational.Co-ordinator,.NHS.\nCancer.Screening.Programmes,.\nSheffield\nProfessor.Robert.Peveler,\nProfessor.of.Liaison.Psychiatry,.\nRoyal.South.Hants.Hospital,.\nSouthampton\nProfessor.Chris.Price,\nDirector.of.Clinical.Research,.\nBayer.Diagnostics.Europe,.\nStoke.Poges\nProfessor.William.Rosenberg,\nProfessor.of.Hepatology.\nand.Consultant.Physician,.\nUniversity.of.Southampton\nProfessor.Peter.Sandercock,\nProfessor.of.Medical.Neurology,.\nDepartment.of.Clinical.\nNeurosciences,.University.of.\nEdinburgh\nDr.Susan.Schonfield,\nConsultant.in.Public.Health,.\nHillingdon.Primary.Care.Trust,.\nMiddlesex\nDr.Eamonn.Sheridan,\nConsultant.in.Clinical.Genetics,.\nSt.James\u2019s.University.Hospital,.\nLeeds\nDr.Margaret.Somerville,\nDirector.of.Public.Health.\nLearning,.Peninsula.Medical.\nSchool,.University.of.Plymouth\nProfessor.Sarah.Stewart-Brown,\nProfessor.of.Public.Health,.\nDivision.of.Health.in.the.\nCommunity,.University.of.\nWarwick,.Coventry\nProfessor.Ala.Szczepura,\nProfessor.of.Health.Service.\nResearch,.Centre.for.Health.\nServices.Studies,.University.of.\nWarwick,.Coventry\nMrs.Joan.Webster,\nConsumer.Member,.Southern.\nDerbyshire.Community.Health.\nCouncil\nProfessor.Martin.Whittle,\nClinical.Co-director,.National.\nCo-ordinating.Centre.for.\nWomen\u2019s.and.Children\u2019s.\nHealth,.LymingtonNETSCC, Health Technology Assessment\nAlpha House\nUniversity of Southampton Science Park\nSouthampton SO16 7NS, UK\nEmail: hta@hta.ac.uk\nwww.hta.ac.uk  ISSN 1366-5278\nFeedback\nThe HTA programme and the authors would like to know \nyour views about this report.\nThe Correspondence Page on the HTA website \n(www.hta.ac.uk) is a convenient way to publish  \nyour comments. If you prefer, you can send your comments  \nto the address below, telling us whether you would like  \nus to transfer them to the website.\nWe look forward to hearing from you."}